0001493152-24-014127.txt : 20240410 0001493152-24-014127.hdr.sgml : 20240410 20240409220020 ACCESSION NUMBER: 0001493152-24-014127 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 100 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEXGEL, INC. CENTRAL INDEX KEY: 0001468929 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 264042544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41173 FILM NUMBER: 24834100 BUSINESS ADDRESS: STREET 1: 2150 CABOT BLVD WEST, STREET 2: SUITE B CITY: LANGHORNE STATE: PA ZIP: 19047 BUSINESS PHONE: 215 702-8550 MAIL ADDRESS: STREET 1: 2150 CABOT BLVD WEST, STREET 2: SUITE B CITY: LANGHORNE STATE: PA ZIP: 19047 FORMER COMPANY: FORMER CONFORMED NAME: AquaMed Technologies, Inc. DATE OF NAME CHANGE: 20090723 10-K 1 form10-k.htm
false FY 0001468929 0001468929 2023-01-01 2023-12-31 0001468929 NXGL:CommonStockParValue0.001Member 2023-01-01 2023-12-31 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2023-01-01 2023-12-31 0001468929 2023-06-30 0001468929 2024-04-10 0001468929 2023-12-31 0001468929 2022-12-31 0001468929 2022-01-01 2022-12-31 0001468929 us-gaap:CommonStockMember 2021-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2021-12-31 0001468929 us-gaap:RetainedEarningsMember 2021-12-31 0001468929 2021-12-31 0001468929 us-gaap:CommonStockMember 2022-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2022-12-31 0001468929 us-gaap:RetainedEarningsMember 2022-12-31 0001468929 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001468929 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001468929 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001468929 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001468929 us-gaap:CommonStockMember 2023-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-12-31 0001468929 us-gaap:RetainedEarningsMember 2023-12-31 0001468929 NXGL:JointVentureMember 2023-03-01 0001468929 NXGL:CGLabsMember 2023-03-01 0001468929 NXGL:RegisteredDirectOfferingMember us-gaap:SubsequentEventMember 2024-02-15 2024-02-15 0001468929 NXGL:RegisteredDirectOfferingMember us-gaap:SubsequentEventMember 2024-02-15 0001468929 NXGL:USTreasurySecuritiesOneMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesOneMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesTwoMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesTwoMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesThreeMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesThreeMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesFourMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesFourMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesFiveMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesFiveMember 2022-12-31 0001468929 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001468929 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001468929 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001468929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001468929 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001468929 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:ContractManufacturingMember 2023-01-01 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:ContractManufacturingMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:OtherIncomesMember 2023-01-01 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:OtherIncomesMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember 2023-01-01 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:ContractManufacturingMember 2022-01-01 2022-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:ContractManufacturingMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2022-01-01 2022-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:BrandedConsumerProductsMember 2022-01-01 2022-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:BrandedConsumerProductsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:OtherIncomesMember 2022-01-01 2022-12-31 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:OtherIncomesMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember 2022-01-01 2022-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember 2023-12-31 0001468929 NXGL:CGLabsMember 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2023-12-31 0001468929 NXGL:KenkodermAcquisitionMember 2023-12-01 2023-12-01 0001468929 NXGL:KenkodermAcquisitionMember 2023-12-01 0001468929 NXGL:CGLaboratoriesIncMember 2023-03-01 0001468929 2023-03-01 2023-03-01 0001468929 NXGL:KenkodermAcquisitionMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember 2023-12-31 0001468929 NXGL:KenkodermAcquisitionMember 2022-01-01 2022-12-31 0001468929 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2023-12-31 0001468929 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2023-12-31 0001468929 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001468929 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001468929 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2023-12-31 0001468929 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001468929 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001468929 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001468929 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001468929 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001468929 us-gaap:ConstructionInProgressMember 2023-12-31 0001468929 us-gaap:ConstructionInProgressMember 2022-12-31 0001468929 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0001468929 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:CustomerRelatedIntangibleAssetsMember 2022-12-31 0001468929 us-gaap:TradeNamesMember 2023-12-31 0001468929 us-gaap:TradeNamesMember 2022-12-31 0001468929 us-gaap:MarketingRelatedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:MarketingRelatedIntangibleAssetsMember 2022-12-31 0001468929 NXGL:SportDefenseLlcMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2020-05-29 0001468929 NXGL:CGLabsJVMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2023-03-01 0001468929 NXGL:KenkodermMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2023-12-01 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2020-05-26 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-05-03 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-05-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 2023-03-23 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember srt:ExecutiveOfficerMember 2023-03-23 2023-03-23 0001468929 NXGL:ContractorMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-08 0001468929 NXGL:ContractorMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-08 2023-03-08 0001468929 srt:DirectorMember 2023-08-17 0001468929 srt:DirectorMember 2023-08-17 2023-08-17 0001468929 NXGL:Dr.NeilChesenMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionOneMember 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionOneMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionTwoMember 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionTwoMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionThreeMember 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionThreeMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionOneMember 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionOneMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionOneMember srt:MaximumMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionTwoMember 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionTwoMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember NXGL:OptionTwoMember srt:MaximumMember 2022-10-01 2022-10-01 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember srt:MinimumMember 2023-01-01 2023-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember srt:MaximumMember 2023-01-01 2023-12-31 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2023-01-03 2023-01-03 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2023-01-03 0001468929 NXGL:OfficersAndEmployeesMember us-gaap:RestrictedStockMember 2022-08-01 2022-08-01 0001468929 NXGL:OfficersAndEmployeesMember us-gaap:RestrictedStockMember 2022-08-01 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2022-01-01 2022-01-01 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2022-01-01 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-12-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-01-01 2023-12-31 0001468929 NXGL:AwardsGrantedOutsideOfThe2019PlanMember 2023-12-31 0001468929 NXGL:AwardsGrantedOutsideOfThe2019PlanMember 2023-01-01 2023-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-12-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-01-01 2022-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-01-01 2023-12-31 0001468929 srt:MinimumMember 2023-01-01 2023-12-31 0001468929 srt:MaximumMember 2023-01-01 2023-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001468929 2021-01-01 2021-12-31 0001468929 NXGL:CGLabsNotesPayableMember 2023-12-31 0001468929 NXGL:CGLabsNotesPayableMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001468929 us-gaap:SubsequentEventMember NXGL:CGLabsNotesPayableMember 2024-03-13 0001468929 NXGL:CGLabsNotesPayableOneMember 2023-12-31 0001468929 NXGL:CGLabsNotesPayableOneMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001468929 us-gaap:SubsequentEventMember NXGL:CGLabsNotesPayableOneMember 2024-03-13 0001468929 NXGL:EconomicInjuryDisasterLoanMember 2020-05-28 0001468929 NXGL:EconomicInjuryDisasterLoanMember 2020-05-27 2020-05-28 0001468929 NXGL:AuctusNoteMember 2021-03-11 0001468929 NXGL:AuctusNoteMember 2021-03-10 2021-03-11 0001468929 2022-03-15 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember us-gaap:PrivatePlacementMember 2021-09-02 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember 2021-09-02 2021-09-02 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember 2022-01-25 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember us-gaap:PrivatePlacementMember 2022-09-06 0001468929 us-gaap:PrivatePlacementMember 2021-09-02 0001468929 us-gaap:PrivatePlacementMember 2021-03-11 0001468929 us-gaap:PrivatePlacementMember 2021-02-03 0001468929 us-gaap:PrivatePlacementMember 2020-12-24 0001468929 us-gaap:PrivatePlacementMember 2020-03-18 0001468929 us-gaap:PrivatePlacementMember 2019-09-10 0001468929 us-gaap:PrivatePlacementMember 2019-11-06 0001468929 srt:MinimumMember us-gaap:PrivatePlacementMember 2023-12-31 0001468929 srt:MaximumMember us-gaap:PrivatePlacementMember 2023-12-31 0001468929 2022-09-05 2022-09-06 0001468929 us-gaap:WarrantMember 2021-12-31 0001468929 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001468929 us-gaap:WarrantMember 2022-12-31 0001468929 us-gaap:WarrantMember 2023-12-31 0001468929 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:Mr.SteinMember 2021-09-02 0001468929 NXGL:Mr.StefanskyMember 2021-09-02 0001468929 NXGL:Dr.JeromeZeldisMember 2021-09-02 0001468929 NXGL:Dr.JeromeZeldisMember 2023-12-31 0001468929 NXGL:Dr.JeromeZeldisMember 2022-12-31 0001468929 country:PA 2023-12-31 0001468929 country:PA 2022-12-31 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:CommonStockMember 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:CommonStockMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:WarrantMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember srt:MinimumMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember srt:MaximumMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember NXGL:NonAffiliatedEntityMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember srt:AffiliatedEntityMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure NXGL:Segment NXGL:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 10-K

 

(Mark One)

 

  ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended: December 31, 2023

 

OR

 

  ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission file number: 001-41173

 

NexGel, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   26-4042544

(State or other jurisdiction

of incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

2150 Cabot Blvd West, Suite B
Langhorne, PA		   19047
(Address of principal executive office)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 702-8550

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒  
Smaller reporting company ☒ Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

 

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2023, the last business day of the registrant’s second fiscal quarter, was approximately $10,695,605 based on the price at which the registrant last sold common equity.

 

As of April 10, 2024, the registrant had 6,227,624 shares of common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive proxy statement relating to its 2024 annual meeting of stockholders (the “2024 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the year to which this report relates.

 

 

 

 

 

 

Table of Contents 

 

Part I    
     
Item 1 Business  
Item 1A Risk Factors 9
Item 1B Unresolved Staff Comments 18
Item 1C Cybersecurity 18
Item 2 Properties 18
Item 3 Legal Proceedings 18
Item 4 Mine Safety Disclosures 18
     
Part II    
     
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters 19
Item 6 [Reserved] 19
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
Item 7A Quantitative and Qualitative Disclosures About Market Risk 24
Item 8 Financial Statements and Supplementary Data F-1
Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 25
Item 9A Controls and Procedures 25
     
Part III    
     
Item 10 Directors, Executive Officers and Corporate Governance 25
Item 11 Executive Compensation 26
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 26
Item 13 Certain Relationships and Related Transactions, and Director Independence 26
Item 14 Principal Accountant Fees and Services 26
     
Part IV    
     
Item 15 Exhibits and Financial Statement Schedules 26
  Signatures 31

 

2

 

Forward-Looking Statements

 

This Annual Report on Form 10-K contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will actually be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

 

  ● our ability to continue as a going concern;
     
  ● inadequate capital;
     
  ● inadequate or an inability to raise sufficient capital to execute our business plan;
     
  ● our ability to comply with current good manufacturing practices;
     
  ● loss or retirement of key executives;
     
  ● our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues, if we are able to do so;
     
  ● adverse economic and geopolitical conditions, including the current conflict in Ukraine, and/or intense competition;
     
  ● loss of a key customer or supplier;
     
  ● entry of new competitors;
     
  ● adverse federal, state and local government regulation;
     
  ● technological obsolescence of our manufacturing process and equipment;
     
  ● technical problems with our research and products;
     
  ● risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains, revenue growth or expense savings;
     
  ● price increases for supplies and components; and
     
  ● the inability to carry out our business plans.

 

For a discussion of these and other risks that relate to our business and investing in shares of our common stock, you should carefully review the risks and uncertainties described elsewhere in this Annual Report on Form 10-K. The forward-looking statements contained in this Annual Report on Form 10-K are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

 

There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed under the section titled and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this information statement. You should evaluate all forward-looking statements made in this information statement in the context of these risks and uncertainties.

 

No assurance can be given that any goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this information statement or to reflect the occurrence of unanticipated events, except as required by law.

 

3

 

Item 1. Business

 

Our Company

 

We were incorporated in Delaware on January 13, 2009. We manufacture high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. We specialize in custom gels by capitalizing on proprietary manufacturing technologies. We have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the company. First, our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture.

 

Contract Manufacturing Business

 

As described above, we have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Our hydrogels are currently being marketed in the U.S. and abroad by our customers for the following applications:

 

  ● Drug Delivery. We believe delivering medication through hydrogel patches has important advantages over traditional methods of drug delivery. Hydrogel patches are less intrusive, painless, allow for pre-planned medication time periods, can potentially release medication in a manner consistent with the body’s own glandular activity (by avoiding dosage spikes and/or digestive alteration), and minimize side effects related to the medication via injection or ingestion.
     
  ● Other Medical Applications. Hydrogel patches are being used for transdermal applications such as hormone replacement therapy and contraception, treatment of acne, shingles, diabetes, motion sickness, treatment of angina with nitroglycerin and treatment of smoking addiction using nicotine and palliatives (i.e., pain relievers).
     
  ● Non-Prescription Therapeutic Applications. Hydrogel patches are also used in the medical community and are also directly marketed to consumers for topical application of over the counter (“OTC”) drugs such as non-prescription acne treatments, pain relievers, diet preparations, cough suppressants, treatment of warts, calluses and corns, and pain relief.
     
  ● Moist Wound and Burn Dressings. Hydrogel dressings have long been used for treating wounds and burns. Clinical trials have demonstrated the benefits of moist wound healing versus traditional dressings. Some of these benefits include immediate anti-inflammatory effects, allowing for freer cell flow and less scarring, increased absorption of exudate, and accelerated healing.
     
  ● Components of Medical Devices. Several medical devices utilize hydrogels as components. These devices include active drug delivery systems such as iontophoresis, warming and cooling devices, medical electrodes and various medical products for sensitive skin.
     
  ● Cosmetic Applications. Hydrogel patches and applications allow for delivery systems of cosmetic skin care products to consumers and skin care providers for uses that include moisturizers, face masks, cooling masks and applicators.

 

We believe our competitive advantage in each of the general hydrogel patch applications described above is that our hydrogel patches are gentler to the skin because we do not use chemical cross-linking agents which are incorporated into other hydrogel patches. Once the gels are manufactured according to a customer’s specifications, the gels are generally shipped to the customer via a contract carrier (e.g., United Parcel Service, Inc.).

 

4

 

Our Facilities

 

We manufacture our hydrogels at what we believe to be one of only two facilities that can produce state-of-the–art hydrogel transdermal products and we have successfully used over two hundred active ingredients combinations in our hydrogels to date. Our facility consists of 13,500 square feet of manufacturing space, which we currently operate at approximately 10% capacity. Given the significant unused capacity, we can expand rapidly to meet increased demand, including for our healthcare and consumer product lines as described in more detail below. At full capacity, we estimate our existing facility would produce approximately 1.4 billion square inches of product annually. In addition, we sublease approximately 6,200 square feet of a 12,000 square foot combined office and manufacturing facility in Granbury, Texas, for our joint venture CG Converting and Packaging, LLC (“JV”). Our facilities are subject to stringent FDA compliance requirements. We also believe our hydrogel facility creates a high barrier to entry into our hydrogel and consumer product business.

 

Consumer Products

 

Beginning in the third quarter of 2020, we began selling our own branded products using our hydrogel technology on the Amazon marketplace. In 2022 we expanded access to our products by launching our own direct to consumer website, Medagel.com. Our hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. The products we sell under our MedaGel brand primarily relate to over-the-counter (“OTC”) remedy solutions, such as blister and pain applications; while the products we sell under our LumaGel Beauty brand primarily relate to beauty and cosmetic solutions, such as wrinkle and skin cream applications. In December 2023 we added a third consumer product brand when we completed the purchase of the Kenkoderm brand. The Kenkoderm skincare line was originally developed by a dermatologist to provide alternative treatments for psoriasis that did not use steroids or biologics that often have side effects.

 

Additionally, we have several more products in our development pipeline. We intend for these products to address various market opportunities including the OTC pharmaceutical drug delivery market, pain management, beauty and cosmetics, sports related applications, cannabinoids (“CBD” and/or “THC”) and general podiatry.

 

Custom and White Label Opportunities

 

We are leveraging our hydrogel products and technologies by allowing other OTC brands to incorporate them into their products. We believe our hydrogels, which do not use chemical cross-linking agents and can be made in paraben free formulations, will be attractive to other OTC brands, especially in the beauty and cosmetics industry, and their customers. We believe these white labeling opportunities will increase the markets’ awareness of us as a consumer-friendly and reliable supplier of customizable patches. Additionally, we created a process where customers have the ability to create their own custom hydrogel products. Customers pay a development fee, eliminating our financial risk in the success or failure of the custom product. As opposed to our contract manufacturing business, where we provide bulk sale of roll stock hydrogel to our customers who then use it as one component in their products which they themselves then manufacture, test, market and sell, our custom and white label business will provide customers with a finished product which they will then brand and re-sell.

 

Medical Devices

 

We entered into the medical device development sector which a focus on analyzing, creating and developing devices and solutions that reduce skin pain and irritation, improve and maintain skin integrity and provide greater comfort and safety for patients at the site of which a medical device interfaces with the human body.

 

We conducted proof of concept studies for the development of our first medical device, which we call NEXDrape and have filed for a patent on this device under the Patent Cooperation Treaty which provides patent protection in the nations who are members of the treaty. The NEXDrape device is an incise surgical drape designed for patients with impaired skin. The elderly, diabetics, trauma patients and those with an adhesive sensitivity can have adverse events from the removal of adhesive drapes. Additionally, patients taking certain medications, such as ELIQUIS® and steroids, may experience impaired skin as well. These groups represent a sizable percentage of the incise surgical drape market, a market we believe to be significant and growing. The incise surgical drape market is currently fragmented with 3M Healthcare being the market leader. Skin tears, infections, rashes, and post-surgical site pain are some of the problems that can occur as a result of the removal of adhesive drapes, and have been reported with other currently available surgical drapes.

 

5

 

We have conducted one animal and two human cadaver proof of concept studies with respect to NEXDrape. As a result of these studies, we believe NEXDrape will represent a gentle to the skin alternative to the current adhesive based standard of care and will provide a unique solution for patients with fragile or compromised skin. Additionally, we believe NEXDrape offers the following benefits over the current incise surgical drape products: (i) no skin irritation; (ii) able to deliver a wide range of antiseptic and antibiotic agents; (iii) eliminates air bubbles; and (iv) prevents dermis removal post-surgery, which reduces the risk of patient infection and discomfort. We intend to file a 510(k) premarket submission with the Food and Drug Administration (“FDA”), which is an application to demonstrate that NEXDrape is as safe and effective (or substantially equivalent to) a legally marketed surgical drape device. There can be no guarantee that the FDA approves our application, if submitted.

 

We are also in the process of developing a product we call NEXDerm which will be an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during and after medical treatment. We believe NEXDerm will be an attractive alternative to Tegaderm™, a 3M Healthcare product. Based on our discussion with medical professionals, Tegaderm™ is often difficult and painful to remove after adhesion, particularly for comprised skin patients. NEXDerm, which will incorporate exclusively licensed technology owned by Noble Fiber, is designed to create a gentle to skin surgical tape impregnated with antimicrobial X-Static® silver fiber. We believe NEXDerm, if successfully developed, will offer the following advantages over Tegaderm™: (i) ability to easily reposition the adhesive tape; (ii) pain-free removal; (iii) gentle to the skin; and (iv) increased infection prevention. As with NEXDrape, we intend to file a 510(k) premarket submission with the FDA to demonstrate that NEXDrape is as safe and effective (or substantially equivalent to) a legally marketed surgical drape device. There can be no guarantee that the FDA approves our application, if submitted.

 

Our current intent with any medical devices will not be to commercialize due to the expense required but to potentially prepare them to go to market and to identify and pursue licensing and partnering arrangements with third parties possessing the necessary resources and capabilities to bring the devices to market.

 

Sales and Marketing

 

Contract Manufacturing, Consumer Products and Customer and White Label Offerings. We continue to focus on sales and marketing efforts in the United States. We use commission-based, fractional sales personnel to supplement our in-house efforts.

 

Medical Devices. We do not intend to spend efforts or resources on selling or marketing our medical device business. Our current intent with any medical devices will not be to commercialize due to the expense required but to identify and pursue licensing arrangements with third parties possessing the necessary resources and capabilities to bring the devices to market.

 

Competition

 

Contract Manufacturing. To our knowledge, NexGel is one of two manufacturers using electron beam technology for high performance hydrogels for the wound care, cosmetic and drug delivery industries.

 

Consumer Products and Medical Devices. As we expand our consumer products and medical device business, we will face a number of competitors. Our competitors include numerous manufacturers; distributors; marketers; online, specialty, mass, and other retailers; and physicians that actively compete for the business of consumers both in the United States and abroad, including companies such as Johnson & Johnson, Pfizer Consumer Healthcare and Procter & Gamble. Most of our competitors have longer operating histories, significantly greater resources, better developed and more innovative sales and distribution channels and platforms, greater name recognition, and larger established customer bases than we do. Therefore, a strategic partnership will be critical to our success in the medical device business. We also face similar challenges with our own consumer branded products and may pursue similar strategic partnerships, though direct to consumer marketing and selling is more feasible.

 

6

 

Custom and White Label Offerings. As our custom and white label offering business will provide customers with a finished product which they will then brand and re-sell, the competition will depend, to a great deal, on the type of product the customer request and will not result in direct competition to us.

 

Sources and Availability of Raw Materials; Principal Suppliers

 

In general, raw materials essential to our business are readily available from multiple sources. For reasons of quality assurance, availability, or cost effectiveness, certain components and raw materials are available only from a sole supplier. The principal suppliers for our raw materials are Berry Global, Inc., DeWolf Chemical, Inc., and Univar, Inc. Our policy is to maintain sufficient inventory of components and raw materials so that our production will not be significantly disrupted even if a particular component or material is not available for a period of time.

 

Because we have no direct control over these suppliers, interruptions or delays in the products and services provided by these parties may be difficult to remedy in a timely fashion. In addition, if such suppliers are unable or unwilling to deliver the necessary components or raw materials, we may be unable to redesign or adapt our technology to work without such components or raw materials or find alternative suppliers or manufacturers. In such events, we could experience interruptions, delays, increased costs, quality control problems, and or be unable to sell the applicable products, all of which could have a significant adverse impact on our revenue.

 

Other than as discussed above, we believe that, due to the size and scale of production of our suppliers, there should be an adequate supply of components and raw materials from our other suppliers.

 

Customers

 

During the year ended December 31, 2023, one major customer accounted for approximately 20%. During the year ended December 31, 2022 one major customer accounted for approximately 29% of our revenue. We cannot be certain as to this customer’s intentions to use our services during and beyond the fiscal year ended December 31, 2023 since we do not currently have a contract with this customer. However, we have been supplying this customer for more than 15 years and have no reason to anticipate any change. Our contract manufacturing business, including with respect to this customer, operates on a purchase order basis.

 

Patents, Proprietary Rights and Trademarks

 

We own or license trademarks covering our company and our products. We filed for a patent on NEXDrape under the Patent Cooperation Treaty which provides patent protection in the nations who are members of the treaty. We also rely upon trade secrets and continuing technological innovations to develop and maintain our competitive position. We also hold certain intellectual property that is not material to our current business and prospects, including patent rights to one patent in Europe, which covers the use of lignin for inhibiting restenosis and thrombosis formation, and coated medical devices where the coating includes lignin. This patent is set to expire in the near future, however we believe the expiration of these patents will not have an adverse impact on our overall business. We hold an exclusive license with right to sub-license from Specialty Pharmaceutical Products, L.L.C. (which was held by our former parent, Adynxx, Inc.) to two issued patents, one in the U.S. and one in Europe, which cover technology relating to a transdermal patch containing transcutol. The transdermal patch is effective to deliver lidocaine to a patient. Neither of these patent rights are material to our current business and prospects. These licensed patent rights are expected to expire in April 2032.

 

Government Regulation

 

Product Regulation. Under the Federal Food, Drug and Cosmetic Act, medical devices are classified by the FDA into one of three classes - Class I, Class II or Class III - depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. While some applications of hydrogels fall under the jurisdiction of the FDA, hydrogels are generally classified as Class I exempt devices and the majority of the hydrogel products that we manufacture are thereby exempt from the FDA filing of any regulatory submissions and/or pre-market notification requirements. To the extent that any FDA regulatory submissions are required, we will be required to file these submissions and maintain all appropriate documentation. With respect to registering the manufacturing facility with the FDA under the Code of Federal Regulations, 21 CFR 820.1, Scope: Part A, it is stated that the regulation does not apply to manufacturers of component parts of finished devices. Currently, hydrogels are sold as component parts to various medical device/cosmetic manufacturers.

 

7

 

Quality Assurance Requirements. The FDA enforces regulations to ensure that the methods used in, and the facilities and controls used for, the manufacture, processing, packing and holding of drugs and medical devices conform with current good manufacturing practice (“cGMP”). The cGMP regulations enforced by the FDA are comprehensive and cover all aspects of manufacturing operations, from receipt of raw materials to finished product distribution, insofar as they bear upon whether drugs meet all the identity, strength, quality and purity characteristics required of them. The cGMP regulations for devices, called the Quality System Regulation, are also comprehensive and cover all aspects of device manufacture, from pre-production design validation to installation and servicing, insofar as they bear upon the safe and effective use of the device and whether the device otherwise meets the requirements of the Federal Food, Drug and Cosmetic Act. To assure compliance requires a continuous commitment of time, money and effort in all operational areas.

 

The FDA also conducts periodic inspections of drug and device registered facilities to assess their current cGMP status. If the FDA were to find serious non-compliant manufacturing or processing practices during such an inspection, it could take regulatory actions that could adversely affect our business, results of operations, financial condition and cash flows. With respect to domestic establishments, the FDA could initiate product seizures or in some instances require product recalls and seek to enjoin a product’s manufacture and distribution. In certain circumstances, violations could support civil penalties and criminal prosecutions. In addition, if the FDA concludes that a company is not in compliance with cGMP requirements, sanctions may be imposed that include preventing that company from receiving the necessary licenses to export its products and classifying that company as an “unacceptable supplier”, thereby disqualifying that company from selling products to federal agencies.

 

We conduct audits of our outside manufacturers and believe that we and our suppliers and outside manufacturers are currently in compliance with cGMP requirements. We are currently registered as a device manufacturer and distributor with the FDA and we intend to register as a drug facility with the FDA when we are required to do so.

 

Environmental Regulation. We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U.S. and other countries. We have made, and continue to make, significant investments to comply with these laws and regulations. We cannot predict the future capital expenditures or operating costs required to comply with environmental laws and regulations. We believe that we are currently compliant with applicable environmental, health and safety requirements in all material respects. However, we cannot assure you that current or future regulatory, governmental, or private action will not have a material adverse effect on our performance, results or financial condition.

 

In the future, if a loss contingency related to environmental matters, employee safety, health or conditional asset retirement obligations is recognized, we would record a liability for the obligation and it may result in a material impact on net income for the annual or interim period during which the liability is recorded. The investigation and remediation of environmental obligations generally occur over an extended period of time, and therefore we do not know if these events would have a material adverse effect on our financial condition, liquidity, or cash flow, nor can we assure you that such liabilities would not have a material adverse effect on our performance, results or financial condition.

 

Federal and State Anti-kickback, Self-referral, False Claims and Similar Laws. Our relationships with physicians, hospitals and the marketers of our products are subject to scrutiny under various federal anti-kickback, self-referral, false claims and similar laws, often referred to collectively as healthcare fraud and abuse laws. Healthcare fraud and abuse laws are complex, and even minor, inadvertent violations can give rise to claims that the relevant law has been violated. Certain states have similar fraud and abuse laws, imposing substantial penalties for violations. Any government investigation or a finding of a violation of these laws would likely result in a material adverse effect on the market price of our common stock, as well as our business, financial condition and results of operations. We believe that we are currently compliant with applicable anti-kickback, self-referral, false claims in all material respects.

 

8

 

Research and Development Costs

 

For the years ended December 31, 2023 and 2022, we incurred approximately $103 thousand and $367 thousand, respectively, in research and development costs. We expect to incur increased costs in the future for our medical device business. Research and development will be an important component in the growth of our business.

 

Employees

 

As of December 31, 2023, we had 19 full-time employees. Of these employees, five are involved with finance, sales, marketing, and administration and 14 are involved with manufacturing and regulatory matters. Our employees are not represented by a labor union or other collective bargaining groups, and we consider relations with our employees to be good. We currently plan to retain and utilize the services of outside consultants for additional research, testing, regulatory, accounting and tax services, legal compliance, and other services on an as needed basis.

 

Properties

 

We maintain a combined corporate office and manufacturing facility in Langhorne, Pennsylvania, where we lease approximately 16,500 square feet of office and manufacturing space which expires on January 31, 2031. In addition, we sublease approximately 6,200 square feet of a 12,000 square foot combined office and manufacturing facility in Granbury, Texas, for our JV. The lease expires in March 2028.

 

We believe that our facilities are well maintained and are suitable and adequate for our current needs.

 

Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims.

 

There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest.

 

Contractual Obligations

 

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

 

Item 1A. Risk Factors

 

You should carefully consider the risks described below and elsewhere in this Annual Report on Form 10-K before making an investment decision. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. Our common stock is considered speculative and the trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The following risk factors are not the only risk factors facing the Company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business.

 

Risks Relating to Our Business

 

Our future success depends upon market acceptance of our existing and future products.

 

We believe that our success will depend in part upon the acceptance of our existing and future products by the medical community, hospitals and physicians and other health care providers, third-party payers, and end-users. Such acceptance may depend upon the extent to which the medical community and end-users perceive our products as safer, more effective or cost-competitive than other similar products. Ultimately, for our products to gain general market acceptance, it may also be necessary for us to develop marketing partners for the distribution of our products. There can be no assurance that our products will achieve significant market acceptance on a timely basis, or at all. Failure of some or all of our future products to achieve significant market acceptance could have a material adverse effect on our business, financial condition, and results of operations.

 

9

 

Our suppliers may fail to deliver components and raw materials and parts according to schedules, prices, quality and volumes that are acceptable to us, or we may be unable to manage these components and raw materials effectively.

 

Our products contain materials and parts purchased globally from many suppliers, including single-source direct suppliers, which exposes us to potential component shortages or delays. Unexpected changes in business conditions, materials pricing, labor issues, wars such as the current conflict in Ukraine, trade policies, natural disasters, health epidemics, trade and shipping disruptions, port congestions and other factors beyond our or our suppliers’ control could also affect these suppliers’ ability to deliver components to us or to remain solvent and operational. Additionally, if our suppliers do not accurately forecast and effectively allocate production or if they are not willing to allocate sufficient production to us, it may reduce our access to components and raw materials, thus requiring us to search for new suppliers. The unavailability of any component or supplier could result in production delays, idle manufacturing facilities, product design changes and loss of access to important technology and tools for producing and supporting our products. Our suppliers may not be willing or able to sustainably meet our timelines or our cost, quality and volume needs, or to do so may cost us more, which may require us to replace them with other sources. While we believe that we will be able to secure additional or alternate sources for most of our components, there is no assurance that we will be able to do so quickly or at all.

 

As the scale of production of our products, we will also need to accurately forecast, purchase, warehouse and transport components at high volumes to our manufacturing facilities. If we are unable to accurately match the timing and quantities of component purchases to our actual needs or successfully implement automation, inventory management and other systems to accommodate the increased complexity in our supply chain and parts management, we may incur unexpected production disruption, storage, transportation and write-off costs, which may harm our business and operating results.

 

We are dependent on significant customers.

 

Our hydrogel manufacturing business is currently our primary source of revenue, and much of this revenue is generated from a limited number of clients, who account for a substantial percentage of our total revenues. For the year ended December 31, 2023, one major customer accounted for approximately 20% of our revenue. The loss of any of our significant customers would have a significantly negative effect on our overall operations.

 

We rely heavily on the Amazon marketplace for the sales and distribution of our consumer products, and if we are unable to maintain a good relationship with Amazon or if Amazon experiences disruptions, our business will suffer.

 

We rely heavily on the Amazon marketplace for the sales and distribution of our consumer products to our end consumers. We believe that we have good relationships with Amazon. However, if we or any of our partners, (or if Amazon believes we or any of our partners have violated) its terms of service, Amazon could limit or terminate its relationship with us. Any limitation or termination of our relationship with Amazon could materially adversely affect one of all of our business, financial condition and our results of operations. Additionally, any prolonged disruption of Amazon’s website or its delivery and distribution of our consumer products could materially adversely impact our business.

 

We have no contracts in place with our customers in either our contract manufacturing or consumer products business. The absence of such contracts could result in periods during which we must continue to pay costs without revenues.

 

Our sales are made on a purchase order basis, we do not have contracts with our customers in either our contract manufacturing or consumer products business. Accordingly, our customers are not required to purchase a minimum amount of our products, and we therefore could have periods during which we have no or limited orders for our products, which will make it difficult for us to operate as we will have to continue paying our expenses. We cannot provide assurance that we will be able to timely locate new customers, if at all, when our existing customers are not placing orders. The periods in which we have no or limited purchase orders for our products would have a material adverse effect on our business and financial condition.

 

10

 

We operate in a highly competitive industry.

 

Competition from other hydrogel manufacturers is intense. There can be no assurance that we can develop products that are more effective or achieve greater market acceptance than competitive products, or that our competitors will not succeed in developing or acquiring products and technologies that are more effective than those being developed by us, that would render our products and technologies less competitive or obsolete.

 

Our competitors enjoy several competitive advantages over us, including some or all of the following:

 

  ● large and established distribution networks in the U.S. and/or in international markets;
  ● greater financial, managerial and other resources for products, research and development, sales and marketing efforts and protecting and enforcing intellectual property rights;
  ● significantly greater name recognition;
  ● more expansive portfolios of intellectual property rights; and
  ● greater experience in obtaining and maintaining regulatory approvals and/or clearances from the FDA and other regulatory agencies.

 

Our competitors’ products will compete directly with our products. In addition, our competitors, as well as new market entrants, may develop or acquire new products that will compete directly or indirectly with our products. The presence of this competition in our market may lead to pricing pressure which would make it more difficult to sell our products at a price that will make us profitable or prevent us from selling our products at all. Our failure to compete effectively would have a material and adverse effect on our business, results of operations and financial condition.

 

As we enter the consumer product business sector to a larger extent, our failure to compete successfully could materially harm our business, financial condition, and operating results.

 

The business of developing and marketing consumer and personal care products is highly competitive and sensitive to the introduction of new, competitive products, which may rapidly capture a significant share of the applicable market. Our competitors include numerous manufacturers; distributors; marketers; online, specialty, mass, and other retailers; and physicians that actively compete for the business of consumers both in the United States and abroad. Most of our competitors have longer operating histories, significantly greater resources, better-developed and more innovative sales and distribution channels and platforms, greater name recognition, and larger established customer bases than we do. Our present and future competitors may be able to better withstand reductions in prices or other adverse economic or market conditions than we can; develop products that are comparable or superior to those we offer; adapt more quickly or effectively to new technologies, changing regulatory requirements, evolving industry trends and standards, and customer requirements than we can; and/or devote greater resources to the development, promotion, and sale of their products than we do. In addition, because the industry in which we operate is not particularly capital intensive or otherwise subject to high barriers to entry, it is relatively easy for new competitors to emerge that will compete with us. Accordingly, competition may intensify, and we may not be able to compete effectively in our markets. If we are not able to compete successfully in the consumer products sector, our business, financial condition, and operating results would be materially adversely affected.

 

Our failure to appropriately respond to changing consumer trends, preferences, and demand for new products and product enhancements could materially harm our business, financial condition, and operating results.

 

Our consumer products business is subject to rapidly changing consumer trends and preferences and product introductions. Our success will depend in part on our ability to anticipate and respond to these changes and introductions, and we may not respond or develop new products or product enhancements in a cost-effective, timely, or commercially appropriate manner. The success of our new product offerings and enhancements depends on a number of factors, including our ability to:

 

  ● accurately anticipate consumer needs;

 

11

 

  ● innovate and develop new products and product enhancements that meet these needs;
     
  ● successfully commercialize new products and product enhancements;
     
  ● price our products competitively;
     
  ● manufacture and deliver our products in sufficient volumes and in a cost-effective and timely manner; and
     
  ● differentiate our product offerings from those of our competitors and successfully respond to other competitive pressures, including technological advancements, evolving industry standards, and changing regulatory requirements.

 

Our failure to accurately predict changes in consumer demand and technological advancements could negatively impact consumer opinion of our products or our business. In addition, if we do not introduce new products or make enhancements to meet the changing needs of our customers in a cost-effective, timely, and commercially appropriate manner, or if our competitors release new products or product enhancements before we do, some of our product offerings could be rendered obsolete, which could cause our market share to decline and negatively impact our business, financial condition, and operating results.

 

If we fail to further penetrate existing markets, the sales of our consumer products, along with our operating results, could be negatively impacted.

 

The success of our consumer product business will be to a large extent contingent on our ability to penetrate existing markets, which is subject to numerous factors, many of which are out of our control. Moreover, our growth in existing markets will depend upon our ability to achieve brand awareness. Therefore, we cannot assure you that our general efforts to achieve market penetration in existing markets will be successful. If we are unable to further penetrate existing markets, our business, financial condition, and operating results could materially suffer.

 

We are subject to governmental regulations in all aspects of our business.

 

Like other companies in the healthcare industry, we are subject to extensive regulation, investigations and legal action, by national, state and local government agencies in the U.S. Regulatory issues regarding compliance with cGMP by manufacturers of medical devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of our products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of health care industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties.

 

As we continue to develop our medical devices, if we fail to protect our intellectual property in the future, our ability to compete could be negatively affected, which could materially harm our financial condition and operating results.

 

As we continue to develop our medical devices, such as NEXDrape, our future success and the market for our products will depend to a significant extent upon the goodwill associated with our trademark and tradenames and our ability to protect our proprietary rights in our innovative products and product enhancements. We own, or have licenses to use, the material trademark and trade name rights used in connection with the packaging, marketing, and distribution of our products in the markets where those products are sold. Therefore, trademark and trade name protection are important to our business. Although most of our trademarks are filed in the United States, we may not be successful in asserting trademark or trade name protection or obtaining new trademark registrations.

 

12

 

We will attempt to protect our innovative products and product enhancements under a combination of patents, trademarks, and trade secret laws, confidentiality procedures, and contractual provisions. However, monitoring infringement or misappropriation of intellectual property can be difficult and expensive, and we may not be able to detect every infringement or misappropriation of our proprietary rights or to prevent third parties from infringing upon or misappropriating our proprietary rights or from independently developing non-infringing products that are competitive with, equivalent to, or superior to our products. Even if we do detect infringement or misappropriation of our proprietary rights, litigation to enforce these rights could cause us to divert financial and other resources away from our business operations and may result in the impairment or loss of all or portions of our proprietary rights. As a result, we cannot assure you that we will be able to adequately protect our intellectual property in any jurisdiction. The loss or infringement of our trademarks, tradenames, or other proprietary rights could impair the goodwill associated with our brands and harm our reputation, which could materially harm our business, financial condition, and operating results.

 

We have limited sales, marketing and distribution capabilities.

 

We currently have limited sales, marketing and distribution capabilities. We must either develop our own sales, marketing and distribution capabilities, which will be expensive and time-consuming, or make arrangements with third parties to perform these services for us. If we enter into third party arrangements, the third parties may not be capable of successfully selling any of our products. If we decide to market any of our products on our own, we will have to commit significant resources to developing a marketing and sales force and supporting distribution capabilities. If we decide to enter into arrangements with third parties for performance of these services, we may find that they are not available on terms acceptable to us, or at all. If we are not able to establish and maintain successful arrangements with third parties or build our own sales and marketing infrastructure, our business and financial condition will be adversely affected.

 

Our products risk exposure to product liability claims.

 

We are exposed to potential product liability risks, which are inherent in the testing, manufacturing and marketing of our products. We may incur significant expense investigating and defending any product liability claims, even if they do not result in liability. Moreover, even if no judgments, fines, damages or liabilities are imposed on us, our reputation could suffer, which could have a material adverse effect on our business, financial condition and results of operations.

 

We are reliant upon two manufacturers for key ingredients used to manufacture of our hydrogels.

 

The Dow Chemical Company and the BASF Corporation are the principal manufacturers of the two polymers, polyethylene oxide and polyvinylpyrrolidone, respectively, that we primarily use in the manufacture of hydrogels. Although we have not experienced significant production delays attributable to supply changes, we believe that developing alternative sources of supply for the polymers used to make our current hydrogels would be difficult over a short period of time. Because we have no direct control over its third-party suppliers, interruptions or delays in the products and services provided by these third parties may be difficult to remedy in a timely fashion. In addition, if such suppliers are unable or unwilling to deliver the necessary raw materials or products, we may be unable to redesign or adapt our technology to work without such raw materials or products or find alternative suppliers or manufacturers. In such events, we could experience interruptions, delays, increased costs or quality control problems, which would have a material and adverse effect on our business, results of operations and financial condition.

 

There can be no assurance that our internal controls over financial reporting will be able to detect fraud or other issues.

 

We will be required under the Sarbanes-Oxley Act of 2002 to include a report of management on our internal controls that contains an assessment by management of the effectiveness of our internal control over financial reporting. Because and so long as we are an emerging growth company, our public accounting firm auditing our financial statements will not be required to report on the effectiveness of internal control over financial reporting, and our stockholders will not have the benefit thereof. Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. However, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. There can be no assurance that all control issues or fraud will be detected. In connection with the Merger, and as we continue to grow our business, our internal controls continue to become more complex and require more resources.

 

13

 

Our ability to provide customers with competitive services is dependent on our ability to attract and retain qualified personnel, including our senior management team.

 

Our ability to grow and provide our customers with competitive services is partially dependent on our ability to attract and retain highly motivated people with the skills necessary to serve our customers. Personnel with the requisite skills or qualifications may be in short supply or generally unavailable. The loss of personnel could impair our ability to perform under certain contracts, which could have a material adverse effect on our consolidated financial position, results of operations, prospects and cash flows.

 

Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results or financial condition.

 

GAAP and related accounting pronouncements, implementation guidelines and interpretations with regard to a wide range of matters that are relevant to our business, including but not limited to revenue recognition, business combinations, impairment of goodwill, indefinite-lived intangible assets and long-lived assets, inventory and equity-based compensation, are highly complex and involve many subjective assumptions, estimates and judgments. Changes in these rules or their interpretation or changes in underlying assumptions, estimates or judgments could significantly change our reported or expected financial performance or financial condition.

 

Our ability to pursue strategic partnerships may impact our ability to compete in the markets we serve or desire to enter.

 

We have entered into, and expect to seek to enter into, additional strategic partnerships with other industry participants as part of an effort to expand our business. However, we may be unable to identify attractive strategic partnership candidates or complete such partnerships on terms favorable to us. In addition, if we are unable to successfully implement our partnership strategies or our strategic partners do not fulfill their obligations or otherwise do not prove advantageous to our business, our investments in such partnerships and our anticipated business expansion could be adversely affected.

 

Achieving our growth objectives may prove unsuccessful. We may be unable to identify future attractive strategic partnerships, which may adversely affect our growth. In addition, our ability to consummate or implement our strategic partnerships may be materially and adversely affected.

 

Risks Relating to our Common Stock and Capital Structure

 

An active trading market may not develop or be sustained, and our stock price may fluctuate significantly once we do trade.

 

Our common stock and certain of our warrants trade on The Nasdaq Capital Market under the symbols “NXGL” and “NXGLW,” respectively.

 

We cannot predict the prices at which our common stock may trade. The market price of our common stock may fluctuate widely, depending on many factors, some of which may be beyond our control, including:

 

  ● actual or anticipated fluctuations in our operating results due to factors related to our business;
  ● success or failure of our business strategies;
  ● our quarterly or annual earnings, or those of other companies in our industry;
  ● our ability to obtain financing as needed;
  ● announcements by us or our competitors of significant acquisitions or dispositions;
  ● changes in accounting standards, policies, guidance, interpretations or principles;
  ● the failure of securities analysts to cover our common stock after we commence trading;
  ● changes in earnings estimates by securities analysts or our ability to meet those estimates;
  ● the operating and stock price performance of other comparable companies;
  ● overall market fluctuations;
  ● results from any material litigation or government investigation;
  ● changes in laws and regulations (including tax laws and regulations) affecting our business;

 

14

 

  ● changes in capital gains taxes and taxes on dividends affecting stockholders; and
  ● general economic conditions and other external factors, including wars such as the current conflict in Ukraine and other geopolitical risks.

 

Furthermore, our business profile and market capitalization may not fit the investment objectives of some of our stockholders and, as a result, these stockholders may sell their shares of our common stock if we are able to list our common stock on The Nasdaq Capital Market. Substantial sales of our common stock may occur, which could cause our stock price to decline. Low trading volume for our stock, which may occur if an active trading market does not develop, among other reasons, would amplify the effect of the above factors on our stock price volatility.

 

Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock and warrants.

 

If we fail to continue to satisfy the continued listing requirements of The Nasdaq Stock Market, LLC such as the corporate governance requirements, the stockholder’s equity requirement or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock and warrants. Such a delisting or even notification of failure to comply with such requirements would likely have a negative effect on the price of our common stock and warrants and would impair your ability to sell or purchase our common stock and warrants when you wish to do so. In the event of a delisting, we expect that we would take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock and warrants to become listed again, stabilize the market price or improve the liquidity of our common stock and warrants, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

We cannot assure you that we will pay dividends on our common stock, and our indebtedness may limit our ability to pay dividends on our common stock.

 

The timing, declaration, amount and payment of future dividends to stockholders will fall within the discretion of our Board of Directors. Our Board of Directors’ decisions regarding the payment of future dividends will depend on many factors, including our financial condition, earnings, capital requirements of our business and covenants associated with debt obligations, as well as legal requirements, regulatory constraints, industry practice and other factors that our Board of Directors deems relevant. There can be no assurance that we will pay a dividend in the future or continue to pay any dividend if we do commence paying dividends.

 

The interests of our principal stockholders, officers and directors, who collectively beneficially own approximately 27% of our stock, may not coincide with yours and such stockholders will have the ability to control decisions with which you may disagree.

 

As of April 10, 2024, our principal stockholders, officers and directors beneficially owned approximately 27% of our common stock. As a result, our principal stockholders, officers and directors will have the ability to substantially influence matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control of our company and make some future transactions more difficult or impossible without the support of our controlling stockholders. The interests of such stockholders may not coincide with your interests or the interests of other stockholders.

 

If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business may be harmed and our stock price may be adversely impacted.

 

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and to effectively prevent fraud. Any inability to provide reliable financial reports or to prevent fraud could harm our business. The Sarbanes-Oxley Act requires management to evaluate and assess the effectiveness of our internal control over financial reporting. In order to continue to comply with the requirements of the Sarbanes-Oxley Act, we are required to continuously evaluate and, where appropriate, enhance our policies, procedures and internal controls. If we fail to maintain the adequacy of our internal controls over financial reporting, we could be subject to litigation or regulatory scrutiny and investors could lose confidence in the accuracy and completeness of our financial reports. We cannot assure you that in the future we will be able to fully comply with the requirements of the Sarbanes-Oxley Act or that management will conclude that our internal control over financial reporting is effective. If we fail to fully comply with the requirements of the Sarbanes-Oxley Act, our business may be harmed and our stock price may decline.

 

15

 

If securities or industry analysts do not publish research about our business, or publish negative reports about our business, our share price and trading volume could decline.

 

The trading market for our common stock, to some extent, may at some point depend on the research and reports that securities or industry analysts publish about our business. We do not have any control over these analysts. If one or more of the analysts elect to cover us and downgrade our shares or lower their opinion of our shares, our share price would likely decline. If one or more of these analysts elect to cover us and subsequently cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

 

Future sales or potential sales of our common stock in the public market could cause our share price to decline.

 

If the existing holders of our common stock, particularly our directors and officers, sell a large number of shares, they could adversely affect the market price for our common stock. Sales of substantial amounts of our common stock in the public market, or the perception that these sales could occur, could cause the market price of our common stock to decline.

 

We may issue additional securities in the future upon conversion or exercise of outstanding securities which would result in dilution to our stockholders.

 

As described elsewhere in this Form 10-K, we have previously issued warrants, restricted stock units, and stock options to fund our operations, pay for services rendered and incentivize our employees and directors. The conversion or exercise of these securities would result in substantial dilution to our stockholders. As of the date of the filing of this Form 10-K, we may be required to issue:

 

  ● 560,650 shares of common stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $2.350742 per share;
     
  ● 3,442,904 shares of common stock issuable upon the exercise of warrants at a weighted average exercise price of approximately $5.42034; and
     
  ● 50,812 shares of restricted common stock issuable upon vesting and another 13,750 shares of vested shares of restricted common stock.

 

We are an “emerging growth company” and a “smaller reporting company” and may elect to comply with reduced public company reporting requirements applicable to emerging growth companies, and are subject to lesser public company reporting requirements applicable to smaller reporting companies, which could make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.” We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the fifth anniversary of the Distribution; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a “large accelerated filer” under the Exchange Act. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. In addition, we are a “smaller reporting company” and accordingly are required to provide less public disclosure than larger public companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

16

 

We will incur costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.

 

As a public reporting company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act and rules subsequently implemented by the SEC, have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will entail significant legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept low policy limits and coverage.

 

Provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and of Delaware law may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.

 

Several provisions of our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and Delaware law may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable. These include provisions that:

 

  ● permit us to issue blank check preferred stock as more fully described under “Description of Our Capital Stock Anti-Takeover Effects of Various Provisions of Delaware Law and Our Amended and Restated Articles of Incorporation and Amended and Restated Bylaws”;
  ● require stockholders to follow certain advance notice and disclosure requirements in order to propose business or nominate directors at an annual or special meeting; and
  ● limit our ability to enter into business combination transactions with certain stockholders.

 

These and other provisions of our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and Delaware law may discourage, delay or prevent certain types of transactions involving an actual or a threatened acquisition or change in control of us, including unsolicited takeover attempts, even though the transaction may offer our stockholders the opportunity to sell their shares of our common stock at a price above the prevailing market price. See “Description of Our Capital Stock Anti-Takeover Effects of Various Provisions of Delaware Law and Our Amended and Restated Articles of Incorporation and Amended and Restated Bylaws” for more information.

 

Our Amended and Restated Bylaws include a forum selection clause, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

 

Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any internal corporate claims within the meaning of the Delaware General Corporation Law (“DGCL”), (ii) any derivative action or proceeding brought on our behalf, (iii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or employees to us or to our stockholders, or (iv) any action asserting a claim arising pursuant to any provision of the DGCL, will be a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware). Specifically, the sole and exclusive forum for such legal actions shall be (i) first, the Court of Chancery of the State of Delaware, (ii) second, if the Court of Chancery of the State of Delaware lacks jurisdiction, the Superior Court of the State of Delaware, or (iii) third, if the Superior Court of the State of Delaware lacks jurisdiction, the United States District Court for the District of Delaware, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. This exclusive forum provision will apply to state and federal law claims, including claims under the federal securities laws (including actions arising under the Exchange Act or the Securities Act), although our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities Act, however, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under federal securities laws. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing provisions. This forum selection provision in our bylaws may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us. It is also possible that, notwithstanding the forum selection clause included in our bylaws, a court could rule that such a provision is inapplicable or unenforceable.

 

17

 

Item 1B. Unresolved Staff Comments

 

None.

 

Item 1C. Cybersecurity

 

Cybersecurity Risk Management and Strategy

 

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.

 

We have implemented a number of security measures designed to protect our systems and data, including firewalls, antivirus and malware detection tools, patches, log monitors, and routine back-ups,. In addition, we have continued our efforts to migrate our platforms to cloud-based computing, which is designed to further strengthen our security posture.

 

Our cybersecurity risk management program is integrated into our overall enterprise risk management program and shares common methodologies, reporting channels, and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.

 

Our cybersecurity risk management program includes the following:

 

  ● the use of external service providers, where appropriate, to assess, test, or otherwise assist with aspects of our security controls;
     
  ● cybersecurity awareness training of our employees, incident response personnel, and senior management; and

 

There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.

 

Cybersecurity Governance

 

Our Board considers cybersecurity risks as part of its risk oversight.

 

The Board oversees management’s implementation of our cybersecurity risk management program and receives updates on the cybersecurity risk management program from management at least annually. In addition, management updates the Board regarding any material or significant cybersecurity incidents, as well as incidents with lesser impact potential as necessary.

 

Ongoing Risks

 

We have not experienced any material cybersecurity incidents. We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition.

 

Incident Response and Assessment Policies and Procedures

 

We align with industry-standard cybersecurity frameworks designed to protect the company and customer data from unintentional disclosure, cybersecurity events, and other threats of all severity levels. As part of our alignment with these frameworks we are in the process of implementing a Cybersecurity Incident Response Plan that outlines actions to be taken after identifying a suspected information security breach and the people responsible for managing those actions. Additionally, this plan will outline communication responsibilities during incidents of all severity levels.

 

Item 2. Properties

 

We maintain a combined corporate office and manufacturing facility in Langhorne, Pennsylvania, where we lease approximately 16,500 square feet of office and manufacturing space which expires on January 31, 2031. In addition, we sublease approximately 6,200 square feet of a 12,000 square foot combined office and manufacturing facility in Granbury, Texas for our JV. The lease expires in March 2028. We believe that our facilities are well maintained and are suitable and adequate for our current needs.

 

Item 3. Legal Proceedings

 

From time to time, we may become involved in lawsuits, investigations and claims that arise in the ordinary course of business. As of the date of this information statement, we are not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would materially affect our financial position, results of operations or cash flows.

 

Item 4. Mine Safety Disclosure

 

Not applicable.

 

18

 

Part II

 

Item 5. Market for the Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock is traded on NASDAQ Capital Markets under the symbol “NXGL” and certain warrants to purchase our common stock issued on December 27, 2021 are trade on NASDAQ Capital Markets under the symbol “NXGLW.”

 

Holders

 

As of April 10, 2024, there were over 1,074 shareholders of record and 6,227,624 shares of common stock outstanding.

 

On November 29, 2021, we effected a 1-for-35 reverse stock split of our issued and outstanding common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, each issued and outstanding share of our common stock, and the per share exercise price of and number of shares of our common stock underlying our outstanding equity awards and warrants, was automatically proportionally adjusted based on the 1-for-35 Reverse Stock Split ratio. No fractional shares of common stock were issued in connection with the reverse stock split, and all such fractional interests were rounded up to the nearest whole number.

 

Sales of Unregistered Securities during the Fiscal Year Ended December 31, 2023

 

The Company did not sell any unregistered securities during the fiscal year ended December 31, 2023.

 

Issuer Repurchases of Securities during the Fiscal Year Ended December 31, 2023

 

The Company did not repurchase any of its securities during the fiscal year ended December 31, 2023.

 

Item 6. [Reserved]

 

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis are intended to help prospective investors understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this information statement.

 

The statements in this discussion regarding industry outlook, expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in “Special Note Regarding Forward-Looking Statements.” Actual results may differ materially from those contained in any forward-looking statements.

 

The NexGel Financial Statements, discussed below, reflect the NexGel financial condition, results of operations, and cash flows. The financial information discussed below and included in this information statement, however, may not necessarily reflect what the NexGel financial condition, results of operations, or cash flows would have been had NexGel been operated as a separate, independent entity during the years presented, or what the NexGel financial condition, results of operations, and cash flows may be in the future.

 

Overview

 

We manufacture high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. We specialize in custom gels by capitalizing on proprietary manufacturing technologies. We have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the company. First, our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture.

 

Joint Venture

 

On March 1, 2023, the Company acquired a 50% interest in its newly formed JV for its converting and packaging business. The JV agreement is effective March 1, 2023. As a result of this transaction, the Company owns 50% of the JV, with the remaining 50% held by CG Labs.

 

19

 

Acquisition

 

On December 1, 2023, we purchased substantially all of the assets Olympus Trading Company, LLC (the “Seller”) related to the Seller’s skincare line focused on reducing symptoms associated with psoriasis operating under the tradename “Kenkoderm” (“Kenkoderm acquisition”).

 

Under the terms of the Kenkoderm acquisition, the Company paid the Seller a cash payment of $546,500.

 

Additionally, the Company shall pay the Seller a cash earn-out of the same amount each quarter, payable in the subsequent month flowing quarter end, of $136,625. The cash earn-out can fluctuate higher or lower based on the quarterly results of the Kenkoderm business during 2024 according to the formula contained in the Asset Purchase Agreement relating to the Kenkoderm acquisition.

 

Results of Operations

 

The following sections discuss and analyze the changes in the significant line items in our statements of operations for the comparison years identified.

 

Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022 ($ in thousands)

 

Revenues, net

 

For the year ended December 31, 2023 revenues were $4,089 and increased by $2,041, or 99.7%, when compared to $2,048 for the year ended December 31, 2022. The increase in our overall revenues was primarily due to sales growth in both our contract manufacturing and branded products, including revenue from the JV from March 1, 2023 through December 31, 2023 of $1,987.

 

The Company has four distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices/Other.

 

Contract Manufacturing

 

Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they package into finished goods. Historically, this has been the Company’s primary source of revenue.

 

Custom & White Label

 

These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.

 

Consumer Branded Products

 

These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names.

 

Medical Devices/Other

 

Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.

 

Gross profit (loss) Our gross profit was $619 for the year ended December 31, 2023 compared to a gross profit of $256 for the year ended December 31, 2022. The increase in the profit recorded for the year ended December 31, 2023, as compared to December 31, 2022, directly correlates to our higher sales. Gross profit was approximately 15.1% for the year ended December 31, 2023 compared to a gross profit of 12.5% for the year ended December 31, 2022.

 

20

 

The components of cost of revenues are as follows for the years ended December 31, 2023 and 2022 ($ in thousands):

 

   Year Ended December 31, 
   2023   2022 
Cost of revenues          
Materials and finished products  $2,147   $541 
Compensation and benefits   451    702 
Share-based compensation   14    - 
Depreciation and amortization   103    83 
Equipment, production and other expenses   755    466 
Total cost of revenues  $3,470   $1,792 

 

Cost of revenues increased by $1,678, or 93.6 %, to $3,470 for the year ended December 31, 2023, as compared to $1,792 for the year ended December 31, 2022. The increase in cost of revenues pertains to an increase in materials and finished products and equipment, production, and other expenses. These increases primarily align with the increased revenues.

 

Selling, general and administrative expenses. The following table highlights selling, general and administrative expenses by type for the years ended December 31, 2023 and 2022 ($ in thousands):

 

   Year Ended December 31, 
   2023   2022 
Selling, general and administrative expenses          
Compensation and benefits  $740   $526 
Share-based compensation   203    282 
Depreciation and amortization   126    16 
Advertising, marketing, and Amazon fees   620    436 
Investor and shareholder services   426    567 
Franchise taxes and corporate insurance   224    405 
Professional and consulting fees   1,339    643 
Other expenses and professional fees   315    362 
Total selling, general and administrative expenses  $3,993   $3,237 

 

Selling, general and administrative expenses increased by $756, or 23.4%, to $3,993 for the year ended December 31, 2023, as compared to $3,237 for the year ended December 31, 2022. The increase in selling, general and administrative expenses is primarily attributable to an increase of compensation and benefits expense, advertising, marketing, and Amazon fees as well as the costs for professional and consulting fees.

 

Compensation and benefits increased by $214, or 40.7%, to $740 for the year ended December 31, 2023, as compared to $526 for the year ended December 31, 2022. The number of employees increased compared to the prior year with the inclusion of the JV.

 

Share-based compensation decreased by $79, or 28.0%, to $203 for the year ended December 31, 2023, as compared to $282 for the year ended December 31, 2022. The decrease in share-based compensation year over year relates to the issuance of stock, restricted stock, and options to our CEO and options to board members in 2023 in comparison to companywide restricted stock awards issued to employees in 2022.

 

21

 

Advertising, marketing, and Amazon fees increased by $184, or 42.20%, to $620 for the year ended December 31, 2023, as compared to $436 for the year ended December 31, 2022. The increase corresponds to increased Amazon sales, partially offset by optimization of Amazon advertising spend in 2023.

 

Investor and shareholder services decreased by $141, or 24.9%, to $426 for the year ended December 31, 2023, as compared to $567 for the year ended December 31, 2022. The decrease is due to the Company’s management of outsourced services.

 

Franchise taxes and corporate insurance decreased by $181, or 44.7%, to $224 for the year ended December 31, 2023, as compared to $405 for the year ended December 31, 2022. The vast majority of this decrease pertains to the Company’s reduction in authorized shares, which lowered its franchise tax expense.

 

Professional and consulting fees increased by $696, or 108.2%, to $1,339 for the year ended December 31, 2023, as compared to $643 for the year ended December 31, 2022. We incurred significant expenses related to our European Medical Device Regulation project in preparation for entering European markets.

 

Other expenses decreased by $47, or 13.0%, to $315 for the year ended December 31, 2023 from $362 for the year ended December 31, 2022. Other selling, general and administrative expenses generally consist of costs associated with our selling efforts and general management, including information technology, travel, training and recruiting.

 

Research and development expenses

 

Research and development expenses decreased by $264 to $103 for the year ended December 31, 2023 from $367 for the year ended December 31, 2022. The decrease is due to the completion of development efforts of two proof of concept studies for drug delivery candidates utilizing our hydrogel technology.

 

Liquidity and Capital Resources

 

Cash Flow (in thousands)

 

   Years Ended December 31, 
   2023   2022 
Net cash used in operating activities  $(3,236)  $(2,992)
Net cash provided by (used in) investing activities   4,456    (5,595)
Net cash provided by (used in) financing activities   379    (3,662)
Net increase (decrease) in cash and cash equivalents   1,599    (12,249)
Cash and cash equivalents at beginning of year   1,101    13,350 
Cash and cash equivalent at end of year  $2,700   $1,101 

 

As of December 31, 2023, we had $2,700 of cash and cash equivalents compared to $1,101 of cash and cash equivalents and $5,508 of marketable securities at December 31, 2022. Net cash used in operating activities was $3,236 and $2,992 for the years ended December 31, 2023 and 2022, respectively. See Notes 2 and 3 of the accompanying consolidated financial statements for a more detailed discussion of our marketable securities.

 

Net cash provided by investing activities was $4,456 million and net cash used in investing activities was $5,595 for the year ended December 31, 2023 and 2022, respectively, consisting of the sales of marketable securities of $5,699, offset by purchases of capital equipment of $696 and the Kenkoderm acquisition of $547 for the year ended December 31, 2023 and consisting of investments in marketable securities of $6,999, the sale of marketable securities for $1,500, and purchases of capital equipment of $96 for the year ended December 31, 2022.

 

Net cash provided by financing activities for year ended December 31, 2023 was $379 which is attributable to the proceeds of equipment notes payable of $315, proceeds from margin line of credit of $245, offset by principal payments of notes payments of $6 and payments of $175 made on the operating lease liability. Net cash used in financing activities for year ended December 31, 2022 was $3,662 which is attributable to the principal payments of convertible notes of $3,511 and payments of $151 made on the operating lease liability.

 

22

 

At December 31, 2023, current assets totaled $5,052 and current liabilities totaled $2,549, as compared to current assets totaling $7,505 and current liabilities totaling $859 at December 31, 2022. As a result, we had working capital of $2,503 at December 31, 2023, compared to a working capital of $6,646 at December 31, 2022. The decrease in the working capital as of December 31, 2023 is primarily attributable to the loss from operations of $3,477.

 

We have never declared or paid any cash dividends on our common stock. For the foreseeable future, we anticipate that all available funds and any earnings generated in our business will be used to finance the growth of our business and will not be paid out as dividends to our shareholders. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board of Directors may deem relevant.

 

Management is exploring new product channel sales in consumer products, such as cosmetics, athletic products, and proprietary medical devices. The Company has increased its focus on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.

 

We have sufficient capital to maintain as a going concern due to the recent capital raise on February 14, 2024 (discussed further within Note 20). We believe we have sufficient cash and marketable securities to operate our business plan into 2025. We intend to maintain and attempt to grow our existing contract manufacturing business. We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media, television and online marketplaces. Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology. Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.

 

We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.

 

Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.

 

Off Balance Sheet Arrangements

 

As of December 31, 2023, we had no off-balance sheet arrangements in the nature of guarantee contracts, retained or contingent interests in assets transferred to entities (or similar arrangements serving as credit, liquidity or market risk support to entities for any such assets), or obligations (including contingent obligations) arising out of variable interests in entities providing financing, liquidity, market risk or credit risk support to us, or that engage in leasing, hedging or research and development services with us.

 

Critical Accounting Policies and Estimates

 

The preparation of our accompanying consolidated financial statements in accordance with generally accepted accounting principles is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider the accounting policies discussed below to be critical to the understanding of our Financial Statements. Actual results could differ from our estimates and assumptions, and any such differences could be material to our Financial Statements.

 

23

 

Share-based compensation – We utilize share-based compensation in the form of incentive stock options. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. The expected term of the awards granted is estimated using the simplified method which computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.

 

Warrant Liability – Warrants to purchase common stock were issued in connection with equity financing raises which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair value of the warrant is recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations. The expected term of the awards granted are based on either the three-year or five-year contractual expiration date.

 

Black Scholes Inputs - The fair value of each stock option award and warrant issued was estimated on the date of grant using a Black-Scholes option-valuation model, which requires management to make certain assumptions regarding: (i) fair value of the common stock that underlies the stock option; (ii) the expected volatility in the market price of our common stock; (iii) dividend yield; (iv) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected term). Under the Black-Scholes option-valuation model, entities typically estimate the expected volatility based on historical volatilities of the entity’s own common stock. Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage. The fair value of the common stock that underlies the stock option is estimated by the Company considering the price of the most recent issuance of the Company’s common stock. The dividend yield is based upon the assumption that the Company will not declare a dividend over the life of the options. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the expected term of the related award.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required.

 

24

 

Item 8. Financial Statements and Supplementary Data

 

FINANCIAL STATEMENTS - TABLE OF CONTENTS

For the Years Ended December 31, 2023 and 2022

 

  Page(s)
Report of Independent Registered Public Accounting Firm (PCAOB ID: 76) F-2
   
Consolidated Financial Statements:  
   
Consolidated Balance Sheets at December 31, 2023 and 2022 F-3
   
Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 F-4
   
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022 F-5
   
Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F-6
   
Notes to Consolidated Financial Statements F-7

 

F-1

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Board of Directors and Shareholders of

NexGel, Inc.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of NexGel, Inc. (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Turner, Stone & Company, L.L.P.

 

Dallas, Texas

April 9, 2024

 

We have served as the Company’s auditor since 2019.

 

F-2

 

NEXGEL, INC

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

   December 31, 2023   December 31, 2022 
ASSETS:          
Current Assets:          
Cash  $2,700   $1,101 
Marketable securities   -    5,508 
Accounts receivable, net   633    222 
Inventory   1,319    502 
Prepaid expenses and other current assets   400    172 
Total current assets   5,052    7,505 
Goodwill   1,128    311 
Intangibles, net   326    20 
Property and equipment, net   1,499    721 
Operating lease - right of use asset   1,855    1,737 
Other assets   95    63 
Total assets  $9,955   $10,357 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Accounts payable  $1,233   $265 
Accrued expenses and other current liabilities   398    130 
Deferred revenue   20    - 
Current portion of note payable   80    15 
Warrant liability   146    242 
Contingent consideration liability   439    - 
Operating lease liability, current portion   233    207 
Total current liabilities   2,549    859 
Operating lease liability, net of current portion   1,727    1,593 
Notes payable, net of current portion   513    268 
Total liabilities   4,789    2,720 
           
Commitments and Contingencies (Note 16)   -    - 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding   -    - 
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,741,838 and 5,577,916 shares issued and outstanding as of December 31, 2023 and 2022, respectively   6    6 
Additional paid-in capital   19,406    19,189 
Accumulated deficit   (14,715)   (11,558)
Total NexGel stockholders’ equity   4,697    7,637 
Non-controlling interest in joint venture   469    - 
Total stockholders’ equity   5,166    7,637 
Total liabilities and stockholders’ equity  $9,955   $10,357 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

NEXGEL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
Revenues, net  $4,089   $2,048 
           
Cost of revenues   3,470    1,792 
           
Gross profit   619    256 
           
Operating expenses          
Research and development   103    367 
Selling, general and administrative   3,993    3,237 
Total operating expenses   4,096    3,604 
           
Loss from operations   (3,477)   (3,348)
           
Other income (expense)          
Change in fair value of warrant liability, net of warrant modification expense   96    76 
Realized gain on investments in marketable securities   191    9 
Loss on debt extinguishment   -    (150)
Interest expense, net   (15)   (1,336)
Other expense   (2)   - 
Other income   19    3 
Total other income (expense), net   289    (1,398)
Loss before income taxes  (3,188)  (4,746)
Income tax expense   -    - 
Net loss   (3,188)   (4,746)
Less: Loss attributable to non-controlling interest in joint venture   31    - 
Net loss attributable to NexGel stockholders  $(3,157)  $(4,746)
           
Net loss per common share – basic and diluted  $(0.56)  $(0.85)
           
Weighted average shares used in computing net loss per common share – basic and diluted   5,671,842    5,574,818 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

NEXGEL, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Years Ended December 31, 2023 and 2022

(in thousands, except share data)

 

   Shares   Amount   Capital   Interest   Deficit   Equity 
   Common Stock  

Additional

Paid-in

  

Non-

controlling

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Interest   Deficit   Equity 
Balance, December 31, 2021   5,572,234   $    6   $18,891   $     -   $(6,812)  $  12,085 
                               
Stock-based compensation   -    -    231    -    -    231 
                               
Restricted stock vesting   5,682    -    67    -    -    67 
                               
Net loss   -    -    -    -    (4,746)   (4,746)
                               
Balance, December 31, 2022   5,577,916   $6   $19,189   $-   $(11,558)  $7,637 

 

   Common Stock  

Additional

Paid-in

  

Non-

controlling

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Interest   Deficit   Equity 
Balance, December 31, 2022   5,577,916   $   6   $19,189   $-   $(11,558)  $   7,637 
                               
Stock-based compensation   3,295    -    217    -    -    217 
                               
Restricted stock issuances   50,907    -    -    -    -    - 
                               
Exercise of warrants   109,720    -    -    -    -    - 
                               
Non-controlling interest contribution   -    -    -    500    -    500 
                               
Net loss   -    -    -    (31)   (3,157)   (3,188)
                               
Balance, December 31, 2023   5,741,838   $6   $19,406   $469   $(14,715)  $5,166 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

NEXGEL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
Operating Activities          
Net loss  $(3,157)  $(4,746)
Adjustments to reconcile net loss to net cash used in operating activities:          
Loss attributable to non-controlling interest in joint venture   (31)   - 
Depreciation and amortization   226    112 
Share-based compensation   217    298 
Realized gain on investment in marketable securities   (191)   (9)
Change in fair value of warrant liability   (125)   (133)
Amortization of right of use asset   217    189 
Warrant modification expense   29    57 
Loss of extinguishment of debt   -    150 
Amortization of deferred financing costs   -    1,324 
           
Changes in operating assets and liabilities:          
Accounts receivable, net   (411)   (13)
Inventory   (760)   (211)
Prepaid expenses and other current assets   (260)   (95)
Accounts payable   968    11 
Accrued expenses and other current liabilities   22    74 
Deferred revenue   20    - 
Net Cash Used in Operating Activities   (3,236)   (2,992)
           
Investing Activities          
Purchases of equipment   (696)   (96)
Investment in subsidiary   (547)   - 
Proceeds from sales of marketable securities   5,699    1,500 
Investments in or purchases of marketable securities   -    (6,999)
Net Cash Provided by (Used in) Investing Activities   4,456    (5,595)
           
Financing Activities          
Principal payments on operating lease liability   (175)   (151)
Proceeds from notes payable   315    - 
Principal payments of notes payable   (6)   - 
Principal payments on convertible notes   -    (3,511)
Proceeds from margin line of credit   245    - 
Net Cash Provided by (Used in) Financing Activities   379    (3,662)
           
Net Increase (Decrease) in Cash   1,599    (12,249)
Cash  – Beginning of year   1,101    13,350 
Cash – End of year  $2,700   $1,101 
           
Supplemental Non-cash Investing and Financing Activities          
Property and equipment and intangibles contributed as capital investment to JV  $500   $- 
ROU asset and operating lease liabilities recognized upon consolidation of JV  $334   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

NEXGEL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

 

1. Description of Business, Stock Split and Basis of Presentation

 

NexGel, Inc. (“NexGel” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the company. First, we launched our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture.

 

NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019.

 

On March 1, 2023, the Company acquired a 50% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC, with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business. The JV is effective March 1, 2023. As a result of this transaction, the Company owns 50% of the JV, with the remaining 50% held by CG Labs.

 

Basis of Presentation

 

The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and are presented in US dollars.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its consolidated wholly-owned subsidiary, NexGelRx, Inc. and the fifty percent (50%) owned JV (see Note 13).

 

F-7

 

2. Going Concern

 

As of December 31, 2023, the Company had a cash balance of $2.7 million. For the year ended December 31, 2023, the Company incurred a net loss of $3.2 million and had a net usage of cash in operating activities of $3.2 million. In addition, the Company had a working capital of $2.5 million as of December 31, 2023. Additionally, we believe we have sufficient cash and marketable securities to operate our business plan into 2025.

 

On February 15, 2024, the Company, entered into subscription agreements with investors, the Company’s Chief Financial Officer and certain members of its board of directors for a registered direct offering (“RDO”) of the Company’s common stock. The RDO sold an aggregate 242,891 units at a price to the public of $4.22 per unit, with each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $4.00 per share. The $4.22 purchase price equals two times the last reported sale price of $2.11 per share of the Company’s Common Stock on February 15, 2024 on The Nasdaq Capital Market. The gross proceeds to the Company from the Offering are expected to be approximately $1.025 million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering for working capital and for general corporate purposes (See Note 20).

 

Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices. The Company has increased focus on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.

 

We have sufficient capital to maintain as a going concern due to the recent capital raise. We intend to maintain and attempt to grow our existing contract manufacturing business. We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media, television and online marketplaces. Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology. Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.

 

We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.

 

3. Significant Accounting Policies and Estimates

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.

 

F-8

 

Segment Reporting

 

The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, Segment Reporting, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company has two reportable segments - the Nexgel segment and the CG labs segment.

 

The Nexgel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania.

 

The CG labs segment is comprised of the JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.

 

Cash

 

Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.

 

Marketable Securities

 

The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs.

 

The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Marketable Securities          
United States treasury bills (due February 23, 2023)  $      -   $492 
United States treasury bills (due April 27, 2023)   -    20 
United States treasury bills (due June 15, 2023)   -    4,384 
United States treasury bills (due July 13, 2023)   -    127 
United States treasury bills (due August 10, 2023)   -    485 
Total  $-   $5,508 

 

Margin Line of Credit

 

We have a brokerage account through which we buy and sell U.S. treasury bills. The provisions of the account allow us to borrow on certain securities held in the account and to purchase additional securities based on the account equity (including cash). Amounts borrowed are collateralized by the securities held in the account and bear interest at a negotiated rate payable monthly. Securities pledged to secure margin balances cannot be specifically identified as a portion of all securities held in a brokerage account are used as collateral. As of December 31, 2023, there was $245 thousand outstanding under this short-term credit line which is included in accrued expenses and other current liabilities within the accompanying consolidated balance sheet (see Note 10). The short-term credit line will be repaid upon the maturity of U.S. treasury bills of $3 million with an original maturity of three months or less which are included in cash within the accompanying consolidated balance sheet.

 

F-9

 

Accounts Receivable, net

 

Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $11 thousand as of December 31, 2023 and $9 thousand as of December 31, 2022.

 

Inventory and Cost of Revenues

 

Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value.

 

The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.

 

The balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS.

 

The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.

 

Research and Development

 

Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.

 

Shipping and Handling Revenue and Expense

 

Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. Shipping revenue and expense are primarily generated through the Amazon marketplace.

 

Property and Equipment, net

 

Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.

 

Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.

 

The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.

 

F-10

 

Impairment of Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.

 

Goodwill and Intangible Assets

 

In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value.

 

The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and no impairments were recognized in the years ended December 31, 2023 and 2022.

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $64 thousand and $63 thousand of prepaid insurance, and $336 thousand and $109 thousand general prepaid expenses and other current assets in the years ended December 31, 2023 and 2022 respectively.

 

Other Assets

 

Other Assets is recorded at historical costs, and as of December 31, 2023 and 2022, the balance is primarily comprised of spare parts for manufacturing equipment. Spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.

 

Fair Value Measurements

 

The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

Level 1 —Quoted prices for identical assets or liabilities in active markets.

 

Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.

 

F-11

 

The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.

 

The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2023     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                    
Marketable securities:                    
United States treasury bills  $-   $-   $-   $- 
Total  $-   $-   $-   $- 

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2022     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                
Marketable securities:                    
United States treasury bills  $5,508   $-   $-   $5,508 
Total  $5,508   $-   $-   $5,508 

 

Warrant Liability

 

Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.

 

Revenue Recognition

 

On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption.

 

The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product.

 

The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment.

 

F-12

 

Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.

 

Disaggregated revenue by sales type ($ in thousands):

 

    2023     2022  
    Year Ended  
    December 31,  
    2023     2022  
Contract manufacturing   $ 2,748     $ 1,033  
Custom and white label finished goods manufacturing     15       34  
Consumer branded products     1,242       815  
Other     84       166  
Total   $ 4,089     $ 2,048  

 

As of December 31, 2023 and 2022, the Company did not have any contract assets or contract liabilities from contracts with customers and there were no remaining performance obligations that the Company had not satisfied except for deferred revenue of $20 thousand at December 31, 2023 that the Company had not satisfied as of the end of the year. The Company had no remaining performance obligations as of December 31, 2022.

 

The Company has four distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices.

 

Contract Manufacturing

 

Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they convert and package into finished goods. Historically, this has been the Company’s primary source of revenue.

 

Custom and White Label

 

These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.

 

Consumer Branded Products

 

These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names.

 

Medical Devices/Other

 

Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.

 

Share-based Compensation

 

On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 12 below for further details regarding the 2019 Plan.

 

F-13

 

The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.

 

Leases

 

ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.

 

The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.

 

Variable Interest Entity

 

The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.

 

If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. As of December 31, 2023, and on a quarterly basis thereafter, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.

 

Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.

 

F-14

 

Comprehensive loss

 

Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented.

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

 

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023 and subsequent interim periods. The Company adopted this new standard in the current year and it did not have a material impact to its consolidated financial statements.

 

Accounting Pronouncements Issued But Not Yet Adopted

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced income tax related disclosures. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures relating to its reportable segments. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

F-15

 

4. Business Segments

 

The Company’s Chief Executive Officer, who serves as the chief operating decision maker (“CODM”), evaluates the financial performance of the Company’s segments based upon segment adjusted operating income or (loss) as the profitability measure. Items outside of adjusted operating income or (loss) are not reported by segment, since they are excluded from the single measure of segment profitability reviewed by the CODM.

 

Summarized financial information concerning the Company’s reportable segments for the years ended December 31, 2023 and 2022 is presented below.

 

For Year Ended December 31, 2023 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Revenue               
Contract Manufacturing  $769   $1,979   $2,748 
Custom and White Label Finished Goods   15    -    15 
Branded Consumer Products   1,242    -    1,242 
Other income   76    8    84 
Total revenue   2,102    1,987    4,089 
                
Cost of sales   1,911    1,559    3,470 
Operating expenses   3,604    492    4,096 
Loss from operations  $(3,413)  $(64)  $(3,477)

 

For Year Ended December 31, 2022 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Revenue               
Contract Manufacturing  $1,033   $-   $1,033 
Custom and White Label Finished Goods   34    -    34 
Branded Consumer Products   815    -    815 
Other income   166    -    166 
Total revenue   2,048    -    2,048 
                
Cost of sales   1,792    -    1,792 
Operating expenses   3,604    -    3,604 
Loss from operations  $(3,348)  $-   $(3,348)

 

As of December 31, 2023 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Assets:               
Current assets:               
Cash  $2,458   $242   $2,700 
Accounts receivable, net   26    607    633 
Inventory   622    697    1,319 
Prepaid expenses and other current assets   312    88    400 
Total current assets   3,418    1,634    5,052 
                
Goodwill   1,128    -    1,128 
Intangibles   122    204    326 
Property and equipment, net   898    601    1,499 
Operating lease – right of use asset   1,543    312    1,855 
Other assets   95    -    95 
Total Assets  $7,204   $2,751   $9,955 

 

Liabilities and Stockholders’ Equity            
Current liabilities:            
Accounts payable  $509   $724   $1,233 
Accrued expenses and other current liabilities   137    261    398 
Deferred revenue   20    -    20 
Current portion of note payable   6    74    80 
Warrant liability   146    -    146 
Contingent consideration liability   439    -    439 
Operating lease liability, current portion   207    26    233 
Total current liabilities   1,464    1,085    2,549 
                
Operating lease liability, net of current portion   1,438    289    1,727 
Notes payable, net of current portion   272    241    513 
Total liabilities  $3,174   $1,615   $4,789 

 

5. Acquisition

 

Kenkoderm Acquisition

 

On December 1, 2023, the Company closed a transaction related to an Asset Purchase Agreement dated November 30, 2023 (the “Purchase Agreement”) with Olympus Trading Company, LLC, a Virginia limited liability company (the “Seller”), whereby the Company purchased all assets related to the Seller’s skincare line focused on reducing symptoms associated with psoriasis operating under the tradename “Kenkoderm” (“Kenkoderm acquisition”).

 

Under the terms of the Kenkoderm acquisition, the Company paid the Seller a cash payment of $546,500. Additionally, the Company shall pay the Seller a cash earn-out of the same amount each quarter, payable in the subsequent month flowing quarter end, of $136,625. The cash earn-out can fluctuate higher or lower based on the quarterly results of the Kenkoderm business during 2024 according to the formula contained in the Purchase Agreement.

 

The Purchase Agreement and the transaction contemplated thereby were not subject to approval by the shareholders of the Company. The Purchase Agreement contains standard representations and warranties regarding the Seller and the Kenkoderm business and certain limited representations and warranties regarding the Company. The Purchase Agreement also contains indemnification provisions for the benefit of the Company and the Seller. Neither the Company nor the Seller shall be liable for more than the Purchase Price under the indemnification provisions except in the case of fraud or willful misconduct. The Seller and the Seller’s President and owner agreed to 3-year non-compete provisions as part of the Purchase Agreement.

 

F-16

 

The provisional fair value of the purchase consideration issued to the Seller was allocated to the net tangible assets acquired. The Company accounted for the Kenkoderm acquisition as the purchase of a business under GAAP under the acquisition method of accounting, and the assets and liabilities acquired were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company. The fair value of the net assets acquired was approximately $169 thousand. The excess of the aggregate fair value of the net tangible assets has been allocated to goodwill.

 

The table below shows a preliminary analysis for the Kenkoderm acquisition ($ in thousands):

 

Provisional purchase consideration at preliminary fair value:     
Purchase price  $547 
Contingent consideration liability   439 
Amount of consideration  $986 
Assets acquired and liabilities assumed at preliminary fair value     
Inventory   56 
Product/technology related intangibles   77 
Marketing related intangibles   36 
Other liabilities   - 
Net tangible assets acquired  $169 
      
Total net assets acquired  $169 
Consideration paid   986 
Preliminary goodwill  $817 

 

Non-controlling Interest in Joint Venture – CG Labs

 

On March 1, 2023, the Company acquired a 50% interest in the JV (see Note 1). The JV is owned 50% by the Company and 50% by CG Labs. CG Labs contributed its existing converting and packaging division to the JV, including, but not limited to, its facilities, equipment, employees, and customers. The Company will contribute $500,000 to the JV, on a schedule to be determined, to be used for equipment and facility upgrades as well as general corporate purposes for the JV. As of December 31, 2023, the Company has contributed its full $500,000 commitment.

 

The JV is considered to be a VIE and we have consolidated the JV.

 

F-17

 

The recorded assets acquired and liabilities assumed in connection with the formation of CG Labs based on their estimated fair values as of the March 1, 2023. The preliminary purchase price allocation is as follow ($ in thousands):

 

Provisional purchase consideration at preliminary fair value:     
Cash contributed by the Company  $500 
Noncontrolling interest portion of CG Labs contributed business   500 
Amount of consideration  $1,000 
Assets acquired and liabilities assumed at preliminary fair value     
Cash contributed by the Company   500 
Fixed assets   213 
Product/technology related intangibles   217 
Marketing related intangibles   70 
Net tangible assets acquired  $1,000 
      
Total net assets acquired  $1,000 
Consideration paid   1,000 
Preliminary goodwill  $- 

 

The allocation of the purchase price to identifiable assets is based on the preliminary valuations performed to determine the fair value of the net assets as of the acquisition date. The measurement period for the valuation of net assets acquired ends as soon as information on the facts and circumstances that existed as of the acquisition dates becomes available, but not to exceed 12 months following the acquisition date. Adjustments in purchase price allocations may require a change in the amounts allocated to net assets acquired during the periods in which the adjustments are determined.

 

The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the Kenkoderm acquisition and CG Labs JV been completed as of January 1, 2022 or to project potential operating results as of any future date or for any future periods ($ in thousands except share and per share amounts):

 Schedule of Unaudited Pro-Forma Results of Operations

   2023   2022 
  

For the Year Ended

December 31,

 
   2023   2022 
Revenues, net  $5,522   $4,014 
Net loss allocable to common shareholders  $(3,071)  $(4,634)
Net loss per share  $(0.54)  $(0.83)
Weighted average number of shares outstanding   5,671,842    5,574,818 

 

F-18

 

6. Leases

 

The Company has an operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania that runs through January 2031. There are two options that can extend the lease term for five years each. The exercise of the lease options to renew is solely at the Company’s discretion.

 

The Company also has a sublease for office and manufacturing space in Granbury, Texas that runs through February 2028.There is an option that can extend the lease term for an additional five years through February 2033. The exercise of the lease options to renew is solely at the Company’s discretion.

 

The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2023 ($ in thousands):

 

Maturity of Lease Liability 

Operating

Lease

Liability

 
2024  $245 
2025   245 
2026   301 
2027   315 
2028   324 
Thereafter   790 
Total undiscounted operating lease payments  $2,220 
Less: Imputed interest   (260)
Present value of operating lease liability  $1,960 
Weighted average remaining lease term   7.4 years 
Weighted average discount rate   3.0%

 

Total operating lease expense for the years ended December 31, 2023, and 2022, was $303 thousand and $246 thousand, respectively, and is recorded in cost of goods sold and selling, general, and administrative expenses in the accompanying consolidated statements of operations.

 

Supplemental cash flows information related to leases was as follows:

 

   December 31, 
   2023 
Cash paid for amounts included in the measurement of lease liability ($ in thousands):      
Operating cash flows from operating lease  $238 

 

7. Inventory

 

Inventory consists of the following ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Raw materials  $899   $295 
Work-in-progress   12    51 
Finished goods   408    156 
Inventory, gross   1,319    502 
Less: Inventory reserve for excess and slow moving inventory   -    - 
Total  $1,319   $502 

 

Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS. The Company builds its contract manufacturing products based on customer orders and immediately ships the products upon completion of the production process.

 

8. Property and Equipment, Net

 

Property and equipment consist of the following ($ in thousands):

 

   Useful Life   December 31,   December 31, 
   (Years)   2023   2022 
Machinery and equipment   3 - 10   $1,280   $973 
Office furniture and equipment   3 - 10    139    59 
Leasehold improvements   6    419    228 
Construction in progress   N/A    387    55 
Total property and equipment        2,225    1,315 
Less: accumulated depreciation and amortization        (726)   (594)
Property and equipment, net       $1,499   $721 

 

Depreciation expense for the year ended December 31, 2023 and 2022 was $132 thousand and $99 thousand, respectively.

 

F-19

 

9. Intangible Assets

 

The following provides a breakdown of identifiable intangible assets as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Product/Technology Related          
Identifiable intangible assets, gross  $325   $31 
Accumulated amortization   (98)   (26)
Product/technology related identifiable intangible assets, net   227    5 
Marketing Related          
Customer related intangible asset, gross   17    17 
Tradename related intangible asset, gross   113    7 
Accumulated amortization   (31)   (9)
Marketing related identifiable intangible assets, net   99    15 
Total identifiable intangible assets, net  $326   $20 

 

In connection with the May 29, 2020 acquisition of Sports Defense, the Company identified intangible assets of $55 thousand representing technology related and customer related intangibles.

 

In connection with the March 1, 2023 CG Labs JV, the Company identified intangible assets of $287 thousand representing technology related and customer related intangibles.

 

In connection with the December 1, 2023 acquisition of Kenkoderm, the Company identified intangible assets of $113 thousand representing technology related and customer related intangibles.

 

These assets are being amortized on a straight-line basis over their weighted average estimated useful life of 2.9 years and amortization expense amounted to $94 and $13 thousand for the years ended December 31, 2023 and 2022, respectively.

 

As of December 31, 2023, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands):

 

      
2024  $119 
2025   126 
2026   63 
2027   13 
2028   2 
Thereafter   3 
Total  $326 

 

F-20

 

10. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consist of the following ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Salaries, benefits, and incentive compensation  $61   $56 
Franchise tax accrual   -    52 
Margin line of credit   245    - 
Other   92    22 
Total accrued expenses and other current liabilities  $398   $130 

 

11. Common Stock

 

At December 31, 2023, the Company has reserved common stock for issuance in relation to the following:

 

Share-based compensation plan   560,650 
Warrants to purchase common stock   3,442,904 
Restricted stock units   64,562 

 

12. Share-based Compensation

 

The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initially reserved a total of 57,143 shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020 and May 3, 2021, respectively, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 57,143 shares of common stock to 485,715 and from 485,715 shares of common stock to 571,429 shares of common stock, all of which may be delivered pursuant to incentive stock options.

 

On March 23, 2023, the Board approved an additional 300,000 shares of common stock to be reserved under the 2019 Plan, such that total of number of shares underlying the Plan is 871,429 of which 609,687 shares have already been awarded or exercised. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is 14,286 shares of common stock.

 

The following table contains information about the 2019 Plan as of December 31, 2023:

 

   Awards           Awards 
   Reserved for   Awards   Awards   Available for 
   Issuance   Issued   Exercised   Grant 
2019 Plan(1)   871,429    649,833    17,916    221,596 
Awards issued in excess of 2019 Plan(2)   -    48,401    48,401    - 

 

(1) Includes incentive stock options and restricted stock units discussed below.
(2) Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.

 

F-21

 

Incentive stock options

 

On March 8, 2023, the Company granted a contractor an option to purchase up to 17,532 shares of the Company’s common stock at a per share exercise price of $2.00 under the Company’s 2019 Plan. This option award vests over a period of 12 months. The options expired unexercised.

 

On August 17, 2023, the Company granted options to purchase up to 90,000 shares of the Company’s common stock at a per share exercise price of $2.05 to members of the Board of Directors, all of which vests over a period of one year with 25% vested upon issuance.

 

On October 1, 2022, the Company appointed Dr. Neil Chesen to the Company’s Scientific Advisory Board and in consideration for his appointment to the board, the Company granted Dr. Chesen an option to purchase up to 65,000 shares of common stock at a per share exercise price of $2.00 under the Company’s 2019 Long-Term Incentive Plan. A portion of the award, 15,000 options, fully vested as of the date of grant and the remaining 50,000 options are contingent upon certain sales based milestones being achieved. The options expire on December 31, 2023 if the milestones are not achieved prior to that date. Also on October 1, 2022, the Company issued a second option grant to Dr. Chesen, to purchase up to 25,000 shares of common stock at a per share exercise price of $2.00 under the Company’s 2019 Long-Term Incentive Plan and are fully contingent upon certain sales based milestones being achieved with 18 months of commercial release. Also on October 1, 2022, the Company issued a third option grant to Dr. Chesen to purchase up to 37,500 shares of common stock at a per share exercise price of $5.50 under the Company’s 2019 Long-Term Incentive Plan and are fully contingent upon certain sales based milestones being achieved within 36 months of commercial release. As of December 31, 2022 the new product has not launched. The product launched in August 2023.

 

On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to 30,000 shares of the Company’s common stock at a per share price of $2.00 under the Company’s 2019 Long-Term Incentive Plan. A portion of the award, 5,000 options, fully vested as of the date of the grant and the remaining 25,000 options are contingent upon certain sales based milestones being achieved. The options expire within 18 months of commercial launch of a new product if the milestones are not achieved prior to that date or 10 years from the grant date, whichever comes first. The product launched in August 2023.

 

On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to 37,500 shares of the Company’s common stock at a per share price of $5.50 under the Company’s 2019 Long-Term Incentive Plan. The options are contingent upon certain sales based milestones being achieved. The options expire within 36 months of commercial launch of a new product if the milestones are not achieved prior to that date or 10 years from the grant date, whichever comes first. The product launched in August 2023.

 

The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2023 and 2022.

 

           Weighted 
       Weighted   Average 
       Average   Contractual 
   Number of   Exercise   Term in 
   Options   Price   Years 
Outstanding at January 1, 2022   434,939   $1.678955    8.56 
Granted   195,000    3.3461538    10.00 
Exercised   —    —    — 
Forfeited   —    —    — 
Cancelled   (100,001)   1.40000    — 
Expired   (5,001)   1.40000    — 
Outstanding at December 31, 2022   524,937   $2.351416    8.38 
                
Granted   117,532   $2.06041    10.00 
Exercised   (3,295)   1.75    — 
Forfeited   —    —    — 
Cancelled   (69,854)   1.965823    — 
Expired   (8,670)   1.703222    — 
Outstanding at December 31, 2023   560,650   $2.350742    7.95 
Exercisable at December 31, 2023   398,150   $1.829884    7.44 

 

F-22

 

As of December 31, 2023 and 2022, vested outstanding stock options had $295 thousand and $124 thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock, respectively. As of December 31, 2023, there was no unrecognized share-based compensation related to unvested stock options, excluding options fully contingent upon certain sales-based milestones being achieved within 18 to 36 months of commercial release.

 

The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate share-based compensation expense for year ended December 31, 2023 and 2022:

 

 

   2023    2022 
Volatility   257.64-258.01%    277.84%
Risk-free interest rate   4.21-4.42%    4.06%
Dividend yield   0.0%    0.0%
Expected term   5 - 5.50 years     5.0 years 

 

The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.

 

Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted-average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage.

 

Restrictive stock awards

 

Effective as of January 3, 2023, the Company granted a restricted stock award of 37,037 shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated December 30, 2022, all of which shares vested monthly from January 3, 2023 through December 31, 2023. Under ASC 718, the Company has measured the value of the 37,037 shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($1.35 per share).

 

Effective as of August 1, 2022, the Company granted a restricted stock award of 84,750 shares of the Company’s common stock to certain officers and employees, all of which shares vest in four equal installments on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Under ASC 718, the Company has measured the value of the 84,750 shares granted based on a closing price of the closing price of the Company’s stock at the grant date of the RSU Grant ($1.82 per share).

 

Effective as of January 1, 2022, the Company granted a restricted stock award of 11,364 shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated November 4, 2021, all of which shares vested monthly from January 1, 2022 through December 31, 2022. Under ASC 718, the Company has measured the value of the 11,364 shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($4.40 per share).

 

       Average 
   Number of   Grant Date 
   Units   Fair Value 
Outstanding at December 31, 2021   —   $— 
Granted   96,114    1.61 
Exercised and converted to common shares   (5,682)   4.40 
Forfeited   —    — 
Outstanding at December 31, 2022   90,432    1.43 
Granted   37,037    1.35 
Exercised and converted to common shares   (50,157)   1.76522 
Forfeited   (12,750)   1.82 
Outstanding at December 31, 2023   64,562   $1.82 
Exercisable at December 31, 2023   13,750   $1.82 

 

Compensation expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation expense for forfeited awards. As of December 31, 2023, there was $68 thousand unrecognized share-based compensation related to unvested RSUs, which the Company expects to recognize through December 2026.

 

Stock based compensation and restricted stock vesting of $217 thousand and $298 thousand has been recorded for the year ended December 31, 2023 and 2022, respectively.

 

F-23

 

Warrants

 

The following table shows a summary of common stock warrants for the years ended December 31, 2023 and 2022.

 

       Weighted   Weighted 
       Average   Average 
   Number of   Exercise   Contractual 
   Warrants   Price   Term in Years 
Outstanding at December 31, 2021   3,637,190   $5.16281    4.63 
                
Granted   —   $—    — 
Exercised   —    —    — 
Forfeited   —    —    — 
Cancelled   —    —    — 
Expired   —    —    — 
Outstanding at December 31, 2022   3,637,190   $5.16281    3.65 
Granted   —    —    — 
Exercised   (109,720)   0.55    — 
Forfeited   —    —    — 
Cancelled   (84,566)   0.89    — 
Expired   —    —    — 
Outstanding at December 31, 2023   3,442,904   $5.414793    2.87 
Exercisable at December 31, 2023   3,442,904   $5.414793    2.87 

 

As of December 31, 2023 and 2022, vested outstanding warrants had $0 and $114 thousand, respectively, intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock.

 

13. Notes Payable

 

CG Labs Notes Payable

 

CG Labs has entered into a $231 thousand promissory note agreement for certain equipment. The equipment was installed in December 2023. The promissory note has a term of five years beginning on March 13, 2024. The promissory note accrues interest at 8% and requires interest only payments through March 13, 2024 and monthly payments of $4 thousand thereafter.

 

CG Labs has entered into a $242 thousand promissory note agreement for certain equipment. The funding advances of $84 thousand have been issued as of December 2023. The promissory note has a term of five years beginning on March 13, 2024. The promissory note accrues interest at 8% and requires interest only payments through March 13, 2024 and monthly payments of $5 thousand thereafter.

 

Economic Injury Disaster Loan

 

On May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan is up to $260,500, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning May 28, 2021 (twelve months from the date of the SBA Note) in the amount of $1,270. The balance of principal and interest is payable thirty years from the date of the SBA Note. In connection therewith, the Company received an $8 thousand advance, which does not have to be repaid. On March 26, 2021, the SBA announced that all EIDL loans issued in 2020 will start repayment 24 months from the date of the SBA Note. The SBA has since extended the repayment start to 30 months from the date of the SBA Note. The Company made its first payment in December 2022. The balances of the principal and accrued interest amounted to $277 thousand and $283 thousand as of December 31, 2023 and 2022, respectively.

 

F-24

 

The future annual principal amounts and accrued interest to be paid as of December 31, 2023 are as follows:

 

   Amount 
For the year ending December 31 ($ in thousands):     
2024  $80 
2025   89 
2026   51 
2027   55 
2028   59 
Thereafter   259 
Total  $593 

 

14. Convertible Notes Payable

 

On March 11, 2021, the Company issued Auctus Fund, LLC, a Delaware limited liability company a one-year senior secured convertible promissory note in the principal amount of $1.68 million, which included $180 thousand of interest which was deemed fully earned as of the issuance date (the “Auctus Note”). The Auctus Note was fully repaid (including all principal and interest) on March 15, 2022 with a one-time cash payment of $1.68 million.

 

On September 2, 2021, the Company issued to certain holders one-year subordinated secured convertible promissory notes in the aggregate principal amount of $1,814 thousand, which included $194 thousand of interest which was deemed fully earned as of the issuance date (the “September 2 Notes”). On January 25, 2022, the Company repaid one of the September 2 Notes in full with a one-time cash payment of $300 thousand of outstanding principal and accrued but unpaid interest. The Company incurred pre-payment penalty of $17 thousand with respect to the repayment of the note and the remaining unamortized debt discount in the amount of $133 thousand was written off and both amounts were recorded as a loss on extinguishment of debt of $150 thousand in accompany statement of operations during 2022. The repayment extinguished the note in its entirety. On September 6, 2022, the outstanding balance on the remaining September 2 Notes’ was repaid in full which consisted of principal of $1,478 thousand.

 

15. Warrant Liability

 

On September 2, 2021, March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019, and November 6, 2019, the Company issued 22,019, 34,285, 7,429, 7,286, 44,286, 35,714 and 114,286 warrants, respectively, as equity issuance consideration, in connection with a private placement of the Company’s common stock. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $0.49 to $5.25 per share at any time on or after their issuance date and on or prior to the close of business 3 years after the issuance date (the “Termination Date”). The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants required classification as a liability pursuant to ASC 815, Derivatives and Hedging. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income (expense) in the statement of operations.

 

On September 6, 2022, the Company agreed to extend the September 10, 2019 and November 6, 2019 warrants an additional six months until March 9, 2023 and May 5, 2023, respectively. The warrants were remeasured as of September 6, 2022 and consequently resulted in a warrant modification expense of $57 thousand.

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Warrants

Outstanding

  

Fair Value

per Share

   Fair Value 
Fair value as of year ended 12/31/2021   265,305        $318 
Modification of warrants   -           57 
Change in fair value of warrant liability   -         (133)
Fair value as of year ended 12/31/2022   265,305         242 
Exercise of warrants   (194,286)       (144)
Modification of warrants   -         29 
Change in fair value of warrant liability   -         19 
Fair value as of year ended 12/31/2023   71,019        $146 

 

F-25

 

The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility of Guideline Public Companies as inputs.

 

16. Commitments and Contingencies

 

Litigation

 

The Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will have a material effect on the financial position, results of operations, or cash flows of the Company.

 

Service Agreement

 

On March 21, 2023, the Company entered into a Services Agreement with GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (“Haleon”) to supply material for a consumer product to be developed and released in the future. There can be no guaranty that a consumer product will be released or, if released, that it will be successful.

 

17. Concentrations of Risk

 

The Company’s revenues are concentrated in a small group of customers with some individually comprising more than 10% of total revenues.

 

For the year ended December 31, 2023, the Company had revenue from one customer that approximated 20% of total revenue. For the year ended December 31, 2022, the Company had revenue from one customer that approximated 29% of total revenue.

 

The Company had one customer with accounts receivable balances that approximated 69% of total accounts receivable as of December 31, 2023. The Company had three customers with accounts receivable balances that approximated 40%, 22% and 18% of total accounts receivable as of December 31, 2022.

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Cash balances are maintained principally at major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. Such cash balances are currently in excess of the FDIC insurance limit of $250 thousand. As of December 31, 2023, the total amount exceeding such limit was $106 thousand. The Company has not experienced any credit losses associated with its cash balances in the past. The Company invests its cash equivalents in U.S. treasury bills with original maturities of three months or less.

 

Marketable securities are comprised of U.S. treasury bills with original maturities greater than three months. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions.

 

F-26

 

18. Related Party Transactions

 

Convertible Promissory Note

 

On September 2, 2021, the Company issued three Secured Convertible Promissory Notes to members of the board of directors in an aggregate amounts of $150,000 to Mr. Stein, $150,000 to Mr. Stefansky (Bezalel Partners, LLC), and $50,000 to Dr. Zeldis as part of the September 2 Notes. The notes were repaid in full in 2022 (See Note 14).

 

Advances

 

Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $25,000 and $40,000 for services as of December 31, 2023 and 2022, respectively, included in accounts payable in the accompanying consolidated balance sheets.

 

19. Income Taxes

 

The Company has established a full valuation allowance for its deferred tax assets based on management’s belief that it is not more likely than not that the related deferred tax assets will be realized. For the years ended December 31, 2023 and 2022, there was no income tax expense or benefit.

 

At December 31, 2023 and 2022, the Company had no recorded tax liabilities for uncertain tax positions. The Company does not expect any significant changes to the estimate amount of liabilities associated with uncertain tax positions in the next 12 months.

 

The income tax (benefit) provision consists of the following:

 

   2023   2022 
   For The Years Ended 
   December 31 
   2023   2022 
Federal:          
Current  $

(617

)  $

(619

)
Deferred   

617

    619 
State and local:          
Current   

(156

)   (159)
Deferred   156    159 
Income tax provision  $—   $— 

 

For the years ended December 31, 2023 and 2022, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows:

 

   2023   2022 
   For The Years Ended December 31, 
   2023   2022 
U.S. federal statutory rate   21.0%   21.0%
State tax rate, net of federal benefit   5.3%   5.3%
Permanent differences          
Non-deductible expenses   (1.9)%   (9.7)%
Timing differences   —   —
Change in valuation allowance   (24.4)%   (16.6)%
Income tax provision   —%   —%

 

For the years ended December 31, 2023 and 2022, differences between the expected tax expense based on the federal statutory rate and the actual tax expense is primarily attributable to the net losses incurred and the corresponding increase to the valuation allowance.

 

F-27

 

As of December 31, 2023 and 2022, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:

 

    2023     2022  
    As of December 31,  
    2023     2022  
Deferred tax assets:                
Net operating loss carryforwards   $ 4,882     $ 4,112  
Other     9       6  
Total deferred tax assets     4,891       4,118  
Valuation allowance     (4,891 )     (4,118 )
Deferred tax assets, net of valuation allowance   $ —     $ —  

 

As of December 31, 2023 and 2022, the Company has approximately $18.6 million and $15.6 million of federal NOL carryovers, respectively, which begin to expire in 2029 through 2036. Similarly, the subsidiary’s Pennsylvania state returns reported state NOL carryovers of approximately $18.6 million and $15.6 million, as of December 31, 2023 and 2022, respectively. However, these loss carryforwards on a separate company basis may be subject to limitations on the amounts that may be utilized pursuant to Internal Revenue Code section 382 and applicable state law. Section 382 imposes significant limitations on the utilization of net operating losses after certain changes of corporate ownership. The Company will need to determine the amount of loss carryforwards that may be utilized in the future as necessary.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the years in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2023 and 2022 because management has determined that it is more likely than not that these deferred tax assets will not be realized.

 

The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2023 and 2022, the Company does not have any significant uncertain tax positions.

 

20. Subsequent Events

 

Management of the Company has performed a review of events and transactions occurring after the consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying consolidated financial statements, noting no such events or transactions other than the following.

 

On February 15, 2024 (the “Closing Date”), the Company, entered into subscription agreements with investors, the Company’s Chief Financial Officer and certain members of its board of directors for a registered direct offering (“RDO”) of the Company’s common stock. The RDO sold an aggregate 242,891 units at a price to the public of $4.22 per unit, with each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $4.00 per share. The $4.22 purchase price equals two times the last reported sale price of $2.11 per share of the Company’s common stock on February 15, 2024 on The Nasdaq Capital Market. The Company issued 485,782 shares of common stock and warrants to purchase up to 242,891 shares of common stock.

 

Subject to certain ownership limitations, each of the warrants will become exercisable on the Closing Date, will have an exercise price of $4.00 per share and will expire five years after the Closing Date. The warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained in the registration statement is not available for, the issuance or resale of shares of common stock underlying the warrants to or by the holder. The holder of a warrant is prohibited from exercising of any such warrants to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 4.99% of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99%.

 

The gross proceeds to the Company from the RDO are expected to be approximately $1.025 million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the warrants. The Company intends to use the net proceeds from the RDO for working capital and for general corporate purposes.

 

The Company retained Alere Financial Partners, LLC (A division of Cova Capital Partners, LLC) to act as the placement agent for the RDO. The Company agreed to pay the placement agent a cash fee of 6% of the aggregate gross proceeds in the RDO received from non-affiliates of the Company and 3% of the aggregate gross proceeds in the RDO received from affiliates of the Company. Additionally, and upon the closing of the RDO, the Company agreed to issue to the placement agent warrants exercisable for a period of five years to purchase up to 6% of the number of shares sold in this offering, or up to 27,725 shares, at a per share exercise price of $4.00.

 

F-28

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Disclosure Controls and Procedures

 

As of December 31, 2023, we conducted an evaluation of the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our Disclosure Controls and Procedures were effective as of December 31, 2023 at a reasonable level of assurance.

 

Change in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the fiscal year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Management’s Annual Report on Internal Control over Financial Reporting and Attestation Report of the Registered Accounting Firm

 

This Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over financial reporting due to a transition period established by rules of the SEC for newly public companies or an attestation report of the Company’s registered public accounting firm which is not required for non-accelerated filers.

 

Item 9B. Other Information

 

Not applicable.

 

Part III.

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

The information required by this Item is set forth under the headings “Directors, Executive Officers and Corporate Governance” and “Section 16(a) Beneficial Ownership Reporting Compliance” in the Company’s 2024 Proxy Statement to be filed with the U.S. Securities and Exchange Commission (“SEC”) within 120 days after December 31, 2023 in connection with the solicitation of proxies for the Company’s 2024 annual meeting of shareholders and is incorporated herein by reference.

 

25

 

Item 11. Executive Compensation

 

The information required by this Item is set forth under the heading “Executive Compensation” and under the subheadings “Board Oversight of Risk Management,” “Compensation of Directors,” “Director Compensation-2023” and “Compensation Committee Interlocks and Insider Participation” under the heading “Directors, Executive Officers and Corporate Governance” in the Company’s 2024 Proxy Statement to be filed with the SEC within 120 days after December 31, 2023 and is incorporated herein by reference.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The information required by this Item is set forth under the headings “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” in the Company’s 2024 Proxy Statement to be filed with the SEC within 120 days after December 31, 2023 and is incorporated herein by reference.

 

Item 13. Certain Relationships and Related Transactions and Director Independence

 

The information required by this Item is set forth under the heading “Review, Approval or Ratification of Transactions with Related Persons” and under the subheading “Board Committees” under the heading “Directors, Executive Officers and Corporate Governance” in the Company’s 2024 Proxy Statement to be filed with the SEC within 120 days after December 31, 2023 and is incorporated herein by reference.

 

Item 14. Principal Accountant Fees and Services.

 

Our independent public accounting firm is Turner Stone & Company, L.L.P., Dallas, Texas, PCAOB Auditor ID 76.

 

The information required by this Item is set forth under the subheadings “Fees Paid to Auditors” and “Policy on Audit Committee Pre-Approval of Audit and Non-Audit Services Performed by the Independent Registered Public Accounting Firm” under the proposal “Ratification of Appointment of Independent Registered Public Accounting Firm” in the Company’s 2024 Proxy Statement to be filed with the SEC within 120 days after December 31, 2023 and is incorporated herein by reference.

 

Part IV.

 

Item 15. Exhibits and Financial Statement Schedules

 

The following documents are filed as part of this report:

 

(1) Financial Statements

 

The following financial statements are included herein:

 

Report of Independent Registered Public Accounting Firm (PCAOB ID: 76)
Consolidated Balance Sheets as of December 31, 2023 and 2022
Consolidated Statements of Operations for the years ended December 31, 2023 and 2022
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022
Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022
Notes to Consolidated Financial Statements

 

(2) Financial Statement Schedules

 

None.

 

26

 

(3) Exhibits

 

1.1   Underwriting Agreement dated December 21, 2021 by and between NexGel, Inc. and Maxim Group LLC (incorporated by reference to Exhibit 1.1 to Form 8-K, filed with the SEC on December 27, 2021).
     
2.1   Form of Asset Contribution and Separation Agreement between Alliqua BioMedical, Inc. and AquaMed Technologies, Inc. (incorporated by reference to Exhibit 2.3 to Form S-1, filed with the SEC on January 9, 2019).
     
2.2   Form of Tax Matters Agreement between Alliqua BioMedical, Inc. and AquaMed Technologies, Inc. (incorporated by reference to Exhibit 2.4 to Form S-1, filed with the SEC on January 9, 2019).
     
2.3   Form of Bill of Sale and Assignment and Assumption Agreement between Alliqua BioMedical, Inc. and AquaMed Technologies, Inc. (incorporated by reference to Exhibit 2.5 to Amendment No. 1 to Form S-1, filed with the SEC on March 11, 2019).
     
2.4   Amendment No. 2, dated April 19, 2019, to Agreement and Plan of Merger (incorporated by reference to Exhibit 2.6 to Amendment No. 3 to Form S-1, filed with the SEC on April 19, 2019)
     
3.1   Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.1 to Form S-1, filed with the SEC on January 9, 2019).
     
3.2   Certificate of Amendment to Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.2 to Form S-1, filed with the SEC on January 9, 2019).
     
3.3   Amended and Restated Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.3 to Amendment No. 1 to Form S-1, filed with the SEC on March 11, 2019).
     
3.4   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on November 14, 2019).
     
3.5   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of NexGel, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 29, 2020).

 

27

 

3.6   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of NexGel, Inc. (incorporated by reference to Exhibit 3.6 to Form S-1, filed with the SEC on December 2, 2021)
     
3.7   Amended and Restated Bylaws of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.5 to Amendment No. 1 to Form S-1, filed with the SEC on March 11, 2019).
     
4.1   12% Senior Secured Promissory Note, dated March 11, 2021, issued to Auctus Fund, LLC (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on March 17, 2021).
     
4.2   First Common Stock Purchase Warrant, dated March 11, 2021, issued to Auctus Fund, LLC (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on March 17, 2021).
     
4.3   Second Common Stock Purchase Warrant, dated March 11, 2021, issued to Auctus Fund, LLC (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the SEC on March 17, 2021).
     
4.4   Form of 12% Subordinated Secured Promissory Note, dated September 2, 2021 (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on September 8, 2021)
     
4.5   Form of Common Stock Purchase Warrant, dated September 2, 2021 (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on September 8, 2021)
     
4.6   Warrant Agency Agreement (including form of Common Warrant) dated December 27, 2021 by and between NexGel, Inc. and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 10.1 to Form 8-K, filed with the SEC on December 27, 2021).
     
4.7   Underwriter Warrant dated December 27, 2021 issued to Maxim Group LLC (incorporated by reference to Exhibit 4.1 to Form 8-K, filed with the SEC on December 27, 2021).
     
4.8   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on February 21, 2024).
     
10.1   Assignment and Amended and Restated Lease, dated as of January 25, 2002, by and between 2150 Cabot LLC, Embryo Development Corporation and Hydrogel Design Systems, Inc. (incorporated by reference to Exhibit 10.1 to Form S-1, filed with the SEC on January 9, 2019).
     
10.2   Amendment to Lease, dated as of February 23, 2007, by and between 2150 Cabot LLC and Hydrogel Design Systems, Inc. (incorporated by reference to Exhibit 10.2 to Form S-1, filed with the SEC on January 9, 2019).
     
10.3   Third Amendment to Lease, dated as of February 27, 2009, by and between Exeter 2150 Cabot, L.P and Hydrogel Design Systems, Inc. (incorporated by reference to Exhibit 10.3 to Form S-1, filed with the SEC on January 9, 2019).
     
10.4   Assignment and Assumption of Lease Agreement, dated as of February 27, 2009, by and among Exeter 2150 Cabot, L.P, Hydrogel Design Systems, Inc. and Aquamed Technologies, Inc. (incorporated by reference to Exhibit 10.4 to Form S-1, filed with the SEC on January 9, 2019).
     
10.5   Fourth Amendment to Lease, dated as of July 24, 2013, by and between Exeter 2150 Cabot, L.P and Aquamed Technologies, Inc. (incorporated by reference to Exhibit 10.5 to Form S-1, filed with the SEC on January 9, 2019).
     
10.6   Form of Stock Purchase Agreement between NexGel, Inc. and certain accredited investors (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on March 27, 2020).
     
10.7   Membership Interest Purchase Agreement dated May 29, 2020 by and among NexGel, Inc. and the members of Sport Defense LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 29, 2020).

 

28

 

10.8   Form of 2019 Incentive Plan (incorporated by reference to Exhibit 10.22 to Amendment No. 3 to Form S-1, filed with the SEC on April 19, 2019).
     
10.9   Form of Incentive Option Agreement under 2019 Incentive Plan (incorporated by reference to Exhibit 10.23 to Amendment No. 3 to Form S-1, filed with the SEC on April 19, 2019).
     
10.10   Form of Nonqualified Stock Option Agreement under 2019 Incentive Plan (incorporated by reference to Exhibit 10.24 to Amendment No. 3 to Form S-1, filed with the SEC on April 19, 2019).
     
10.12   Securities Purchase Agreement, dated March 11, 2021, between NexGel, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 17, 2021).
     
10.13   Security Agreement, dated March 11, 2021, between NexGel, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on March 17, 2021).
     
10.14   Registration Rights Agreement, dated March 11, 2021, between NexGel, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the SEC on March 17, 2021).
     
10.15   First Amendment to the Senior Secured Promissory Note, Warrants, and Securities Purchase Agreement (March 11, 2021) dated August 13, 2021 by and between NexGel. Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 10-Q filed with the SEC on August 16, 2021).
     
10.16   Form of Securities Purchase Agreement, dated September 2, 2021 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September 8, 2021).
     
10.17   Form of Security Agreement, dated September 2, 2021 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on September 8, 2021).

 

29

 

10.18   Form of Security Agreement, dated September 2, 2021 (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the SEC on September 8, 2021).
     
10.19   Form of Registration Rights Agreement, dated September 2, 2021 (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the SEC on September 8, 2021).
     
10.20   Form of Lock-Up Agreement, dated September 2, 2021 (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the SEC on September 8, 2021).
     
10.21   Second Amendment to the Senior Secured Promissory Note, Warrants, and Securities Purchase Agreement (March 11, 2021) dated October 28, 2021 by and between NexGel. Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on November 3, 2021).
     
10.22   Third Amendment to the Senior Secured Promissory Note, Warrants, and Securities Purchase Agreement (March 11, 2021) dated December 10, 2021 by and between NexGel. Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.23 to Form S-1, filed with the SEC on December 10, 2021).
     
10.23   Asset Purchase Agreement dated November 30, 2023 between NexGel, Inc. and Olympus Trading Company, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on December 5, 2023).
     
10.24   2024 Executive Employment Agreement, dated December 26, 2023 by and between NexGel. Inc. and Adam Levy (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on December 29, 2023).
     
21.1*   Subsidiaries
     
23.1*   Consent of Turner, Stone & Company, L.L.P.
     
31.1*   Rule 13a-14(a) Certification of Principal Executive Officer
     
31.2*   Rule 13a-14(a) Certification of Principal Financial Officer
     
32.1**   Section 1350 Certification of Principal Executive Officer
     
32.2**   Section 1350 Certification of Principal Financial Officer
     
97*   NexGel, Inc. Policy for the Recovery of Erroneously Awarded Compensation, effective December 1, 2023.
     
101.INS*   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Filed herewith.

 

** Furnished herewith.

 

30

 

Signatures

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NexGel, Inc.
     
Date: April 10, 2024 By: /s/ Adam Levy
    Adam Levy
    Chief Executive Officer and President

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated as of the dates set forth below.

 

Signature   Date   Title
         
/s/ Adam Levy   April 10, 2024   Chief Executive Officer and President (Principal Executive Officer)
Adam Levy        
         
/s/ Adam Drapczuk III   April 10, 2024   Chief Financial Officer (Principal Accounting and Financial Officer)
Adam Drapczuk III        
         
/s/ Steven Glassman   April 10, 2024   Director
Steven Glassman        
         
/s/ Scott Henry   April 10, 2024   Director
Scott Henry        
         
/s/ Nachum Stein   April 10, 2024   Director
Nachum Stein        
         
/s/ Jerome B. Zeldis   April 10, 2024   Director
Jerome B. Zeldis        

 

31

 

 EX-21.1 2 ex21-1.htm

 

Exhibit 21.1

 

Subsidiaries of the Registrant

 

Name of Subsidiary   State of Organization
CG Converting and Packaging, LLC (50% owned)   Texas
NexGelRx, Inc. (wholly owned)   Delaware
Sport Defense LLC (wholly owned)   Delaware

 

 

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-264282) of NexGel, Inc. of our report dated April 10, 2024, relating to the consolidated financial statements which appear in this Annual Report on Form 10-K.

 

/s/ TURNER, STONE & COMPANY, L.L.P.

 

Dallas, Texas

April 10, 2024

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002)

 

I, Adam Levy, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of NexGel, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 10, 2024

 

  /s/ Adam Levy
  Adam Levy
 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002)

 

I, Adam Drapczuk, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of NexGel, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 10, 2024

 

  /s/ Adam E. Drapczuk III
  Adam E. Drapczuk III
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

 EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the Annual Report of NexGel, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Adam Levy, Chief Executive Officer, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

Date: April 10, 2024

 

  /s/ Adam Levy
  Adam Levy
 

Chief Executive Officer

(Principal Executive Officer)

 

A certification furnished pursuant to this Item will not be deemed “filed” for purposes of section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the small business issuer specifically incorporates it by reference.

 

 

 

 EX-32.2 7 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the Annual Report of NexGel, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Adam Levy, Chief Financial Officer, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

Date: April 10, 2024

 

  /s/ Adam E. Drapczuk III
  Adam E. Drapczuk III
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

A certification furnished pursuant to this Item will not be deemed “filed” for purposes of section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the small business issuer specifically incorporates it by reference.

 

 

 

 EX-97.1 8 ex97.htm

 

Exhibit 97

 

 

 

NEXGEL, INC.

 

POLICY FOR THE

RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

 

 

 

A. OVERVIEW

 

In accordance with the applicable rules of The Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), NEXGEL, INC. (the “Company”) has adopted this Policy (the “Policy”) to provide for the recovery of erroneously awarded Incentive-based Compensation from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.

 

B. RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

 

(1) In the event of an Accounting Restatement, the Company will reasonably promptly recover the Erroneously Awarded Compensation Received in accordance with Nasdaq Rules and Rule 10D-1 as follows:

 

  (i) After an Accounting Restatement, the Compensation Committee (if composed entirely of independent directors, or in the absence of such a committee, a majority of independent directors (the “Committee”) serving on the Board of Directors (the “Board”) shall determine the amount of any Erroneously Awarded Compensation Received by each Executive Officer and shall promptly notify each Executive Officer with a written notice containing the amount of any Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable.

 

  (a) For Incentive-based Compensation based on (or derived from) the Company’s stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement:

 

  i. The amount to be repaid or returned shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company’s stock price or total shareholder return upon which the Incentive-based Compensation was Received; and
  ii. The Company shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation as required to the Nasdaq.

 

  (ii) The Committee shall have discretion to determine the appropriate means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances. Notwithstanding the foregoing, except as set forth in Section B(2) below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer’s obligations hereunder.

 

1

 

 

  (iii) To the extent that the Executive Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously Awarded Compensation that is subject to recovery under this Policy.
     
  (iv) To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company when due, the Company shall take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.

 

(2) Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee (which, as specified above, is composed entirely of independent directors or in the absence of such a committee, a majority of the independent directors serving on the Board) determines that recovery would be impracticable and any of the following two conditions are met:

 

  (i) The Committee has determined that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making this determination, the Company must make a reasonable attempt to recover the Erroneously Awarded Compensation, documented such attempt(s) and provided such documentation to the Nasdaq; or
     
  (ii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.

 

C. DISCLOSURE REQUIREMENTS

 

The Company shall file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission (“SEC”) filings and rules.

 

D. PROHIBITION OF INDEMNIFICATION

 

The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company’s enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or awarded to an Executive Officer from the application of this Policy or that waives the Company’s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).

 

2

 

 

E. ADMINISTRATION AND INTERPRETATION

 

This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.

 

The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy and for the Company’s compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith.

 

F. AMENDMENT; TERMINATION

 

The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or Nasdaq rule.

 

G. OTHER RECOVERY RIGHTS

 

This Policy shall be binding and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or Nasdaq, their beneficiaries, heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.

 

H. DEFINITIONS

 

For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.

 

(1) “Accounting Restatement” means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a “Big R” restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “little r” restatement).

 

3

 

 

(2) “Clawback Eligible Incentive Compensation” means all Incentive-based Compensation Received by an Executive Officer (i) on or after the effective date of the applicable Nasdaq rules, (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Clawback Period (as defined below).

 

(3) “Clawback Period” means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date (as defined below), and if the Company changes its fiscal year, any transition period of less than nine months within or immediately following those three completed fiscal years.

 

(4) “Erroneously Awarded Compensation” means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.

 

(5) “Executive Officer” means each individual who is currently or was previously designated as an “officer” of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).

 

(6) “Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company’s financial statements or included in a filing with the SEC.

 

(7) “Incentive-based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

 

(8) “Nasdaq” means The Nasdaq Stock Market.

 

(9) “Received” means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.

 

(10) “Restatement Date” means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

 

Effective as of December 1, 2023

 

4

 

 

Exhibit A

 

ATTESTATION AND ACKNOWLEDGEMENT OF POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

 

By my signature below, I acknowledge and agree that:

 

  ● I have received and read the attached Policy for the Recovery of Erroneously Awarded Compensation (this “Policy”).
  ● I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy.

 

  Signature:  
     
  Printed Name:  
     
  Date:  

 

5

 EX-101.SCH 9 nxgl-20231231.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Description of Business, Stock Split and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies and Estimates link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Warrant Liability link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Concentrations of Risk link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Significant Accounting Policies and Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Significant Accounting Policies and Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Description of Business, Stock Split and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Fair Value of Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Disaggregated Revenue by Sales Type (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Significant Accounting Policies and Estimates (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Unaudited Pro-Forma Results of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Acquisition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Supplemental Cash Flows Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Property and Equipment, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Breakdown of Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Schedule of Estimated Annual Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Schedule of Reserved Common Stock For Issued Securities in Relation (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Schedule of Information about Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Schedule of Incentive Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Schedule of Assumptions used in Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Schedule of Restricted Stock Units Granted (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Schedule of Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Share-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Schedule of Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - Schedule of Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - Warrant Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - Concentrations of Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - Schedule of Income Tax (Benefit) Provision (Details) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000077 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000078 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000079 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 nxgl-20231231_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 nxgl-20231231_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 nxgl-20231231_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, par value 0.001 [Member] Warrants to Purchase Common Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Noncontrolling Interest [Member] Retained Earnings [Member] Business Acquisition [Axis] Joint Venture [Member] CG Labs [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Registered Direct Offering [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Financial Instrument [Axis] US Treasury Securities One [Member] US Treasury Securities Two [Member] US Treasury Securities Three [Member] US Treasury Securities Four [Member] US Treasury Securities Five [Member] US Treasury Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Consolidated Entities [Axis] Nexgel [Member] Segments [Axis] Contract Manufacturing [Member] Subsegments Consolidation Items [Axis] Reportable Subsegments [Member] Custom and White Label Finished Goods [Member] Branded Consumer Products [Member] Other Incomes [Member] Kenkoderm Acquisition [Member] Ownership [Axis] C.G. Laboratories Inc. [Member] Long-Lived Tangible Asset [Axis] Machinery and Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Construction in Progress [Member] Finite-Lived Intangible Assets by Major Class [Axis] Technology-Based Intangible Assets [Member] Customer-Related Intangible Assets [Member] Trade Names [Member] Marketing-Related Intangible Assets [Member] Sport Defense LLC [Member] Technology Related and Customer Related Intangibles [Member] CG Labs JV [Member] Kenkoderm [Member] Plan Name [Axis] 2019 Plan [Member] Title of Individual [Axis] Executive Officer [Member] Contractor [Member] Director [Member] Dr.Neil Chesen [Member] Award Type [Axis] Option One [Member] Option Two [Member] Option Three [Member] Dr.Leonard Nelson [Member] Equity Option [Member] Chief Executive Officer [Member] Restricted Stock [Member] Officers and Employees [Member] Awards Granted Outside Of The 2019 Plan [Member] Restricted Stock Units (RSUs) [Member] Debt Instrument [Axis] CG Labs Notes Payable [Member] CG Labs Notes Payable One [Member] Economic Injury Disaster Loan [Member] Class of Warrant or Right [Axis] Auctus Note [Member] Secured Convertible Promissory Note [Member] Sale of Stock [Axis] Private Placement [Member] Warrant [Member] Customer [Axis] Customer One [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Accounts Receivable [Member] Customer Two [Member] Customer Three [Member] Related Party, Type [Axis] Mr. Stein [Member] Mr.Stefansky [Member] Dr.Jerome Zeldis [Member] Geographical [Axis] PANAMA Subscription Agreements [Member] Placement Agent [Member] Non Affiliated Entity [Member] Affiliated Entity [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS: Current Assets: Cash Marketable securities Accounts receivable, net Inventory Prepaid expenses and other current assets Total current assets Goodwill Intangibles, net Property and equipment, net Operating lease - right of use asset Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable Accrued expenses and other current liabilities Deferred revenue Current portion of note payable Warrant liability Contingent consideration liability Operating lease liability, current portion Total current liabilities Operating lease liability, net of current portion Notes payable, net of current portion Total liabilities Commitments and Contingencies (Note 16) STOCKHOLDERS’ EQUITY Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,741,838 and 5,577,916 shares issued and outstanding as of December 31, 2023 and 2022, respectively Additional paid-in capital Accumulated deficit Total NexGel stockholders’ equity Non-controlling interest in joint venture Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues, net Cost of revenues Gross profit Operating expenses Research and development Selling, general and administrative Total operating expenses Loss from operations Other income (expense) Change in fair value of warrant liability, net of warrant modification expense Realized gain on investments in marketable securities Loss on debt extinguishment Interest expense, net Other expense Other income Total other income (expense), net Loss before income taxes Income tax expense Net loss Less: Loss attributable to non-controlling interest in joint venture Net loss attributable to NexGel stockholders Net loss per common share - basic Net loss per common share - diluted Weighted average shares used in computing net loss per common share - basic Weighted average shares used in computing net loss per common share - diluted Balance Balance, shares Stock-based compensation Stock-based compensation, shares Restricted stock issuances Restricted stock issuances, shares Net loss Exercise of warrants Exercise of stock warrants, shares Non-controlling interest contribution Balance Balance, shares Statement of Cash Flows [Abstract] Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Loss attributable to non-controlling interest in joint venture Depreciation and amortization Share-based compensation Realized gain on investment in marketable securities Change in fair value of warrant liability Amortization of right of use asset Warrant modification expense Loss of extinguishment of debt Amortization of deferred financing costs Changes in operating assets and liabilities: Accounts receivable, net Inventory Prepaid expenses and other current assets Accounts payable Accrued expenses and other current liabilities Deferred revenue Net Cash Used in Operating Activities Investing Activities Purchases of equipment Investment in subsidiary Proceeds from sales of marketable securities Investments in or purchases of marketable securities Net Cash Provided by (Used in) Investing Activities Financing Activities Principal payments on operating lease liability Proceeds from notes payable Principal payments of notes payable Principal payments on convertible notes Proceeds from margin line of credit Net Cash Provided by (Used in) Financing Activities Net Increase (Decrease) in Cash Cash  – Beginning of year Cash – End of year Supplemental Non-cash Investing and Financing Activities Property and equipment and intangibles contributed as capital investment to JV ROU asset and operating lease liabilities recognized upon consolidation of JV Accounting Policies [Abstract] Description of Business, Stock Split and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Significant Accounting Policies and Estimates Segment Reporting [Abstract] Business Segments Business Combination and Asset Acquisition [Abstract] Acquisition Leases Leases Inventory Disclosure [Abstract] Inventory Property, Plant and Equipment [Abstract] Property and Equipment, Net Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Equity [Abstract] Common Stock Share-Based Payment Arrangement [Abstract] Share-based Compensation Debt Disclosure [Abstract] Notes Payable Convertible Notes Payable Warrant Liability Warrant Liability Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Risks and Uncertainties [Abstract] Concentrations of Risk Related Party Transactions [Abstract] Related Party Transactions Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events Use of Estimates Segment Reporting Cash Marketable Securities Margin Line of Credit Accounts Receivable, net Inventory and Cost of Revenues Research and Development Shipping and Handling Revenue and Expense Property and Equipment, net Impairment of Long-Lived Assets Goodwill and Intangible Assets Prepaid Expenses and Other Current Assets Other Assets Fair Value Measurements Warrant Liability Revenue Recognition Share-based Compensation Income Taxes Leases Variable Interest Entity Comprehensive loss Recently Issued Accounting Standards Accounting Pronouncements Issued But Not Yet Adopted Schedule of Marketable Securities Schedule of Fair Value of Financial Assets Schedule of Disaggregated Revenue by Sales Type Schedule of Reportable Segments Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Schedule of Business Acquisitions Schedule of Unaudited Pro-Forma Results of Operations Schedule of Future Minimum Lease Payments Schedule of Supplemental Cash Flows Information Related to Leases Schedule of Inventory Schedule of Property and Equipment Schedule of Breakdown of Identifiable Intangible Assets Schedule of Estimated Annual Amortization Expense Schedule of Accrued Expenses and Other Current Liabilities Schedule of Reserved Common Stock For Issued Securities in Relation Schedule of Information about Incentive Plan Schedule of Incentive Stock Option Activity Schedule of Assumptions used in Share-based Compensation Schedule of Restricted Stock Units Granted Schedule of Common Stock Warrants Schedule of Debt Instruments Schedule of Warrant Liability Schedule of Income Tax (Benefit) Provision Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Acquisition percentage Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Net loss Net cash used in operating activities Working capital Sale of stock, number of shares issued in transaction Sale of stock, price per share Sale of stock, description of transaction Class of warrant or right, exercise price of warrants or rights Sale of stock, consideration received on transaction Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Total Marketable securities, due date Platform Operator, Crypto-Asset [Table] Platform Operator, Crypto-Asset [Line Items] Contract manufacturing Custom and white label finished goods manufacturing Consumer branded products Other Total Shor term line of credit U.S. treasury bills held for sale Allowance for doubtful accounts Goodwill and intangible asset impairment Prepaid insurance General prepaid expenses Remaining performance obligations Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Total revenue Cost of sales Operating expenses Loss from operations Assets: Current assets: Intangibles Operating lease – right of use asset Liabilities and Stockholders’ Equity Current liabilities: Cash contributed by the Company Noncontrolling interest portion of CG Labs contributed business Consideration paid Inventory Product/Technology related intangibles Marketing related intangibles Other liabilities Total net assets acquired Preliminary goodwill Fixed assets Revenues, net Net loss allocable to common shareholders Net loss per share - basic Net loss per share - diluted Weighted average number of shares outstanding - basic Weighted average number of shares outstanding - diluted Cash payment for acquire assets Payments to acquire businesses, cash earn-out Net tangible assets acquired Minority percentage Payment to acquire business Schedule Of Future Minimum Lease Payments 2024 2025 2026 2027 2028 Thereafter Total undiscounted operating lease payments Less: Imputed interest Present value of operating lease liability Weighted average remaining lease term Weighted average discount rate Schedule Of Supplemental Cash Flows Information Related To Leases Operating cash flows from operating lease Operating lease expense Raw materials Work-in-progress Finished goods Inventory, gross Less: Inventory reserve for excess and slow moving inventory Total Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Useful Life (Years) Total property and equipment Less: accumulated depreciation and amortization Property and equipment, net Depreciation expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Identifiable intangible assets, gross Accumulated amortization Total 2024 2025 2026 2027 2028 Thereafter Total Intangible assets Expected life Amortization expense Salaries, benefits, and incentive compensation Franchise tax accrual Margin line of credit Other Total accrued expenses and other current liabilities Share-based compensation plan Warrants to purchase common stock Restricted stock units Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Awards Reserved For Issuance Awards Issued Awards Exercised Awards Available for Grant Number of options, outstanding, beginning balance Weighted average exercise price, outstanding beginning balance Weighted average remaining contractual term Number of options, granted Weighted average exercise price, granted Weighted average remaining contractual term, granted Number of options, exercised Weighted average exercise price, exercised Number of options, forfeited Weighted average exercise price, forfeited Number of options, cancelled Weighted average exercise price, cancelled Number of options, expired Weighted average exercise price, expired Number of options, outstanding, ending balance Weighted average exercise price, outstanding ending balance Number of options, exercisable Weighted average exercise price, exercisable Weighted average remaining contractual term, exercisable Volatility Risk-free interest rate Dividend yield Expected term Number of units outstanding beginning Weighted average grant date fair value outstanding beginning Number of units, granted Weighted average grant date fair value, granted Number of units, exercised and converted to common shares Weighted average grant date fair value, exercised and converted to common shares Number of units, forfeited Weighted average grant date fair value, forfeited Number of units outstanding ending Weighted average grant date fair value outstanding ending Number of units exercisable Weighted average grant date fair value exercisable Number of warrants, outstanding beginning balance Weighted average exercise price, outstanding beginning balance Weighted average remaining contractual term Number of warrants, granted Weighted average exercise price, granted Number of warrants, exercised Weighted average exercise price, exercised Number of warrants, forfeited Weighted average exercise price, forfeited Number of warrants, cancelled Weighted average exercise price, cancelled Number of warrants, expired Weighted average exercise price, expired Number of warrants, outstanding ending balance Weighted average exercise price, outstanding ending balance Number of warrants, exercisable Weighted average exercise price, exercisable Weighted average remaining contractual term, exercisable Common stock reserved for issuance Common stock reserved for issuance Number of options, granted Common stock reserved for issuance Additional common stock reserved for issuance Shares reserved for issuance, awarded Shares reserved for issuance, exercised Number of shares granted Exercise price of options Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Award vesting rights, percentage Number of options, vested Number of options, expected to vest Options, expiry date Expiration period Intrinsic value Period of recognition of stock based compensation expense Restricted stock vesting, shares Share price Unrecognized share based compensation expense Stock based compensation and restricted stock vesting Intrinsic value of vested outstanding warrants 2024 2025 2026 2027 2028 Thereafter Total Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Notes payable Agreements terms Interest rate Debt instrument periodic payment Advance payment of promissory note Borrowing capacity Loan advance Principal and accrued interest Principal amount of debt Debt Instrument, Periodic Payment, Interest Interest expense Outstanding principal and accrued unpaid interest Pre payment penalty Unamortized debt discount Gains loss on extinguishment of debt Warrants outstanding, beginning balance Fair value, beginning balance Warrants outstanding, warrant modification Fair value, modification of warrants Warrants outstanding, change in fair value of warrant liability Fair value, change in fair value of warrant liability Warrants outstanding, exercise of warrants Fair value, exercise of wararnts Warrants outstanding, ending balance Fair value, ending balance Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Warrants outstanding Exercise price Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk, percentage Cash, FDIC insured amount Cash, exceeding Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Number of debt instruments Debt instrument face amount Due from related parties, current Federal: Current Deferred State and local: Current Deferred Income tax provision U.S. federal statutory rate State tax rate, net of federal benefit Non-deductible expenses Timing differences Change in valuation allowance Income tax provision Deferred tax assets: Net operating loss carryforwards Other Total deferred tax assets Valuation allowance Deferred tax assets, net of valuation allowance Income tax expense (benefit) Unrecognized tax benefits Deferred tax assets, operating loss carryforwards, state and local Subsequent Event [Table] Subsequent Event [Line Items] Exercise price, per share Warrants expire term Common stock outstanding percentage Gross proceeds from issuance of initial public offering Cash fee of aggregate gross proceeds percentage Warrants exercisable period Warrants to Purchase Common Stock [Member] Common Stock, par value 0.001 [Member] Warrant liability current. Change In Fair Value Of Warrant Liability And Warrant Modification Expense. Sport Defense LLC [Member] Technology Related and Customer Related Intangibles [Member] CG Labs JV [Member] Kenkoderm [Member] Finite lived intangible assets amortization expense after year four. 2019 Plan [Member] Share based compensation arrangement by share based payment award number of shares available for exercised. Stock issued during period value stock warrants exercised. Awards Granted Outside Of The 2019 Plan [Member] Stock issued during period shares stock warrants exercised. Dr.Neil Chesen [Member] Option One [Member] Option Two [Member] Option Three [Member] Contractor [Member] Dr.Leonard Nelson [Member] Share based compensation arrangement by share based payment award options cancelled in period. Share based compensation arrangement by share based payment award options grants in period. Warrant modification expense. Property and equipment contributed as capital investment to JV. Rou asset and operating lease liabilities recognized upon consolidation of jv. Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 2. Net assets acquired in acquisition. Contingent consideration liability. Joint Venture [Member] CG Labs [Member] Working capital deficit. Officers and Employees [Member] Share based compensation arrangement by share based payment award equity instruments other than options exercisable non vested number. Share based compensation arrangement by share based payment award equity instruments other than options non vested exercisable weighted average grant date fair value. Share based compensation arrangement by share based payment award equity instruments other than options exercises in period weighted average grant date fair value. Registered Direct Offering [Member] Unrecognized share based compensation expense. The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan. Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. Other Assets Policy [Policy Text Block] Warrant Liability Policy [Policy Text Block] Revenue from contract manufacturing. Revenue from finished goods. Revenue from consumer products. Revenue classified as others. Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants plan. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of warrants outstanding and currently exercisable under the warrants plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants. Weighted average price at which option holders acquired shares when converting their warrants into shares. Weighted average price at which grantees could have acquired the underlying shares with respect to warrants that were terminated. Weighted average price at which grantees could have acquired the underlying shares with respect to warrants that were terminated. Weighted average price at which grantees could have acquired the underlying shares with respect to warrants of the plan that expired. Weighted average remaining contractual term for non option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term, exercisable. Intrinsic value of vested outstanding warrants. Economic Injury Disaster Loan [Member] New Accounting Pronouncements [Policy Text Block] C.G. Laboratories Inc. [Member] CG Labs Notes Payable [Member] CG Labs Notes Payable One [Member] Nexgel [Member] Advance payment of promissory note. Elimination [Member] Auctus Note [Member] Secured Convertible Promissory Note [Member] Outstanding Principal And Accrued Unpaid Interest. Pre Payment Penalty Warrants Liability Disclosure [Text Block] Schedule Of Fair Value Warrant Liability [Text Block] Fair Value Adjustment Of Warrants Shares Warrant Modification. The tabular disclosure of supplemental cash flows information related to leases. Customer One [Member] Customer Two [Member] Customer Three [Member] Number of debt instruments. Mr. Stein [Member] Mr.Stefansky [Member] Dr.Jerome Zeldis [Member] Kenkoderm Acquisition [Member] Subscription Agreements [Member] Cash fee of aggregate gross proceeds percentage Non Affiliated Entity [Member] Placement Agent [Member] Warrants exercisable period Business acquisition pro forma weighted average number of shares outstanding basic. Business acquisition pro forma weighted average number of shares outstanding diluted. Payments to acquire businesses, cash earn-out US Treasury Securities One [Member] US Treasury Securities Two [Member] US Treasury Securities Three [Member] US Treasury Securities Four [Member] US Treasury Securities Five [Member] Class of warrant or right exercise price of warrants or rights. Shipping and handling revenue and expense policy text block. Contract Manufacturing [Member] Custom and White Label Finished Goods [Member] Branded Consumer Products [Member] Other Incomes [Member] Loss attributable to non-controlling interest in joint venture. Property and equipment and intangibles contributed as capital investment to jv. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses ChangeInFairValueOfWarrantLiabilityAndWarrantModificationExpense Other Nonoperating Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Parent Shares, Outstanding Marketable Security, Gain (Loss) Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Interest in Subsidiaries and Affiliates Payments to Acquire Marketable Securities Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Notes Payable Repayments of Convertible Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Lessee, Operating Leases [Text Block] Inventory Disclosure [Text Block] WarrantsLiabilityDisclosureTextBlock Cash and Cash Equivalents, Policy [Policy Text Block] WarrantLiabilityPolicyPolicyTextBlock Share-Based Payment Arrangement [Policy Text Block] Income Tax, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Revenue from Contract with Customer, Including Assessed Tax Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Acquisition, Pro Forma Revenue Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Inventory, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Net Finite-Lived Intangible Asset, Expected Amortization, Year One Finite-Lived Intangible Asset, Expected Amortization, Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Five Finite-Lived Intangible Asset, Expected Amortization, after Year Five Other Liabilities, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1 Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Long-Term Debt, Maturity, Year Five Long-Term Debt, Maturity, after Year Five Long-Term Debt Warrants and Rights Outstanding Class of Warrant or Right, Number of Securities Called by Warrants or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Current State and Local Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Deduction, Percent Effective Income Tax Rate Reconciliation, Percent Deferred Tax Assets, Other Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 13 nxgl-20231231_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Apr. 10, 2024
Jun. 30, 2023
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41173    
Entity Registrant Name NexGel, Inc.    
Entity Central Index Key 0001468929    
Entity Tax Identification Number 26-4042544    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 2150 Cabot Blvd West    
Entity Address, Address Line Two Suite B    
Entity Address, City or Town Langhorne    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19047    
City Area Code (215)    
Local Phone Number 702-8550    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status No    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 10,695,605
Entity Common Stock, Shares Outstanding   6,227,624  
Documents Incorporated by Reference [Text Block] Portions of the registrant’s definitive proxy statement relating to its 2024 annual meeting of stockholders (the “2024 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the year to which this report relates.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 76    
Auditor Name Turner, Stone & Company, L.L.P    
Auditor Location Dallas, Texas    
Common Stock, par value 0.001 [Member]      
Title of 12(b) Security Common Stock, par value $0.001    
Trading Symbol NXGL    
Security Exchange Name NASDAQ    
Warrants to Purchase Common Stock [Member]      
Title of 12(b) Security Warrants to Purchase Common Stock    
Trading Symbol NXGLW    
Security Exchange Name NASDAQ    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets:    
Cash $ 2,700 $ 1,101
Marketable securities 5,508
Accounts receivable, net 633 222
Inventory 1,319 502
Prepaid expenses and other current assets 400 172
Total current assets 5,052 7,505
Goodwill 1,128 311
Intangibles, net 326 20
Property and equipment, net 1,499 721
Operating lease - right of use asset 1,855 1,737
Other assets 95 63
Total assets 9,955 10,357
Current Liabilities:    
Accounts payable 1,233 265
Accrued expenses and other current liabilities 398 130
Deferred revenue 20
Current portion of note payable 80 15
Warrant liability 146 242
Contingent consideration liability 439
Operating lease liability, current portion 233 207
Total current liabilities 2,549 859
Operating lease liability, net of current portion 1,727 1,593
Notes payable, net of current portion 513 268
Total liabilities 4,789 2,720
Commitments and Contingencies (Note 16)
STOCKHOLDERS’ EQUITY    
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,741,838 and 5,577,916 shares issued and outstanding as of December 31, 2023 and 2022, respectively 6 6
Additional paid-in capital 19,406 19,189
Accumulated deficit (14,715) (11,558)
Total NexGel stockholders’ equity 4,697 7,637
Non-controlling interest in joint venture 469
Total stockholders’ equity 5,166 7,637
Total liabilities and stockholders’ equity $ 9,955 $ 10,357
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 25,000,000 25,000,000
Common stock, shares issued 5,741,838 5,577,916
Common stock, shares outstanding 5,741,838 5,577,916
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenues, net $ 4,089 $ 2,048
Cost of revenues 3,470 1,792
Gross profit 619 256
Operating expenses    
Research and development 103 367
Selling, general and administrative 3,993 3,237
Total operating expenses 4,096 3,604
Loss from operations (3,477) (3,348)
Other income (expense)    
Change in fair value of warrant liability, net of warrant modification expense 96 76
Realized gain on investments in marketable securities 191 9
Loss on debt extinguishment (150)
Interest expense, net (15) (1,336)
Other expense (2)
Other income 19 3
Total other income (expense), net 289 (1,398)
Loss before income taxes (3,188) (4,746)
Income tax expense
Net loss (3,188) (4,746)
Less: Loss attributable to non-controlling interest in joint venture 31
Net loss attributable to NexGel stockholders $ (3,157) $ (4,746)
Net loss per common share - basic $ (0.56) $ (0.85)
Net loss per common share - diluted $ (0.56) $ (0.85)
Weighted average shares used in computing net loss per common share - basic 5,671,842 5,574,818
Weighted average shares used in computing net loss per common share - diluted 5,671,842 5,574,818
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Noncontrolling Interest [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 6 $ 18,891 $ (6,812) $ 12,085
Balance, shares at Dec. 31, 2021 5,572,234        
Stock-based compensation 231 231
Stock-based compensation, shares        
Restricted stock issuances 67 67
Restricted stock issuances, shares 5,682        
Net loss (4,746) (4,746)
Balance at Dec. 31, 2022 $ 6 19,189 (11,558) 7,637
Balance, shares at Dec. 31, 2022 5,577,916        
Stock-based compensation 217 $ 217
Stock-based compensation, shares 3,295       560,650
Restricted stock issuances
Restricted stock issuances, shares 50,907       64,562
Net loss (31) (3,157) $ (3,188)
Exercise of warrants
Exercise of stock warrants, shares 109,720        
Non-controlling interest contribution 500 500
Balance at Dec. 31, 2023 $ 6 $ 19,406 $ 469 $ (14,715) $ 5,166
Balance, shares at Dec. 31, 2023 5,741,838        
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating Activities    
Net loss $ (3,157) $ (4,746)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss attributable to non-controlling interest in joint venture (31)
Depreciation and amortization 226 112
Share-based compensation 217 298
Realized gain on investment in marketable securities (191) (9)
Change in fair value of warrant liability (125) (133)
Amortization of right of use asset 217 189
Warrant modification expense 29 57
Loss of extinguishment of debt 150
Amortization of deferred financing costs 1,324
Changes in operating assets and liabilities:    
Accounts receivable, net (411) (13)
Inventory (760) (211)
Prepaid expenses and other current assets (260) (95)
Accounts payable 968 11
Accrued expenses and other current liabilities 22 74
Deferred revenue 20
Net Cash Used in Operating Activities (3,236) (2,992)
Investing Activities    
Purchases of equipment (696) (96)
Investment in subsidiary (547)
Proceeds from sales of marketable securities 5,699 1,500
Investments in or purchases of marketable securities (6,999)
Net Cash Provided by (Used in) Investing Activities 4,456 (5,595)
Financing Activities    
Principal payments on operating lease liability (175) (151)
Proceeds from notes payable 315
Principal payments of notes payable (6)
Principal payments on convertible notes (3,511)
Proceeds from margin line of credit 245
Net Cash Provided by (Used in) Financing Activities 379 (3,662)
Net Increase (Decrease) in Cash 1,599 (12,249)
Cash  – Beginning of year 1,101 13,350
Cash – End of year 2,700 1,101
Supplemental Non-cash Investing and Financing Activities    
Property and equipment and intangibles contributed as capital investment to JV 500
ROU asset and operating lease liabilities recognized upon consolidation of JV $ 334
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Description of Business, Stock Split and Basis of Presentation
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Description of Business, Stock Split and Basis of Presentation

1. Description of Business, Stock Split and Basis of Presentation

 

NexGel, Inc. (“NexGel” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the company. First, we launched our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture.

 

NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019.

 

On March 1, 2023, the Company acquired a 50% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC, with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business. The JV is effective March 1, 2023. As a result of this transaction, the Company owns 50% of the JV, with the remaining 50% held by CG Labs.

 

Basis of Presentation

 

The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and are presented in US dollars.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its consolidated wholly-owned subsidiary, NexGelRx, Inc. and the fifty percent (50%) owned JV (see Note 13).

 

 
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Going Concern
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

2. Going Concern

 

As of December 31, 2023, the Company had a cash balance of $2.7 million. For the year ended December 31, 2023, the Company incurred a net loss of $3.2 million and had a net usage of cash in operating activities of $3.2 million. In addition, the Company had a working capital of $2.5 million as of December 31, 2023. Additionally, we believe we have sufficient cash and marketable securities to operate our business plan into 2025.

 

On February 15, 2024, the Company, entered into subscription agreements with investors, the Company’s Chief Financial Officer and certain members of its board of directors for a registered direct offering (“RDO”) of the Company’s common stock. The RDO sold an aggregate 242,891 units at a price to the public of $4.22 per unit, with each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $4.00 per share. The $4.22 purchase price equals two times the last reported sale price of $2.11 per share of the Company’s Common Stock on February 15, 2024 on The Nasdaq Capital Market. The gross proceeds to the Company from the Offering are expected to be approximately $1.025 million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering for working capital and for general corporate purposes (See Note 20).

 

Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices. The Company has increased focus on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.

 

We have sufficient capital to maintain as a going concern due to the recent capital raise. We intend to maintain and attempt to grow our existing contract manufacturing business. We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media, television and online marketplaces. Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology. Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.

 

We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.

 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies and Estimates
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies and Estimates

3. Significant Accounting Policies and Estimates

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.

 

 

Segment Reporting

 

The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, Segment Reporting, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company has two reportable segments - the Nexgel segment and the CG labs segment.

 

The Nexgel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania.

 

The CG labs segment is comprised of the JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.

 

Cash

 

Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.

 

Marketable Securities

 

The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs.

 

The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Marketable Securities          
United States treasury bills (due February 23, 2023)  $      -   $492 
United States treasury bills (due April 27, 2023)   -    20 
United States treasury bills (due June 15, 2023)   -    4,384 
United States treasury bills (due July 13, 2023)   -    127 
United States treasury bills (due August 10, 2023)   -    485 
Total  $-   $5,508 

 

Margin Line of Credit

 

We have a brokerage account through which we buy and sell U.S. treasury bills. The provisions of the account allow us to borrow on certain securities held in the account and to purchase additional securities based on the account equity (including cash). Amounts borrowed are collateralized by the securities held in the account and bear interest at a negotiated rate payable monthly. Securities pledged to secure margin balances cannot be specifically identified as a portion of all securities held in a brokerage account are used as collateral. As of December 31, 2023, there was $245 thousand outstanding under this short-term credit line which is included in accrued expenses and other current liabilities within the accompanying consolidated balance sheet (see Note 10). The short-term credit line will be repaid upon the maturity of U.S. treasury bills of $3 million with an original maturity of three months or less which are included in cash within the accompanying consolidated balance sheet.

 

 

Accounts Receivable, net

 

Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $11 thousand as of December 31, 2023 and $9 thousand as of December 31, 2022.

 

Inventory and Cost of Revenues

 

Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value.

 

The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.

 

The balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS.

 

The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.

 

Research and Development

 

Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.

 

Shipping and Handling Revenue and Expense

 

Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. Shipping revenue and expense are primarily generated through the Amazon marketplace.

 

Property and Equipment, net

 

Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.

 

Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.

 

The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.

 

 

Impairment of Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.

 

Goodwill and Intangible Assets

 

In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value.

 

The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and no impairments were recognized in the years ended December 31, 2023 and 2022.

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $64 thousand and $63 thousand of prepaid insurance, and $336 thousand and $109 thousand general prepaid expenses and other current assets in the years ended December 31, 2023 and 2022 respectively.

 

Other Assets

 

Other Assets is recorded at historical costs, and as of December 31, 2023 and 2022, the balance is primarily comprised of spare parts for manufacturing equipment. Spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.

 

Fair Value Measurements

 

The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

Level 1 —Quoted prices for identical assets or liabilities in active markets.

 

Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.

 

 

The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.

 

The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2023     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                    
Marketable securities:                    
United States treasury bills  $-   $-   $-   $- 
Total  $-   $-   $-   $- 

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2022     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                
Marketable securities:                    
United States treasury bills  $5,508   $-   $-   $5,508 
Total  $5,508   $-   $-   $5,508 

 

Warrant Liability

 

Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.

 

Revenue Recognition

 

On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption.

 

The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product.

 

The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment.

 

 

Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.

 

Disaggregated revenue by sales type ($ in thousands):

 

    2023     2022  
    Year Ended  
    December 31,  
    2023     2022  
Contract manufacturing   $ 2,748     $ 1,033  
Custom and white label finished goods manufacturing     15       34  
Consumer branded products     1,242       815  
Other     84       166  
Total   $ 4,089     $ 2,048  

 

As of December 31, 2023 and 2022, the Company did not have any contract assets or contract liabilities from contracts with customers and there were no remaining performance obligations that the Company had not satisfied except for deferred revenue of $20 thousand at December 31, 2023 that the Company had not satisfied as of the end of the year. The Company had no remaining performance obligations as of December 31, 2022.

 

The Company has four distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices.

 

Contract Manufacturing

 

Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they convert and package into finished goods. Historically, this has been the Company’s primary source of revenue.

 

Custom and White Label

 

These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.

 

Consumer Branded Products

 

These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names.

 

Medical Devices/Other

 

Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.

 

Share-based Compensation

 

On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 12 below for further details regarding the 2019 Plan.

 

 

The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.

 

Leases

 

ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.

 

The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.

 

Variable Interest Entity

 

The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.

 

If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. As of December 31, 2023, and on a quarterly basis thereafter, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.

 

Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.

 

 

Comprehensive loss

 

Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented.

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

 

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023 and subsequent interim periods. The Company adopted this new standard in the current year and it did not have a material impact to its consolidated financial statements.

 

Accounting Pronouncements Issued But Not Yet Adopted

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced income tax related disclosures. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures relating to its reportable segments. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Segments
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Business Segments

4. Business Segments

 

The Company’s Chief Executive Officer, who serves as the chief operating decision maker (“CODM”), evaluates the financial performance of the Company’s segments based upon segment adjusted operating income or (loss) as the profitability measure. Items outside of adjusted operating income or (loss) are not reported by segment, since they are excluded from the single measure of segment profitability reviewed by the CODM.

 

Summarized financial information concerning the Company’s reportable segments for the years ended December 31, 2023 and 2022 is presented below.

 

For Year Ended December 31, 2023 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Revenue               
Contract Manufacturing  $769   $1,979   $2,748 
Custom and White Label Finished Goods   15    -    15 
Branded Consumer Products   1,242    -    1,242 
Other income   76    8    84 
Total revenue   2,102    1,987    4,089 
                
Cost of sales   1,911    1,559    3,470 
Operating expenses   3,604    492    4,096 
Loss from operations  $(3,413)  $(64)  $(3,477)

 

For Year Ended December 31, 2022 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Revenue               
Contract Manufacturing  $1,033   $-   $1,033 
Custom and White Label Finished Goods   34    -    34 
Branded Consumer Products   815    -    815 
Other income   166    -    166 
Total revenue   2,048    -    2,048 
                
Cost of sales   1,792    -    1,792 
Operating expenses   3,604    -    3,604 
Loss from operations  $(3,348)  $-   $(3,348)

 

As of December 31, 2023 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Assets:               
Current assets:               
Cash  $2,458   $242   $2,700 
Accounts receivable, net   26    607    633 
Inventory   622    697    1,319 
Prepaid expenses and other current assets   312    88    400 
Total current assets   3,418    1,634    5,052 
                
Goodwill   1,128    -    1,128 
Intangibles   122    204    326 
Property and equipment, net   898    601    1,499 
Operating lease – right of use asset   1,543    312    1,855 
Other assets   95    -    95 
Total Assets  $7,204   $2,751   $9,955 

 

Liabilities and Stockholders’ Equity            
Current liabilities:            
Accounts payable  $509   $724   $1,233 
Accrued expenses and other current liabilities   137    261    398 
Deferred revenue   20    -    20 
Current portion of note payable   6    74    80 
Warrant liability   146    -    146 
Contingent consideration liability   439    -    439 
Operating lease liability, current portion   207    26    233 
Total current liabilities   1,464    1,085    2,549 
                
Operating lease liability, net of current portion   1,438    289    1,727 
Notes payable, net of current portion   272    241    513 
Total liabilities  $3,174   $1,615   $4,789 

 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisition
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisition

5. Acquisition

 

Kenkoderm Acquisition

 

On December 1, 2023, the Company closed a transaction related to an Asset Purchase Agreement dated November 30, 2023 (the “Purchase Agreement”) with Olympus Trading Company, LLC, a Virginia limited liability company (the “Seller”), whereby the Company purchased all assets related to the Seller’s skincare line focused on reducing symptoms associated with psoriasis operating under the tradename “Kenkoderm” (“Kenkoderm acquisition”).

 

Under the terms of the Kenkoderm acquisition, the Company paid the Seller a cash payment of $546,500. Additionally, the Company shall pay the Seller a cash earn-out of the same amount each quarter, payable in the subsequent month flowing quarter end, of $136,625. The cash earn-out can fluctuate higher or lower based on the quarterly results of the Kenkoderm business during 2024 according to the formula contained in the Purchase Agreement.

 

The Purchase Agreement and the transaction contemplated thereby were not subject to approval by the shareholders of the Company. The Purchase Agreement contains standard representations and warranties regarding the Seller and the Kenkoderm business and certain limited representations and warranties regarding the Company. The Purchase Agreement also contains indemnification provisions for the benefit of the Company and the Seller. Neither the Company nor the Seller shall be liable for more than the Purchase Price under the indemnification provisions except in the case of fraud or willful misconduct. The Seller and the Seller’s President and owner agreed to 3-year non-compete provisions as part of the Purchase Agreement.

 

 

The provisional fair value of the purchase consideration issued to the Seller was allocated to the net tangible assets acquired. The Company accounted for the Kenkoderm acquisition as the purchase of a business under GAAP under the acquisition method of accounting, and the assets and liabilities acquired were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company. The fair value of the net assets acquired was approximately $169 thousand. The excess of the aggregate fair value of the net tangible assets has been allocated to goodwill.

 

The table below shows a preliminary analysis for the Kenkoderm acquisition ($ in thousands):

 

Provisional purchase consideration at preliminary fair value:     
Purchase price  $547 
Contingent consideration liability   439 
Amount of consideration  $986 
Assets acquired and liabilities assumed at preliminary fair value     
Inventory   56 
Product/technology related intangibles   77 
Marketing related intangibles   36 
Other liabilities   - 
Net tangible assets acquired  $169 
      
Total net assets acquired  $169 
Consideration paid   986 
Preliminary goodwill  $817 

 

Non-controlling Interest in Joint Venture – CG Labs

 

On March 1, 2023, the Company acquired a 50% interest in the JV (see Note 1). The JV is owned 50% by the Company and 50% by CG Labs. CG Labs contributed its existing converting and packaging division to the JV, including, but not limited to, its facilities, equipment, employees, and customers. The Company will contribute $500,000 to the JV, on a schedule to be determined, to be used for equipment and facility upgrades as well as general corporate purposes for the JV. As of December 31, 2023, the Company has contributed its full $500,000 commitment.

 

The JV is considered to be a VIE and we have consolidated the JV.

 

 

The recorded assets acquired and liabilities assumed in connection with the formation of CG Labs based on their estimated fair values as of the March 1, 2023. The preliminary purchase price allocation is as follow ($ in thousands):

 

Provisional purchase consideration at preliminary fair value:     
Cash contributed by the Company  $500 
Noncontrolling interest portion of CG Labs contributed business   500 
Amount of consideration  $1,000 
Assets acquired and liabilities assumed at preliminary fair value     
Cash contributed by the Company   500 
Fixed assets   213 
Product/technology related intangibles   217 
Marketing related intangibles   70 
Net tangible assets acquired  $1,000 
      
Total net assets acquired  $1,000 
Consideration paid   1,000 
Preliminary goodwill  $- 

 

The allocation of the purchase price to identifiable assets is based on the preliminary valuations performed to determine the fair value of the net assets as of the acquisition date. The measurement period for the valuation of net assets acquired ends as soon as information on the facts and circumstances that existed as of the acquisition dates becomes available, but not to exceed 12 months following the acquisition date. Adjustments in purchase price allocations may require a change in the amounts allocated to net assets acquired during the periods in which the adjustments are determined.

 

The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the Kenkoderm acquisition and CG Labs JV been completed as of January 1, 2022 or to project potential operating results as of any future date or for any future periods ($ in thousands except share and per share amounts):

 Schedule of Unaudited Pro-Forma Results of Operations

   2023   2022 
  

For the Year Ended

December 31,

 
   2023   2022 
Revenues, net  $5,522   $4,014 
Net loss allocable to common shareholders  $(3,071)  $(4,634)
Net loss per share  $(0.54)  $(0.83)
Weighted average number of shares outstanding   5,671,842    5,574,818 

 

 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases
 12 Months Ended
Dec. 31, 2023
Leases  
Leases

6. Leases

 

The Company has an operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania that runs through January 2031. There are two options that can extend the lease term for five years each. The exercise of the lease options to renew is solely at the Company’s discretion.

 

The Company also has a sublease for office and manufacturing space in Granbury, Texas that runs through February 2028.There is an option that can extend the lease term for an additional five years through February 2033. The exercise of the lease options to renew is solely at the Company’s discretion.

 

The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2023 ($ in thousands):

 

Maturity of Lease Liability 

Operating

Lease

Liability

 
2024  $245 
2025   245 
2026   301 
2027   315 
2028   324 
Thereafter   790 
Total undiscounted operating lease payments  $2,220 
Less: Imputed interest   (260)
Present value of operating lease liability  $1,960 
Weighted average remaining lease term   7.4 years 
Weighted average discount rate   3.0%

 

Total operating lease expense for the years ended December 31, 2023, and 2022, was $303 thousand and $246 thousand, respectively, and is recorded in cost of goods sold and selling, general, and administrative expenses in the accompanying consolidated statements of operations.

 

Supplemental cash flows information related to leases was as follows:

 

   December 31, 
   2023 
Cash paid for amounts included in the measurement of lease liability ($ in thousands):      
Operating cash flows from operating lease  $238 

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventory

7. Inventory

 

Inventory consists of the following ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Raw materials  $899   $295 
Work-in-progress   12    51 
Finished goods   408    156 
Inventory, gross   1,319    502 
Less: Inventory reserve for excess and slow moving inventory   -    - 
Total  $1,319   $502 

 

Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS. The Company builds its contract manufacturing products based on customer orders and immediately ships the products upon completion of the production process.

 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, Net
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net

8. Property and Equipment, Net

 

Property and equipment consist of the following ($ in thousands):

 

   Useful Life   December 31,   December 31, 
   (Years)   2023   2022 
Machinery and equipment   3 - 10   $1,280   $973 
Office furniture and equipment   3 - 10    139    59 
Leasehold improvements   6    419    228 
Construction in progress   N/A    387    55 
Total property and equipment        2,225    1,315 
Less: accumulated depreciation and amortization        (726)   (594)
Property and equipment, net       $1,499   $721 

 

Depreciation expense for the year ended December 31, 2023 and 2022 was $132 thousand and $99 thousand, respectively.

 

 
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

9. Intangible Assets

 

The following provides a breakdown of identifiable intangible assets as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Product/Technology Related          
Identifiable intangible assets, gross  $325   $31 
Accumulated amortization   (98)   (26)
Product/technology related identifiable intangible assets, net   227    5 
Marketing Related          
Customer related intangible asset, gross   17    17 
Tradename related intangible asset, gross   113    7 
Accumulated amortization   (31)   (9)
Marketing related identifiable intangible assets, net   99    15 
Total identifiable intangible assets, net  $326   $20 

 

In connection with the May 29, 2020 acquisition of Sports Defense, the Company identified intangible assets of $55 thousand representing technology related and customer related intangibles.

 

In connection with the March 1, 2023 CG Labs JV, the Company identified intangible assets of $287 thousand representing technology related and customer related intangibles.

 

In connection with the December 1, 2023 acquisition of Kenkoderm, the Company identified intangible assets of $113 thousand representing technology related and customer related intangibles.

 

These assets are being amortized on a straight-line basis over their weighted average estimated useful life of 2.9 years and amortization expense amounted to $94 and $13 thousand for the years ended December 31, 2023 and 2022, respectively.

 

As of December 31, 2023, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands):

 

      
2024  $119 
2025   126 
2026   63 
2027   13 
2028   2 
Thereafter   3 
Total  $326 

 

 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities

10. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consist of the following ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Salaries, benefits, and incentive compensation  $61   $56 
Franchise tax accrual   -    52 
Margin line of credit   245    - 
Other   92    22 
Total accrued expenses and other current liabilities  $398   $130 

 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Common Stock

11. Common Stock

 

At December 31, 2023, the Company has reserved common stock for issuance in relation to the following:

 

Share-based compensation plan   560,650 
Warrants to purchase common stock   3,442,904 
Restricted stock units   64,562 

 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Share-based Compensation

12. Share-based Compensation

 

The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initially reserved a total of 57,143 shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020 and May 3, 2021, respectively, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 57,143 shares of common stock to 485,715 and from 485,715 shares of common stock to 571,429 shares of common stock, all of which may be delivered pursuant to incentive stock options.

 

On March 23, 2023, the Board approved an additional 300,000 shares of common stock to be reserved under the 2019 Plan, such that total of number of shares underlying the Plan is 871,429 of which 609,687 shares have already been awarded or exercised. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is 14,286 shares of common stock.

 

The following table contains information about the 2019 Plan as of December 31, 2023:

 

   Awards           Awards 
   Reserved for   Awards   Awards   Available for 
   Issuance   Issued   Exercised   Grant 
2019 Plan(1)   871,429    649,833    17,916    221,596 
Awards issued in excess of 2019 Plan(2)   -    48,401    48,401    - 

 

(1) Includes incentive stock options and restricted stock units discussed below.
(2) Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.

 

 

Incentive stock options

 

On March 8, 2023, the Company granted a contractor an option to purchase up to 17,532 shares of the Company’s common stock at a per share exercise price of $2.00 under the Company’s 2019 Plan. This option award vests over a period of 12 months. The options expired unexercised.

 

On August 17, 2023, the Company granted options to purchase up to 90,000 shares of the Company’s common stock at a per share exercise price of $2.05 to members of the Board of Directors, all of which vests over a period of one year with 25% vested upon issuance.

 

On October 1, 2022, the Company appointed Dr. Neil Chesen to the Company’s Scientific Advisory Board and in consideration for his appointment to the board, the Company granted Dr. Chesen an option to purchase up to 65,000 shares of common stock at a per share exercise price of $2.00 under the Company’s 2019 Long-Term Incentive Plan. A portion of the award, 15,000 options, fully vested as of the date of grant and the remaining 50,000 options are contingent upon certain sales based milestones being achieved. The options expire on December 31, 2023 if the milestones are not achieved prior to that date. Also on October 1, 2022, the Company issued a second option grant to Dr. Chesen, to purchase up to 25,000 shares of common stock at a per share exercise price of $2.00 under the Company’s 2019 Long-Term Incentive Plan and are fully contingent upon certain sales based milestones being achieved with 18 months of commercial release. Also on October 1, 2022, the Company issued a third option grant to Dr. Chesen to purchase up to 37,500 shares of common stock at a per share exercise price of $5.50 under the Company’s 2019 Long-Term Incentive Plan and are fully contingent upon certain sales based milestones being achieved within 36 months of commercial release. As of December 31, 2022 the new product has not launched. The product launched in August 2023.

 

On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to 30,000 shares of the Company’s common stock at a per share price of $2.00 under the Company’s 2019 Long-Term Incentive Plan. A portion of the award, 5,000 options, fully vested as of the date of the grant and the remaining 25,000 options are contingent upon certain sales based milestones being achieved. The options expire within 18 months of commercial launch of a new product if the milestones are not achieved prior to that date or 10 years from the grant date, whichever comes first. The product launched in August 2023.

 

On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to 37,500 shares of the Company’s common stock at a per share price of $5.50 under the Company’s 2019 Long-Term Incentive Plan. The options are contingent upon certain sales based milestones being achieved. The options expire within 36 months of commercial launch of a new product if the milestones are not achieved prior to that date or 10 years from the grant date, whichever comes first. The product launched in August 2023.

 

The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2023 and 2022.

 

           Weighted 
       Weighted   Average 
       Average   Contractual 
   Number of   Exercise   Term in 
   Options   Price   Years 
Outstanding at January 1, 2022   434,939   $1.678955    8.56 
Granted   195,000    3.3461538    10.00 
Exercised   —    —    — 
Forfeited   —    —    — 
Cancelled   (100,001)   1.40000    — 
Expired   (5,001)   1.40000    — 
Outstanding at December 31, 2022   524,937   $2.351416    8.38 
                
Granted   117,532   $2.06041    10.00 
Exercised   (3,295)   1.75    — 
Forfeited   —    —    — 
Cancelled   (69,854)   1.965823    — 
Expired   (8,670)   1.703222    — 
Outstanding at December 31, 2023   560,650   $2.350742    7.95 
Exercisable at December 31, 2023   398,150   $1.829884    7.44 

 

 

As of December 31, 2023 and 2022, vested outstanding stock options had $295 thousand and $124 thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock, respectively. As of December 31, 2023, there was no unrecognized share-based compensation related to unvested stock options, excluding options fully contingent upon certain sales-based milestones being achieved within 18 to 36 months of commercial release.

 

The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate share-based compensation expense for year ended December 31, 2023 and 2022:

 

 

   2023    2022 
Volatility   257.64-258.01%    277.84%
Risk-free interest rate   4.21-4.42%    4.06%
Dividend yield   0.0%    0.0%
Expected term   5 - 5.50 years     5.0 years 

 

The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.

 

Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted-average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage.

 

Restrictive stock awards

 

Effective as of January 3, 2023, the Company granted a restricted stock award of 37,037 shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated December 30, 2022, all of which shares vested monthly from January 3, 2023 through December 31, 2023. Under ASC 718, the Company has measured the value of the 37,037 shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($1.35 per share).

 

Effective as of August 1, 2022, the Company granted a restricted stock award of 84,750 shares of the Company’s common stock to certain officers and employees, all of which shares vest in four equal installments on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Under ASC 718, the Company has measured the value of the 84,750 shares granted based on a closing price of the closing price of the Company’s stock at the grant date of the RSU Grant ($1.82 per share).

 

Effective as of January 1, 2022, the Company granted a restricted stock award of 11,364 shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated November 4, 2021, all of which shares vested monthly from January 1, 2022 through December 31, 2022. Under ASC 718, the Company has measured the value of the 11,364 shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($4.40 per share).

 

       Average 
   Number of   Grant Date 
   Units   Fair Value 
Outstanding at December 31, 2021   —   $— 
Granted   96,114    1.61 
Exercised and converted to common shares   (5,682)   4.40 
Forfeited   —    — 
Outstanding at December 31, 2022   90,432    1.43 
Granted   37,037    1.35 
Exercised and converted to common shares   (50,157)   1.76522 
Forfeited   (12,750)   1.82 
Outstanding at December 31, 2023   64,562   $1.82 
Exercisable at December 31, 2023   13,750   $1.82 

 

Compensation expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation expense for forfeited awards. As of December 31, 2023, there was $68 thousand unrecognized share-based compensation related to unvested RSUs, which the Company expects to recognize through December 2026.

 

Stock based compensation and restricted stock vesting of $217 thousand and $298 thousand has been recorded for the year ended December 31, 2023 and 2022, respectively.

 

 

Warrants

 

The following table shows a summary of common stock warrants for the years ended December 31, 2023 and 2022.

 

       Weighted   Weighted 
       Average   Average 
   Number of   Exercise   Contractual 
   Warrants   Price   Term in Years 
Outstanding at December 31, 2021   3,637,190   $5.16281    4.63 
                
Granted   —   $—    — 
Exercised   —    —    — 
Forfeited   —    —    — 
Cancelled   —    —    — 
Expired   —    —    — 
Outstanding at December 31, 2022   3,637,190   $5.16281    3.65 
Granted   —    —    — 
Exercised   (109,720)   0.55    — 
Forfeited   —    —    — 
Cancelled   (84,566)   0.89    — 
Expired   —    —    — 
Outstanding at December 31, 2023   3,442,904   $5.414793    2.87 
Exercisable at December 31, 2023   3,442,904   $5.414793    2.87 

 

As of December 31, 2023 and 2022, vested outstanding warrants had $0 and $114 thousand, respectively, intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock.

 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Notes Payable
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Notes Payable

13. Notes Payable

 

CG Labs Notes Payable

 

CG Labs has entered into a $231 thousand promissory note agreement for certain equipment. The equipment was installed in December 2023. The promissory note has a term of five years beginning on March 13, 2024. The promissory note accrues interest at 8% and requires interest only payments through March 13, 2024 and monthly payments of $4 thousand thereafter.

 

CG Labs has entered into a $242 thousand promissory note agreement for certain equipment. The funding advances of $84 thousand have been issued as of December 2023. The promissory note has a term of five years beginning on March 13, 2024. The promissory note accrues interest at 8% and requires interest only payments through March 13, 2024 and monthly payments of $5 thousand thereafter.

 

Economic Injury Disaster Loan

 

On May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan is up to $260,500, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning May 28, 2021 (twelve months from the date of the SBA Note) in the amount of $1,270. The balance of principal and interest is payable thirty years from the date of the SBA Note. In connection therewith, the Company received an $8 thousand advance, which does not have to be repaid. On March 26, 2021, the SBA announced that all EIDL loans issued in 2020 will start repayment 24 months from the date of the SBA Note. The SBA has since extended the repayment start to 30 months from the date of the SBA Note. The Company made its first payment in December 2022. The balances of the principal and accrued interest amounted to $277 thousand and $283 thousand as of December 31, 2023 and 2022, respectively.

 

 

The future annual principal amounts and accrued interest to be paid as of December 31, 2023 are as follows:

 

   Amount 
For the year ending December 31 ($ in thousands):     
2024  $80 
2025   89 
2026   51 
2027   55 
2028   59 
Thereafter   259 
Total  $593 

 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Convertible Notes Payable
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Convertible Notes Payable

14. Convertible Notes Payable

 

On March 11, 2021, the Company issued Auctus Fund, LLC, a Delaware limited liability company a one-year senior secured convertible promissory note in the principal amount of $1.68 million, which included $180 thousand of interest which was deemed fully earned as of the issuance date (the “Auctus Note”). The Auctus Note was fully repaid (including all principal and interest) on March 15, 2022 with a one-time cash payment of $1.68 million.

 

On September 2, 2021, the Company issued to certain holders one-year subordinated secured convertible promissory notes in the aggregate principal amount of $1,814 thousand, which included $194 thousand of interest which was deemed fully earned as of the issuance date (the “September 2 Notes”). On January 25, 2022, the Company repaid one of the September 2 Notes in full with a one-time cash payment of $300 thousand of outstanding principal and accrued but unpaid interest. The Company incurred pre-payment penalty of $17 thousand with respect to the repayment of the note and the remaining unamortized debt discount in the amount of $133 thousand was written off and both amounts were recorded as a loss on extinguishment of debt of $150 thousand in accompany statement of operations during 2022. The repayment extinguished the note in its entirety. On September 6, 2022, the outstanding balance on the remaining September 2 Notes’ was repaid in full which consisted of principal of $1,478 thousand.

 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Warrant Liability
 12 Months Ended
Dec. 31, 2023
Warrant Liability  
Warrant Liability

15. Warrant Liability

 

On September 2, 2021, March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019, and November 6, 2019, the Company issued 22,019, 34,285, 7,429, 7,286, 44,286, 35,714 and 114,286 warrants, respectively, as equity issuance consideration, in connection with a private placement of the Company’s common stock. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $0.49 to $5.25 per share at any time on or after their issuance date and on or prior to the close of business 3 years after the issuance date (the “Termination Date”). The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants required classification as a liability pursuant to ASC 815, Derivatives and Hedging. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income (expense) in the statement of operations.

 

On September 6, 2022, the Company agreed to extend the September 10, 2019 and November 6, 2019 warrants an additional six months until March 9, 2023 and May 5, 2023, respectively. The warrants were remeasured as of September 6, 2022 and consequently resulted in a warrant modification expense of $57 thousand.

 

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Warrants

Outstanding

  

Fair Value

per Share

   Fair Value 
Fair value as of year ended 12/31/2021   265,305        $318 
Modification of warrants   -           57 
Change in fair value of warrant liability   -         (133)
Fair value as of year ended 12/31/2022   265,305         242 
Exercise of warrants   (194,286)       (144)
Modification of warrants   -         29 
Change in fair value of warrant liability   -         19 
Fair value as of year ended 12/31/2023   71,019        $146 

 

 

The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility of Guideline Public Companies as inputs.

 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

16. Commitments and Contingencies

 

Litigation

 

The Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will have a material effect on the financial position, results of operations, or cash flows of the Company.

 

Service Agreement

 

On March 21, 2023, the Company entered into a Services Agreement with GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (“Haleon”) to supply material for a consumer product to be developed and released in the future. There can be no guaranty that a consumer product will be released or, if released, that it will be successful.

 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Concentrations of Risk
 12 Months Ended
Dec. 31, 2023
Risks and Uncertainties [Abstract]  
Concentrations of Risk

17. Concentrations of Risk

 

The Company’s revenues are concentrated in a small group of customers with some individually comprising more than 10% of total revenues.

 

For the year ended December 31, 2023, the Company had revenue from one customer that approximated 20% of total revenue. For the year ended December 31, 2022, the Company had revenue from one customer that approximated 29% of total revenue.

 

The Company had one customer with accounts receivable balances that approximated 69% of total accounts receivable as of December 31, 2023. The Company had three customers with accounts receivable balances that approximated 40%, 22% and 18% of total accounts receivable as of December 31, 2022.

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Cash balances are maintained principally at major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. Such cash balances are currently in excess of the FDIC insurance limit of $250 thousand. As of December 31, 2023, the total amount exceeding such limit was $106 thousand. The Company has not experienced any credit losses associated with its cash balances in the past. The Company invests its cash equivalents in U.S. treasury bills with original maturities of three months or less.

 

Marketable securities are comprised of U.S. treasury bills with original maturities greater than three months. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions.

 

 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
 12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

18. Related Party Transactions

 

Convertible Promissory Note

 

On September 2, 2021, the Company issued three Secured Convertible Promissory Notes to members of the board of directors in an aggregate amounts of $150,000 to Mr. Stein, $150,000 to Mr. Stefansky (Bezalel Partners, LLC), and $50,000 to Dr. Zeldis as part of the September 2 Notes. The notes were repaid in full in 2022 (See Note 14).

 

Advances

 

Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $25,000 and $40,000 for services as of December 31, 2023 and 2022, respectively, included in accounts payable in the accompanying consolidated balance sheets.

 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

19. Income Taxes

 

The Company has established a full valuation allowance for its deferred tax assets based on management’s belief that it is not more likely than not that the related deferred tax assets will be realized. For the years ended December 31, 2023 and 2022, there was no income tax expense or benefit.

 

At December 31, 2023 and 2022, the Company had no recorded tax liabilities for uncertain tax positions. The Company does not expect any significant changes to the estimate amount of liabilities associated with uncertain tax positions in the next 12 months.

 

The income tax (benefit) provision consists of the following:

 

   2023   2022 
   For The Years Ended 
   December 31 
   2023   2022 
Federal:          
Current  $

(617

)  $

(619

)
Deferred   

617

    619 
State and local:          
Current   

(156

)   (159)
Deferred   156    159 
Income tax provision  $—   $— 

 

For the years ended December 31, 2023 and 2022, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows:

 

   2023   2022 
   For The Years Ended December 31, 
   2023   2022 
U.S. federal statutory rate   21.0%   21.0%
State tax rate, net of federal benefit   5.3%   5.3%
Permanent differences          
Non-deductible expenses   (1.9)%   (9.7)%
Timing differences   —   —
Change in valuation allowance   (24.4)%   (16.6)%
Income tax provision   —%   —%

 

For the years ended December 31, 2023 and 2022, differences between the expected tax expense based on the federal statutory rate and the actual tax expense is primarily attributable to the net losses incurred and the corresponding increase to the valuation allowance.

 

 

As of December 31, 2023 and 2022, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:

 

    2023     2022  
    As of December 31,  
    2023     2022  
Deferred tax assets:                
Net operating loss carryforwards   $ 4,882     $ 4,112  
Other     9       6  
Total deferred tax assets     4,891       4,118  
Valuation allowance     (4,891 )     (4,118 )
Deferred tax assets, net of valuation allowance   $ —     $ —  

 

As of December 31, 2023 and 2022, the Company has approximately $18.6 million and $15.6 million of federal NOL carryovers, respectively, which begin to expire in 2029 through 2036. Similarly, the subsidiary’s Pennsylvania state returns reported state NOL carryovers of approximately $18.6 million and $15.6 million, as of December 31, 2023 and 2022, respectively. However, these loss carryforwards on a separate company basis may be subject to limitations on the amounts that may be utilized pursuant to Internal Revenue Code section 382 and applicable state law. Section 382 imposes significant limitations on the utilization of net operating losses after certain changes of corporate ownership. The Company will need to determine the amount of loss carryforwards that may be utilized in the future as necessary.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the years in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2023 and 2022 because management has determined that it is more likely than not that these deferred tax assets will not be realized.

 

The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2023 and 2022, the Company does not have any significant uncertain tax positions.

 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

20. Subsequent Events

 

Management of the Company has performed a review of events and transactions occurring after the consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying consolidated financial statements, noting no such events or transactions other than the following.

 

On February 15, 2024 (the “Closing Date”), the Company, entered into subscription agreements with investors, the Company’s Chief Financial Officer and certain members of its board of directors for a registered direct offering (“RDO”) of the Company’s common stock. The RDO sold an aggregate 242,891 units at a price to the public of $4.22 per unit, with each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $4.00 per share. The $4.22 purchase price equals two times the last reported sale price of $2.11 per share of the Company’s common stock on February 15, 2024 on The Nasdaq Capital Market. The Company issued 485,782 shares of common stock and warrants to purchase up to 242,891 shares of common stock.

 

Subject to certain ownership limitations, each of the warrants will become exercisable on the Closing Date, will have an exercise price of $4.00 per share and will expire five years after the Closing Date. The warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained in the registration statement is not available for, the issuance or resale of shares of common stock underlying the warrants to or by the holder. The holder of a warrant is prohibited from exercising of any such warrants to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 4.99% of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99%.

 

The gross proceeds to the Company from the RDO are expected to be approximately $1.025 million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the warrants. The Company intends to use the net proceeds from the RDO for working capital and for general corporate purposes.

 

The Company retained Alere Financial Partners, LLC (A division of Cova Capital Partners, LLC) to act as the placement agent for the RDO. The Company agreed to pay the placement agent a cash fee of 6% of the aggregate gross proceeds in the RDO received from non-affiliates of the Company and 3% of the aggregate gross proceeds in the RDO received from affiliates of the Company. Additionally, and upon the closing of the RDO, the Company agreed to issue to the placement agent warrants exercisable for a period of five years to purchase up to 6% of the number of shares sold in this offering, or up to 27,725 shares, at a per share exercise price of $4.00.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies and Estimates (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.

 

 
Segment Reporting

Segment Reporting

 

The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, Segment Reporting, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company has two reportable segments - the Nexgel segment and the CG labs segment.

 

The Nexgel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania.

 

The CG labs segment is comprised of the JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.

 
Cash

Cash

 

Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.

 
Marketable Securities

Marketable Securities

 

The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs.

 

The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Marketable Securities          
United States treasury bills (due February 23, 2023)  $      -   $492 
United States treasury bills (due April 27, 2023)   -    20 
United States treasury bills (due June 15, 2023)   -    4,384 
United States treasury bills (due July 13, 2023)   -    127 
United States treasury bills (due August 10, 2023)   -    485 
Total  $-   $5,508 

 
Margin Line of Credit

Margin Line of Credit

 

We have a brokerage account through which we buy and sell U.S. treasury bills. The provisions of the account allow us to borrow on certain securities held in the account and to purchase additional securities based on the account equity (including cash). Amounts borrowed are collateralized by the securities held in the account and bear interest at a negotiated rate payable monthly. Securities pledged to secure margin balances cannot be specifically identified as a portion of all securities held in a brokerage account are used as collateral. As of December 31, 2023, there was $245 thousand outstanding under this short-term credit line which is included in accrued expenses and other current liabilities within the accompanying consolidated balance sheet (see Note 10). The short-term credit line will be repaid upon the maturity of U.S. treasury bills of $3 million with an original maturity of three months or less which are included in cash within the accompanying consolidated balance sheet.

 

 
Accounts Receivable, net

Accounts Receivable, net

 

Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $11 thousand as of December 31, 2023 and $9 thousand as of December 31, 2022.

 
Inventory and Cost of Revenues

Inventory and Cost of Revenues

 

Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value.

 

The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.

 

The balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS.

 

The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.

 
Research and Development

Research and Development

 

Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.

 
Shipping and Handling Revenue and Expense

Shipping and Handling Revenue and Expense

 

Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. Shipping revenue and expense are primarily generated through the Amazon marketplace.

 
Property and Equipment, net

Property and Equipment, net

 

Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.

 

Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.

 

The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.

 

 
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.

 
Goodwill and Intangible Assets

Goodwill and Intangible Assets

 

In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value.

 

The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and no impairments were recognized in the years ended December 31, 2023 and 2022.

 
Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $64 thousand and $63 thousand of prepaid insurance, and $336 thousand and $109 thousand general prepaid expenses and other current assets in the years ended December 31, 2023 and 2022 respectively.

 
Other Assets

Other Assets

 

Other Assets is recorded at historical costs, and as of December 31, 2023 and 2022, the balance is primarily comprised of spare parts for manufacturing equipment. Spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.

 
Fair Value Measurements

Fair Value Measurements

 

The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

Level 1 —Quoted prices for identical assets or liabilities in active markets.

 

Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.

 

 

The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.

 

The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2023     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                    
Marketable securities:                    
United States treasury bills  $-   $-   $-   $- 
Total  $-   $-   $-   $- 

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2022     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                
Marketable securities:                    
United States treasury bills  $5,508   $-   $-   $5,508 
Total  $5,508   $-   $-   $5,508 

 
Warrant Liability

Warrant Liability

 

Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.

 
Revenue Recognition

Revenue Recognition

 

On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption.

 

The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product.

 

The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment.

 

 

Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.

 

Disaggregated revenue by sales type ($ in thousands):

 

    2023     2022  
    Year Ended  
    December 31,  
    2023     2022  
Contract manufacturing   $ 2,748     $ 1,033  
Custom and white label finished goods manufacturing     15       34  
Consumer branded products     1,242       815  
Other     84       166  
Total   $ 4,089     $ 2,048  

 

As of December 31, 2023 and 2022, the Company did not have any contract assets or contract liabilities from contracts with customers and there were no remaining performance obligations that the Company had not satisfied except for deferred revenue of $20 thousand at December 31, 2023 that the Company had not satisfied as of the end of the year. The Company had no remaining performance obligations as of December 31, 2022.

 

The Company has four distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices.

 

Contract Manufacturing

 

Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they convert and package into finished goods. Historically, this has been the Company’s primary source of revenue.

 

Custom and White Label

 

These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.

 

Consumer Branded Products

 

These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names.

 

Medical Devices/Other

 

Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.

 
Share-based Compensation

Share-based Compensation

 

On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 12 below for further details regarding the 2019 Plan.

 

 

The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur.

 
Income Taxes

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.

 
Leases

Leases

 

ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.

 

The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.

 
Variable Interest Entity

Variable Interest Entity

 

The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.

 

If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. As of December 31, 2023, and on a quarterly basis thereafter, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.

 

Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.

 

 
Comprehensive loss

Comprehensive loss

 

Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented.

 
Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

 

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023 and subsequent interim periods. The Company adopted this new standard in the current year and it did not have a material impact to its consolidated financial statements.

 
Accounting Pronouncements Issued But Not Yet Adopted

Accounting Pronouncements Issued But Not Yet Adopted

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced income tax related disclosures. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures relating to its reportable segments. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies and Estimates (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Marketable Securities

The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Marketable Securities          
United States treasury bills (due February 23, 2023)  $      -   $492 
United States treasury bills (due April 27, 2023)   -    20 
United States treasury bills (due June 15, 2023)   -    4,384 
United States treasury bills (due July 13, 2023)   -    127 
United States treasury bills (due August 10, 2023)   -    485 
Total  $-   $5,508 
Schedule of Fair Value of Financial Assets

The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2023     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                    
Marketable securities:                    
United States treasury bills  $-   $-   $-   $- 
Total  $-   $-   $-   $- 

 

   Level 1   Level 2   Level 3   Fair Value 
       December 31, 2022     
   Level 1   Level 2   Level 3   Fair Value 
Assets                                
Marketable securities:                    
United States treasury bills  $5,508   $-   $-   $5,508 
Total  $5,508   $-   $-   $5,508 
Schedule of Disaggregated Revenue by Sales Type

Disaggregated revenue by sales type ($ in thousands):

 

    2023     2022  
    Year Ended  
    December 31,  
    2023     2022  
Contract manufacturing   $ 2,748     $ 1,033  
Custom and white label finished goods manufacturing     15       34  
Consumer branded products     1,242       815  
Other     84       166  
Total   $ 4,089     $ 2,048  
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Segments (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Reportable Segments

Summarized financial information concerning the Company’s reportable segments for the years ended December 31, 2023 and 2022 is presented below.

 

For Year Ended December 31, 2023 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Revenue               
Contract Manufacturing  $769   $1,979   $2,748 
Custom and White Label Finished Goods   15    -    15 
Branded Consumer Products   1,242    -    1,242 
Other income   76    8    84 
Total revenue   2,102    1,987    4,089 
                
Cost of sales   1,911    1,559    3,470 
Operating expenses   3,604    492    4,096 
Loss from operations  $(3,413)  $(64)  $(3,477)

 

For Year Ended December 31, 2022 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Revenue               
Contract Manufacturing  $1,033   $-   $1,033 
Custom and White Label Finished Goods   34    -    34 
Branded Consumer Products   815    -    815 
Other income   166    -    166 
Total revenue   2,048    -    2,048 
                
Cost of sales   1,792    -    1,792 
Operating expenses   3,604    -    3,604 
Loss from operations  $(3,348)  $-   $(3,348)

 

As of December 31, 2023 ($ in thousands)

 

   Nexgel   CG Labs   Total 
Assets:               
Current assets:               
Cash  $2,458   $242   $2,700 
Accounts receivable, net   26    607    633 
Inventory   622    697    1,319 
Prepaid expenses and other current assets   312    88    400 
Total current assets   3,418    1,634    5,052 
                
Goodwill   1,128    -    1,128 
Intangibles   122    204    326 
Property and equipment, net   898    601    1,499 
Operating lease – right of use asset   1,543    312    1,855 
Other assets   95    -    95 
Total Assets  $7,204   $2,751   $9,955 

 

Liabilities and Stockholders’ Equity            
Current liabilities:            
Accounts payable  $509   $724   $1,233 
Accrued expenses and other current liabilities   137    261    398 
Deferred revenue   20    -    20 
Current portion of note payable   6    74    80 
Warrant liability   146    -    146 
Contingent consideration liability   439    -    439 
Operating lease liability, current portion   207    26    233 
Total current liabilities   1,464    1,085    2,549 
                
Operating lease liability, net of current portion   1,438    289    1,727 
Notes payable, net of current portion   272    241    513 
Total liabilities  $3,174   $1,615   $4,789 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisition (Tables)
 12 Months Ended
Dec. 31, 2023
Business Acquisition [Line Items]  
Schedule of Unaudited Pro-Forma Results of Operations

 Schedule of Unaudited Pro-Forma Results of Operations

   2023   2022 
  

For the Year Ended

December 31,

 
   2023   2022 
Revenues, net  $5,522   $4,014 
Net loss allocable to common shareholders  $(3,071)  $(4,634)
Net loss per share  $(0.54)  $(0.83)
Weighted average number of shares outstanding   5,671,842    5,574,818 
Kenkoderm Acquisition [Member]  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions

The table below shows a preliminary analysis for the Kenkoderm acquisition ($ in thousands):

 

Provisional purchase consideration at preliminary fair value:     
Purchase price  $547 
Contingent consideration liability   439 
Amount of consideration  $986 
Assets acquired and liabilities assumed at preliminary fair value     
Inventory   56 
Product/technology related intangibles   77 
Marketing related intangibles   36 
Other liabilities   - 
Net tangible assets acquired  $169 
      
Total net assets acquired  $169 
Consideration paid   986 
Preliminary goodwill  $817 
CG Labs [Member]  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions

The recorded assets acquired and liabilities assumed in connection with the formation of CG Labs based on their estimated fair values as of the March 1, 2023. The preliminary purchase price allocation is as follow ($ in thousands):

 

Provisional purchase consideration at preliminary fair value:     
Cash contributed by the Company  $500 
Noncontrolling interest portion of CG Labs contributed business   500 
Amount of consideration  $1,000 
Assets acquired and liabilities assumed at preliminary fair value     
Cash contributed by the Company   500 
Fixed assets   213 
Product/technology related intangibles   217 
Marketing related intangibles   70 
Net tangible assets acquired  $1,000 
      
Total net assets acquired  $1,000 
Consideration paid   1,000 
Preliminary goodwill  $- 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases  
Schedule of Future Minimum Lease Payments

The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2023 ($ in thousands):

 

Maturity of Lease Liability 

Operating

Lease

Liability

 
2024  $245 
2025   245 
2026   301 
2027   315 
2028   324 
Thereafter   790 
Total undiscounted operating lease payments  $2,220 
Less: Imputed interest   (260)
Present value of operating lease liability  $1,960 
Weighted average remaining lease term   7.4 years 
Weighted average discount rate   3.0%
Schedule of Supplemental Cash Flows Information Related to Leases

Supplemental cash flows information related to leases was as follows:

 

   December 31, 
   2023 
Cash paid for amounts included in the measurement of lease liability ($ in thousands):      
Operating cash flows from operating lease  $238 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory

Inventory consists of the following ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Raw materials  $899   $295 
Work-in-progress   12    51 
Finished goods   408    156 
Inventory, gross   1,319    502 
Less: Inventory reserve for excess and slow moving inventory   -    - 
Total  $1,319   $502 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment consist of the following ($ in thousands):

 

   Useful Life   December 31,   December 31, 
   (Years)   2023   2022 
Machinery and equipment   3 - 10   $1,280   $973 
Office furniture and equipment   3 - 10    139    59 
Leasehold improvements   6    419    228 
Construction in progress   N/A    387    55 
Total property and equipment        2,225    1,315 
Less: accumulated depreciation and amortization        (726)   (594)
Property and equipment, net       $1,499   $721 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Breakdown of Identifiable Intangible Assets

The following provides a breakdown of identifiable intangible assets as of December 31, 2023 and 2022 ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Product/Technology Related          
Identifiable intangible assets, gross  $325   $31 
Accumulated amortization   (98)   (26)
Product/technology related identifiable intangible assets, net   227    5 
Marketing Related          
Customer related intangible asset, gross   17    17 
Tradename related intangible asset, gross   113    7 
Accumulated amortization   (31)   (9)
Marketing related identifiable intangible assets, net   99    15 
Total identifiable intangible assets, net  $326   $20 
Schedule of Estimated Annual Amortization Expense

As of December 31, 2023, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands):

 

      
2024  $119 
2025   126 
2026   63 
2027   13 
2028   2 
Thereafter   3 
Total  $326 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following ($ in thousands):

 

   December 31,   December 31, 
   2023   2022 
Salaries, benefits, and incentive compensation  $61   $56 
Franchise tax accrual   -    52 
Margin line of credit   245    - 
Other   92    22 
Total accrued expenses and other current liabilities  $398   $130 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Reserved Common Stock For Issued Securities in Relation

At December 31, 2023, the Company has reserved common stock for issuance in relation to the following:

 

Share-based compensation plan   560,650 
Warrants to purchase common stock   3,442,904 
Restricted stock units   64,562 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Information about Incentive Plan

The following table contains information about the 2019 Plan as of December 31, 2023:

 

   Awards           Awards 
   Reserved for   Awards   Awards   Available for 
   Issuance   Issued   Exercised   Grant 
2019 Plan(1)   871,429    649,833    17,916    221,596 
Awards issued in excess of 2019 Plan(2)   -    48,401    48,401    - 

 

(1) Includes incentive stock options and restricted stock units discussed below.
(2) Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.
Schedule of Incentive Stock Option Activity

The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2023 and 2022.

 

           Weighted 
       Weighted   Average 
       Average   Contractual 
   Number of   Exercise   Term in 
   Options   Price   Years 
Outstanding at January 1, 2022   434,939   $1.678955    8.56 
Granted   195,000    3.3461538    10.00 
Exercised   —    —    — 
Forfeited   —    —    — 
Cancelled   (100,001)   1.40000    — 
Expired   (5,001)   1.40000    — 
Outstanding at December 31, 2022   524,937   $2.351416    8.38 
                
Granted   117,532   $2.06041    10.00 
Exercised   (3,295)   1.75    — 
Forfeited   —    —    — 
Cancelled   (69,854)   1.965823    — 
Expired   (8,670)   1.703222    — 
Outstanding at December 31, 2023   560,650   $2.350742    7.95 
Exercisable at December 31, 2023   398,150   $1.829884    7.44 
Schedule of Assumptions used in Share-based Compensation

 

   2023    2022 
Volatility   257.64-258.01%    277.84%
Risk-free interest rate   4.21-4.42%    4.06%
Dividend yield   0.0%    0.0%
Expected term   5 - 5.50 years     5.0 years 
Schedule of Restricted Stock Units Granted

 

       Average 
   Number of   Grant Date 
   Units   Fair Value 
Outstanding at December 31, 2021   —   $— 
Granted   96,114    1.61 
Exercised and converted to common shares   (5,682)   4.40 
Forfeited   —    — 
Outstanding at December 31, 2022   90,432    1.43 
Granted   37,037    1.35 
Exercised and converted to common shares   (50,157)   1.76522 
Forfeited   (12,750)   1.82 
Outstanding at December 31, 2023   64,562   $1.82 
Exercisable at December 31, 2023   13,750   $1.82 
Schedule of Common Stock Warrants

The following table shows a summary of common stock warrants for the years ended December 31, 2023 and 2022.

 

       Weighted   Weighted 
       Average   Average 
   Number of   Exercise   Contractual 
   Warrants   Price   Term in Years 
Outstanding at December 31, 2021   3,637,190   $5.16281    4.63 
                
Granted   —   $—    — 
Exercised   —    —    — 
Forfeited   —    —    — 
Cancelled   —    —    — 
Expired   —    —    — 
Outstanding at December 31, 2022   3,637,190   $5.16281    3.65 
Granted   —    —    — 
Exercised   (109,720)   0.55    — 
Forfeited   —    —    — 
Cancelled   (84,566)   0.89    — 
Expired   —    —    — 
Outstanding at December 31, 2023   3,442,904   $5.414793    2.87 
Exercisable at December 31, 2023   3,442,904   $5.414793    2.87 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Notes Payable (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Debt Instruments

The future annual principal amounts and accrued interest to be paid as of December 31, 2023 are as follows:

 

   Amount 
For the year ending December 31 ($ in thousands):     
2024  $80 
2025   89 
2026   51 
2027   55 
2028   59 
Thereafter   259 
Total  $593 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Warrant Liability (Tables)
 12 Months Ended
Dec. 31, 2023
Warrant Liability  
Schedule of Warrant Liability

The warrants outstanding and fair values at each of the respective valuation dates are summarized below:

 

Warrant Liability 

Warrants

Outstanding

  

Fair Value

per Share

   Fair Value 
Fair value as of year ended 12/31/2021   265,305        $318 
Modification of warrants   -           57 
Change in fair value of warrant liability   -         (133)
Fair value as of year ended 12/31/2022   265,305         242 
Exercise of warrants   (194,286)       (144)
Modification of warrants   -         29 
Change in fair value of warrant liability   -         19 
Fair value as of year ended 12/31/2023   71,019        $146 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Income Tax (Benefit) Provision

The income tax (benefit) provision consists of the following:

 

   2023   2022 
   For The Years Ended 
   December 31 
   2023   2022 
Federal:          
Current  $

(617

)  $

(619

)
Deferred   

617

    619 
State and local:          
Current   

(156

)   (159)
Deferred   156    159 
Income tax provision  $—   $— 
Schedule of Effective Income Tax Rate Reconciliation

For the years ended December 31, 2023 and 2022, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows:

 

   2023   2022 
   For The Years Ended December 31, 
   2023   2022 
U.S. federal statutory rate   21.0%   21.0%
State tax rate, net of federal benefit   5.3%   5.3%
Permanent differences          
Non-deductible expenses   (1.9)%   (9.7)%
Timing differences   —   —
Change in valuation allowance   (24.4)%   (16.6)%
Income tax provision   —%   —%
Schedule of Deferred Tax Assets and Liabilities

As of December 31, 2023 and 2022, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:

 

    2023     2022  
    As of December 31,  
    2023     2022  
Deferred tax assets:                
Net operating loss carryforwards   $ 4,882     $ 4,112  
Other     9       6  
Total deferred tax assets     4,891       4,118  
Valuation allowance     (4,891 )     (4,118 )
Deferred tax assets, net of valuation allowance   $ —     $ —  
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Description of Business, Stock Split and Basis of Presentation (Details Narrative)
Mar. 01, 2023
Joint Venture [Member]  
Restructuring Cost and Reserve [Line Items]  
Acquisition percentage 50.00%
CG Labs [Member]  
Restructuring Cost and Reserve [Line Items]  
Acquisition percentage 50.00%
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Going Concern (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Feb. 15, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cash   $ 2,700 $ 1,101
Net loss   3,157 4,746
Net cash used in operating activities   3,236 $ 2,992
Working capital   $ 2,500  
Registered Direct Offering [Member] | Subsequent Event [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sale of stock, number of shares issued in transaction 242,891    
Sale of stock, price per share $ 4.22    
Sale of stock, description of transaction each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $4.00 per share. The $4.22 purchase price equals two times the last reported sale price of $2.11 per share of the Company’s Common Stock on February 15, 2024 on The Nasdaq Capital Market.    
Class of warrant or right, exercise price of warrants or rights $ 4.00    
Sale of stock, consideration received on transaction $ 1,025    
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Marketable Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total $ 5,508
US Treasury Securities One [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total $ 492
Marketable securities, due date   Feb. 23, 2023
US Treasury Securities Two [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total $ 20
Marketable securities, due date   Apr. 27, 2023
US Treasury Securities Three [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total $ 4,384
Marketable securities, due date   Jun. 15, 2023
US Treasury Securities Four [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total $ 127
Marketable securities, due date   Jul. 13, 2023
US Treasury Securities Five [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Total $ 485
Marketable securities, due date   Aug. 10, 2023
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Fair Value of Financial Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Platform Operator, Crypto-Asset [Line Items]    
Total $ 5,508
US Treasury Securities [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total 5,508
Fair Value, Inputs, Level 1 [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total 5,508
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total 5,508
Fair Value, Inputs, Level 2 [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total
Fair Value, Inputs, Level 3 [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Total
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Disaggregated Revenue by Sales Type (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Contract manufacturing $ 2,748 $ 1,033
Custom and white label finished goods manufacturing 15 34
Consumer branded products 1,242 815
Other 84 166
Total $ 4,089 $ 2,048
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies and Estimates (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Shor term line of credit $ 245,000  
Allowance for doubtful accounts 11,000 $ 9,000
Goodwill and intangible asset impairment 0 0
Prepaid insurance 64,000 63,000
General prepaid expenses 336,000 109,000
Remaining performance obligations 0 0
Deferred revenue 20,000
US Treasury Securities [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
U.S. treasury bills held for sale $ 3,000,000  
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Reportable Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Total revenue $ 4,089 $ 2,048
Cost of sales 3,470 1,792
Operating expenses 4,096 3,604
Loss from operations (3,477) (3,348)
Current assets:    
Cash 2,700 1,101
Accounts receivable, net 633 222
Inventory 1,319 502
Prepaid expenses and other current assets 400 172
Total current assets 5,052 7,505
Goodwill 1,128 311
Intangibles 326 20
Property and equipment, net 1,499 721
Operating lease – right of use asset 1,855 1,737
Other assets 95 63
Total assets 9,955 10,357
Current liabilities:    
Accounts payable 1,233 265
Accrued expenses and other current liabilities 398 130
Deferred revenue 20
Current portion of note payable 80 15
Warrant liability 146 242
Contingent consideration liability 439
Operating lease liability, current portion 233 207
Total current liabilities 2,549 859
Operating lease liability, net of current portion 1,727 1,593
Notes payable, net of current portion 513 268
Total liabilities 4,789 2,720
Reportable Subsegments [Member]    
Segment Reporting Information [Line Items]    
Total revenue 4,089 2,048
Cost of sales 3,470 1,792
Operating expenses 4,096 3,604
Loss from operations (3,477) (3,348)
Current assets:    
Cash 2,700  
Accounts receivable, net 633  
Inventory 1,319  
Prepaid expenses and other current assets 400  
Total current assets 5,052  
Goodwill 1,128  
Intangibles 326  
Property and equipment, net 1,499  
Operating lease – right of use asset 1,855  
Other assets 95  
Total assets 9,955  
Current liabilities:    
Accounts payable 1,233  
Accrued expenses and other current liabilities 398  
Deferred revenue 20  
Current portion of note payable 80  
Warrant liability 146  
Contingent consideration liability 439  
Operating lease liability, current portion 233  
Total current liabilities 2,549  
Operating lease liability, net of current portion 1,727  
Notes payable, net of current portion 513  
Total liabilities 4,789  
Contract Manufacturing [Member] | Reportable Subsegments [Member]    
Segment Reporting Information [Line Items]    
Total revenue 2,748 1,033
Custom and White Label Finished Goods [Member] | Reportable Subsegments [Member]    
Segment Reporting Information [Line Items]    
Total revenue 15 34
Branded Consumer Products [Member] | Reportable Subsegments [Member]    
Segment Reporting Information [Line Items]    
Total revenue 1,242 815
Other Incomes [Member] | Reportable Subsegments [Member]    
Segment Reporting Information [Line Items]    
Total revenue 84 166
Nexgel [Member]    
Segment Reporting Information [Line Items]    
Total revenue 2,102 2,048
Cost of sales 1,911 1,792
Operating expenses 3,604 3,604
Loss from operations (3,413) (3,348)
Current assets:    
Cash 2,458  
Accounts receivable, net 26  
Inventory 622  
Prepaid expenses and other current assets 312  
Total current assets 3,418  
Goodwill 1,128  
Intangibles 122  
Property and equipment, net 898  
Operating lease – right of use asset 1,543  
Other assets 95  
Total assets 7,204  
Current liabilities:    
Accounts payable 509  
Accrued expenses and other current liabilities 137  
Deferred revenue 20  
Current portion of note payable 6  
Warrant liability 146  
Contingent consideration liability 439  
Operating lease liability, current portion 207  
Total current liabilities 1,464  
Operating lease liability, net of current portion 1,438  
Notes payable, net of current portion 272  
Total liabilities 3,174  
Nexgel [Member] | Contract Manufacturing [Member]    
Segment Reporting Information [Line Items]    
Total revenue 769 1,033
Nexgel [Member] | Custom and White Label Finished Goods [Member]    
Segment Reporting Information [Line Items]    
Total revenue 15 34
Nexgel [Member] | Branded Consumer Products [Member]    
Segment Reporting Information [Line Items]    
Total revenue 1,242 815
Nexgel [Member] | Other Incomes [Member]    
Segment Reporting Information [Line Items]    
Total revenue 76 166
CG Labs [Member]    
Segment Reporting Information [Line Items]    
Total revenue 1,987
Cost of sales 1,559
Operating expenses 492
Loss from operations (64)
Current assets:    
Cash 242  
Accounts receivable, net 607  
Inventory 697  
Prepaid expenses and other current assets 88  
Total current assets 1,634  
Goodwill  
Intangibles 204  
Property and equipment, net 601  
Operating lease – right of use asset 312  
Other assets  
Total assets 2,751  
Current liabilities:    
Accounts payable 724  
Accrued expenses and other current liabilities 261  
Deferred revenue  
Current portion of note payable 74  
Warrant liability  
Contingent consideration liability  
Operating lease liability, current portion 26  
Total current liabilities 1,085  
Operating lease liability, net of current portion 289  
Notes payable, net of current portion 241  
Total liabilities 1,615  
CG Labs [Member] | Contract Manufacturing [Member]    
Segment Reporting Information [Line Items]    
Total revenue 1,979
CG Labs [Member] | Custom and White Label Finished Goods [Member]    
Segment Reporting Information [Line Items]    
Total revenue
CG Labs [Member] | Branded Consumer Products [Member]    
Segment Reporting Information [Line Items]    
Total revenue
CG Labs [Member] | Other Incomes [Member]    
Segment Reporting Information [Line Items]    
Total revenue $ 8
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Business Acquisitions (Details) - USD ($)
 12 Months Ended
Dec. 01, 2023
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Preliminary goodwill   $ 1,128,000 $ 311,000
Kenkoderm Acquisition [Member]      
Business Acquisition [Line Items]      
Cash contributed by the Company $ 546,500    
Noncontrolling interest portion of CG Labs contributed business 439,000    
Consideration paid 986,000    
Inventory 56,000    
Product/Technology related intangibles 77,000    
Marketing related intangibles 36,000    
Other liabilities    
Total net assets acquired 169,000    
Preliminary goodwill $ 817,000    
CG Labs [Member]      
Business Acquisition [Line Items]      
Cash contributed by the Company   500,000  
Noncontrolling interest portion of CG Labs contributed business   500,000  
Consideration paid   1,000,000  
Product/Technology related intangibles   217,000  
Marketing related intangibles   70,000  
Total net assets acquired   1,000,000  
Preliminary goodwill    
Fixed assets   $ 213,000  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Unaudited Pro-Forma Results of Operations (Details) - Kenkoderm Acquisition [Member] - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]    
Revenues, net $ 5,522 $ 4,014
Net loss allocable to common shareholders $ (3,071) $ (4,634)
Net loss per share - basic $ (0.54) $ (0.83)
Net loss per share - diluted $ (0.54) $ (0.83)
Weighted average number of shares outstanding - basic 5,671,842 5,574,818
Weighted average number of shares outstanding - diluted 5,671,842 5,574,818
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisition (Details Narrative) - USD ($)
 12 Months Ended
Dec. 01, 2023
Mar. 01, 2023
Dec. 31, 2023
Business Acquisition [Line Items]      
Payment to acquire business   $ 500,000 $ 500,000
C.G. Laboratories Inc. [Member]      
Business Acquisition [Line Items]      
Minority percentage   50.00%  
Kenkoderm Acquisition [Member]      
Business Acquisition [Line Items]      
Cash payment for acquire assets $ 546,500    
Payments to acquire businesses, cash earn-out 136,625    
Net tangible assets acquired $ 169,000    
Joint Venture [Member]      
Business Acquisition [Line Items]      
Acquisition percentage   50.00%  
CG Labs [Member]      
Business Acquisition [Line Items]      
Cash payment for acquire assets     500,000
Net tangible assets acquired     $ 1,000,000
Acquisition percentage   50.00%  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Future Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Leases  
2024 $ 245
2025 245
2026 301
2027 315
2028 324
Thereafter 790
Total undiscounted operating lease payments 2,220
Less: Imputed interest (260)
Present value of operating lease liability $ 1,960
Weighted average remaining lease term 7 years 4 months 24 days
Weighted average discount rate 3.00%
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Supplemental Cash Flows Information Related to Leases (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Leases  
Operating cash flows from operating lease $ 238
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Leases    
Operating lease expense $ 303 $ 246
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 899 $ 295
Work-in-progress 12 51
Finished goods 408 156
Inventory, gross 1,319 502
Less: Inventory reserve for excess and slow moving inventory
Total $ 1,319 $ 502
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 2,225 $ 1,315
Less: accumulated depreciation and amortization (726) (594)
Property and equipment, net 1,499 721
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 1,280 973
Machinery and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 3 years  
Machinery and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 10 years  
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 139 59
Furniture and Fixtures [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 3 years  
Furniture and Fixtures [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 10 years  
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 6 years  
Total property and equipment $ 419 228
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 387 $ 55
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, Net (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 132 $ 99
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Breakdown of Identifiable Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total $ 326 $ 20
Technology-Based Intangible Assets [Member]    
Finite-Lived Intangible Assets [Line Items]    
Identifiable intangible assets, gross 325 31
Accumulated amortization (98) (26)
Total 227 5
Customer-Related Intangible Assets [Member]    
Finite-Lived Intangible Assets [Line Items]    
Identifiable intangible assets, gross 17 17
Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Identifiable intangible assets, gross 113 7
Marketing-Related Intangible Assets [Member]    
Finite-Lived Intangible Assets [Line Items]    
Accumulated amortization (31) (9)
Total $ 99 $ 15
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Estimated Annual Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 119  
2025 126  
2026 63  
2027 13  
2028 2  
Thereafter 3  
Total $ 326 $ 20
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 01, 2023
Mar. 01, 2023
May 29, 2020
Finite-Lived Intangible Assets [Line Items]          
Expected life 2 years 10 months 24 days 2 years 10 months 24 days      
Amortization expense $ 94 $ 13      
Sport Defense LLC [Member] | Technology Related and Customer Related Intangibles [Member]          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets         $ 55
CG Labs JV [Member] | Technology Related and Customer Related Intangibles [Member]          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets       $ 287  
Kenkoderm [Member] | Technology Related and Customer Related Intangibles [Member]          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets     $ 113    
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Salaries, benefits, and incentive compensation $ 61 $ 56
Franchise tax accrual 52
Margin line of credit 245
Other 92 22
Total accrued expenses and other current liabilities $ 398 $ 130
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Reserved Common Stock For Issued Securities in Relation (Details)
 12 Months Ended
Dec. 31, 2023
shares
Equity [Abstract]  
Share-based compensation plan 560,650
Warrants to purchase common stock 3,442,904
Restricted stock units 64,562
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Information about Incentive Plan (Details) - shares
 12 Months Ended
Dec. 31, 2023
May 03, 2021
May 26, 2020
2019 Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Awards Reserved For Issuance 871,429 [1]   57,143
Awards Issued [1] 649,833    
Awards Exercised [1] 17,916    
Awards Available for Grant 221,596 [1] 485,715  
Awards Granted Outside Of The 2019 Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Awards Reserved For Issuance [2]    
Awards Issued [2] 48,401    
Awards Exercised [2] 48,401    
Awards Available for Grant [2]    
[1] Includes incentive stock options and restricted stock units discussed below.
[2] Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Incentive Stock Option Activity (Details) - Equity Option [Member] - 2019 Plan [Member] - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of options, outstanding, beginning balance 524,937 434,939  
Weighted average exercise price, outstanding beginning balance $ 2.351416 $ 1.678955  
Weighted average remaining contractual term 7 years 11 months 12 days 8 years 4 months 17 days 8 years 6 months 21 days
Number of options, granted 117,532 195,000  
Weighted average exercise price, granted $ 2.06041 $ 3.3461538  
Weighted average remaining contractual term, granted 10 years 10 years  
Number of options, exercised (3,295)  
Weighted average exercise price, exercised $ 1.75  
Number of options, forfeited  
Weighted average exercise price, forfeited  
Number of options, cancelled (69,854) (100,001)  
Weighted average exercise price, cancelled $ 1.965823 $ 1.40000  
Number of options, expired (8,670) (5,001)  
Weighted average exercise price, expired $ 1.703222 $ 1.40000  
Number of options, outstanding, ending balance 560,650 524,937 434,939
Weighted average exercise price, outstanding ending balance $ 2.350742 $ 2.351416 $ 1.678955
Number of options, exercisable 398,150    
Weighted average exercise price, exercisable $ 1.829884    
Weighted average remaining contractual term, exercisable 7 years 5 months 8 days    
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Assumptions used in Share-based Compensation (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility   277.84%
Risk-free interest rate   4.06%
Dividend yield 0.00% 0.00%
Expected term   5 years
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 257.64%  
Risk-free interest rate 4.21%  
Expected term 5 years  
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 258.01%  
Risk-free interest rate 4.42%  
Expected term 5 years 6 months  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Restricted Stock Units Granted (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of units, exercised and converted to common shares (109,720,000)
Restricted Stock Units (RSUs) [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of units outstanding beginning 90,432
Weighted average grant date fair value outstanding beginning $ 1.43
Number of units, granted 37,037 96,114
Weighted average grant date fair value, granted $ 1.35 $ 1.61
Number of units, exercised and converted to common shares (50,157) (5,682)
Weighted average grant date fair value, exercised and converted to common shares $ 1.76522 $ 4.40
Number of units, forfeited (12,750)
Weighted average grant date fair value, forfeited $ 1.82
Number of units outstanding ending 64,562 90,432
Weighted average grant date fair value outstanding ending $ 1.82 $ 1.43
Number of units exercisable 13,750  
Weighted average grant date fair value exercisable $ 1.82  
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Common Stock Warrants (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]      
Number of warrants, outstanding beginning balance 3,637,190 3,637,190  
Weighted average exercise price, outstanding beginning balance $ 5.16281 $ 5.16281  
Weighted average remaining contractual term 2 years 10 months 13 days 3 years 7 months 24 days 4 years 7 months 17 days
Number of warrants, granted  
Weighted average exercise price, granted  
Number of warrants, exercised (109,720,000)  
Weighted average exercise price, exercised $ 0.55  
Number of warrants, forfeited  
Weighted average exercise price, forfeited  
Number of warrants, cancelled (84,566,000)  
Weighted average exercise price, cancelled $ 0.89  
Number of warrants, expired  
Weighted average exercise price, expired  
Number of warrants, outstanding ending balance 3,442,904 3,637,190 3,637,190
Weighted average exercise price, outstanding ending balance $ 5.414793 $ 5.16281 $ 5.16281
Number of warrants, exercisable 3,442,904    
Weighted average exercise price, exercisable $ 5.414793    
Weighted average remaining contractual term, exercisable 2 years 10 months 13 days    
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Aug. 17, 2023
Mar. 23, 2023
Mar. 08, 2023
Jan. 03, 2023
Oct. 01, 2022
Aug. 01, 2022
Jan. 01, 2022
Dec. 31, 2023
Dec. 31, 2022
May 31, 2021
May 03, 2021
May 26, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Common stock reserved for issuance               25,000,000 25,000,000      
Restricted stock vesting, shares               64,562        
Unrecognized share based compensation expense               $ 68,000        
Stock based compensation and restricted stock vesting               217,000 $ 298,000      
Intrinsic value of vested outstanding warrants               $ 0 $ 114,000      
Director [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted 90,000                      
Exercise price of options $ 2.05                      
Award vesting rights, percentage 25.00%                      
Chief Executive Officer [Member] | Restricted Stock [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of units, granted       37,037     11,364          
Restricted stock vesting, shares       37,037     11,364          
Share price       $ 1.35     $ 4.40          
Officers and Employees [Member] | Restricted Stock [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of units, granted           84,750            
Restricted stock vesting, shares           84,750            
Share price           $ 1.82            
2019 Plan [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Common stock reserved for issuance               871,429 [1]       57,143
Common stock reserved for issuance                   571,429   57,143
Number of options, granted               221,596 [1]     485,715  
Common stock reserved for issuance                     485,715  
Additional common stock reserved for issuance   300,000                    
Shares reserved for issuance, awarded   $ 871,429                    
Shares reserved for issuance, exercised   $ 609,687                    
2019 Plan [Member] | Equity Option [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of shares granted               117,532 195,000      
Exercise price of options               $ 2.06041 $ 3.3461538      
Intrinsic value               $ 295,000 $ 124,000      
2019 Plan [Member] | Equity Option [Member] | Maximum [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Period of recognition of stock based compensation expense               36 months        
2019 Plan [Member] | Equity Option [Member] | Minimum [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Period of recognition of stock based compensation expense               18 months        
2019 Plan [Member] | Executive Officer [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of shares granted   14,286                    
2019 Plan [Member] | Contractor [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted     17,532                  
Exercise price of options     $ 2.00                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period     12 months                  
2019 Plan [Member] | Dr.Neil Chesen [Member] | Option One [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted         65,000              
Exercise price of options         $ 2.00              
Number of options, vested         15,000              
Number of options, expected to vest         50,000              
Options, expiry date         Dec. 31, 2023              
2019 Plan [Member] | Dr.Neil Chesen [Member] | Option Two [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted         25,000              
Exercise price of options         $ 2.00              
2019 Plan [Member] | Dr.Neil Chesen [Member] | Option Three [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted         37,500              
Exercise price of options         $ 5.50              
Expiration period         36 months              
2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option One [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted         30,000              
Exercise price of options         $ 2.00              
Number of options, vested         5,000              
Number of options, expected to vest         25,000              
Expiration period         10 years              
2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option One [Member] | Maximum [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Expiration period         18 months              
2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option Two [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Number of options, granted         37,500              
Exercise price of options         $ 5.50              
Expiration period         10 years              
2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option Two [Member] | Maximum [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                        
Expiration period         36 months              
[1] Includes incentive stock options and restricted stock units discussed below.
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Debt Instruments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Debt Disclosure [Abstract]  
2024 $ 80
2025 89
2026 51
2027 55
2028 59
Thereafter 259
Total $ 593
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Notes Payable (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 13, 2024
May 28, 2020
Dec. 31, 2023
Dec. 31, 2022
Short-Term Debt [Line Items]        
Principal and accrued interest     $ 277 $ 283
CG Labs Notes Payable [Member]        
Short-Term Debt [Line Items]        
Notes payable     231  
CG Labs Notes Payable [Member] | Subsequent Event [Member]        
Short-Term Debt [Line Items]        
Agreements terms 5 years      
Interest rate 8.00%      
Debt instrument periodic payment $ 4      
CG Labs Notes Payable One [Member]        
Short-Term Debt [Line Items]        
Notes payable     242  
Advance payment of promissory note     $ 84  
CG Labs Notes Payable One [Member] | Subsequent Event [Member]        
Short-Term Debt [Line Items]        
Agreements terms 5 years      
Interest rate 8.00%      
Debt instrument periodic payment $ 5      
Economic Injury Disaster Loan [Member]        
Short-Term Debt [Line Items]        
Interest rate   3.75%    
Debt instrument periodic payment   $ 1,270    
Borrowing capacity   260,500    
Loan advance   $ 8    
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Convertible Notes Payable (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 02, 2021
Mar. 11, 2021
Dec. 31, 2023
Dec. 31, 2022
Sep. 06, 2022
Mar. 15, 2022
Jan. 25, 2022
Short-Term Debt [Line Items]              
Principal amount of debt           $ 1,680  
Interest expense     $ 15 $ 1,336      
Gains loss on extinguishment of debt     (150)      
Secured Convertible Promissory Note [Member]              
Short-Term Debt [Line Items]              
Interest expense $ 194            
Outstanding principal and accrued unpaid interest             $ 300
Pre payment penalty             17
Unamortized debt discount             $ 133
Gains loss on extinguishment of debt       $ 150      
Secured Convertible Promissory Note [Member] | Private Placement [Member]              
Short-Term Debt [Line Items]              
Principal amount of debt $ 1,814       $ 1,478    
Auctus Note [Member]              
Short-Term Debt [Line Items]              
Principal amount of debt   $ 1,680          
Debt Instrument, Periodic Payment, Interest   $ 180          
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Warrant Liability (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 06, 2022
Dec. 31, 2023
Dec. 31, 2022
Fair value, modification of warrants $ 57 $ 29 $ 57
Fair value, change in fair value of warrant liability   $ (125) $ (133)
Warrant [Member]      
Warrants outstanding, beginning balance   265,305 265,305
Fair value, beginning balance   $ 242 $ 318
Warrants outstanding, warrant modification  
Fair value, modification of warrants   $ 29 $ 57
Warrants outstanding, change in fair value of warrant liability  
Fair value, change in fair value of warrant liability   $ 19 $ (133)
Warrants outstanding, exercise of warrants   (194,286,000)  
Fair value, exercise of wararnts   $ (144)  
Warrants outstanding, ending balance   71,019 265,305
Fair value, ending balance   $ 146 $ 242
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Warrant Liability (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Sep. 06, 2022
Dec. 31, 2023
Dec. 31, 2022
Sep. 02, 2021
Mar. 11, 2021
Feb. 03, 2021
Dec. 24, 2020
Mar. 18, 2020
Nov. 06, 2019
Sep. 10, 2019
Subsidiary, Sale of Stock [Line Items]                    
Warrant modification expense $ 57 $ 29 $ 57              
Private Placement [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Warrants outstanding       22,019 34,285 7,429 7,286 44,286 114,286 35,714
Private Placement [Member] | Minimum [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Exercise price   $ 0.49                
Private Placement [Member] | Maximum [Member]                    
Subsidiary, Sale of Stock [Line Items]                    
Exercise price   $ 5.25                
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Concentrations of Risk (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Concentration Risk [Line Items]    
Cash, FDIC insured amount $ 250  
Cash, exceeding $ 106  
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 20.00% 29.00%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 69.00% 40.00%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   22.00%
Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   18.00%
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions (Details Narrative)
$ in Thousands
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 15, 2022
USD ($)
Sep. 02, 2021
USD ($)
Integer
Related Party Transaction [Line Items]        
Debt instrument face amount     $ 1,680  
Mr. Stein [Member]        
Related Party Transaction [Line Items]        
Number of debt instruments | Integer       3
Debt instrument face amount       $ 150,000
Mr.Stefansky [Member]        
Related Party Transaction [Line Items]        
Debt instrument face amount       150,000
Dr.Jerome Zeldis [Member]        
Related Party Transaction [Line Items]        
Debt instrument face amount       $ 50,000
Due from related parties, current $ 25,000 $ 40,000    
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Income Tax (Benefit) Provision (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Federal:    
Current $ (617) $ (619)
Deferred 617 619
State and local:    
Current (156) (159)
Deferred 156 159
Income tax provision
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
U.S. federal statutory rate 21.00% 21.00%
State tax rate, net of federal benefit 5.30% 5.30%
Non-deductible expenses (1.90%) (9.70%)
Timing differences 0.00% 0.00%
Change in valuation allowance (24.40%) (16.60%)
Income tax provision 0.00% 0.00%
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Net operating loss carryforwards $ 4,882 $ 4,112
Other 9 6
Total deferred tax assets 4,891 4,118
Valuation allowance (4,891) (4,118)
Deferred tax assets, net of valuation allowance
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income tax expense (benefit)
Unrecognized tax benefits 0 0
Deferred tax assets, operating loss carryforwards, state and local 18,600,000 15,600,000
PANAMA    
Deferred tax assets, operating loss carryforwards, state and local $ 18,600,000 $ 15,600,000
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events (Details Narrative) - Subsequent Event [Member] - Subscription Agreements [Member]
$ / shares in Units, $ in Thousands
Feb. 15, 2024
USD ($)
$ / shares
shares
Registered Direct Offering [Member]  
Subsequent Event [Line Items]  
Sale of stock, number of shares issued in transaction | shares 242,891
Sale of stock, price per share | $ / shares $ 4.22
Exercise price, per share | $ / shares $ 4.00
Warrants expire term 5 years
Gross proceeds from issuance of initial public offering | $ $ 1,025
Registered Direct Offering [Member] | Minimum [Member]  
Subsequent Event [Line Items]  
Common stock outstanding percentage 4.99%
Registered Direct Offering [Member] | Maximum [Member]  
Subsequent Event [Line Items]  
Common stock outstanding percentage 9.99%
Registered Direct Offering [Member] | Common Stock [Member]  
Subsequent Event [Line Items]  
Sale of stock, number of shares issued in transaction | shares 485,782
Sale of stock, price per share | $ / shares $ 2.11
Registered Direct Offering [Member] | Warrant [Member]  
Subsequent Event [Line Items]  
Sale of stock, number of shares issued in transaction | shares 242,891
Placement Agent [Member]  
Subsequent Event [Line Items]  
Sale of stock, number of shares issued in transaction | shares 27,725
Exercise price, per share | $ / shares $ 4.00
Cash fee of aggregate gross proceeds percentage 6.00%
Warrants exercisable period 5 years
Placement Agent [Member] | Non Affiliated Entity [Member]  
Subsequent Event [Line Items]  
Cash fee of aggregate gross proceeds percentage 6.00%
Placement Agent [Member] | Affiliated Entity [Member]  
Subsequent Event [Line Items]  
Cash fee of aggregate gross proceeds percentage 3.00%
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( >PB5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 'L(E827DV3.\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:1;!4.7%\4G!<&!XEM(;EM8TX;DI-VWMXU;A^@'\#%W__SN M=W"-"=+T$5]B'S"2PW0S^K9+TH0-.Q %"9#, ;U.Y93HIN:NCU[3](Q["-H< M]1ZAXOP6/)*VFC3,P"(L1*8::Z2)J*F/9[PU"SY\QC;#K %LT6-'"40I@*EY M8CB-;0-7P PCC#Y]%] NQ%S]$YL[P,[),;DE-0Q#.:QR;MI!P/OSTVM>MW!= M(MT9G'XE)^D4<,,ND]]6]P_;1Z8J7JT+OBX$WW(AZSM9UQ^SZP^_J[#OK=NY M?VQ\$50-_+H+]0502P,$% @ ![")6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" 'L(E8:3]D5U\) !>/ & 'AL+W=OO29QF5ZT%Y\O/W6X6 M+$B"LPY=DA2.S"A+,(>O;-[-EHS@4 8E<=>QK'XWP5':NKZ4OXW9]27->1RE M9,Q0EB<)9F\W)*:KJY;=VOSP%,T77/S0O;Y@,1(,_X*R*K;.&A,%.<$9_&WZ.0+ZY:9RT4DAG.8_Y$5W\C MZP+UA%Y XTS^CU;%N3VWA8(\XS19!\,=)%%:_,6O:Q [ 6=638"S#G#>!=A> M38"[#G /#?#6 9XD4Q1%&)*P*=.%N MMK?D;&[IQM$JWI*@@US[%#F6XRINR->'#Y>L@VQ+AGN*\%M]^-_S%*YNJ:Y> M*8V[!>Q*/;>N-#3(H9UP]/RV)"J\^G#;:O^A8J"-$IW%YVR) W+5@MX@(^R% MM*X__&;WK0L5$4-B%3[>EH^G+> 0X(02T'V,YRI ^O@9CC,55U\;UI20(;$* MH=Z64.^P&C1,TQS'Z(DL*>,J4GH=SG(E*&U44U"&Q"J@^EM0_0.;&L,P,,EQ MI1Z67JNV6FG#FM(R)%:A-=C2&AQ&:TQ81$/1?2,80I1]U!ZE38==VV-KXYM" M,R16@7:VA79V&+3[* N@+:[9W<3?@%I,T&.>3 E3PM*+6);=]FQ[H*QC^MC&N RI57$Y M)2[G$%Q/9!YE',9)CAYQHJY?>J%'\OJ%Q*RH*YY_;-SYUQ)S6AB;TJM2JU,[6U];KZF M]HQ?T2@$=-$L"K!,RS0-52_I]-N>Y3D]3V7M?'UP8WK'R/KM,NVW]?GZFAZT M+\H@B97@3M&$PW" *$,^S:$R0IVDH;KY[G$5=TJ 1LV *;4JP-(.V/H=(/CGXRGEZ"9^"=%WDJD,AJ^7:LSR&%[! M+LV"K<_QM2R?5U3)4B\YR2.HR3=*=$8-@RFU*KK2,MCZ+/\].E]\@P;\3%>I M$IM>[@&G\P5ERNKKZV,;@SN&>[!+^V#K<_[WX+9=WYC1ER@-U U8KSD>*K$9 MM1&FU*JSIZ6/@\@V^60$5R/22_P$48'U0RZKX]KC.D8!L(I#82CS_L?J)SX6-!4Y[?VB PL MIWW6ZUE*6D:-@RFU*JW2.#@'&8?O)([;OU+H\=&$X S8A6B497D-/+WFHVJT M]?5!C;$=PSDXI7-P#G(.?]$8DES,"GO/E/-&>Y1J8!DU"J;4JK!*H^ <9!0V M\T?%E'>4SN6 J9YLVZ-8 \VH.3"E5H56F@/G(',P2CEAQ>*SF&C#&XI*:'K% M'T2%VM='-:9V#!O@E#; .<@&R-8('HB3.67*29 ].H\T;>,@(" #(F$AJ*1G MU F84JO2*YV J0<#";Z MEA'$%P3=O7(BMF?L+HT6:U?*+0GZ:]2NC>KC&N]*.(8=<$L[X!ZTKC!90.JF MJW5[9.IA&34%IM2JL$I3X!ZTJC#.IW$4H/N88N4(JE=I6&;?J-KM6LV3:F*[ MW,NU;?7/>WVK=]E]4='9V0)TV.H!31)H=Q-.@U^G4+$PW!7Z,^=@S],0NC@E M,9-9O;]6Z^V4L>\X@[[8*/52@7&,]-\MTW]7G[1O5HZSG=EOZ+RF8MUJ1B _ M"PCZ^4Q>Q0PLP/RWDIS^$F.1(],T.Z$SV4.R[8+8A]_.''MPD8GM@U$:R=1P MR>CK&\K$!)18<30:C9"\^RBK[@U"4,O$ MKD@D=H^AU8)(P5 LOI"P@Y[A/E0W@%81='53@F:0C84GJPB&6W'/WSJ3#MC6 M(&< ZHLU%884((%3N=$5NHHD]M 14"4(MNQ4(C?X+P9Y-92 <8>M.;\)I:U MH02K110LBGMGQ4U+IB13+B;J'V;CIGX,O^:6?LW5NZN1?_^$AGD8<;$J5K<#;H]>_1!CU+"94JM2*PV;>^#NKOLHQ6D006TO:^X=8W))#+Q;L9_X MIV"I[A?^SXU?^KC&,(_AX]S2Q[EZ_[6I??<1]!*C6R4GO<*@KX1DU*Z94JM" M*NV:J[=9&TAU&R3VA#_G+"5,+%N(J=(/.%E>;/+(4_30>>B,E02->CA3:E6" MI8=S]99K0U#,&8MFJ:2X9Q,9>&67OV@%52 MQ"4,E2\XS@FR.I9EHY]?B9AO5W9K>N&FB:)1M5M3:E6HI9/S]!;L.>(Q$?F' M[7RI>#QR \#_/*+?Y3-2PC3J]$RI56&63L_3.[UGAD,YM_R6 M3&FL9+AGW]@_OSPH*1EUH\IM2JOG9= ]&[L.V;">F7"&8QS!LPR4O'+^K[/I#OPC:K=FE*K@BV]AJ?W M!DWZ/KW2YA')WJ_N,2EY&G4AIM2J/$L7XNGMP0'=GUY ='_?E9B,^@M3:E5, MI;_P]NSM.KS_V[-05-__&;4:IM0*7MV=%S+%^H5\L35#@=BR6;R;N?UU^_+L M4+XRVBU/+]Z\_8K%\D>&8C*#4*LS@/K/BI=9BR^<+N7KG5/*.4WDQP7!(6'B M!#@^HY1OOH@+;%\IOOXO4$L#!!0 ( >PB5BD@)[&K 8 '8= 8 M>&PO=V]R:W-H965T&ULK5EM<]HX$/XK&J[3:6=(L"1L0YHP MDY)>V[FVR37I=>ZC8HN@J[&H+.?E?OVM#+'!DA6XYD,"-JO5L^M=/8_DXSNI M?A1SSC6Z7V1Y<=*;:[T\&@R*9,X7K#B42Y[#+S.I%DS#I;H9%$O%65H-6F0# M$@318,%$WIL<5_WO),WIWT<._QQE=Q,]?FQF!R MO&0W_)+K;\L+!5>#VDLJ%CPOA,R1XK.3WBD^FM+(#*@L_A+\KMCXCDPHUU+^ M,!8!#QC"?:N&#P<Q4\!'/-"CZ5 MV7>1ZOE);]1#*9^Q,M-?Y=T'O@XH-/X2F175?W2WM@UZ*"D++1?KP8!@(?+5 M)[M?)V)C !YV#"#K 637 70]@%:!KI!589TQS2;'2MXA9:S!F_E2Y:8:#=&( MW#S&2ZW@5P'C]&0J\T)F(F6:I^@MRUB><'1IW!7H 'V[/$.O7KQ&+Y#(T=5< ME@7+T^)XH&%F,WZ0K&=YNYJ%=,QRQI-#1'$?D8!0Q_#I[L/)]O !Q%L'3>J@ M2>4OZ@JZ5(KG&IT6!<1YY(IGY8"Z'9C>.BJ6+.$G/6B>@JM;WIN\_ U'P1M7 M=,_D;"M66L=*?=XG4U;,70&N1@VK4:;7;RTF<-L(XP#71EN AC6@ MH1?09Z9^<,VN,XX*GI1*:,&=)>5UX\X:H*DGG,%B]VJ*5G5E"[0 ML85G:%6L;8/C#LRC&O/(B_E*:I;M &_D2%=(6OALHQBLW #'-<"Q%^![*=,[ MD64N4&,['YB,6J!L(XH[NAP'#;$$3]2?9OF-@,XH.EMC[6)K9A*UT#F,2-"! M;H/V\!.%"$I(Z8>J /G/4BQ!F^ANH-C.XW#<;AB'54RZ$MF0%?;RP^0<@#(M M\AN4<1 L0,O*:!,D9ZB$RZH@G9B)C7D4AFW,#JN8QAV@&];!?MHYKWJZNUG6 MPS>G'5O0;)N(=@!KV ?[Z6?5S1Y@-EV,QW;6;"L0%_:SUQF?<<"8@E(!/5"ZDVNS M$FD3JW^:G>38=@0-NV$_O3WVQ%*J:N<'ZUXN-?=6B\UH(RL@!S5VE II2(_X M2>\[4XIMU(-3?!&;T/"PS7H.(S+L4#*DH3WBISW8[ADF,>E,8.,1U99 M.(@Q[E+1I&%&XF?&J5PLA#;*>46*]?*2 %KTRB0=X>BU$[?7\Q[;^V=PM!U] M0ZUDY!5KEU?GTS\^G'\Z>_?U\N5O(X+C-^C=G]\^7OWM#/A_$*CG2.F9O&V' MWG R\7,R[./7LJ+0,OG1A\Y2Z)9E)4%45A5%8EKDI=P.XQA5IRIM(+;I_:^75'VX=RC5"@?J%@ M.@=H=X?L$4_ZWD!NXR'NC^BHREO8#^.X/\:1/Z>P_3&KWQE/^.(:9GH\F:WL MS!EK']1BL>35$7OFE 34EB=M!>,UV4Y;HU^H7[^ND$Z1CUSX>!A90EQD>=; F;70)]>L2V#>4BS*KCM93/A.)<.[3J:TM#O P MQNT]I],.AV$'S]"-$^)=9,@7?O^>9ZN*G,L,E&'QN*B9\Q&W,J2VW!A&XS:G M.ZSBJ.N,@3:JA/I5R1>9'X"*U4IFF:EJD6L.=:O-RXI_)%PAH7Z]LGHF>SX,EU2)K&JWK3P/HQ$K=$^Q4BTF>P806>\; M'&2/YF:D;D1>@8&9!#FSOC"OWNI7K9/_ %!+ P04 " 'L(E8M#BSS=T" #9 M"0 & 'AL+W=O>\?EYS MC#W>F.118]G@)3#]9)N^TG]UIK79A98PI33[R13^<09.BB# M)5Y3=<^W=U ;BHQ>RJFT_VA;Q4:Q@]*U5+RHDS5!05AUQ8_U1.PD^/T]"4&= M$)R:$-8)H35:D5E;-UCA9"SX%@D3K=5,P\Z-S=9N"#.O<:Z$?DITGDJFG$E. M28859.@:4\Q20',C)]'[&1; 5 Z*I)A^0!_16^0BF>N[0]E#H7Z# "\*.].GIZ4$[W=6>&^-!8SRP>H,]>G.E+>MZ5(@OT2UA MVCC!%,VX)+:^?EPMI!*ZRGYV6:VTPVYML_0N98E3F#AZ;4D0&W"2=V_\@?>I MR_A_$FM-0]A,0WA(/9GI50-"Z)>O2RU]N$ E%FB#Z1JZ;%=:L=4R'XA-XO4\ MSQ^[FUT_QZ):H/T&M'\>:%6'"*]5S@7Y UD7<*49[:!$GOT]0SX>UX*.&NCH M5=!$RG4WM[_W8M[WS>(P5;2QZG[@KLQ'9W]EUSZ/F"Q8HP MB2@L=:;7B[6$J,X154?QTF[%"Z[TQFZ;N3Y[@3 !^OF2<_74,;M[LC17UZ-$Z]W5 M>*RBA&5478H=R^'-1LB,:KB5V[':24;CTBE+Q\3S@G%&>3Y:+LIG'^1R(0J= M\IQ]D$@564;EMQN6BL/U"(^.#S[R;:+-@_%RL:-;=L?TY]T'"7?C)DK,,Y8K M+G(DV>9Z] I?K)%)5_D>'RC:?$E$HFL=J,=: P40:1_5X M-]5X9& \3- [D>M$H5_SF,7G <8 OF% C@QNB#/B:Q9=(A^_1,0CO@70ZL?= MB0..WTRH7\8+!N+=YI'(6#N5Z*]7:Z4EE.O?MMFJ@OGV8&8-7ZD=C=CU"!:I M8G+/1LN??\*!]XN-Z1,%.^,]:7A/7-&7']F>Y053+U'.M(UIY3XIW4USV2\G MWFR^&.]/&?2-B#>9-49GR*8-LJD3V4HH;>I9U@AMX*H(TY-Q_4GH=<#UC7 X M)W9P00,N<()[(X52:"?%AEMG+>B-&>#NI/5MR#2PPPH;6*&SBNNUGV\1>P#% M4/99"Y^R>)\HV!G=64-W]IWB58S**$'0U$ $]J!N.[-X;:1G_2KP_$Y&^C9^ M$-HS,F\@SIT0[T#I(!\OT9;ED)NTA$ICD 1NVHL10QO:>1_)?-Z%:S$B_@!> M[+7*XCD1?Q(:8(H?JJ0ZU/2L.\R##DZ+E1]XDP&@)Q*(G4#?FB6XD2([@@7) MLX+$O>$OH$V$790V,W^HBV'2PB3N-:D3)D%^2WUY7L_F"RM0\I0+\ZFBG=-N M]10[96NY2FB^96;;L:%2B;^GF33E_\+&:PO[;00@>;YG2E<[,'@"&^M[ MINDZ94BQJ)!<\X'E,^DWI3GN4N@;S0<8M-**W=I:+AT 'K.UABDVZ[S@*AGJ MG>YH]E)"UIKL:_$%GGH#=%HQQFXUOLTU@X'UL5H&-S.XK[DP?G?";4:^/U0V MK39CIQ;6CKM:BQ$4PGQ $4BKL,2ML.7J6S/XF&='Q)H^V%L$Z6OG MA8]GLPY4F]DDG S4+&DUEK@U]K:!YRI<=Y#_T1^>(- YT5:EB5,.E^]!@U+( MBY4>^;$<6,P<.6B5E+B5]"U3Z@J514.UEGQ=5-JB!$]+C_)X]O&$I4EI$]XE( M8R;M2>M_DT+2IMU=G\W,D;1688E;81OXL#5%L(8R4%N54%CQ%^;\BD=6S%7, MV2D8[W(:>*=_O119G6;3 0:MJ!*WJ+H8Q#PM=/<8J.80/(:#U6F00RNYQ"VY M7\KC0-BIT3U\(Q+]@!'BZ&5X_CDV#-C!BN 5.2Z.C]LGC8GSJ_* M<];.\QM\M:K.C=LPU3'V.RJW/%S'3!TC MOLDZGFEMF.U%.YFDW;W8V0L%Y)@)(%>2X_3?K\ 8&P%*[.K&-K;.<\3[2D(' M/-L1^L36&'/P4N0ENS'6G&^NIU.6K'&!V!79X%+\LB*T0%P6:7K3 F6E,9_5W]W2^8QL>9Z5^)8"MBT*1']\Q#G9W1C0.'QQESVN>?7% M=#[;H$=\C_FWS2T51].6DF8%+EE&2D#QZL;X *]CRZP"ZA9_9WC'3CZ#ZE0> M"'FJ#CZE-X99]0CG..$5 HFW9[S >5Z11#^^-U"CS5D%GGX^T./ZY,7)/""& M%R3_)TOY^L8(#)#B%=KF_([L_L+-";D5+R$YJU_!;M_6MPV0;!DG11,L>E!D MY?X=O31"G 18UDB U0184H#MC03838 M!XQUR6D"'+E+_DB VP2X4@ 98B MCE-PS\6;&#:< ;(21R1Y6I,\Q93]!J+OVXS_ !/P[7X)?G_W!W@'LA)\79,M M0V7*9E,N>E,QITF3^>,^LS6:N2C$T*JS@'\_X^(!T_\&, LUYD.:9M4813FX M15DZ$9U:H$W&Q;$"NE1#OY R(26G)!>_/()/)<<4,ZXB1FKB'>9BF@N-(T1+ MP60J5JQF?27B[+IA4V%[Z[W5>F_5''N$\Q'EJ$PP0!PL<7(%;/@>6*8%A[S< MDYR:5*U6SW-O-GT^M:G? @9!"+NMELH>5F(Z_J693N2B,K, MP_+\^@OTS#^'QKA.6*03%FN"=>QS6OLY([[;2NQ=)?YA*0Q8HB6=8< %G?&;IA$4Z M8;$F6,=>K[774]I[)RZ1-$NJG02KK^H98]MJJ1PT5LDZPUBO-TX]7YI:FE)% MFCBQLLL=Z?U6>O]"Z55SR^]?E;Q NH8NE(G/G3@Z89%.6*P)UG$O:-T+E.Y] M$15D3MB@1\K(,Z:))LY2$R<*>F-OXOB.M*F,7VO5D3MLY0XOV?=:0_*'K^Y[ MPUX780B#4%J"E#TZ0[9^M@F$KAM(NO6;^9X]LL9 \U@KFC^S\QT4L$%*6U\_ MA+*.ZMSG+C1::9%66JR+UG7QI.*'VC; :M09RT\#ZFPGH7R=UI4MT@6*&Y S MTNVN \>Z&ZH+[TOVP0WR5$#;"EUY$EU07RLFD4Y:I)46#^CA>J;GFB/F'*M[ MJ"[OS]O%JF'G3!!-H*4N4*0+%&L =;T\EOI07>M?MBV&_=+7-4/3E^?:!96V M8J[II$5::?& ()[C>M;(5#O>#H#J^P&J?:\Z])R)I0FT;$"=O9=\%R<:;N1* M8R=NFCG=9D$PHNBQ H?J$CQZP33)&*[NW^\0I:CDP^KJJKYU@9:Z0)$N4*P! MU'7Q6,Q#=35_ZN)^W3IXJ5RV^N4\-$/?,N5U2VM%KY46::7%NFA=&X]5/7RE MK"?EY/0Q4G9XC%1_F3UL1W?=NHI^7: E[!?BKFG*:Y^F;/$KV;IV'*M^>%'9 M;P\Z\'K=/] $AH[IR35-OYGCA;)R_483Z/C0E2\;_78N]$9NAUC'NM[ZJ;I^ M4"%KH*[W'1C8TJV(A3KWNL9"#'*X$W MKWPA/=W_;V)_P,FF?L[_0#@G1?UQC5&*:=5 _+XBA!\.JK\.M/]>F?\/4$L# M!!0 ( >PB5@(^]5&PO=V]R:W-H965T&ULK5IM;]LV$/XKA%<,+3#7%BG9<988R,N*=5BWH%FWS[1$VVQE424I MI]FOWU%21$NB&*?SEUA2CJ?GCL=['DJZ>!#RB]HRIM&W79JIR]%6Z_Q\,E'Q MENVH>BMREL%_UD+NJ(93N9FH7#*:E(-VZ01/I[/)CO)LM+PHK]W)Y84H=,HS M=B>1*G8[*A^O62H>+D?!Z.G"1[[9:G-ALKS(Z8;=,_TIOY-P-FF\)'S',L5% MAB1;7XZN@O.;L!Q06OS-V8,Z.$8FE)407\S)^^1R-#6(6,IB;5Q0^-FS&Y:F MQA/@^%H['37W- ,/CY^\ORN#AV!65+$;D?[#$[V]')V-4,+6M$CU1_'P*ZL# MBHR_6*2J_(L>*MOY8H3B0FFQJP<#@AW/JE_ZK4[$P8!@-C UP-P=T X,(#4 M T@9:(6L#.N6:KJ\D.(!26,-WLQ!F9MR-$3#,S.-]UK"?SF,T\L;D2F1\H1J MEJ![#3\P1UHAL48W5&W1.YAGA<;HT_TM>OWJ#7J%>(;^VHI"T2Q1%Q,-&(RG M25S?[[JZ'QZX7X#1!Y'IK4*_9 E+V@XF +Z) #]%<(V]'F]9_!:1X">$IY@X M -TDTJE#/(:F18CC0-9;\9HU>9IYI^]WDPJJM>2K0M,5),CD161C MR)>6(DU-,GBF&=Q:FQ1]%G"&]I#80C)7:JK[1>U)[TRY%Y,[8N0)=MX$._<& M>\O 7\QIQ2!9@NA.2,W_+2^X8IGW8L%XUHFE;Q,$V%V\9PW.,R_.^RV5;&SH M*4&QV %GJT&(9WV(07>%.6P69VZ(BP;BP@OQ(Z,I_Q?P;:A9-QF4QIY5"\Y4 M"6B"+ZRJ)\7B0@[VP46_6H)%MUP<1@LW_&!JB6_J#>!F2[,-,UC7E$NTIVG! M#.T]4"DI!)%RNN(IUX].DILZ8..H ]MI1<@ \@/*#KS(KPZ*UB"61JJ8 ^AB MB"K%M!-R<$2A.(R"LZ%48PL8>P'_4Z=T)Q*^YG$%G'TS9>WL(+6[=KUVD?9M M#HBE#=1R=^!ERJH90B+9-\,!!5?;LI[A2L)6[JQ^!_4B%P?4CEJ9CZ8# 5EN M#OSDW"T5$+A,2EBU:YY1X$/H[;%0VBWDO*Y?$EK8#XW@<" V2_"!G^&K!:PZ MM&W*7Y6]_6D!#U%X<%(./Y6W=C(LBP=^&K^*8U$8K0/\QOC>--Z?C+QQ!NY@ MZ##H]ER753#4NRP!!WX&?I\9Y2"DNZOVJ70\GTV[P!Q6^ !^&YFEW,#/N7>2 MY90G3WVIJB&AMTS"/@S6#/2!JKBKG:Q)5[L)UZS-RNW\9_J_+$84+_8\C#V;Z+?EUKR")@GW46?REL[:,O5V,_5=X6,M]0L$:- MOA8\-^+#&7:?4,>S16]R'%:+@5TUMJR+O4163\V3S%?%2O&$4W<_KUVU$$1A M5W/Z;_@=R\.2)O:3YIT4,6.)0FLI=DC1M,K]T7L7W*?(:+;H*E6'%2B[ 6F' M+9/BYYGTZ0&'D4 2Y8<%='P0WMN\0.9A!R]#-@9V#]@2,_83<]/$8+KV/(%& MMGI$K^N.]@8=W2OZY!N&46_1."@ZBH9(&EN2Q@MO1WO7Z.UG4'JY_L4=[43> MVD]"+?<3/_??20XQYS0UTJ1^KGPHUE,&U>K?:!/7%GK>W6@[K:(![4*L "!^ M =#N#YG0S"NR2%\+D* ']<1B@%@Q0/QBP#4;ZR.B-D9FW M&(0I=ZH#TN=]'/;*\/]O[MM160%!_ +BF79^;*,D?6U!YEWJ=1B-R6PVH$^) M%0[$+QQ,#.\SF +3OU[?LNKHC>%A$YH3KTL%]+2"PVH<8!P.D"BQ:H'XU4*9 M\1]_.,/3X&?S$U0_<';-H*PRDW"HJD=&I1.]ZR'WM/O(P&5%R-!3+&(5 /$K M@ :\1?V+V45Z\#J>>,^GW8V9PZH551NNY7KBY_K[(L_3\CTJM*4_S*L4@]_J M%+,#/KK,3ZH'3N6M_:+0ZH'P.3U@N%\_EAEH=CCE&8=D91O3L!4JWSR9UU'0 M$BB?EUPTIH+7;EX9;1A$EC /]?"^#_^L3P MB5CNJ +?9P8 $$. 8 >&PO=V]R:W-H965T&ULM5=- M<]LV$+WS5V"4:2:94?1EQTT3VS.RTZ0YI/7$27O(Y 2*Q)C$* !T++ZZ_L6 MI&C)M7WI]"(1Q'[OVP?P>.W\5:B(HKBMC0TGHRK&YNUT&HJ*:ADFKB&+G97S MM8Q8^G(:&D]2):7:3!>SV=&TEMJ.3H_3NPM_>NS::+2E"R]"6]?2;\[(N/7) M:#[:OOBBRRKRB^GI<2-+NJ3XK;GP6$T'*TK79(-V5GA:G8R6\[=GARR?!/[4 MM X[SX(SR9V[XL4G=3*:<4!DJ(AL0>+OAL[)&#:$,*Y[FZ/!)2ON/F^M?TBY M(Y=C,2BE:R-?&+6_]&?3ZOV5[A3$B_8MW)'AV,1-&&Z.I> M&1'4VG;_\K:OPX["F]DC"HM>89'B[ARE*-_+*$^/O5L+S]*PQ@\IU:2-X+3E MIEQ&CUT-O7CZGD+A=9,JY%;BK T0"&$L+J,KKL1E8W04TBIQ)H,.+'+A*9"- MDE6.IQ$QL*5IT?L[Z_PM'O$W7XC/SL8JB%^M(K5O8(K@APP6VPS.%D]:?$_% M1!S,QV(Q6QP\8>]@J,A!LG?TB+UE4;C61FU+<>&,+C0%\7V9A^B!H!\/9=S9 M.WC8'D_5V]#(@DY ?.W]#H]/FS^='LW1/1'@[1'CYE_7_HWY/^'LYF/LG^ M6QSB=[K]2&8L/EDT\\7S9V\6B]F[[F5:S-\)YT6L2/1[YZYNI-WTFR\Q$K9= MH4$MK&851E&L920O"H -7L8B\8"'JYQD+0KO0GB%Y*Y(C86\;LFU033.;&HH M51OE74D&X<-K]] &4@(D")9ID48A/8U%34H7T@BE96E=B+J )(!B@R)0ALF4 M;TN0A 'S^$W*OW"A)A:RU0FQO=N'?T8 M5-TT9I. 83@YG#OJZ#2,+SB@TS0,2G-!6 !6[)"Q4LDNW3:>? MDND[PBU<5SJRVYR,< W2CJW57(LQ;Q45@H4T)V YWES;O0JN=:QV.YAMX]R& M][23B5@:P^GU!G?4/.WV3PDN7KD'%K9LG7VU!R!]"[%Q5CB96"^A=)B/!T"% MT4 K _\!MK;%61E;@B>N:Y=9-0#IY(10+8BP$U8;837I4;+G2'D#ZDT BN MDQDA9*E,F.:F;Y+DDY$$9,O4W:;:A#1\1249NN1U&D#Q@B;EA(/3Q57'0?>H M0"I$3W")QSP N.P0P^Q@ '43-[)AM/$8USKP]2-+R/XN,? RL C\,QH;&8+L MPNE\]*J5=RTH2&* <'!P=C]263U8"%<(P>9>I"&[-_@RUZ#8#5?*K58()?=.HI&5TT7'*:QS=QU"R#PG MGE$*G0ZX+)*:Q5!B/)":@$!L(#"DC8B !P.99 R^;B38!(NGOL.2(A2BYA$< M6IO5(]4H.Z2!O$2^-5PN5>RT)>L@4^N2.)#X-; 'FM'NF4/D_XXR=;@ M-IQ2-QKD#L*[LLP.>+>\;N5GS,?7'>3>.WMZD>%\R0D,1(PU6R;VPKQ96:>, M]PXO/LS<#=4Y6C _Y%O)_)>)^,-FGZ5'A?M[2IJ=@?QE<=UJ'E@I7L_$,F22 M@8][98I6K+H@+JKBHP"E'YBQ72T9O>/5IP!&1,<[C(JD>Q*6S0%ATT& M:$;"#3N&+:"W9A/(C##V;;J'Y?+BZ'D"0^H>=-ETX7P[5(H9XQDKKX8 M''#2YT..VZPYEI0.1_-P"<1."6#,M*J;K3Z-?]6%8^+6[UG#"8@:O$(KL.") MU[@/>,Q*!XPOM^,L02-!%,96>H5!!8@+!OB+U+Z'KH+3G6L]"E6FCQ?VCII$JA).ZN M[;-WMVJ]/M_EP;4N.W=YN+H'D!R)B$F 4#)NE^?G@%)2^?UYAYL\0-HS/3T M-,"]/CC_*31$47WN6AMN%DV,_+-UOG.QUQZW>KT'O2M4SJ MVE6Q7C];==K8Q>VU/'OO;Z_=$%MCZ;U78>@Z[8^OJ76'F\5F,3WX8'9-Y >K MV^M>[^@CQ7_V[SWN5C-*;3JRP3BK/&UO%G>;EZ\O>;P,^)>A0SBY5IQ)Z=PG MOOFYOEFL.2!JJ8J,H/&SIWMJ6P9"&+^/F(MY29YX>CVAOY7/MW9^Q. MW3M;D;?7JPA(?K&JQNFOT_3B&],WA7KG;&R"^INMJ3X'6"&6.:!B"NAU\23B M&ZIR=;%9JF)=7#R!=S$G>"%XS[Z!]^!WVIK_:M; DA,-KC6U3I*PM7KO*9"- MZ8';JK?&:EL9W:J/>$C07PSJWW=EB!X*^L]C%*4 +AX/@+OJ9>AU13>+GM?R M>UKW+ZX\$5>78&J^Y"!F90&>I*\G-UEBHV MA$%=K^U1-;I66E4Z-&B3%AP2T_D75>3/U45>R+\BOU(/-GM+I1]@ 6IS)4B7 M9TA+!<[)4ZV,C0YV48;*FSY5;.=IK,G!Q 8C]H0>\>$,X?OO7A2;YZ^"NF\, MG9;T8;LUR(@+G^$WPK14)TD%#M8 MG3:UWQ3&P_G +2"]2$S3SL34ESI%09M MR3-//_""Q?K5AS2#FZE.N?FDHPR0%38(\3@_Y[2 [ M55P6RQ=_W:C+O"@4Z:I1@S41TV&'(?*BO, !]#0:A?O&I_@V^;JX4N^T MA8US<3(3,*-OG;!C8%VWA!*&0;D MJYFLT%$T%1[IV+1\.2&%E WN$!%%%E-'M:E0Y)KVB#'DV2]GZN3E*NQ; 07< M.EBK8F(D#D;"+.Q0/0>LQ\>]Z8D;1@30NX@P643)E2$9KA\RG>YE=^"\==JR M#J9M(65=MI1A-:;;N[VI@3<+,D1=FM;$HZS!%<0O^I!XEMH."Q MF/=,%Z"08Z")!Q>,-,B0Y-HZN_L)8NU251OHBWRVU^U BDG@L;GZE;)&[U'Y M@?O",&ZE>Q,1&*+E+5TZ!-1IM1-'J$9'J(&#(1PP6N%THM>0"4-S]Q)".T-B M 4:X:B_RV['9(:N,/H^B!K[X+*;888N+0214#@%U"$%P=1M )1R&(7B"L8BF M'$Q;2_7.BRFD86=LG;0,-]# Q9IT)'1QO3.@E6@, >FUCY9=0:<,!NX1(!G[ M4^/X!NFFRD&P$@>32FDX' GQ^T\X4NFZEKJ &,&F>EY8NE\Z:@R$]9*5X%7[ M'4T(5 NF&(03^P;IW@V[!L]$0BQ[#?O#06=OPK2MC6,3",CBAE!O!X^*^>".\MP+YF*CY%!?4#Y3OXGSA.+PV\-F.#HN/#E;R2'1]$?Q-JS M^Y^*#\Z"OF3AM(Z;H?AYK9F MAZT))_.:>V_H^>QR#MR)&PLE4YN=FD>2W*3N-AH<<*D]SIECR!;DL0NEL)CA M_,3CF;=,MB,XB]IK;QQ;JFS34D!A_=1/MH,8U62CIZ6;:S/6!.RE*HT[;&H6 MSW!6BH42A3!X/F6$9=:X V+VK"8=Q\PE1K%@C)<\F.%2;.C$[T[DPO'!3LT6 M52-TZE))$8$H^]&7UWJO39!G]\$+&@O?FA,'$^+X"^:\%P+<#LYS('X\V(G'6;5?2_5_&AQ.H@P'K8/C MZ4?>JH(1'%X37BG2"RA;39/._YPDV;=*(BM5&LNP5 SE#:\\F@&8P2?@,3.P MF"K*F7)N3*E42@%[+II@/$4%"2 EP1670@CC7].-&=*4['P3N[EZ[&"_.OE( MPP:TDT]1/N,,-J;OM?GI_+5[ES[RO@Q/G\KOL$,8=$U+6TQ=Y\^O%LJGS\]T M$UTOGWREBSB:R&6#+W;R/ #OMPYM.-[P O/? &[_ %!+ P04 " 'L(E8 MIWX%(94> "I5P & 'AL+W=ON&LC8SM8'%Q/U!D2V),D4J3G+'VUV^= MJNH')<[$NQ<7V(U'$KN[NKH>IQ[-[V];][G;6-N;+]NZZ7YXL.G[W8M'C[IB M8[=Y-V]WMJ%?5JW;YCU]=.M'W<[9O.1!V_K1XO3TR:-M7C4/7G[/W[UW+[]O MA[ZN&OO>F6[8;G.W?V7K]O:'!V_5NM-CR\>O?Q^EZ_MM>T_[MX[^O0H MS%)66]MT5=L89U<_/+@\>_'J L_S Y\J>]LE?QOL9-FVG_'A3?G#@U,09&M; M])@AIW]N[)6M:TQ$9/RA?_37OG?:RS#M[U=:_566_^>'!LP>F MM*M\J/M?V]N_6=W/8\Q7M'7'_S6W\NS%DP>F&+J^W>I@HF!;-?)O_D7YD QX M=GK'@(4.6##=LA!3^6/>YR^_=^VM<7B:9L,?O%4>3<15#0[ENG?T:T7C^I?7 MU;JI5E61-[VY+(IV:/JJ69OW;5T5E>U,WI3FIZZO:/^V^_Y13TMBX*-"IW\E MTR_NF/YL87YIFW[3F9^:TI;C"1X1K8'@A2?XU>+>&7^TQ=RGW]U#[46@]N*^V?_OQW7O]-/$G\^S_VA9\[&S6;M*OOBPL1G-M\M= MSJI(/_8;:XJVZ6B&DIXIS:IJ\J:H\MIT/7U!>M]WIFKP$$Q/U>]),_J-^?GR M\CU9@S^&B@@D36C(=.!AT[?TZ;,U-BP+JO*.S,T.JW:T9MYG^6I%!H'7S[?8 M2$>S[5H'&FBYKZ.+9R8^;'=YLPT4NOV1L^!OB-C8YTCFOK\"SYWF]S9$]BDTH 6,I7" M7RSK;,WTW^3UH-_&1?' *J]N3A>MH MA:$N35D1_YQ9N7;+O I[G9MKNP9WLE^9G> *SOUUX%\B.-<]49"[LC.O6OK' M//SK7YXM%J??O;Z\?L5_GGWW[=3SYJHM60YY0W[4Y?55&/2AW56%63P[G=U! MSS_LE[6EPY0?3=4QZUP%)JI MW0E)2H]9-OO2M9AVY]IR*'HYUHW-ZWY3T"$QPR%6PY:8E^]VM>ZAFV6WFZK8 M@ XY2)+!MWFSWK2NH;7>VZ;I]O5-WE0YBU=V];.I\V5W[P;^_LD,^ @B\/E* M!!5,.GOZ'0:0=#%+,A!&"O\Y7V.ORZ$CB]"1;!U3];/+F^7@]C/SP7XA7&"N M\F[#_\D.:2CP"PU9YLUG$3;PK-Z;NB*]+5FXNYY5::8Z@=4_SJ_GIB=HT=$R M9EG5=6=V@RLV3 )K?T[&PU5$*\D3B1V=$-D%WK6S-MN*JZ%=U[0)$F1S2^X> M_R8K@C!ZT.YI O>98,]J:$HY,-DTFX#<.59LL1$X,M=^4:V&YK!>T0&5I#YD M>3"FHS/K/55D%3,Y#3((R>IS\PNOFB]KFUW;0I^5HY5C,D5-*DAB3E]7?:=D M8@ =>AA F]K8NCSIVQ//B'!J8F4F^O%X33S>;#1= M^B'CN3%O-CWR8U/!C%_W+'H'I_D0XO?:+MU @-HLSI74;\P)_?_B^>(K1E^2 MVM9F\52'GM _7S'J[T-CS=GC,.AB=O[LXJO&D14X.P_CSA9/OX;&84U(V)R= MQO6>/SQZ3/PGN0Z>TLV#&=X1;ZRZLUO-MOD-V2#S=*UGTF( M2$#4T4+*VV&]41&ZM60!]WS2'0S'A *Q3,',WU1=*HM^0G:R9'UA%):M [QK MFZP@:POQ3L0,RNL!1QA,"],X;_-,7A+]M K 1QPI%KD=#P4@(E/X,%I3&.%O MR8L+R,F$&"@>-)=T *JNJK?)/O M68;9=-3[>2K,N]J6:\N;Y,7@:W%DM*=:D E!3,)2M([I=K9@7U^3R%0E60&8 M1#$/S;D')1VA MBL)6-]CIC%C0FP\N![#3GV'G]&=F.%LRMI01>*:NV=@OM-V>Q0:4 :*"WV5K MA!T)VT4$PT !>-"CL@*+@E5M*:XJ+US!#@@WP(BB\I M^*X0%2*+P$LVG664++(5))CUBY#YFK$0'0 <6]>/:2'49QOR[D!8Q/\E'POB M$WXL.:I;,CHJ DPDX39;B@3\V3&)V)Z=F>?FC8\F&.]=M1U[U%\M?3L0R?%G M(F]X8SW*'*&<^^JDT0+)?"LC%'P,%H*SF-..28C3;%3CVF9AL4OT5Q3 K/IY* MP )6H$W9& 8I.F+X0=%CO>\J5O]$H+J<9LYJ8@]Y(-J=HOH9_OA=TDD\9#7T ML&&EI8BA%.80!O[,HF^+3=/6[9HGI"UP@ ;B27I2VGE_/FR(,J?8E)"ZN * M%%@,B84WR'6IVYGP3G-3::AN4^V$5V'LL,,XFKRV:=I#?Z=O,OH3@BT,4@L"D[ E7T+#,<+E MMX#I9.#R&G%9ZSZ3CIW02(+KB-0XEH=MV@!$MVW)F_:'PY.1Y\A94_-^TI;> MDLT"G"6A9R%#3%2OR/*P!28Q[;'C]E:5_7*;_ZLEH?DMKTE,Q41??;J676A, M[FV,4QNC ;I!QHDX;+>3R98DQ3)&_%-1+E*]9D(>:;HR@Q_5$R-I%P$1T^J3 M ? 9+9G2WV")B\H5PY:69Q->5@4($8-,H) X,RG8P!%,20X; GT3/X+I ST4 MX?,3EN4PYH9((,3I(U 70Z*>AR2D AD;T;7.;T1P$1R8^]IM(R>%BF?>2?,AD7K$QDIBJWJNRLDK: PKA\,$F8H1=$5-A M#;JN+01C6$+0AKW-R\ MI=",+!<0_Q93^O2LLWY],=Z3P^/:G+D1F$,?JZBEY0$A2"Q!D^$\605W>:6^ M@*VL;=B"LX8R%7IXI>2@&.B62 'YK'4F5DBC'/ _QME5DL3:" OSS1+M"H< MXV4"][%=%_=.GD##4P]TR-23J\6PF)_)[EF.E8MEQ(QD9):FWAFDTL[(K=]# MNE@'3VA*)\<((>4FII66C:IQ?%3.@N%X/%E"/-!![HZ54GD%UV#83/<5$ND^ MN/#)\KLE&F=95X28\J10P DHFCV89A;\9J\Y@6,L>R0X^_1=K^+:?M+V6+*=02K!@0S<0Q!HI]@,W.#7BA M65<FY\)OL*8L#]Z$Z30R_:;)D/M9._5(B]( MCCN.CS32-#'CP?#>FP DU#V,&8FZ-Z)0T$IDC)/ !1<8"6X@ 12"@.@7XD9\ MQA@$E6S85BEA,T$LHN:P6:5UHRSX6O=,N PJE.:AJ$*$"SKQ3U^YVBZ?'J?T9ABDX(0%E3&WZ#C=IZ].>(:$P:N'Y$&D'F\")X' MR&NB>4].DPU>WC2#^NNCO"'M(0LV\DYJ[9?*Y_'&ZG=\ZAKYY,YC7V'AV%MJ M&$AV+"Z2P>%0O(BJ[=B"^,,^-!OYD<:JG6 '$@D]B.>M0X'>E@HTP!M%,L'# MD+GS'H_1)0D%3N(S7#M7FV#X@Y=(6.()&%DTC;UHWJ8E" L05F8_^5@#W[]# MXM9<:5Y1K8=_TJ9/MORDST FFG8/ )9@J4O0>!*O?V.>7)@GY^;\_(DY.WTN MI&1*PNC#_2C;'^F?5*-F&H"&U$$D:A0P=SO)NSJM38_2(%G Q1!)0_B+YQ, M-RQ_YZ:)=HR*8&5K\6V:ZI43W$NP@O@#&(?-N[NAF#8 +LPOCZ/$;"7FD0'( M07H7,S>OT:7PB0_\%_%Z O%3"1R("A+L[E!X-A4908I+.47%CB/]=9M,=Z2* M<6B5Y("J9C>(&PS6-.-$7_7'8*6_A'?.4 3]*+*$29U%>,A6+'KM$KQAJTK' M,C3Q\]R\B[_ITLZNI#:0-)5(M)>!I551[1C=B]H/7'OF= (KM8,0)5.\&H>LA$./LSDI,^%XK9S/I)@J% M-+@4W[&!SZ-?O_4QA#BGR.,>9A"C+.G?AMW=JD7MY?A8?9,)_\@DD/DJ 5 M/F&C)V[TQ,UY,BP[,KE?,TBG_V6JL>#%_85NJ6.'_X^JV_';_X+PQ?\[X5)\ MCV3RY["!R5_-;Y*'R-X&.Z3?<#00*N#DP[9D&\@S%I\%BU=D%R1R)IUHM+>7 M@9&6P%62X%%R\GZAEXE[0H"B-*Y>G)X]#\DSXM/9H1/P#3Q)SL2EN8UCV _: M6 E9K;FAA8P]FR3&DI;#5+8;YA4YN\\G)+.H!%%TR?M(0'I;6E2F^\Q/.CO0 MA;"ZDA=0BZ(\:;!1I@3*&+^H;B7M!0!&*"L4^:[J41)_'75.ZD"L[)D&R'[) MZ$4.%@>"9O=6-72$UCQ4T!7,U5TYT[E/UJ+ CMF8&^^:[.\$6% I8J$^>W98 MJFHYR+F\OM(.P">G3V8A[\M.[$K3S6):LJM0'1B9>0&"&E_Q9KJ0C27D4[:2 M @*4D!9(=$DA:NJ2Q.XLY+;-0;E):A)'U2U?O\FX?G-0UV*8.KBC&EE@52>T MQ%&C0MJ!5 C$WK65)'.QD3N@YJ\0;MIEWH4]- @,6L M7=;5.M?XE]4OAJ3D@I4*WQ\0EQ?7:$>%M%&X$7L8P_GYX@+DB&6.LXU=P1T! M&CTUODM9,^2.K!Q!US!)PDM6\@;Y0<;0#9_O)5&#G#"I M# SC/@;3DOHK0N-SV*HDC?>^HY;&_$[GW:'VY'/HX=GET,/A:W(^B[S41FCM M>&$W[A! DMBP3)R? @H\.243M5.^89\3 M.PR3.L9[6ME,E"&$]60YR;-(G3(5 -"22Z:/5\S&9M:;Z#27=U"O%U(%N?K5 MDOZ$@ O]UJ2A U9-?_W< 'ERHX%F]#2IF:FY2BHJH3&)"]_)M#-.CJ9IE;GY M6R"RWL^DK\!3F_20<7N:Y#YM$ZJ]L7>+$*(;E%29X]XS.4I720IST_%P]2G:7;3=3MOWLL3F_P +,R&G1,@E(Y8_RQ5XXUT"X9/,26^DA#CBLQ2!M[%K8I0; M92M2C+QI-*29^@BTS5E.']#2!WVXD!'R9R05%!KRY(V(J&\ ^RXX:Y3*4O\I M/#9_S;>[[\QOS.6WX/+,>!Z:5\K#]Z&G!B3]8KG(1D>,/ 2ZU_VACE8P 19D MW.=AR ?6TAQ-1^DO'/"7@*3^VH% Q_ U7!S,ZTZ4BPO&?MY9S-'O?2.^B5WX M5O(E8T!P:$=ZM#2!CZP\4^&49('V&JTGUGAN$C%-&"C]05D0O';50R^;%6)% M, M-9/[-..II;@$MS1:K("JWE;P'TKW0!Z8-/6;$&M7D&A!E!Q$1]4F M;^@TC$C;&4K+?3ZAK3TE(P-,'P-?TVW1 +NR-N5_'IU4 %'O!/YS-Y*O,P6 MP9X-'KQ&XZ+T./&N&GM+I.N\T3+-@[YEA_IV*$E@ZY$-Q-'K,7%-MB004S"3 MQHSW4,KOUX.!EJ^N:2.K0#ERV(WU#=KZ?,8YUO$YL1N9*0U2)!(7E9S:A_%1 M<;IG4L_88)LFW\*D'-B81V*R#[Z5JHC9[)>.SC)>N*&364I!V]8Q,+K+WDG/ MU5TF+Y!B=%%O=- #9N_YWJK',)L"@P$=B0 C)M?[1HR19)+")1;WL8MG-P) MD 0BHHAM!_8'<_=(-9/1=,D4:C91(L.#98C)8CMB2""7_4#_W%RS J@U.=BW M7EI;PA-=LIX4$>68!J28O>+]7&U8".]P[!XQO'K\^GX%=]Q7H)KKQ\ Y]]P (*>K/=UCDY-DJ"MY>-^ MB,?5)?$H/!%=TC79A'^T)#%G"\ET2O)T<"R6):L-U&.=N]"['::1H"M\] T[ MQ%&]RF#)D+1[:[L8[+9.G6T[]$B6JE:C_,4@X<[[BC[/UR(+B2*8WS);]DR2 M(QWRHLT?0U[+/0"Q^N$W^0CP'+N;]S*I,H04JC-E1XI*$IN4 8@U4,N-'./GDLQJ\ $YQZ$/72 MQ\A_MFYE*Y@2M9R%;\B0"WN68_*]9/?0^(IT4_8!%V3]![XM.S%8,W&^*)*V M .PEBA.-S_MXWUCV'!-3:/Y);N7>U4Y RTF3U4'#)X8@?<$8H="4'FE6ZP#> M)#,@/RQM?^O!WL259$G-T&S0KK3CZ8"2S-] D2NH?.N 1CE)9?PXM14.\M': MI1TU$Q>*37*;X>[2;H=$H%[+2T]$M!3>4!/+[)><\XUXA)G/NQXH\.6+KWPC*U;0>%8N1\(%$C"H^F!) MTM7$3+&TR#8G;$+:X)I-WH$71"Y5QX%@XWA#U<$]-<:571]6]+7?:1ZUZ:'+ MYNBD>P%&\^Q2+HX&FI.M\%63>#^,(]%V-9/*.(&Z)FG?F[[:/\YC"10X$CK6 MZ%P:84-C&#=<,%:D7V'>9S"?U;;RW,$#2B!KOMQ/3$= >+B>'KSLH*#>*>V0ZI\NS9Q2*:M@.S5LMC[427_JC4R!QC?WC2 MKDX0+?HH^==W'\.U_%13N8,VT==Y1D_Z)YS58YJ$V[P.S@3K#&BEDF8P'>QU M/6G2G5[R_F6RF+T.;Y60*78^R84T9$BRAB7)>+R+TL CDJTQ6CCX^=!L1:'. M1NKCJ8VM+^I!<"MM.VP/Z0O]LI$5R+FBG 9_(I$F9R@ONTE.RWXRO7^HZ$\; MC/#2CYZMY1C%2@CUC%WO/ &;M F33-P3DRMH?R>KYU5K0>$A>*T_E4A /S^7D3R MI:Q+9&3QT(W-'>ZY?ABSVS>!D"TNN*7X4!:.)4#D^6<^PW:#0^N: $U5_;'RW.$%PTF@B57NU__$35.3+?W:Y[3&]6=Y2ILP M<5T5F(P-B(BYYM1"#JT=7_^4@W.*3L=,R@-_LW#K7X]-EY5RQ]$D^JOTH6VY M)4EP?A4A1IP\OE) QWD,\>G-3P%#$%Q' .=$K=D^Q7K_,[P[S/Q JLLSG+/*P]8EV&!_AB0 MGW;U7JT/0^E\15^-O3Z'+O[J=A"%BN\ND^1SSR.[H835V0&KCR F;2_<7;K_ M )LV>HY[CO)P]EE6(==^Q'/AJ\PE*8I1)M[3$(X9G;]SWU9V&(@>%L=QR\=? M4U8Y5003CSJY"_2?G;,ZLTP: !6X19R;-/OXVQP;QE>:(/5PQ9=GN!S M<+A\\"^A7IAF&N(+E23.01J0:XW@RN Z:^[8U7A:260YN\&+(&^L=+5/?*5= M(,PXA&7\)?N.Z%"T&4H;P'+Q/ +A 1QRO=D?W9D..'9!\:H/#X>GP/5HEVE[ M[,C=A)T%NBS2F'JEV6]#?O'N!:0E(2M?@^(R4O9&&N FWZ;VFHC)I*NFY>:* MF5SNC<^2VVK:00&UWBF1"34QCE>P<8PJ'.C\F]<0D'+';EOZ7AJ?M5X"^B=9 M2ZT]40PC21=L3H*-CPW?^N&I;PF1BQ^_1-TA1\XE]/]%;N!3X4/W:^>/+MB[35/7F1D3Y)-$Q/&44B M>S\^9I695T./BH#Y)W'M4@^/-A&\0'CIS<1F%NM3M]:M^26Q7#MJ>GF3:O@VO(?V4EZ_&A^7E]C*&Z@0/J]HZ.G\ MZ>,'DK3P'_IVQR]C7;9]WV[YSXTE'^+P /V^:MO>?\ "X>V\+_\-4$L#!!0 M ( >PB5@!J4HT&@8 !4. 9 >&PO=V]R:W-H965THT>?@&VD[8!DL:(VPT6B_W D3@SW$CB ME*1LS_[Z/:0>'C?V;+'8+R)%79Y[[I/4^8-4W_2&5V]34\R@(TGG#1#N[/'=KM^KR7':F%BV_ M5:2[IF%J=\UK^7 Q"V?CPA>QWAB[,+\\W[(UO^/F]^VMPMM\0JE$PULM9$N* MKRYF5^'I=6+EG<#?!'_0>W.REBRE_&9?/E07L\ 2XC4OC45@&.[Y#:]K"P0: M?PR8LTFEW;@_']%_S?$857[&N-E_DPR]\L&=A\4I9 M:_>DAUXV*F94=MK(9M@,!HUH^Y$]#G[8VY 'KVR(A@V1X]TK=QHK6=,?7\+71YW,#6/MQ7@X0USU$ M] I$&-$GV9J-IO=MQ:OG '/PF4A%(ZGKZ"#B.UZ>4!SZ% 51? OGHR,'5[Z M"MY@&WWA6ZF,:-?TCZNE-@HI\<^7[.W1XI?1;)FSRQ]_ M"-/@[ #79.*:'$+_:P$Y"/$RP>3$^PZ:?MMPNI'-EK6['W_(HS [TW2S$7Q% M[Q]YV=F"\3ZO5J+DRJ>'C20'IHEI,MA:.E$T",6<5RM>"E>M#?O&%;VQF%%P M=O/YW2+WK.Z8X3W$2K2L+06K"2BNQ[0E)[ER'_]$S=,C;UN'%75; MJ!K6B%7_0K5@]8F.:$O9 Q,:JGU\4A[J^1*&+84M3 [:CC3G>(G],'P1A,: MEQ:5H_ JI+<'J3BUTJ _V=2"['(W4O()[H8Q4+ESPT%.EC[U?^N.8UW?Q,']D262L- MJ[TO_)ZW'?=NT'ML)=,GUG8K3#IE#3ZB+"WP#/TBLV/D9TGNW;B.ZOA_W0C# M+2"0?Q*M0 ^MZ&>(YEC9REB74AT%DR>09)7Z0%^"MC8LXJ[D%+,(0S\6BH-A/LL#[ M/"4=?\01K"$4^VF04%)$%J)(O8](P3Z9A@P%3YCZ!@!A3,=VFB;]:#$S3/^+ M\Z/_E_-#/XACC&_'^5]T?9Q@2YP<<'WNHH/G<[>':6KCD:;?.3Y(+>5IU/+2YV44IID%&**'QHX18CU8Y2!#LM,A@? MAX5WBV; 1/5DNHV3= XNGS& '1'E.250V'OZS]^1?#E04X1RX0>+R+.1?1!U MC<4PRIV_,8**8>U:+%TD0":"J^,H!17K7G0]2X'_T8EMWTVM)7F1PQ1;*$E1 M[$6L1@?EY#I;>$;*7L6L\SLL.EJVLI+8<0_]?#'FSD"YL!E5+ 9[>L_;!N); M2LZ[BQ!CX1?8^5'T75EP[5F&=T:6WS:RKKC20VNE]V!M=F/LO/IIR^D4)6_+ M=JXQ'M$BL!TJBQ)7+!'"!"'5H:4>",<>*(5QAB"'%!>Y]XZO."0J;ZJ P*9_ M,+%Q=R"<#O /3BX"89?S1BXA(%U@"RIC]/JF=6^@G:&;I)OD!,%LE!#39;8.&( M,RH"1IQ3E!>VZ*/,^U7:F\C@@E=W11G2,PEI$8[\]GD=(>?#K ]>BNYTA/:< M0<-+M\'YWE4=;6WM?D@TN93H;^W3ZO3/<]5?]9_$^Q^F3TRM!3I0S5?8&IQD MBUF?^>.+D5MW\5]*@\[KIAO\MW%E!?!])6'\\&(53'^"E_\!4$L#!!0 ( M >PB5A6I MRO0@ #47 9 >&PO=V]R:W-H965T'.+%G!B^3U-DP!.=KO;7+<-^I+%X7 ?:(FVN)%(+4G% MR;^_F2'U8L=.^^%P0%/;$F;[2YMYD0CCT6N;(7O$I"13X8Q?%L4'"I>I?G].S67)[KRN52B5O# M;%44W#Q=B5QO+GK#7OW@LUQG#A\,+L]+OA9?A/M6WAKX-6BTI+(0RDJMF!&K MB]YB>'8UP?6TX$Z*C>U\9^C)4NM[_/$^O>C%:)#(1>)0 X>/!W$M\AP5@1E_ M!YV]9DL4['ZOM;\CW\&7);?B6N=_RM1E%[W3'DO%BE>Y^ZPWOXO@SQ3U)3JW M]#_;^+7328\EE76Z",)@02&5_^2/ 8>.P&E\0& 4!$9DM]^(K/R%.WYY;O2& M&5P-VO +N4K28)Q4&)0OSL!;"7+NV/2-SN@ M[ZJR\,1:=JV+I53<9X)*V<):R/B.]^S?BZ5U!K+D/_N \-N,]V^#S#FS)4_$ M10^H885Y$+W+GW\:SN*W+S@Q:9R8O*3]>S%Z47B_:=.3J.OZ/X6ZUZDPQ=;3 M3RJ"<(AB*0P+$>DSEPG$LN3JB26YMB)EG %LRG)/,R-R[N"ITX!S@/FV,DD& MU&&+M1$"*.U82HL^Z@>O?QS[#=@KW.#GGTY'H_AM+18U8O1B^/8UD,1E[%/^ M5)2595\-3Z5:UW;UV8X+E 9A MZBWZ;),)(Y9/79>C,I@$7N- TT8 M@P_LU>X+*()-?&M'3]BW5B6L@J>T,*+E,.SX#Y@FW8#=_HB"#HB,V MG,NZ!.&K1!CG'8SD@\)J)TL((6)B@-IJX,KX! !CB2 MYZLJA[9HP6L@D_/0[(1BAX^W +A,ZY33&X5+$4,B\/CX27 #[JECK!'"B:@# M'+>0VZ8!['D,R(!6 C)RQ:5AD)J5J*7J&H*A0DN,]UM:6^T6$<@%BY5&)]T" MHZ"D0HZN)2(=:A!1%"J*1Z")9)+H2J%H'?*]I$:_MBP#2WF;N#Y6ORT6MYVP M=<4+X3*=DI3?$#*V7^,?U1:JM@!C;M<6>T(;D6B38EUM"-O= =L%:'3X O"$ M$):"YKD.OH%A *K.9=I64; -B+ZO"CR/#4*[@ZB/ 1:81PE3H,B?H*@-9V\H MTHZR?8FS+7! ;V E)+! >BN8<<$BGC]A 7\9_U='/LEU9<$'^_J,?8'I.ZUR MLKL98CK=V4:WG20[D%* 5]>8UMVSM@*71$8'/#QD7O5OW4 M]%NI:A98-I]'?W!S+ZA'[ELPGD6?J(IU;3F./K[ )1_GZ*MV /&^S/#OK[= MH):(.-QVG%MKG6*U HG3X1S&'JPNRAF=PU"P!H>A\0I+E>Y&@]7L#@"HC._L M0^CDU[^Q#WQI<28#-Y-L_T#68LZF\3_"'_R+^W'WMQ!O6G"YTL+5&^8 MF=[_ZON<8!E_$-MTPKUN[GR-ZQ#VQ^(MJ9^K M[@ -42_=9KNM2;T%B:=V-[7*[5P/]=377*PW*P@#\/?_3\)K')8H$>2R0O>V MITUD91Q'D"V=9,&D]LE2:K.+VY:NVF#4<9BR0\R)_P%IO^<+6O%./K8),QJ. M?Y3=I*G!,Q\.$V^IAT9X>=K"9>I84@ELH,S0]PAY2MX-" MLSMJV >8 ([@!E;[ 4*JALI1\&8%N[Q(_ZJL0V_1W,-U MP;*"8R:2IWBH@2%V+>HYE!.7=N:R?0BEE<'J3G$E<&G732837_IXQQP\(#:! M]5-<5"D8=.F8 ,/',:&+DT^5.X(LG EI+C64.GB0"+->)QKH9PDC$ BI/$P^ M/ZPZXN&TA64'+WG0V; 57JE50*=:D,*ZT56>^MZQ% ++'QY'!#[:/1EM3:"0 M)'45N[F+2!0'\%RT.7+#587$\(5^A$< ,D;3,;#4#OD%]K2'Y=HR+X]E:%51 M7\5\0'F$JO,XA"G::04L'$3H6$FFEO[,8YILV.D6WQI\H<0=T_TA^]SB^ZG% MEVX]T)WH76#>O_ 0A=JK+E_&0_[G96?!0Q(T +[E';0)?I3@..(3?KQ<$*% M,->V3E"L-@[/A06P9/MD?,1>C?OQ?,A>X]=)?S:>L->M?.LDO(U/IA._+CXY M'<.R/^G"$X/S ,X /51%IH)[) 2.5H[.TAB):7\V'_9/)R,T=C[IGPY/V;ZK ML4'G*K,09DT7MMC8 &1_J]D\;>Z$%_XJM%WN+Y2A8ZSQ()R+%8C&)_-ICQE_ M2>M_.%W2Q>A2.Z<+^IH)#LC@ GB_TI!2X0=NT-R47_X74$L#!!0 ( >P MB5C7.^%8B@0 * * 9 >&PO=V]R:W-H965T+UA X+$L=,TZ]H :[?>]=#B@K9W^ZS83"Q,EGR2W#3__DC9 M>6G:%3N@+[)-/GSXD*)TMC+VARL1/3Q52KOSN/2^/AT,7%YB)5S?U*CIR\+8 M2GAZM,N!JRV*(CA5:I FR7A0":GCZ5EX-[/3,]-X)37.++BFJH1=7Z RJ_-X M&&]>W,EEZ?G%8'I6BR7>H_^[GEEZ&FQ1"EFA=M)HL+@XC[\,3R]&;!\,_I&X M(EZ@4 Q&-?SO,>!N2'??7&_2KD#OE M,A<.+XWZ+@M?GL>3& I;:# \JOP8GIFS0HL6Q,:+T*JP9O(26 MODKR\],;I)3N7_L1OF,*MT;YT\$T76#P'&!")+9-TP^0B M?1/Q*^9]R(8]2),T>P,OVV:6!;SQ_\ZL]]^-=<.IJD>-Y3&WNT#YB/'W_ M;CA./K_!:K1E-7H+_0U6;_J]SFK"@QNC15+?0:2N% :*!]:X67>@F* M;8 V, C(356AS:50U$6Z6="N:"P;T4HJZ=?D6H HJ-6D\PSPB& 6"YE3%&5R MX;$ J>%&Z&5IK,8>S%!KMU:/0DL1^5)XL(UVX$MKFF4)?U(8VNY4UFS89Z(6 M0="O7QGBR%N3;R@D"ZWR%[]9U(*Y4RK)TVM^4[' M5I @U7,50XE8G]^MT//&KGOP@$^BR_"9+E1*\$R;)?T Q^6;/H4+.%433A600O2"H(;:J](S7:LR,,X3D= M# %.5*;1/DCH9<5N&SY2S+M.M-*%UK2F>K5LARTN7$0@-$BPFJ/=#A/X<,0E M\:5I',5S'T_AG@ZWHE'(]E<-%0_AECJ^:BH(.PIF8ETQ^^A6<&F)#5FVGVZV M!/_:QC_X$E'8$1Q!.CKFY?%F,88L&?+BA,B%-Q/(TE$4JB\65%IW$2?0\'&F&)1S)=(O4%'_([E]"%)_W12\L-;Z 0"%D_@=\@ MY!0=AL4GNEUTFXHKW&UP/E)>UK$7NH56:0]6@E//DHRD'<-]4]<*61"*D0M7 MPH)Z\7GK651A>%&'JW9H,@;]M(WKGC?%/B)<,N)50+S>0[S;(;9C.-JGS-7- MHN!:"UFT^S4T/?/*55.TDY33KLB=>I##<7$.2_*B?Z-=Y^UE&_;)H<+4']D$ M7CNY!GNW!CH3EN%NY"!4KKU ;-]NKU]?VEO'SKR]N]T*NY0T/10NR#7IGQS' M8-O[4/O@31WN('/CZ483EB5=(=&R 7U?&.,W#QQ@>RF=_@=02P,$% @ M![")6.V@ /<\ P WP8 !D !X;"]W;W)K&UL MA55=;],P%'W/K[C*)@32UGQTW;K25MH'$T@@3=M@#X@'-[E)+!P[V,ZR\NNY M=KJT2*,\)/''/7*%2W")/P M9>".EY5U ]%RWK 2[]%^;6XU]:*!)>/?T/6QXS2$K#56U1LP*:BY[+_L M>;,/.X!I_ ] N@&D7G>_D%=YS2Q;SK7J0+MH8G,-;]6C21R7+BGW5M,L)YQ= M?I)/**W2ZWEDBME#TW] DQ2^*&DK Q]DCOG?!!'I&,2D+V(NT[V, MUYB-8)P<01JGXSU\X\''X=4)W M0V:F81DN0KH"!O43ALLW!\EI_'Z/W)-![LD^]OVYV M]7=C9*-CNP- *,D57 MRE@#J@!;(11*T-7DLH2WA\ EC:G6,)F;=S.XIR*0MP(#BMTR4)ZP7J'VN=KM M!"YQ+GMI<,ZIL=<'C=:E:35 !VD21+<<,GI M'.=0*I4;.(FGD$Q.MPZ.H-3*11^-DW.8Q&GPF<"SK2S8&"=#&O Y<]1D PRY M@UH].8=\"#Z&X^!!629(54]YZ$AWZ+@!5]4L/:2*6;]95ZINF%R_.9BFR=E[ M QW3Z/8+^[4HJFA%P86@PF6#C%ZH::<[1[%:PT7-?BMY!(],4 VT'G/U[7X4 M/&RY8=5R03O *464*W]628EL"VJTVMF@KFX!89_VO(/4$L#!!0 ( >PB5AT9] &)0, /H& 9 M >&PO=V]R:W-H965TPB+)RK9E%DTP)+;J]TA8I.5/O&X)O K3V:@\]DK?5WO_@K6X1]3P@E MILXC\1:E]$!$XV&'&78AO>/Q?(_^OLF=_HF[?(8>+]72-E_8MK8#BIC6UNERYTSK4JAVY$^[.APY3/J_<& [!];P M;@,U+-]RQY=SH[=@O#6A^4F3:N--Y(3R3;EWADX%^;GERE!_C7L&KC)X]U"+ MBBKN>O 1W3QR%,";1>D.[*8%8[\ BQG<:>4*"^]4AME+@(B8=?38GMX-.XOX M%M,K2.(>L#Y+SN E7;I)@S?ZGW1[L))(B>GD?WC MF=F*I[@(Z758-(\8+M^\BD?]/\[P'G2\!^?0?[=-9\%.4YU"P/XL\&?8 M52S5]#RM YV#*Q!R+>F5"[6!B]<@%.WIVI*'O9S!/>E)5DL,R/9TI."KQ;R6 M\$'D"-1Y+-=HFNX?+X*+?Y ;>]E<"?]AP1U/"\K1M'@'=@G$?7@-<8]-_#@= M)\&G/!,HC3J8PG 8?D%Y[H64&HJR,?D1O86$$@W@*C$V"6TK> MF;J5%\J6C#943PL?HVM()F,8#H,OVG'I3P[Y'J*Q'F-#HI?$0XIF[8Q$*JW+ M6G*'&6D+=2<5O%4OE5JZ5IFZW$_;K5L\.YNU?X8Z;C5 6).;DVK\:#T,PK=*V"Z>K1MW6 MVI%6-M."?DYHO &=YUJ[_<('Z'YWRY]02P,$% @ ![")6!5T'-45! M(PH !D !X;"]W;W)K&ULE59M3^LV%/Z>7W&4 MH0DD1IJ4OK&V4GG9'=N0$+"[#],^N,E)8^'8N;9#8;]^QTX;RFC+18H2VSGG M>CI6M15N&.+PKK%J+I MN&(+O$?[9W6K:1:U*!DO41JN)&C,)^$L/CL_=?)>X"O'I=D8@_-DKM2CFUQG MD[#C#$*!J74(C#Y/>(%"." RX]L*,VPIG>+F>(W^B_>=?)DS@Q=*_,4S6TS" M80@9YJP6]DXM?\65/SV'ERIA_!N6C6RO&T):&ZO*E3)94'+9?-GS:A\V%(:= M'0K)2B'Q=C=$WLI+9METK-42M),F-#?PKGIM,HY+=RCW5M-?3GIV>BTMDPL^ M%P@S8]":<60)UOV,TA7$>0.1[("($[A1TA8&KF2&V5N B.QIC4K61ITG>Q$O M,3V!;GP,22?I[L'KMDYV/5Y_!]X7I;(E%P*8S."=QW#)32J4J37"W[.YL9I" MY9]M^]"P=+>SN/0Y,Q5+<1)2?AC43QA.?_PA[G=^WN/#:>O#Z3[T[SNHO1#; M#1R=!.]WY*' (%>",I;+!51:/?$,#3"84^(_9FHI0>5 :]+RG#.GR5]!6 /" MC!.BL\1RCKH]3W\(-$C@\("TP!:J-K1FCL[@GFI.5A,$*9YO4EUO4KVS-WA# MLCD)/*-C"VZURNK41@^8%E()M7B!.Q3,8A9<[W7D&!9:&0,'T$UZ[AT'LS2M MR]HK RN5MOQ?YHO,X6@(1W"8].&H);2OA+HA_&#GCD%2-4Z2 ?2"&Z8?T;I3 M6!M[X8L"N=>"_4]_;6\\H"=XT(S(6(D?R\==&.QQK1L[UT;DV:M1GW%H-(*X M%SPHR\1WR;O][M,[Z=")!ZF26ECX3:8%X+$#SW69RIF4M%Z0:0/< MUYZF?ID/JLQ52SQKB&>;Q%<-L:LBIW[_1F[8@SCINT$?^EWWI43SWR$D >TO M%:[<.A=7P=X$\K8>$&TT;DKIA;^>&$A5+6W3P]O5]@8T:QK_JWAS?:*X7'!I M0&!.JIV302\$W5Q)FHE5E;\&S)6E^N&'!=WB4#L!^I\K9=<31]#>"Z?_ 5!+ M P04 " 'L(E8UX2G_\," ")!@ &0 'AL+W=O KQPW9F\,KI)4J4.?L*FQ_?, LLI8 M53;!I*#DLGZS;7,.>P$7T0L!21.0>-UU(J_RAEDV'6NU >W0Q.8&OE0?3>*X M=!]E837MX(\3N%?2%@9N98[YGP0AB6T5)SO%5\E1QAO,NM"+3R&)DMX1 MOEY[ CW/-WR!;\Z>62J:ROUQ,&'@^RPU5E//_#A4<\W8.\SH[M'(K%F&DX N MBD']A,'T]:MX&+T[HK??ZNT?8_\/7^PH_V'U<=3M_%MB:. =W(TIBI##.;M"!;D3'DET&'_352'F@?+E#9= M ^U/.JZ;7$LEG0433!/X%%*4N.261HZ5RXSHR$-(:^FR,>\K)S",Z3$8=NXT MDUG!#8)E6_(;WTIP!H.D<\_TBJIP9^U49QIS;B'I#^"L4ZN]3(!R?U:60EA3 MU%\>W0GT+B_H&?\-NFZ#@," MEQ0:=<\' >C:^.J)56MO-JFR9%U^6-"_ K4#T/Y2*;N;N 3MWV?Z"U!+ P04 M " 'L(E8CV,8@94" "Y!0 &0 'AL+W=O)]MP=YES<<>38W^L",BR::&_A4O9K,">4^R@8-[0K2 M87:MJXHN9X,Z?YJ'2$2W'N:=>M6JDW?4<<+NM<+2LEM50/$6$)*5WD]R]+-* M+A)O(!^Q<3QD292,+_#&?7YCSYN^P[M];@2^LE_+K45#O\#OL%@VAM,+]'_^P$NJL][B^/1X!3+ECB@>X5J M"Z:_VR'#$AB%U5R]LI);UND+EK=:Z[54]TQ8VW"5 Q.N$"7W]83:$W9:4F$+ MM9^Q#76,HI' ](ZMC[ W1JB0V!W!:'T#>6,$"K".NNZH@TW)#7QR=>9]4.^Q M[7&UY(I-IM%P.HD&C]P8KM Z$W5CPB5@6O@%&P@L *L@ 9 >&PO=V]R:W-H965T'_]O@8(BK)D>9*=_6)2)/#0W>CC->@76]5\:M="=.QS5=;MR[-UUVV>75RT M^5I4O/741M1XLU)-Q3O\;&XNVDTC>*$G5>5%Z/OI1<5E?7;Y0C_[T%R^4'U7 MREI\:%C;5Q5O[EZ)4FU?G@5G]L&5O%EW].#B\L6&WXAKT7W W*;;MY)Z1)DNE/M&/=\7+,Y\$$J7(.T+@N-R* MUZ(L"0AB_#%@GHU+TL3IO47_0>L.79:\%:]5^;LLNO7+L^R,%6+%^[*[4MN_ MB4&?A/!R5;;Z+]N:L7%TQO*^[50U3(8$E:S-E7\>[#"9D/D/3 B'":&6VRRD MI7S#.W[YHE%;UM!HH-&-5E7/AG"RIDVY[AJ\E9C775ZO>2/.2:^"O585]KKE M9*X7%QW0:B'T0F\:-0UTGCI25U?:5T_\#NX5L<63T- M=G0-3Z%^T2R>1CLL9A)[S MT!+LU[5P0C^8LP\EK]FF4;>R$"U#/F#=6K ;V*^3]0U3*R;K''9$E#'X;?Z) MJ0TAM"ZK5?U'STNYDD"_]PY2=(W,._O&'0;P#03,I1&BH>!JG2???Y.%H?_\ M>G'5ZMO@^=-#!-;7L@/R1C0Z:T$JQK>\*?"LD"1^73#Q1R]O>4G[;L 9QU,% ME9IQ\'8M\S6B[8XM!T5I"2A;WKF.K%FNJJ6LM80N@SWPJ .*J%P-MC=]PV5! M W+>KJ$B6;LEFP&C@H*#45;:IF1_7M\1))\NHL=COD8W$,YI"(^V;\23L(OD M97G'AJTO@-^ICIZ_8XI;+4DN(=\Z[MNVU>]$-QK_]+)I<4@C]2-XR MB9LGP=.=^O'->PUVLI5F2EO-<"OE^M9"X:ERT*7K&?Q"T<=MP99U_\T?&RJ=]9 MU[82<.TYE,0I>.IA-JV_Z3$9Z8WU&_H)XR=1.-%M@D:I)9@];_>5Y)W#*:>8 MR,/NF+U&2H0.A/ M"SW?=WID@.8HW&@/"DO9#L(Y.MVP6]@6CVXI_] R4A4$ M&H1.IT=]A4[.BM;%5S9S-#;;(?Y(*#-"84*;Q@!V=8 M1Q?A 7E)LXZK1[(,8IS:X#2QNOHL,/>)4=\F"\DB+K;ER-+$U\_]RIGV7#?RC)=7T7?(_$.>8FQPO M&Z9MDMW=4#Y*WNGBM*NGE@@::PCB_GOEV-$11K-)7^]>7;9K7NLUWYLU%\.: MSN^ZJ8(OV!O47R2/&^$,5VAALCW8I?-+K]=4J[$.,^WQ$E8?G.6#CII_D*C. M>Q0KHFO:M3KV=U[W:$OMQK XBMUY-$=\!5XZR^9)PC(O29T?AST*YB9I1%X4 MIT$29; [!>*. VC3AL_O7QVTDRLANQ,C7A.I*$N,>!)H[A2PIQ C]FE!.^BM M=GP,21X8<$_!^QPI9$E(*LYT"HF2( 89R;PHVZEHBJ1),:D?!P>8&>F+@9>$\RV),C&.VT(S[<+SU;]>F2#41;9_(K'E!\L!L M01@C85'(4KS:)("N1]W4.D[S:2.&1(=[33SOA:@ACG3'J(&E4#FGQH\2J1PX MA<[LFTTI@E25\S+O*8F8,C8TG,?T=$A/2BI'Y_F*RM%X55>&A MYM;D)L)P?E.02I:4Z<)DYJ4Q+IF'N/J.A;.9A_W_SKF2[:?S52,$(U9$9)@U MI$KLA2#C'ISK.US\%$/?V#[S3HJR8 @;O--_R:V%IM =):?$I.W$\_>B3-R*^!*H+7:QW,O",&V!>E.J#?R'HV#H719Z*3[47=WXK/JN MWV.OO(,<0WNP46UW/NRL(ZI-J]"E@$BHB& .>:Z:PK3#>V4,I8GI MSY]@%_7IHWEL)8',44(ENK8JADZ>AM'1%)J7Q8C"4HPU%YPL@R%.W,8YO M?.\ 53M5WPW53NP9G9N'<)0]SQ]KH75N/7A3]GJX [/?2.IG\UW1,4/,J0*Z M)\3&5GE,GS$YM"V +KEIRR<[!Y+ Z='MSNEL&3W% ?>M;&Q -AFM!LA1T1VV MHS/#=BBAYWPHG8/F$[$FXACVM.&-]J--OT3B,$]JJ4V*K%FA8J[(#(TV/_KB MQO(JXTY\\@)%N$5.H].=87'L%HC@75X*;PX/^U_1> "'\E$*ATN :G&PAFV^3C&W4TMDL3M+OHCS M=\JQS%B95MD8UH2F$.#E2,@$9*QAP>6M&W3/7)NAU]=?S2G-.R)*?+.V%P]]1[T MKZ_>_"!P(Q25X8)BX>]5K:O=1$.%/^J#F8&)6;H[H;A&]#=0R#%#?^"R8;^1 M;1^C1<%(Q[X=F92E?//4#8*8*&\PH7FTYTAZ$&)(Z=9+S;:!@:99"()&:CW, M_AXGI'/?C<$W062C4:))1'Z)1#[HV\QPQC1!?=])]20(R>?T.^SZHQPRC=TD M#0LIHU3#'%<$,[#=COW/Z]@+//=JLKM6V)3YK/A8>G)1O[>3'VD]VHOU\ M;1!-P%EQ=KWFV'W:9O,P"L=&<]J'CHJ9;G/H08]WG8>Q&;DI7#Z8DPLE7I"& M&7'+=!<0!\$[:9C^RM;SH1&V+7OH_:-1?DS#R$N3 PT?U@]M\=R=A13$OI=\ M9>>946"G&B*;_U7JH75TXSATYWZLU8N#>#9'C^%ELS_1=3XT]>OZSC%(3,OI M,TKMQSY'7DP^(%>BN=&?R8F+]'5GOB6/3\&ULC5;;;ALW$'W?KQALC, !7.]%DB7;D@#YTM: G1AQFSX4?:!V1Q*; M77+#(:.H7Y\A5]K(@.ST15R2,X?G<(8S&J^U^4PK1 O?ZDK1)%Y9VUPD"14K MK 6=Z@85[RRTJ87EJ5DFU!@497"JJR1/T[.D%E+%TW%8>S33L7:VD@H?#9"K M:V$V5UCI]23.XMW"1[E<6;^03,>-6.(3VC^;1\.SI$,I98V*I%9@<#&)9]G% M5=_;!X-/$M>T]PU>R5SKSWYR5T[BU!/""@OK$00/7_$:J\H#,8TO6\RX.]([ M[G_OT'\-VEG+7!!>Z^HO6=K5)![%4.)"N,I^U.O?<:MGX/$*75'XA75KFP]C M*!Q976^=F4$M53N*;]M[V',8I2\XY%N'//!N#PHL;X05T['1:S#>FM'\1Y : MO)F<5#XH3];PKF0_.WVO+1(\BHV85SA.+$/ZC:38NE^U[OD+[ED.#UK9%<&M M*K%\#I PEXY0OB-TE;^*>(/%*?2R$\C3O/<*7J\3V MX9R_BS2W<2"HJ3OGV3G:67KS#M=TS[KZ'_ M/!2ONA\FE_5.HV>XP=C 0M^5=$&A2$80?\G2/T<1GU@$,?+_Q-S +>%5FQ61'?J7\>6'$Y! M# WW6BCXH*('L8%\%'(F/0&[8D&Z;H3:/*?@-\@*50I30N5]2UTX+C&6N,!\ M<=);\^W;T9YGE[>WMWW =DB"2GF"!P!>S-*)FXE#YR@)Z$?A+UE5TL^L/G^YN?LG. M@<66Z _3*MK3[Y&SX27!W!'G"]$I/#I#3B@+X4*$A0*-Y>K=TIHYN])&_B?: MFJE*F"T-HK^C9[?@I;8.N^V=B/;^&[Z^0C:BBD2MG>H(=[?'20"N\20X+<[2 MDT&:0N]T.(#L)!^F'/9\..28]D*6+)SU;U[95^-#FBA>=" M2#/WE1I;6H$+X41",_8)QZ2UF]=I6 M+V:JLH)+W&HP55$P?5BA4/NY%WHO"_<\RZU;\!>SDF7X@/9[N=7D^1U+R@N4 MABL)&G=S;QE>KT8NO@[XP7%OCFQPE<1*/3KG2SKW B<(!2;6,3":GG"-0C@B MDO&GY?2ZE YX;+^PW]2U4RTQ,[A6XB=/;3[WIAZDN&.5L/=J_QG;>JX<7Z*$ MJ4?8-['1Q(.D,E85+9@4%%PV,WMNS^$(, W. *(6$-6ZFT2UR@VS;#'3:@_: M11.;,^I2:S2)X])=RH/5M,L)9Q=K)9]06QX+A*_*HH$M.S#R9KXE>A?D)RW5 MJJ&*SE"%$=PI:7,#GV2*Z;\$/NGJQ$4OXE;11<8-)@,8AGV(@FAX@6_8%3NL M^<9G^6(+&VX2H4RE$7XM8V,U?1B_3U7;< U/<[G'";[-TQG>00-F=/H\T1UJHHF3P M-Z;"%)958BL#-Y5,^W![N^X#@PT*MF=TM((7W%*0X"SF@ML#)"V:@9+X_H", M6@-*KMR4T&VD%/$JJ-2JH#Q*'WJ2M &7M812$UO&FR=*T9EP8$[@@:#"97'NBF<36.567=+&)EJ?749DZ]'K4+ MH/V=HF);QR7H_AZ+OU!+ P04 " 'L(E8^ZKE8$D$ 1"@ &0 'AL M+W=OBO5N^ZS83"S4MCQ)SLO]^B-EQTW1+NCAOM@613Y\2).4YENE[TV& M:&%7Y*6YZ&765F>^;Y(,"V$&JL*2=E9*%\+24J]]4VD4J3,JYSBP+_,6\$FN\0_MW=:MI MY7P4RU(8O%+Y3YG:[*(W[4&**U'G]KO: M?L$VGA'C)2HW[@G;1C<@Y:0V5A6M,3$H9-F\Q:[-PY'!=/@;@[ U"!WOQI%C M^5%8L9AKM07-VH3&'RY49TWD9,D_Y1/R(R0"BH _A,(Q. MX$5=D)'#&_^?(!N(Z'D([HTS4XD$+WI4_ ;U!GN+-Z^"\?#\!,&X(QB?0G\9 MP9,0SQ,,1H,WKZ9A-#N'UH77N8!OI7>'E<5BB1I"EVQ*^8W0209!<%A?XU+7 MU*X0'23T=UJ;V(F&G='TL'[ #88L"V9]$&4*?ZI-(QX?I#9#[TH5E2CW((VI M,84P[-,61'$_G(Y@TH_#&3W#Z1CBV+VB47\2Q,2Q60X'\0Q&@W!$S+3<"&YS MX[&[+YBN9;E^'*ES33[8-1Q#0*V36H-[8)(4\GC M1N1@Y Z*IC'JTLJ\R9(W:\K:0=V(/8R:=9]&G*G0#:E\/X"_B$ 'O$6-M%^@ M,+4FGL* 6L&3F!QFHDJ#OVHL;;YG3!I/9"&)V@&/6*5R)1/!1#W$V M:7L4&I '%02A'P4^%S6$XU$_&HXH U$P]6Z.\L,V73K>4X*\JTR4:^2,/F3C M2 ORCO%[>!M$$;Q[&8NP8Q'&H?=IASJ1!A_Y?QO,FII_1Y]Q3,@GJ(:S_T0U MF+V,9@23P#7H:PCB\7&Y='"R_>=%LJ*Y432U/\Z.H6)/<+ZET855;ZI?FZ&]IM;W= M-CY/QV!R;H .VN0>*BV35BF3)*(E-?)&Y>3?I8D8?*XI))Z^<%LON\N(H2S1>&A.[$[:W7<^-,?\@WIS6:)10I/-0(XK M,AT.)J,>Z.8"TBRLJMRAOU26KA#N,Z,[&VI6H/V54O:P8 ?=+7#Q+U!+ P04 M " 'L(E8J*M+IFL# !T!P &0 'AL+W=OU!DVM9. MECQ1;II_/TIVW SK!=A>$E,B/WX4Q4^+G75?J4+T\%)K0\ND\KZY2E.2%=:" M)K9!PSN%=;7P;+HRI<:AR&-0K=-L.KU(:Z%,LEK$M2>W6MC6:V7PR0&U=2W< M_A:UW2V367)8^*S*RH>%=+5H1(D;]%^:)\=6.J#DJD9#RAIP6"R3F]G5[5GP MCPZ_*MS1T3>$2K;6?@W&IWR93 ,AU"A]0!#\]XQKU#H ,8V_>LQD2!D"C[\/ MZ#_$VKF6K2!<6_V;RGVU3"X3R+$0K?:?[>X>^WK. YZTFN(O[#K?\RP!V9*W M=1_,#&IENG_QTI_#4<#E]!L!61^01=Y=HLCR3GBQ6CB[ Q>\&2U\Q%)C-)-3 M)C1EXQWO*H[SJ[6M:^7YE#V!,#FLK?'*E&BD0EJDGE,$QU3V<+<=7/8-N%D& MCXQ0$7QOQ?\I&.X4 M26VI=0B_WVS).[XU?[QU#%V2^=M)PB1=42,D+A,>%4+WC,GJ_;O9Q?3Z1 EG M0PEGI]#_>\].PKU-=G8Q&9T^J@?E52G":(U^J3 X-\+L^6[N88L\Y-L_>?# M6]!8"@V-LQ(QY_@.3&JA:@)?"0_"*4)0ABT$Z]B)]0&D;1TOVP*V+3%GH@D\ M"L-2$2B!(C#6\XPXQZ;>@]@)AR-V[VAXCZ['WRFMH1+/"")LH%-,"(LB$+1= MUH)SA1.5I#UMWA\' 'L@@YS+I_/2ASB"5X!=LI7\*,6+W;#_:A^"@T, MS6 A10?W*+2O)-<.]U9W!_SAR^8C/#RLXARL[YQ='E"Y77G;]8^[F>,SRW?#+$/K'&LJ"V%^Z%C1>AZ8"? U8!)2 MF!!B+)2M<,+X?=_D?X&/8E_8=P"T;@RJ&.QQ%ZGZ#L9K)?ELJ&CU!-Z:I/1( M"3E3&?6>PE4ROA/%875X4FXZ)7UU[]XC[EFI#/'U+3AT.OGN/ '7:7QG>-M$ M7=U:SRH=/RM^%M$%!]XOK/4'(R08'MK5WU!+ P04 " 'L(E8W9X^-BD$ M !'"0 &0 'AL+W=O:&ELL:%(+4G%\;_O&\I6G,()T(M$ MD3./[ST.24U7SC^%DCG22V5LN.B7,=9GPV'(2ZY4&+B:+486SEEE& MZ1C.IK5:\@/'Q_K.XVO8H12Z8ANTL^1Y<='_.CZ[/)3X%/"'YE78:9,HF3OW M)!^WQ45_)(38'US%=LC "!QH\-9K^;4A)WVUOTFZ0=6N8J\)4S?^HB MEA?]TSX5O%"-B?=N]1MO]!P)7NY,2$]:M;&3HS[E38BNVB2#0:5M^U8O&Q]V M$DY'[R1DFX0L\6XG2BRO552SJ77%VY6S. M-GHE'@5R"[K7X6DZC,"6B&&^P;EL<;)W<,89?7<#V@R/J!LE$T^P)MT2B<)[_@=/-$52-F"'B'91Q1LU!SHKZ_S /UY M_'N?ZA9SLA]3=LQ9J%7.%WULB<#^F?NSSY_&QZ/S#Q@?=HP//T+_'VOS(DL;4H5,H86GK7 MU +3%B[[@&J.)06T$5?H9UTT"%P#H:J]#MHNJ7) C*6R-![]+,G1165ZVPD' MA-W7BR73FI4GENHBU 97<_9=?1R01&Q(4ZF*+6%:>%>1L]QQDKDBJ;KV[D57 M24(VHNS+KNR$\"8IZ5!Y[AH;Q8V<];.:&\:18!3<"'M@C[_0(9 S&I_N]72A M+5*U,O &)=C@K(M;''C"+[4+@(ENQ_#M0N6>"QW)RWIA-.@0"8[B8-6P5P)4 M* _2D_A' [(FH:/^>PAZXIC8!\X;KV4?#.A*8CLYPD .==DG( %L4*W3XH%? MI?YQGAX'#X/_J-"Q:3G*1A,,=#;@2O-U6J(;+M@C]IHA3L?>K0S+C%@\7[M6 M(?TB'F6C\YOKVZO4')__2B@M6.%YV1@5G5^3T97&C40/35ZV2M^PAS(/S2", M$N47="?G$@O@MLPDO)> 9.PGRHY&J,-C^MYYU'OU:%/\J70A"0G)@8C;$%!K MFFMC-B7OO%["& .GXC9[B;C8%J#%PS,<3F?F0,ICIWH#61=E_=EK!D$X:=<] MXT( "L0$$;PMQK?)7\+6]'%_#VU\,+"H6)9#A!5)'@Q-&ULE93;;MLP#(;O\Q2"-^RJ MB ])NJ)+#"3MAFU MZ#= =BP"]EF8J$Z>)22-&\_2G:]%$@#],829?+C3PGD M=&?PWM8 CCTHJ>TLJIUK+N/8EC4H;H>F 4U_5@85=V3B.K8- J]"D))QEB3G ML>)"1_DTG"TQGYJ-DT+#$IG=*,5QOP!I=K,HC1X/;L6Z=OX@SJ<-7\,=N._- M$LF*>THE%&@KC&8(JUDT3R\78^\?''X(V-F#/?.5%,;<>^-3-8L2+P@DE,X3 M."U;N (I/8AD_.V849_2!Q[N'^D?0NU42\$M7!GY4U2NGD47$:M@Q3?2W9K= M1^CJF7A>::0-7[9K?4?D7&ZL,ZH+)@5*Z';E#]T]' 1<),\$9%U %G2WB8+* M:^YX/D6S8^B]B>8WH=003>*$]H]RYY#^"HIS^2U([J!B2XYNS[XAUY:'^[+3 MV!'?>\5EQUJTK.P95IJQ&Z-=;=E[74'U%!"3L%Y=]JAND9TD7D,Y9*/TC&5) M-CK!&_75C@+O_,75LM_SPCHDZ\^QPEOLZ#C6-\ZE;7@)LX@ZPP)N(-3]!<^T4G6<:7IQ7!PXF:NC-X".E%(&"S1*&&MP3W[8ARPKWIP M!XT#50"R++P3O9:K@:)4P_6>D?>&N*Y& )9.DK,D2?JU6^;5ENL2++O&X> S M4 Y@OT!6PIXQSE1+-ZLGW,)PK/QA)9 ZW"#YUMPRKAG-'NNXKH1>4\=*CV;5 M!KSS:Y9-0LIQF_G8\\0'W:0 UV%F6%::C79M8_6G_5B:M]WXW[V=:3<%,$WJS,(XZ/6QK&JV WH'^KPS=PB5CI+-QGD08 /\0 9 >&PO=V]R:W-H965TQ?#D\H#7^P6?%2UMZUVP)5.MO_+'^_2L-V! E%'B6(/$XYZN*,M8$6#\ M6^OL-5NR8/M]I?U7;SMLF4I+5SK[4Z5N<=8[ZHF49K+*W(U>_D:U/8>L+]&9 M];]B&=:.QSV15-;IO!8&@EP5X2D?:C^T!(X&SPB,:H&1QQTV\BC?2B?/3XU> M"L.KH8U?O*E>&N!4P4&Y=0:S"G+N_'V1Z)S$G7P@>]IWT,CC_:26O@S2HV>D MAR/Q01=N8<6[(J5T4T$?4!H\HQ6>R]%6C6\IB<5XN"]&@]%XB[YQ8]_8ZYM\ MUS[Q5MDDT[8R)/Z^F%IGD!'_=-D<-(Z[-7*5G-A2)G360QE8,O?4.W_U8C@9 MO-F"]Z#!>[!-^W?CL56Z&]OP.([::L7=@J(KG9>R>!0+:059)Z>90A*E0HI9 ME67B7F:5#&63H6YED9 PCE+.<\&8.U#DZ5UA+&N#!2@>6Y+%#+J%KWZL71 M:/CZ#>8H4S03;B$=Y(6RHM!.Y-I0E*FOE#WR5.$'_1JW()1[)ATT=NVU5 X MY34R4_]1&@O4IY=Z)&E@#J>B0")1/B73)).01BR182D8B+ESTG;5B M[:R4)=A_*CB48>U.J:"9>;I*-&C+ JR>>0TSS6Y4Q?Q$W()7TRHC MGFIEY^[E2LOU2DODH3",B"W$MN(O;Z$OMC;J]DI*RL37\I?.1' M;UIO@!_]9( $/91@[CKTM8O7><8KD+:N"!VZD<="[:9)_=%@<8,>"O9E26'\1@R_C>Z)K2G@N.5*EB!R"5DHX^Z^ 6( M*A@US8(["XOJWQW&".:.V#V.D14[T9U"6YFW19NPU<_H"O4Y)Z&*3E[8'1W$ M!U[C?C8OVB"GY)9$Q;>Y4ENZF2O/^)Y58SJJ\Z0M#IXJ MC<))18&AI'-&32OF2=BEO4J.#/H)^Q1L4/G*J/6A_O%I2UVD[%M,@ZQL(]GA MQ5A'+MGE1#?(9RFI(@.OC M(FS($']7X[]*Q)IS".ZSU*: MU()5#O:/CD;^.1R.HC^8S<6QF$1WVLDLZO(()(Z'?OU1]'GE_*B5PF'!'K]@ M38OK6MB:6NPJ@B[6^ZF(^DXL2]3+ Y+.<5M\*89',3,M_S1O[P&* 8UT0=YWH2ES0Q:=#=ER,2-KP@Z&K<9&OG!_K#\S M2>*4[.UZ"O.S=3GL,PE^"?Q4 MXW^"V+,&DV4FBX*Q\^'4T5QY:D'PO@:#X),0>L8$QI@Y1&\%K7$'A\=7_3V& M8=N^F&JTPU);Y?L;[U;07/+'1F9P!G(3->GV@Z"*;37ED'A&1C"\A2KDF._5 M#/<>W*\KZWL&V5A(+,M&FRM\_[2K*44A*"4-#\]2GGX:^"#-'-DG,AH!M%!_/JP)TRX;H&ULC5;;;MLX$'WW5PS4 M1=$"AB^*,Y<2)VMK'OT%7.@IZ8V_CRI0FA/AD.?5]PH/[ M&WPIK6M4P-3-A[YUK(KH MU-3#=#0Z *FV1Z%M?NW/3,+D*M#=\Y\HNF4>[YDFN[.D_&R6;A7L^K( O# MZ5FKYOS X8_VSF$VW*(4NF'CM37DN#Q/+L8GEQ.QCP9_:E[YG7<2)9FUCS+Y MO3A/1D*(:\Z#("@\ECSCNA8@T/B^QDRV6XKC[OL&_3IJAY9,>9[9^B]=A.H\ M.4JHX%(MZG!O5Y]YK6=?\');^SC2JK--CQ/*%S[89NT,!HTVW5,]K>.PXW T M^HE#NG9((^]NH\CR2@4U/7-V14ZL@28O46KT!CEM)"D/P>&KAE^8/BPRS]\7 M; )]6F+T9\, 6/DXS-<0EQU$^A.(<4HWUH3*TR=3<#VAOW*1VE>V_@[6U%[D6\@U\527]?9#XXE,0_K^GMT/9>1Y,V.?&MROD\ M01]X=DM.IN_?C0]&IV]PG6RY3MY"_[6$O V1C@:]_TN^409=AGX*/5M2J)AF MMFF5>:9*>6K928=S00J]MI1V@A5WKLH4A&@9KV(K>;)YOG!.FSFI,K"+:#D^ MV%H7*@ D4[4R.5-WL,@:!8MN@3&*F$F7/?@XII4,0L(O\FJSGW4OMW-0HKOM MBF_H"1$A>+ KM,]KZQ= T2;R4'G>Z1+[%Z1*;4!*JYI\P(*@^'[/V""6QKY) MP0I=X*MND]+6.,[@-Z!;T[OFS"UPI-%X/];LA#Z(T?MW1VDZ.IV!G^R _N2X M-#[]V-]-0)^P)>)00$(0&IG/G6Z[4VONN&.*@R%4L%@R#@7G7R ([/CPU-.L MTES2]5;H;5GJG%U/,HAGP"E-#3<9.R_YU8#-K'*%3 KM<%0"&NI<+(.Y]AVO M[A.,2HYI^+"6=G]UNU%$+XMJRPC):*SI@7/^.*"OL( 3(2FH-)$'?7,ICW22 M]H^.QS09I"F&T:A[2P=CK!WM]P^/TJT-BOL;^/00K(THNS+05.F6:MUHI%>R MAL JI'3-;*4<,AH#6=>4,9@Q\1.[7'N5U4RVR^UNOOJ=<:664J4;:Z;6(:P" M_%O'M<350L^L$+S)X/B8CF6 V-[<68_N#YI7#Y%,$&)MC8,N]AL.#XQ2&FO"@][7'2FQ M4"/O5CV_ZJHH5[ZBDF/@#F@O1JW71>V TL/^(<1).%\[1H<[=US#;AYO=&.![:6W83&2#[2_4]%]02P,$% @ ![")6'!Y4%N1( %V8 M !D !X;"]W;W)K&ULM3UK;]M&MM_G5PRRQ2(! M9,62'E"@FU\ %VMBB M.&?.G#GOR@@9MJN?ST].+YYNLK)^\_I&>?7"O?[1=6Y6U^>!TTVTVF=N] M,95]^.G)[(E_\+%G+Y1!=FF755^]$^_,/(@EX@ MO-Q6#?VK'_C=%R^?Z+QK6KN1P8#!IJSY9_9%")$,N#P],F N ^:$-T]$6/Z< MM=GK'YU]T [?!FCX"RV51@-R98V[WKVW)5E\LRS^I67^6Y[>JV MK%?Z@ZW*O#2-SNI"_]*T):P?/CWUSY_]^+R%V1'&\UQF>L,SS8_,-)OKWVS= MKAO]2UV8H@_@.: =<)][W-_,1R'^;/*I/IM-]/QT?C8"[RS0XHS@71R!-[3^ M_[E:-*T#WOG?H14SO+-A>"A0WS?;+#<_/0&):8R[-T]>__UOLXO3'T:P/0_8 MGH]!?_VY,=HNX^8,X3<*81@_ *M2L/K3VBCX>INYC.0(OFS71N>V;H!(!;Q3 MZ&599W5>9I5N6G@ 4MLVNJSQ)50<9;L#MF[7^M>KJP\@RW]U)C#'EK5K27'VE'@+!#'#D*8I@C!:X*<(DEWX:M3<3VM@7B9*YH M]!L+/_33O__M'MU>T;^G7VP[.A]_6U+4@+$JW]J*O;ZS#HD]V6N9Y? MGD[T,#[_,E]6!OA,B% VM*NNQ/T5D0%^[Y:@2CJ'@^ A;(W+3E;P?F4F>@T& MY.0!ML.= !.W"&6]*YQ%L%MGBRYOF>/6)JO:=0[\0[R '-]M8%^S[;:2-303 M]; N\S7BP3P&XO$NJU=KZVJ8ZX.IZV97W6=UF1'GJ^M?=94MFM$%_/-WW>%' M1 (_7[,,(9%F+W_ <#X1!*%B,%&WF4K7.NB:V"G&V#[0ZQ^=5F]Z-QNHC^9 M+]DX*UX$5KP89<7KK%D/<=_HJ&'N0U :_U'[%,GQ&UC (JOO6"IQ!ZN=KDI0 M< 5I@:8EG3,1Y8&T^#R]G>H6/*@&%JT7954U>MNY?$T$(369@99U)5 .N!OD M$_@%%"CM@3-&;=B*PAY40%*0>/T 3@W^3&9$Q.!%LP, [@Z\NV57%\P^O 6D M*S/G2 .R,D4&JS 0BKF#="RCF_@R M;.++T4W\C1#/%I4!D@2H%G0"/R[81*A(R M31P -%^;JCAI[8G?I\#B;"T&MYLV>7^'$1[0<@6O@@I08.]JWG#-&^X-5#J] MXSTL4?&WR8YY-H)E )@5[DWZK3.Y=059"^2UKH8YJ_(_\& %?KQ^6MFF>09C M%&VXMYR('40#[ 8T7B?L3.80/*^ZZ> ?F=/F@&@S[5%UG14T:FG1GB'K'24L MP <'SVP6H-F\DT=2!K_,]=/OV.#;KH%GS;/O]2T$+$57D?Q$&G4_.+L^_:1PHJ=E9&#>;O_P6'+L5A"-Z=AKGNWRA M/MD66)C7^F+RXO1R3/(O@^1??DWR5VBOX#&RP36X364[)/FC8(Y*/L!6?=CZ M#Z/6V3W84[UP]@YX'/A7_#D40MNMUL+A#P:LV8X8L4&U.R#?Q/)HLN_+)A45 M#Y!\.;"DJ%(7UB%Q;*URL)PH?8D4H&[Q?FT8#!/#.&\Q=%8 _C +^KAQ)%M7 MVQ^*?C<8DJ?1%J$)>P;.(OO2BI%!O8"*!404-9%HAL6.U?_7L5NP1H"A8 Y0 M+V6Z-BO;EN32@OH VF0[$C'2;-5NFLK:MC+%RM B:3+TFX@=%EG%#C $J^"R MPSRZV9J<_+8*.+HL0$FAQF:]ILD[XX %OA_"?&BW8>F*G)RL24@ -!K62!-< M/N#X *]_I^?G+_39F 2\"A+P:E0"Q$=MP)G.37F/Q)H %0>%8!32L!!X\&H/ MO/[D,HQP_.PN?$TL0:: 3$V,P%)'4)LOL"$M,3;2#F,UY(C":MZPA#%82,) MCG10]:R-'YN!- '#HD(?Q(@");1DM-M>W+RC$B*FX2@MB@BZY-8UB8N&PRM3 MK]!*@^B6&X./5)R;3>\V _XNT#\BI#L([X >WM?5IKXOG:W)=)+4#GC,Z[*! MN9&!B79@R0'AJ?X0=X1^O- _P5M"P;J]%JR M50^@%H4%"$F($DS!'/"U;6+!FLWTJS&YFIW&?-?IJ&3=A-@<"7)M&_)K/AIX MV@V[E^, AP4LS**&9M'Q:Z!<7ZJ &J!>,+R 0D3OF,12E)#?,E1Q;^J\M I:+.!(B+ MQ@+GY\BA$[9_H$>7)U6Y)$XJV3'$&6!1)J8NQ!,F5S,#.[5K2M*E">\W&4!6 M%9 'O U8G82[$_SE3\[?TI!EUZ)!* R$T@43!\*Q.Y)2DZ]K6]D5 80E4%(% MD0=&3W&G]?EX.HJ'A$D0PK(]A0B:) 9(>(_)9;'A@VO6!4=,"6#OK7OE$G9/ MH\PP_=&55<'P5\ AJF9/?* N@TAPC6&XVX*[!NL'<-^MRR[0*8[LMC@/@E4E3 ME?(]/%'P*S(V$TB4'6JO#9@]&(XC7/: (1GHXJS"A(5U=R!C)S 20C-,85#^ M#=7H&@,F:PM:M-\< @9&+B-)S=I!M?\ ZA5#%V!Z8C(,SZLE*$DR%L"F+:[8 M/HBP7VVR_UA@FC^R"MB4K\"DE6>1WC1,=(YDJCN@(*F\U@@C1)B_:C MNZ'T#]96] _ KA"H+&C]/]!HY*7+NPU,3]:F*'-$ MA&T'>-A F4'&1J>,,,E0AZ"\L1%\B75QEC2EQ:V$6E5@](CF0-G^Y[]A2!HH,W+52U. M>D>:PC.>7@%-VO54?SPRF?)>!W$BV "D/K!U6>U$HY#>,'L8H@.%>PF[99:P M\ZBRFL;F'%50OB-]'R!%E32V<_.X<_/Q]#;HFRTERP"5?\ _Q#EBTKE.Q@L; MW,I1V$?RWC*A^MJ$NO?FVK_IDC>%YN36B3TNO%+_1H50!]4B6>>^OIE@K0$E M!Q@%(CH5R'4,C;CK;()Q=A]JHXRSTA.[O*TR](O'-C)6^6:C9;G7X%S#LEIV M '^!F)@XYFAX-0YM>.O\%.IP"MW[SOCO4.'&M%R;.D?L".)0#H2Z3[RO"]8>O"T<%M.Q:F0Z4EV114WD MGZ1B2B$5K P\NQ'46?=Z1%,\*:(-!0"VKC!M%.'#K7(&"8ZO)U.P$[)722#E M(;1"[T"3I6Y+K'_Z4-C7.(]S-.YE58+3G"7U7JZ,]K5HO>6 MF&3JX-/QVI_/4=,Z,?PW14-**JD;I>],F;?2K@/!A263PP;.2DF'QD&&8Q\% METY&SCAI=46IX*H:%\38IC ;[U/X%4(VTI[(%3>!E^>5'K;A'JO9'&@4EI.[3;@(V.> M.H37T=Q&FONZ&R)4D+U8IHA-V,UF[8FFH#"N5TM5.+4_^]>04Q)+8(B/ MV1#R0O:\&[&,J=>B>UX+J4WB?=2PTC*12&V)>)'VP^008AF_0W5DINKF@&J$ M&%+] #6,C XGP??1QZ^CU4QVDW1S5M>=N$$'Y0U8@PKJ_"BVYDOID_E]37&X MZY)3R)P/V)B$?2=$$BR@IKZR\YN]K^&R ^4B*HUL741T+U-F M'+:KF4+\-Z2-.(C!&()F]HX$.>W %+@3=^@Q4;50P: E)/ (]Y2M9#8!; MVU'M%CM?9N.M+Q^P5:\,L2&SXGLL4NEKJ5",*+I'-,C(A.JK$VK_IDG?M/2F M+YXD^F$D&N*\1).$D$G^[CM]<:XOSO39V86>G8Y7#6(KRFR\%X77,T*X1_2@ M$$PEM.E]&(\%O81\I45B(IFRD..,U.IE]IHMU[*<=)?U\K4J>()3?9N\B+\A MHS?=XD_JR+1]WQV-5L5>C93/6"!V'/IC-(^>.!EV=U_F)H0%")]?QR8QPQD$ M'H#%$N]TNF 4J#+ MFGU]L2[![KE\3?E^\A72;S<)N /M&X>624*]K+<=.VG!@"JJFI1_=88;;&EW MR%'&AER>0J?^07C)E"01=H$K)4,*K-/5\?-4OX_?R=3.++DFG'35;FE.)DU?4<]992;Y;2;.*>8$2B]NQ]6)_4;<%LRP$K2[]3IBA83% X:?0A& M.Y<;[D.L3 ]A05(%))/4-?H+;4S?>Y1XR6 M@8CPS.5J!#\^EIV/"[=2AQ0.]"-\7BI][WS[ST;A74WP2A1G> MMR*F%%N8/.N:$(E09N($,T/(%?WVRSJC(,VW)ZK!U;']C]UHOA&-]T.$V$GKIHL;5 NQ]O7$JV$GV*G,SNHM,-:=ES+CNNS9)@Z, O?,DC _S;4 MD??]>(<8-X"%_WMM8?'I(Q"?_[\CSEUK$4WZ'!8P^.VH[8DM/K/Q'I\_."VH MWWEE-FAU'M'=(X!5 *SE"472H7,,O( -:"[P+?([#@Y+T%J<(0.)K>7<%'GJ MTCHF?(XV.0/_(?1S4ZLGNO62/YN?SEZ%9#[LXFS?1/FVX20WZM(X$) J+_MJ2'DZC1EL8[.AJE0#,CU6PQGUF>:Q@V8^WD'C*U ?&24$/<2YXU". M52\)M$I Z_>U^B>XI-BT0"IA=KG?-6$I*W!U>RVG-"Y.+R:A3D8NP+44%5DQ MJ^M0J.X928Y!)"%!Q&Y"]0IP+"RGHM$1XQ,TV)R-:88F*81-0@53[W4^<'G\ MH-'"MQ(H:B78:[&@"*ES!^T:T]A+1+C$4;V>CCVNY9AT:TM.U#HCC6N^T8+< MID;1 FSE98#QVNM@TWA:J0GM\1(YDQC8156N,DD8D7J(.1QP8 0+WU47IV?' MPO1Z.GKQ>3QG$O;/EY"1STDFJ.K1Y-1')^F&VI]CE(JB QL!P4D DM"2E%"- M=0J*DFKLQ'!2?:!D:,^63/6';,=)6*Q-@4BC6=G%[!.7(/)P;BXLE8M7.W\@ M"\;\"?O=8!N$K^6%=Q==B^Z2% E5I*6V[ MS"TS*0,@+AEG\6E&U3<#WH2D>?J]UC%&E?U^/UO2*A>\:K\T;H-$K2O?WM7H MMU//FV3KI6"A1)TF%>C0<$P]6 G8"14^TCSD5/\C(%GM)MSBYK%->L.I[9SK M&J8.C4>Q)QO\:]<)J@QC=$\.\KM? ]T M0GTD>Q #CF&.HD8D%"-N\X]",$( M (1;@O )("2G/?X-GH.BX\C!\53]\R#7@VULV.H]>7F.CN%LDBWSU[HLW.<@#KHU$%'WFPR/Y_KR]D+Q=FGRW,]N[@(GNGYY/3R%2%R"HA< MD4?UM6R05]X%QD? W0%'+H08;6/&9+-A*?RB4'J++ M[(^&LFL;'J.)0_6Z9>&B!AL/=Q+K;SM_6%+'DY*&,V)]AV!?C[3878MT).$9 M"D8YS[>37$>BC:2#0U&XB6[L2+#8UX+Q%"\T>):4@HFB#-702YJ1-:X6AEM-P MFBY%0U%6O^?XZF:#!UN6QJ3TSZ*1"D[4>PY/J#'6UY"#@T&6#2UXA>W^W&Y+ MJZK- Z N<*-FF@9Y4_ORML])2-8#'8A;+]M$O2$%.#$Y$:E/>.]*^?5Z9\!2 M+"''/]B5 X-=&W_P2MY7E$7O[Q.9D8G@P%55-E')KGWJ;Q4ERP;EC!2VKK,- MJI0]'?.<5?;>4RXCZO5NX6 OXZ%HV)D%-]:8*@9NQ_2='%PXHO("*EHF]4H' M#S:ASM]1+P5OPF3(&0CD2!PP.C)B5LA3P+G@@5+W=?\T =74DT"$!=$V2/Z@ M[IZ+9)(W71"&DHOER'5O&B RZXX8$O!=$8C_5-^2 (@VV5NWW'FP0%O@B M[#'4!%UK!1)'JR8]Q33((@FPO&BQ#5FD<=GA23*8):0"/2ICH77L#IZ/=P?? M)I="7">70@S&UX_H#D[@JQ0^!MEROG-^24'VJ^$@&Y]1:/SYAS'%#41*V M!W^H,CS9 &R^,<233_%UL9LT"M^(=O,6%->_++#U;,[);,Z/=XYDIR#91AE> M92X?H-#"AT,C=G\E-%#&BQ@'W MTF3.K\4@&ST>RH^P#I#7P,A;MS0EZCM1[[GO"..[%@PE#G:<(AU7$[$5?3[> MBG[#B;]/>)/,H&IX1+MG F5^(51ZX M#X@36P -Q3[M6]W#1/E3KWS)"IUTA%&.$T$_#RV%4B38H"N]A@.W^>CD!.7Q M3I(&=UN.,RL.L8, #DS/H+C?*^9,/SE"I*=+EX@TL943>0,,ZP/# M$"H \Z@%2-.R/$P^4N1(ETUX!8T0P#T0=J@Q.[C\IJ::WD!:+!X%!Z2YZ(OU M6&6^9)2MQ5>(^+3JKEU;NDR%SJG'ZBU!I5(X.A#@5I5M4''I;*P_B5MXF0/* M*CU.H08OH.)XABO>'3C=_065>Z?WR2MOVC"C[XT8II%--YT7!SO=LELY55=\ MVT? .5D*G1F-I^8ICK?+"7>.@):HDR;LX7NU^EE =J0.F(XD.N/C#*%EEOJ[ MR-.&;]'N3%"OEYO24P=?$ 1)\OG6AG0$,@_UF\3ELC$1_9TF^'@5BEJ4:3U' MF)+[34A8O])Q,H^G3^;CIT_H^,2PUG[$01.&AK4/=7D^C]IV3]-6_)H=. '8 MJ[S3)I+O<&*7)QC^^[3'Q_>?PUU8J?*@HQF)"IDJ>-._X8QPSF#\1/,@F^ \ M'3:3106E$LC3R MK/:^WM>D4CY!H&\92EQ1+O.6Q)@?<]?FZ7A]FCVP>.(C>K@-SS52%<"6Y-7V.5-=\6 M2I;N'IQX;@3I8ZS(=02)\\EZ[^'WJ>.9-U #%JGKCI*Z+ /.1T5F6?%PXY@"V:/_M. M",AI%3\O"6?O>D.J71C,Q&.7@JTSBIR]:B+=;KX8EY>-7)^0'.4(.OT %>G; MSF'+*!]"P53$?Z)'N!-OJ:LI];3'E'Q+ *5Q5VI/$AJZD9"8%B^Q>C#5?>\6 MJY1XE"D./L<6NRQOKS4J,W#K:U'$JPZTE3^[[V?EN4Y\L<)?72'7A5#1A#(0 MTA#KZ 05G02I8RLWKRJ$0,DI.? :\ B"=0.*@"K]_5"%K!^JD4H81_$)R:\> MA$N%FMM:'W^-Q^^@RDC8^IM%M3UI]P >R]*#:=,!E.M_R:POM #5]7 M&G0#]5?7)W[S($RH UW0F0XD$/;UMF?;.>PV9=]71+\O/$>LX*BO$(^,S<>/ MC(7MO/&W*?U"C8B#WL,CSHIY^&H/_N A,>E-7.%5-?R6],KC?1WHRY*68UF4 M3&[(W-K^_1?,74Z\^OY.9H$)5+A#2GA+IN4BVP$0^99[1S?41LCQ41G]H @\ M7E EX[RC\_O-+\'1@3 ' U_'NH>4:.PRN<2;T*Z#*X4SW"Q5K\KFURR%5XYM M6,=RB89=;W"D'1]A[#->-1AZEM!]P/X_98,/./J[VD1/A4W*VYU M4*^$M:_P=UY@8H5,+MO =<;ZLL\!X+TGK2P49 E=._N%N<(3Y MN:9SN03Z <(0ZN_I0&Z2D\FY7 PBI!7LFK#&T(7DRY%QDI"ZE-LX?6N0\G ' MKBR)FBQF$]V1\_V4$*-54S;OIE9TB>K\='8Q(<)Y;*]N/]/3$[PG-7;@WR0' M(T[\Y:'O^):!I^P7G,TOGGV?'O=)KAF5-P&'89!C/!W/JLW'SZJE?\:@SRO" M>&^Z%NMN^M] ^BOF@$$>_]9IU#=/@P0/'D"X/G. \/.SD]-7>J+32H=7P[-RJ_)=<$\ M,IE]:#N?)W^K8V/PB5@Q<67R%P0 *0+ 9 >&PO=V]R:W-H965T^KDQZ^M^ M7R6$!:8&(O J'G!6RP*"T0T_FXP M_=:E-3SL[]#O7.P4RY)IO)7%[SPU^=0?^Y#BBE6%>92;G[")9VCQ$EEH]P^; M>NUPZ$-2:2/+QI@8E%S4+?O>[,.!P3AXQ2!J#"+'NW;D6'YFALTF2FY V=6$ M9CLN5&=-Y+BPA[(PBKYRLC.S!<\$7_&$"0/S))&5,%QD\" +GG#4P$0*7[3A M%#^-WCVQ98'Z_:1OR+=%Z">-GYO:3_2*GS"">RE,KN&+2#$]!N@3Z99YM&-^ M$YU$_(S))<1A#Z(@BD_@Q>U.Q YO] I>5_1_SI?:*%+.7UT1UWAQ-Y[-IFN] M9@E.?4H7C>H%_=G;-^$H^'2"[:!E.SB%/EM0=J95@2!7<,_4,QI[,K# I%+< M$/C=RG+-Q!9REH+)$5:RH%RV&U7N/>O6,S!M6='Y8+E$U9Z1 MTQ)U(GAW 5P0E*PTS>GWU[ +QWLM'.\([G#@.6R+ZW5;?A7<8 H+XR1LZ.K2 ME=K"DA<%*3JM$.YPJ2JZDB"*&ZH7\(%^@X_1&=;SM>(%1%>-Z0=JSK#ZI1(( MX; U&O3B\> LNV(+8=S:A='5.1RKC.X2"(.]O_'0>Y*&%4VLP]XP&,,)90Y; M90[/5N8=XPJ^L:*J1UPPD7!R.=<:3:=$3V*_+M&])'=J-)ITJDQ>*];R>-GQ ML#.-IM^^&4?AU2=:VW)CCAM=PR9W(CVRSCDJII)\^P,-GP[<^Q5?L( 0ZC9J MVOC S/M7^IQCU,#?=Z7E]6F9U"IH?T?:V,_^!^+1_TZ\ENZ>IANW 71^/27T M42OTT=E"_\PURS*%&;-$'RE 04>_W,*"T7L)3]LU=JG]I(-NM1]Y\M3>DW:> M#'GZ@3;/X'IPI_Z!3'GNS6Y/UCN^=6_I7;=OI%]J8'<^ M[ 5Q[-VZ8L:SC\ FI_.$@BU)!I1XG,J7%#(I4PW'&.$0XH%U0#4C^5TJ9HG M6LFT2BA)PUXTB& <#KW?*%$5C <0CD;MT0]ZP?BC(Q(,NH^\?U YD8?,U8<: M7"50%U'M;%N"SNO*:[^\KE])NQD7&@I457F:IKPGI@Y-K584MI:"-< M-ZO.'"#H@'4 M6*+N:6(@2:] +T'2K1B&/= 2;1.519>DXGB_?N=0EN*LCC<,>Q%)Z9SO?.=J M^FRM]'>S$,+"_;)NS/EH8>WJ=#PVY4(LN3E1*]'@EYG22V[QJ.=CL]*"5TYI M68]9$*3C)9?-:'+FWEWKR9EJ;2T;<:W!M,LEUYM+4:OU^2@<]2]NY'QAZ<5X M-M;6_4^KW8^I,07JEJXYZP[F0C-H*R-58MM\K(8"F;;N7WVSCL M*.3!$PILJ\ <[\Z08_F:6SXYTVH-FJ01C3;.5:>-Y&1#2;FU&K]*U+.3R];@ M&V/@5LPQUM; BZ]\6@MS?#:VB$]2XW*+==EAL2>P0@:?5&,7!MXTE:@> XR1 MV,".]>PNV4'$UZ(\@2CT@04L.H 7#=Y&#B]] F_K)-R(E=)6-G/X_6)JK,;: M^&.?OQU:M!^-^N74K'@ISD?8$$;H.S&:/'\6IL&K USC@6M\"'URB_U7M;4 M-=ORI;P,>=I']R#@?KJWKAGEGZ+R9K+A32EY#;+INIW:IE1-*71#L;(+ 5=J MN>+-YOFSG(79*X-].3 S?06ALI/="*X-"*H%P$R*Y53H(9O FXHV#*0!QZ>Q M2&)*8^($>N>]_H$L5&O0D#GV/HO[N:CAZAU\Y%,# M7Y7EM7*U5U9;H0^BSF)$0K=X7 MC)A&SJ5:"C0+.>2QYUABC!U+-!\&C,CD&<1^D!?(VUBJ#\.Q8^E+&.(S20J( M_#@+O"\KH;FK!=E*5JJ<,TVI1WU'4^-'@Y8"FD008I9N%#@V&Q M2F\@Q62G18;.1V'A7>,PX+)Z<)WRI%R RT<,T \&>0XQ&NPB_??O6'PYHJ:8 MRL0/$N919M>RKO%ER'(7;UR1BN7-7$Y=)I ,PU!'+$4J%%Z[<13$CU:N:&YT MGN1%CJY0H\1%L9.Q6N"O.[C)%KX"33_G%/P67SI:U%EQY+B'?I[TM;.E7%!% M%(&N[ MZ7/GU0\JIT.6O!7?N,%X!$E $RICL6L6AFE"(=WB2#V0CAU0"*,,DQQ"5.3> M:S$3*%%Y0P<$5/[!P,;]?.*O \:G4=B'/8\4LACRP/O&-3;?@X$-A+'KK3AU M_8[Q)OOXXV)DM>V#'>$X*E 8GS^E9Y#Q>R<&+BP@!X!U&(9EF<<0A+V_'9Y'6'- MAUF7O!2GTQ&.YPPM[+M(C'>N>SC6YNY2:\"51'?S&]X.]^:+[KKX(-Y=NC]Q M/97W!ZM6[O(X518GK]LN\.XO- G@]YE"Y[<',C#\FYC\ M!5!+ P04 " 'L(E8W^Y/G.4$ !2#P &0 'AL+W=OS[-G" $^]4RY[<1B.>CD7JC,]]6/79GJJ M2R>%@FO#;)GGW#Q>@-2KLT[4V0S##DM*ZW2^=D8&N5#5/W]8?X@MATFXQR%>.\2>=[609_F*.SX] M-7K%#%DC&CWX4+TWDA.*LG+K#,X*]'/3\^1S*:SP7^C%!SZ78 ]/>PZ1:;Z7 MK%$N*I1X#TH4LRNM7&;9:Y5"N@O00THUKWC#ZR)N17P%R1'K1UT6AW&_!:]? MQ]GW>*,]>!>EQ1%KV7; ?[W%,7;I(+=_-P5=0?:;(:E?3FS!$SCK8$-8,/?0 MF?[\4S0*?VDA/*@)#]K0I[?8?VDI@>D%^ZAXF0H'*;LV^J6O1G8#%@O/TO3[ M @RG@&Q3$*W+- ?!-HL'_V;Q@%)%^8H#M&(N _8G<%.5!,.$0CX'0TG=LKR! M>U EV"Y3*$$';-@=QC'^#[IA- C>X9C4F#4NI4ZH.IG3+-%YCMFS&3>0:9F" ML>CQHM\-QQ$[I,=!=]0?L,,G?R19V=-L>#0<5';AT:2/9I]\[R))?H_!+(&I MTE/%\+P3!EHZZ[A*A5HBQ=$XZDX&,9$=#[J3:,):$CZL$SYL3?COH.XTQI+O MENB5_VJ-Y=F*]XWE.:K9CKY_/XU^ .%Q37C\U?W41+ZQ=UHAFPE_R"!POE+G MM.5A >D5UB]#"RE0P''K8UQQ^6B%98MUGSSEGF_K\0$3"N=U:;'T[.')3E\V M!A%@C]X+VC*Y9$5ID@QW+&P8W$73=9\R[G;(++@P[)[+$DZ"ZXU'841"O3(< MC(,9*CO6/2CW!9 4?"ZD<(]LT#\.SG-=H@DRV[4Z8,>347!N+:!@^/ ,=9I* M:W^!#<8MG@MH?!^YX%*A4CB-@\,1A9F6B>LY2#*EI5X^XA%!!U?-XQ] . J?SD?A]]>-=LS]PF$@T89VRR]K:E^[H#Y@MZGU$7F\X*K1Q*U, S>:>5MD"5I VH" M8"8059LOO]L.UH8P8>Q7O*@;TOQ_UKSG8B$6;\3#4\'$4?]KM3&.GA/'S4-UXZM'ZPGA>79.>S*O; M)@:^%,HR"0MT#8_&>)8RU06N>G&Z\)>FN79X!?./&5YZP9 !SB^T=IL76J"^ M1D__ 5!+ P04 " 'L(E8OEXODHT# ";" &0 'AL+W=O M[;-BT[$PR?))X+XDDD@\?4J3HV4;I'Z9$M/!3BLK,P]+: M>AI%)BM1,M-3-58D*926S-)6KR-3:V2Y-Y(B2N)X%$G&JW Q\V=+O9BIQ@I> MX5*#::1D^N4*A=K,PWZX.WC@Z]*Z@V@QJ]D:']'^62\U[:(.)><2*\-5!1J+ M>?BE/[T:.GVO\!?'C3E8@XMDI=0/M[G-YV'L"*' S#H$1G_/>(U".""B\?<6 M,^Q<.L/#]0[]QL=.L:R8P6LEOO/8*6'\+VQ: MW=$HA*PQ5LFM,3&0O&K_V<]M'@X,)O$[!LG6(/&\6T>>Y5=FV6*FU0:TTR8T MM_"A>FLBQRMW*8]6DY23G5W<(85DX/R)K02:BUED"=2)HFP+<-4").\ ]!.X M5Y4M#7RK<=E(\(1AR5ZH^.U1XJ>AGTH,"B6HWWBU!NMN%GP$A :\:CO9M\2*VA1L MB<"D:BH+K,K!R;5-=*#Z)[S'\=J)^AUW]#O]S_3XV=2W098 2=N7.I?'W_;YHEV)?Y0;2^*5]7$15C.H%C=QT=# R) M>NW'H@%?)NWLZ$Z[R?NE'3A[]79LWS.]YI4AEP69QKTQW:%N1V&[L:KVXV>E M+ TSORSIZP&U4R!YH93=;9R#[GMD\0]02P,$% @ ![")6.-*F8JO @ MT@4 !D !X;"]W;W)K&ULA91=3]LP%(;O\RN. M,C0-B9*/?JSMVD@4AH8T) 1L7$R[<)/3Q,*Q,]MIX=_O.&E#)Y7NIO''.8_? MM_8YLXW2SZ9 M/!2"FGF?F%M-0T"DQ98,G.N*I2TLU*Z9):F.@],I9%E35(I M@C@,1T')N/236;-VIY.9JJW@$N\TF+HLF7Y=H%";N1_YNX5[GA?6+03)K&(Y M/J#]4=UIF@4=)>,E2L.5!(VKN7\131<#%]\$_.2X,7MC<$Z62CV[R4TV]T,G M" 6FUA$8?=9XB4(X$,GXLV7ZW9$N<7^\HU\WWLG+DAF\5.*)9[:8^V,?,ERQ M6MA[M?F&6S]#QTN5,,TO;-K8?NQ#6ANKRFTR*2BY;+_L9?L_["6,PW<2XFU" MW.AN#VI47C'+DIE6&] NFFANT%AMLDD]4+>*CQ"M,SZ$? MG4$<5-*I2I-<*OBZ6QFI[%[T.66V#_,-"5RM14+,6Y M3[5@4*_13SY^B$;AER-R!YWJ\6-6?"P F,)Q/ZC2=#[XG*M<=EK](J)WD&Z!T-(^^:2T[O.8-Q]I^3IFRS8>B5#&O E=6BR 8;<0:G6SB'O M@GO0\QZ598)4M<@3!X5#UQCLU5F).F^ZB8%4U=*V)=>M=@WKHJW3M_"VV]TR MG7-I0."*4L/SST,?=-M!VHE555.U2V6I!S3#@IHN:A= ^RNE[&[B#NC:>/(7 M4$L#!!0 ( >PB5CF^,ZU" , )L& 9 >&PO=V]R:W-H965T,,A 8(ZEO-^28"VVW 'K%W0[@6'PWU0 M;#H6)DN>)#?;?OTH.W$S(,U]L42*?/A0%.GE7INOMD!T\+V4RJ["PKEJ$44V M+;#D]DI7J.@DUZ;DCD2SBVQED&>-4RDC-AQ.HI(+%:Z7C6YCUDM=.RD4;@S8 MNBRY^7N]781P>%0]B5SBOB-;+BN_P$=VG:F-(BCJ43)2HK- *#.:K\#I> MW(R\?6/P6>#>GNS!9[+5^JL7_LY6X= 30HFI\PB\12D]$-'X=L ,NY#> M\71_1'_7Y$ZY;+G%6RV_B,P5JW 60H8YKZ5[T/N_\)#/V..E6MKF"_O6=D01 MT]HZ71Z<22Z%:E?^_7 /)PZSX0L.[.# &MYMH(;E&^[X>FGT'HRW)C2_:5)M MO(F<4+XHC\[0J2 _M]X8JJ]Q/X"K#-Y^JT5%-^X&<$_OH?>1;R7:_C)R%,G; M1^D!]:9%92^@Q@SNM'*%A;<-NXCX!M,K2.(!L"%++N E M7=Y)@S?YG[P'L)%C'_G6/&Q_ 4>JP8M4@T\6\UK">Y$C4(6QW*)IJGPJ M!+U_D!O;;TKO/RRXXVE!29@6[YE= O$07D,\8#._SJ=)\"'/14I$:Z.$JPV> M\XB3.8SGP7ND]BZTS$"4E=%/Z"TL3& 4SX&Q67!+R3M3M_.$LB6C'5V8A?OH M&I+9%,;CX*-V7/J3YWR?H[$!8V.BE\1CBF;M@J926I>UY XS&B9T_:G@[;@B M1UYJX\3/5M&;L@GTH3>>CZ ?;,X&&("BOO47,)K/:9VR&,X]NNAD8)1H=LU8 MM%3<6KEV=G3:;O)>MP/GV;P=VW?<[(2R(#$GU^'5=!R":4=A*SA=->-GJQT- MLV9;T-\#C3>@\UQK=Q1\@.Y_M/X%4$L#!!0 ( >PB5A^*KK7B , #0) M 9 >&PO=V]R:W-H965TKRKJ%:#I> MLQ4^H/UU?:=I%G51"EZC-%Q)T%A.PEE\.1\Z>V_P&\>-V1N#8[)4ZM%-;HM) M.'" 4&!N701&CR>\0B%<((+QUS9FV*5TCOOC7?2OGCMQ63*#5TK\S@M;3<*+ M$ HL62/LO=K\@EL^'F"NA/%WV+2VPRR$O#%6U5MG0E!SV3[9\W8?]APN!N\X M)%N'Q.-N$WF4U\RRZ5BK#6AG3='4!ZOI+2<_.[V5ELD57PJ$ MF3%H#1PM&,W,\3BR%-]91?DVUKR-E;P3*T[@FY*V,G C"RS>!H@(6(VH2V0&EYR5WYOB=WB$9OHL,T%A4&I1*D92Y7L-;JB1=H M@,%R'PK?A\)?H;!VGYEQ1E1HNP+[JM @@:,OY 6V4HVA-7-\"?^3=? F MR?XD\!E=MN!.JZ+);;3 O))*J-4+W*-@%HO@MI?(":RT,@:^0)H,W3T.9GG> MU(UW!E8K;?G?S']^CD87< Q'20;'74+[FE"W"3_8N1.0])U.DG,8!M^8?D3K MJK #>^4_%T2O"_8O_QW>^)RN8*$9)6,U?FP?IW#>0RV-';41,7L%]5\(C480 M#X.%LDQ\RM[M=T;W9 ]@AIV@AI^6E WQO+:XYY)V1")XY(9#B)/,#3+(4O>D\^6?%Y $],4@O9;64=S6 MN*W?H=)%>YV,3O+*]VL#N6JD;9M:M]K]$LS:3OAJWOY/T%%<<6E 8$FN@]-S M*I%N>W0[L6KM^^)269*-'U;T6X/:&=#[4BF[F[@$W8_2]!]02P,$% @ M![")6-/5G6?( @ :P8 !D !X;"]W;W)K&UL MG57;;MLP#'W/5Q!>,;1 6R?.96V6&$AOV( 5"YIN>QCV(-MT+%26,DENTK\? M)3M>!J3!MA=9%_*<0XJB)VNEGTR!:&%3"FFF06'M:AR&)BVP9.9\1J%<$ DXV>#&;24SG%WOD6_\[%3+ DS M>*W$-Y[98AIJH3Q(ZQKV^%E &EEK"H;9U)0Y,X+MVE+*RF4TY^ M-IZEJ:XP@]L-7;-! TQF\-D6J.&ZTAJEA4^<)5QPR^GT^)$E LW))+1$[B#" MM"&ZJHFB5XAZ$=PK:0L#MS+#[$^ D%2WTJ.M]*OH(.(-IN?0[YU"U(WZ!_#Z M;2KZ'F_T"MZ'[LB[E&[.]'= ]J;%8LQ6E +\:@ M?L8@?ONF-^J^/Z!WT.H='$*/%_1 LTH@J!S^[1KW17*0:W\D#6D'=TF5)TT; M4K%3.ZFBIVRLDTLVD"M!'8'+)1P? 9>TIRI#".9D#/\?6H>J LN$#EUE["XZ MKDQ^S;F,5]+6O:#=;3OIK&X@O\WK-ES'84!@3J[= M\W?# '3=VNJ%52O?3A)EJ3GY:4%_ ]3.@,YSI>QVX0C:_TO\"U!+ P04 M" 'L(E8#Q.?1I\" #H!0 &0 'AL+W=O"J0Y[6*+$OGIIR1RMM7FP58 R)YKJ>P\J!";:1C:O(*:VS/=@**5 M4IN:(YEF$]K& "]\4"W#.(K2L.9"!=G,S]V:;*9;E$+!K6&VK6MN7I8@]78> MC(+]Q)W85.@FPFS6\ VL '\VMX:LL*<4H@9EA5;,0#D/%J/I,G'^WN&7@*T] M&#.7R5KK!V=<%_,@?1&0+P+B+WN;B.O\I(CSV9&;YEQWD1S Y^JCR9Q0KE+6:&A54%Q MF%WHNJ;#6:'.']B''WPMP7ZU6,K\(7]7JPM&GH+?XXE MV2'&QQ&N/J:VX3G, RH "^8)@NS]NU$:?3TA,.D%)J?HV8KJK6@E,%VRNXY> ML%?70\^075O;TOP*\M8(%&"94.0NN7OCQU(ZN>GQE!8XH-.'>@VFOX$APPJ< MG(:K%U9QR\Q>8]YIM%XCM0DF2"-7.3AI9B>-H?:$4DOJ T)MINP_)#Q85=S M)U>67@>U*MMMUTBNV"2-ANDD&MQS8[A"ZT0TK\_]ZX'WG"S M$?)P$S75_I#-2-K^6U1NH,?EA1*P;C'&B]U!KWAMN@;^[97U!+ M P04 " 'L(E8ZW2DF6GD96DZ(NUD+R\RSGGTCI95^*[7'"NX+;(2WDZ6"BU/!X. MY73!"R:=:LE+')E5HF *'\5\*)>"L]0L*O(A==UP6+"L'(Q.S+M+,3JI5BK/ M2GXI0*Z*@HF[,YY7Z],!&6Q>7&7SA=(OAJ.3)9OS:ZZ^+"\%/@U;*VE6\%)F M50F"STX'8W)\%NOY9L+7C*_ESCWH2"95]5T_?$Q/!ZYVB.=\JK0%AI<;?L[S M7!M"-_YM; [:+?7"W?N-]?G@P5;J,G#Z>-R;/:)-UCDE#X5)5J(>%=F?+TOH$A^M MBV_YU &/V$!=ZO78\]J@/6,O[ WZS 1]R>X08PK&0K!RSLW]W^.)5 (!\T]7 M]+5MK]NV)M&Q7+(I/QT@2R07-WPP>OV"A.Z;'L_]UG._S_KH&DF9KG(.U0P^ MEC4G#;@G2#A\,T7W$>5PF;.RR_=^ZY\7W)I5.1(U*^>@- !@BJ5$;DO('FRG M%APK0A*S&S"IG<)2\6+"15NN8WB.S]9XS40JH;Y85W4"4\!5<&\(QCH9(BR;*MR@'ER5F9*09A))K_V>:+UT++U-:U!JW!H_=I9/JZ+ M;-96YCI:?(F9E5EJ4GZ_2JK",0'GBXS/=):F*^/@Q6R63;FP89RR O[@-W=. M#UJ#%JW!,]"Z2<:U\?3") /&6I4S==<%UE[CW43K0G#=;[+_,',Z%UKE6'GW M^D5,2?1&X[JK2G6[0,>::N5,&2QLX:LAJ>W=<28D<"UU]]!O:?2;U7A#'7A& M,JQOIIGPM+U!N'.!3=)JKAA%:11JQ7+KSY79LYJUL(?/7!3HK7710.X2P<+A M+^VJ=8'84.B7SA!3\#LK5]B.H>8K!=_S[<1+X"40)XSB) @@=H+0^M! BR2! M[;HN>([GAR3P8B"NX[K6EG(FM?3-CU<+V^B,9ZIGQKGF<)[CC /BNK@-@4-T MPW?UAIM)[VZ7F=!3@CT3?@CP1TFB$% =8H0A4L<+B(_N3!R$>>#9- K-W%/Q<@"%J3^ ;$TD8Q(B5!P'&=ABY]2:N1]'Q)T;H01"Z M=ABX381NY%.(G"381&!XT;G02V*;F(7$B6D2QSXN]'WH48.P58/PR6HP1FTM M&FRN9*VR^XXB7=+0NU.W-,#/[E\360/'^EJA#F2YE@4:1$[HXR5V$(2O@$:1 M@\EZ95UE\OO13'".-A770@T"Q0-\AV*C<+ 2K_#BACCU+;(]1>6 NXSG*2#& M<,S\:@QP(^]*,SF P,&B!#C44XBH+43TY$)<;1M)+45?3!]JF-"5^E[;3TA] M_XX;@=L1-3,">+KE5CWU/CI^YU!;9M\ MV_8W7?XA&=H.OWL V%AJVGS3_+O;_4.*>':(R".)KF3@D)#&6J?"+2X?<&BG M4_W*GK]OQJ8?[AM_E&Q=$7I.&#R(<']\>!Y)[(AJ+KE.\),M/];\"HV)./E5 MX6'/MGV?VHGKF_!\XD<)]BLGCI[0[OPB5CD48+ H ( +<% 9 M >&PO=V]R:W-H965T@[;;#L(-LT[%06?(DN6G_?I2<>AF0YA**(OGX:.5QOE7Z MR52(%EYJ( 2UQI,6]=,OZY0J.TB& 9O%_=\4UEW$:;SAFWP >WW9JW) M"WN4@MV=PDV1*/3GGME@$D2.$ G/K$!B9 M9[Q"(1P0T?BSPPSZEJYP__R&?N-GIUDR9O!*B9^\L-4BF 908,E:8>_5]BON MYDD<7JZ$\;^P[7+CRP#RUEA5[XJ)07>-/,MK M9EDZUVH+VF43FCOX47TUD>/2/6?S&;!4?1;S&_!Q&PT\01_'H M"-ZHGW3D\2;OXF46KKG)A3*M1OBUS(S5]*_X?6C:#FMT&,LI968:EN,B("D8 MU,\8I!\_#"?1YR-,QSW3\3'T](&45[3T'*H$S_I6$M.6I&#-(:Y'T0YS?:QP M4+;6?0$6F 67!Y68?&4Y/B )EJ-80+7,V M&U"K,9S -'*G!*:7SDX@&3I[ 4GB[!22RP'-2NNJI $@=JZR-.0)149PZ+'" M/3'5J#=^91C('<].5_UMOY66G1C_I7G:UR:Y$*N)G=FFM/OTLQU(J481>X.?[O[W M.^.[C%="/JD"4<-+57(U\0JMZY'OJ[3 BJI342,W)[F0%=5F*1>^JB72S#E5 MI4^"H.]7E'$O&;N]6YF,Q5*7C..M!+6L*BI?IUB*U<0+O[.)[-O$" M"X0EIMHJ4#,\XP66I14R&+_7FEX;TCINSS?JURYWD\N<*KP0Y2/+=#'Q!AYD MF--EJ>_$ZANN\^E9O524ROW"JK&- @_2I=*B6CL;@HKQ9J0OZWO8!8]S^*3,MS2DS?CIYI%)2KN$'HW-6 M,OT*1_=T7J(Z'OO:Z%LK/UUK31LM\H%62.!&<%THN.(99N\%? /6TI$-W93L M5;S$]!2BL LD(-$>O:C--G)Z_4.SW95D(Q'MEK!%,E(U37'BF2I0*)_12[Y\ M"OO!USV <0L8[U-/9J;HLF6)('(X"':OW&[8^P([JT9;@:E3I2G/&%^ &2"G M3,(S+9>H@&I FA:611=H2E#5Z(K(&5!751G5UE+BNJS9'\Q@;FM]!'N3Z?S[ M\AXW4#^WH*XMT(,%@AHES H;ZVVS<]T" U4VTBM2"6@?((3$CT+3GT@(I-_K M1D$//IOG-.C4*5/X+OY1.(R[9-"'8S.-8Z.\!Y4,_PLU'!Z&&<%9V W"H;FK M,.[#KE?M;S6<"N7"M54%J5ARW?2>=K?MW.=-PWHS;]K^#94+QA64F!O7X/2L MYX%L6FFST*)V[6LNM&F&;EJ8KP]*:V#.&UL MC59M;^,V#/ZN7T'XKH<4Z)+8:=(T30+TY885V-V*MG?#,.R#8M.)<+;D27+3 M_OM1LN.Z6^KEBR5+)/60?$1QOE7ZA]D@6GC.,VD6P<;:8C88F'B#.3=]5:"D MG53IG%OZU>N!*33RQ"OEV2 :#B>#G L9+.=^[4XOYZJTF9!XI\&4><[URQ5F M:KL(PF"W<"_6&^L6!LMYP=?X@/9;<:?I;]!8242.T@@E06.Z""[#V=7$R7N! M[P*WIC4'Y\E*J1_NYS99!$,'"#.,K;/ :7C":\PR9XA@_%W;#)HCG6)[OK/^ ML_>=?%EQ@]GP'86H5H@\[NH@C_*&6[Z<:[4%[:3)FIMX5[TV@1/2 M)>7!:MH5I&>7MS)6.<(C?T8#O4>^RM 63#N!05R;N:K,1.^8"2/XHJ3= M&/@L$TS>&A@0I@98M -V%75:O,&X#Z/P!*)A-.JP-VH<'7E[D_]U%&Z$B3-E M2HWPY^7*6$W4^&N?SY7%T7Z+[KK,3,%C7 1T'PSJ)PR6GSZ$D^%%!][3!N]I ME_7E UV_I,P05 HM[+TKE)@*>PQW6CT)=S?V(>^TO1_YXP:9J ZR[J#5[J!B M=Q#$BBZCL<9ALAN$5&5TJ85S=AUJ35*"Q^A-PG/X+B:G,,Q*:9(>PFX=5IB#Y9;!"X3R%3T WCL? M[I$B'XM,'F@N^ M_B5 X7 2AN);6J5?0#N0N@9) EMA-UZ$+E;)LT9=&,9-S1KSEC.'.M_-GC=> MM42_]1_ZD%8<^C?N*.P/X:@>:M(XG]WF"4AZ%PG>3G?GR;@_(AW_97=(KX-T MQ$H$>4$4B]&PKTK^1(A*Z2V.0"H7CU*^"KRA]5J#91]W. _:7JDO#_'G=#+Y6><'EBW?W[,*X MM[K"YP+#*WQU17.DKDH:>AY6%0[S0FGJ5-XDAUNKQ:JT[J5D5G75P0,"TN+H M?YUJ;>Y,L5?L,_85+:/NC(CJ&$0O&OG#M7ZA5FW+=6*H5)V>3*>1'\,P8K\1 M6 WG,&&/RO*,[8L(:9R'7G[*ON_HQEITJP2.W81D6@6TA:VY-_L(>V@I';2Z MFASUVO=N+F6EM%6#TZPV[>%EU16]BE>]Y1>NUT(:R# EU6'_C.JEKOJUZL>J MPO=(*V6IX_+3#;6XJ)T [:=*V=V/.Z!IFI?_ %!+ P04 " 'L(E8KE#Y M"V0" #%!@ &0 'AL+W=OM"Y$*:%NK=D*@=2^JO3#A O'3GT7Z+[];">-F 1HFL:; MQ';N_O>[N^22[+79X@: V$LN%0Z##5%Q'8:8;2#GV-(%*/MDI4W.R6[-.L3" M %]ZIUR&<13UPYP+%:2)/YN:--$E2:%@:AB6><[-KQ%(O1\&[>#U8";6&W(' M89H4? USH._%U-A=V*@L10X*A5;,P&H8W+2O1P-G[PT>!>SQ8,U<)@NMMVYS MNQP&D0,""1DY!6YO.QB#E$[(8CS7FD$3TCD>KE_5/_O<;2X+CC#6\H=8TF88 M? C8$E:\E#33^Z]0Y]-S>IF6Z*]L7]M& Z#@<.[>X) MA[AVB#UW%4.1G[5%@_2B> F1&%KY!> ML5&)U@#QBLU)9ULV+Z0@QM62C3@*="93 PB*N'=Y-P'B0B+[QHWAKL#ODY L MEU,/LYIA5#'$)Q@>N&FQJ'W%XBCN_.D>VG2:G.(FI]CK=4[HW6FAB#U:R-( M>WJ ? 'FYS&NLSKN>[C&@FW!#D>1>]< +W;H'?/%O@F>RX%"O\&%& R]SJL MX1AEI?/1Z[CYL$NC5B\)=T>"]YK@O;/!QU_8/5_@V;Z>5?C'XO0;OOXE^]J_ M /J@01_\I[X._J*OX<%4<@/>?N9KH9!)6%FOJ#6P73+5T*PVI L_J!::[-CS MRXW]SX!Q!O;Y2FMZW;C9U_RYTM]02P,$% @ ![")6+]4^ 'P! ,!0 M !D !X;"]W;W)K&ULQ5C;;MLX$'W/5Q!J4+1 MUKI8OJ6V@<9NNP4V:1!OM@]%'VAI; F11(6DXA38C]\A),/X@ 0)+G.$K$Q BD3"]-4W@!Q%1T6 H)?EDQ'E.)5;XV14_[J"B&TFAFUL&^["=2!5 M@SD=IW0-"Y#WZ2W'FEFB^&$,B0A90CBL)L9'^W)NN\I ]_@GA(W8*Q-%9&I3R""#RI("C^/<$,HD@AH1^/!:A1CJD,]\M;],^:/))94@$S%GT/ M?1E,C*%!?%C1+))W;/,G%(1Z"L]CD="_9%/TM0SB94*RN#!&#^(PR?_IY M]X!%7@N14H]F!@8603P)S"F;]_8?>M#G;AM@LU; JL( M[Y;"NTWHTQD509U:C5:GJI6#N1I,A>BGJ3.PK+'YM*_"<2?;MNRR4X5=KV37 M:V1W@T=*Q$3=AKUJM#R580[6VW.^:_<&!PR/.[D#MU_/L%\R[+_*T,,Y))D M7P4I/"O5AL!PIP^;4(902[\1]E3Z_6/Z3K=_0+]_O I&(Z>>_J"D/VBD_QV/ M6\75HVDH:51'M!'@5**#8PZ]HY7Y@'0H)'!?#/.1X[2#? M5BO@2J,?UQ O@?\D_Y)%MA3PF*EX^NE)_6Z_U0G8.."I K8)-F\)K"+TJ!1Z M]'^?6*,VA6\3;-X26$5XV]I=YJS&-;Z@$1"V(GAM]!XN2)*II:L;BFN;$%D> M#"7.@J#Z[ETG<#'.?MQR7&M;LSZGBM85656_O*FR?HE[*0P\('AJY M>K4RY8##_8.KXSB'(C4.>[)(+:%517)V(CFGB.2#\'B8ZAP.6U];5LW80#T\ MKC&O(![#S%+HPUJA;MAV!:M: !@NXI0FO]Z^&3KVX(,X\U@%4RK.4+)1 M.0Q&&75#A4\?R2P_\<^N*7\ V:E-R1KGX>05V1):=47N$B2[ M,0V8SE!CO3"V$\XXX2K=OZB9SJ*/*#O57@&+$?=O,^[AIFXUT6D+K2KA+M6Q MFW.=@TVM=Y^O;\OZ=<<#/)1]MV]\UJ8KE] ZE:S.%FK>%EDMG[CVEQ,#7 M^DE*H")9(O,GB+*U?/;ZJ!][#MIGZCE,/]'L8/*W--R7ZS 1)((50EJ= 9ZR M/'^>RBN2I?K!9LFD9+$N!D!Q/E0'_+YB3&XK:H#RD7#Z'U!+ P04 " ' ML(E8^1_X\0D$ !V& &0 'AL+W=O,1E6K(U[;8SK>TC7,03YL[[@:V1F*'T00BX#%B,-J8EWARQEQ M=4#ZQ/< ]J)PC325!6./>O#9GUB.S@A"6$H-0=7/#F80AAI)Y?'O$=3*UM2! MQ>MG])N4O"*SH )F+/P1^'(SL486\F%%DU!^8_M/<"3D:;PE"T7Z%^T/SP[[ M%EHF0K+H&*PRB(+X\$M_'0M1",!U >080/X;X-4$N,> M'+V(;.4UC65=#KF M;(^X?EJAZ8NT-FFT8A/$>AOGDJN[@8J3T[DZ%WX2 F(K=$OY(TBZ4*,Y+!,> MR $>G^MYH)0?$#GZ&%^C=Z_^X#>H2!&]QN6"!K[8FQ+E8G&LY?'53\>5B4U MJU[#LH=N[I#%V%ZL#3> E(20?-./B!1%^9$.CG5X6&/DN(Q#]5E3@L[58OK55Z*;9T M"1-+R5 WX$U_?,//'#^JJI+1V"E*KE9E5P3^O2>21I6,32&52>%JL@=YXS&]JXBZ7Z6=-^8],,Y?D.J3/XHHSMJ(^3[/3,*V0C: ME')'8"7^%QG_B],)^:++*G4$5JH2=G(_X[23LCFN@9:/0$4Q$Z=:R[A@PW#7 M:C8C-MVU5_*[VG*EY^'K>L:YZ<)&MU*KZ T'\\?9C-N8^/_AJ7!NJK![.EWC M%M;,4*F.T,J5RIT<-ENY>F6W,%C5RNZ__$R[HWZ-MG,+AHW>I96V.[56K^3W M)8E["'MOT';NI[#94-5H^X8EW"SM%H;+P+LCM'(14=J=FKBNTVBTL5[6T1R^DCM;));LN(N=G50MEFQ,;[9L[O*EDK93L&9=N%IK#NR"M&ZR 6*(25 M0G1Z0V4*^*')?1A(MDW[Q LF)8O2RPU0'[A^0-U?,2:?![KUG/VK8?H;4$L# M!!0 ( >PB5AMA3N@V0, )L9 9 >&PO=V]R:W-H965T;R%%/-+FD,FGVPH2[&00_;D\IP!7I=!:>(&GC=Q4TPR)YJ7]^Y8-*>%2$@& M=PSQ(DTQ>_X("=TO'-]YN?&5/&V%NN%&\QP_P0K$0W['Y,AM4-8DA8P3FB$& MFX7SP;]>!B,54+[QC<">'UPC5^:B(, ?W0D(*@#@E,#PCH@+ NM,BO+ MNL$"1W-&]XBIMR6:NBBY*:-E-213R[@23#XE,DY$*ZF+=9$ HAOT"1.&ON&D MJ$8DPUE,<((^< Z"H[Q&5QUYS7,! M[<")_OS#GWA_=95N"4PC(FR("$WHT3T5..FJT!C6G13J*J["&94X:JO91>.Q M-YN[NXZD1TW2(V/2#RMT+[UC\^JW+%-(BR!:41,&B(FPY1K#.NAW IG?))RITW24V/2[+6#T'QJP0YLG[KNTMM!TF@[,EG]6F=?PMLBPA*:3T7HMW^A@CDO= M'-=#ZS70B6)OO9%O-D?'Q1Z8I3S /!E6SQ*:3D+KM?S1>:5LU7K90M/):,V7 M;[0T!BD/L$+=4GX]D%Y;ZZ=\LZ$Z1>T#M_8!ELP@ 4MH.DVM@_.GY^T'JU[. M%II.1NOF?*-',O3# &_5W0^O!])K:PV:;W9HQ_LA-*M]@(,S++ E-/V8I/5[ M@7?>@Q*KKLX6FDY&Z^H"HU$ZKG9S7 ^U6P#2:SLX$#.;M%/4/FSW-T_<6P+G M."T+6DL8A.?M!ZO6T!::3D9K#0/S.=SQ?AC@TKK[X?5 56WNPY=3:;M8]26@&@B:EX?ICU0(FI:76\!K8.H%^7Q#J7@9J//YYGM, M]#]02P,$% @ ![")6,.A3KD P 1 @ !D !X;"]W;W)K&ULK9;1;M,P%(9?Y2A,""18TB1-RV@C;2T(+B:F=8,+Q(6; MG";6'#O83KN]/;;3A:[-.BZX:6SGG-_?[]@^G6R$O%,EHH;[BG$U]4JMZS/? M5UF)%5&GHD9NWJR$K(@V75GXJI9(.G%C5S*=B$8SRO%* M@FJJBLB'"V1B,_4&WN/ -2U*;0?\=%*3 A>H;^LK:7I^IY+3"KFB@H/$U=0[ M'YS-QC;>!7RGN%$[;;!.ED+"_:"Y+J?>V(,<5Z1A^EILON#6S]#J98(I]PN;;6S@ M0=8H+:IMLB&H*&^?Y'Z[#CL)@^29A'";$.XGQ,\D1-N$R!EMR9RM.=$DG4BQ M 6FCC9IMN+5QV<8-Y?8K+K0T;ZG)T^G";(N\80AB!7.J2%%(+(C&'*YQC;Q! M6#[ @C!4&RZK[V9;A MHF4(GV$8A' IN"X5?.(YYD\%?&.HH!F_YX> M'L&)ND6.G%[RC-YYEHF&:\H+N!*,9M2LYL_SI=+2[.)??0O6ZD7]>O9DGZF: M9#CUS-%5*-?HI:]?#9+@8Y_9_R3VQ'K<68^/J:;,RC4::9>BS MW.K$3L?>/>LT',7CB;_>M7(8- BBJ MZ@CCL$(?'$=TI [-W85-2C<#($AFL M**?F7.50")&KE_G;28:[:,,]^L.0*.YG3SKVY*7E-?PJ30\(P#O<8#X/&.SZ>0(XZR-%1R&^Z1-D'-#J<*][#.0P9)$D_SKC#&1_% MN1&:L#Z<\<'FBH/QASV@PZ PV-FF+9&_G(K)%L:U;;T:)VU_Y2:+.]7;,T91ZE M#3#O5T+HQXZ=H/OCD/X!4$L#!!0 ( >PB5BO1JUDS , "P- 9 M>&PO=V]R:W-H965T$Y9)F?.5JG\QG5EO,64R '/,=-OUERD1.FAV+@R%T@2:Y0R-_"\ ML9L2FCG1U,XM1#3EA6(TPX4 6:0I$2]WR/A^YOC.8>*1;K;*3+C1-"<;7*)Z MRA="C]P:):$I9I+R# 2N9\ZM?S/W0V-@5_Q&<2\;SV"DK#C_;@:?DYGC&4;( M,%8&@NB_'?Q9@3JU3V/8?#Z@_VS%:S$K(G'.V>\T4=N9<^5 @FM2 M,/7(]Y^P$C0R>#%GTO["OEP[&3L0%U+QM#+6#%*:E?_DN0I$P\ _91!4!L%; M@^$)@[ RL)%S2V96UCU1))H*O@=A5FLT\V!C8ZVU&IJ9;5PJH=]2;:>B)=UD M=$UCDBFXC6->9(IF&UAP1F.*$DB6P$>IJ Z8'KV_1T4HD_ K$8*8#?@ E_"T MO(?W[SY,7:4)&5@WKIS?E$'806C^S\V#'CIA'=W0XHU/XJT4+#$N!%4ZFA?P"5ERJ?CE U%F M[N4";ID^222+$?29A+G A"KXPJ6$;U\T&GQ6F,H_NF);N@Z[79OC?R-S$N/, MT>=;HMBA$_WX@S_V?NJ*RYG CJ(TK*,T[$./EENM7*%(P;P!OH;8AJ%+=(DT MM$@F1>VB8#CR/&_J[IIR>AW^1SFC6LZH5\[QCB:\6*EUP73"LJ=+=JDJ 4<- M5;[?%C5J:;]N+CHB.Z[)CGO)_L)YLJ>,V8-.,T6R#5TQ!"*EKB$TS0D5.FMW M[L6XQ?HMX[X51W0G-=U)+]V%0,W(,)6%,#'NXC5I>1T/V]'L6!6>#.=5S>^J M/YR8H2 ,\HHG/NMZ*[%STZ]:!,)PW.;97N9[I_?]NB9ZW4OT$4V--ZD^1V&[ M ?/!\A6C&V+J:R?CZ[_=\+X51SQ][[5 >;U,[W&-0N<#W33L,"LZ=[R":/K5 M?4PKE/V>NM,"]&0$OU%E_5X13TOXJKLL_=&^-.H!?'O =(6B,[WW(_[;_'XN MM&/]P:O^X/\KA)7O4AL]#98#4(=O9:53LX2M#I:-BB2L M^_L/6Z7!Y+*.$W#6.N\V^LX4Q<:VXQ)LG2M[MGJV;OEO;:/[9O[.7 5L/_L* M4]XC'HC8Z&0/#-<:TAM,]!D796M>#A3/;7>[XDKWRO9QJZ\S*,P"_7[-N3H, MC(/Z@A3]!5!+ P04 " 'L(E8.WGGFA,/ !"A0 &0 'AL+W=OLJ:/C]]>Q[\NJ6Q.EPQ7;( M?TK^W$H_!T,L=W7]U_#+V^7U+!Q;2\?-IR/-U&8Y5?SCW($ZB : M1MEQT(EG\=&S&/7LMFZ[(>/;8L7!!-Y='DN3LB@-1YZI@TB:4]BSY.A9@GKV MRQ-OBFW*\$_]7MW"[B7*S%&8)R/WU$$L"2/8O?3H7HJZ]U/=ML%]4Z^#>N=H M78$.ILK<+_L%3$<>0J/8U'>;'5W,T)OO=M,TP\U7M"WOVE>0=YG+.\R1L9-8 M\V.L.9['1?L(!9@K"TO3<)R^ZB!"0@(O/@D%GH2H2]\O%O5F0(Z&+WCY<4"3 M%T'%.Q F0L6%A+&1F\ @2B?N,B+!'D'=?%OUNU)7-Y]!OXBZ-(R,-R9@5!Q. M.4:%8Q1U['W#GXIR>;S]@QYC@[I[Y$U/!^3,!AVGP,8P_MZ!022=\EM 'D&A M9+_9&[C(@%6+Z=A'=53:#YMP4@ 2P1'IQ[I>/I>K%>A8!-P/-!L[IHYB9.JF M$7!$<#QZ6W5%]5#>3: 1 >"(CK=[8! -)QP3:$1P.'K?#/M\]WF;A?SO3?DT M$)OI&UK%'!+ERHVCCDKIU!H*9"(X- GD7/&>UP=??9%10KX+FH'(#V"_Z3_< MYB7HN8I%)(OCL>? J)2E$ZX+Q"(H2-S\LKV]D7LF4Z;-%=?4,0F;<$S "\'Q M97=3(XZI&)+GZJH!2!.R>&+9J( :&AHA_:HL[LI5V94._*VFG0 M K@H#EQ'?'TJ/@_@"@8,X!=5@!4819.)+98*_*(X?O7^-1N.XI?T?8'>J_C$ M\O$^# PB;&*[HP+$* YB;_@][WU<8@\M5(4F.H98?!HX1P(L/03"41SA#O?$ M]L&S?]CL][VJ[CB:+2JD94I #A.I8I /8JCWA]%TQ12/H!4R_T3C\9AX.&,C2$0G]DB001,TO-@\AC+ MB^/]N<\=,#@5 (&-!1@43NWV B0I#I*G!%.WAZAH2.-(^1;445F<3S@J0)/B MH(FL<$^;ACO29*$!S$SI^ $:&A7G$[#/!+ R_!GNYW['. +,.5XS]5DM)N/T M ;19.*AGPE<9#@N[M)#DQ9,A;PH52I.P"B:3G%I)I"1X<@HEUS(J)"-3V(91"PH0.RFWAT[K7>[LG8: MM. )\>7U[MBHWHU/9!N(H NQ[\)X;%(8Q[VPC5)PAOCR"GIL4$''I[$-0["% MV'D9/38HH^.SVD8E=3TY*+C')@5W?"+;0 21B'U4YF.3RCP^LVUD@D[$/LOS ML4EY'O? -D+!)F*'=?S8J(Z/SV@;D2 7\?^AX!\;%?QQ3RPC300#23P=#"0F M!P/XY+;!"::1.#A!2(Q.$/"9;",15"/!J<:P/3;%H@O>%=7FOO]ATPS9>3AI M"/X)+,XB\#G/996NK)VND* IB<^SB,3I680K:Z=+(:A.!-*M4.IR_:-IP4H"^Y]#+*WCOHG86I-IQ44)A4R%1:X#2=3SVN4$WE\.MMP!"YG M."ZC73B9BK<)'6]^^ 2V 0CTSG#TOJ@))X->YE,"] '7F8#K#"^ F#;A9%!/ M)E'N'A^ FPG S7# Q9IP,J#;0VW"P2>P#4!@#DZJ.]TH.#3V$;@L#]W.1\!0E!Q?^4*EP1G\0V"('_.?Y,;]J#DSM]>G=E M[31HP1)RG"68].#D4!/H^%P,G\CS.;\')50HQYMOXI+9!"?Z0X_S!J ,G!UB$ MTHV0;B& 1.D_,$PSWO8&R4CV-@ULQI'94DZ1-J#B)<].$<)CF-EBDZ,+@OUM%2*5J\ M$F'=BW,P/'J_50G0!^<@H20H%)J<&6B34^4=C*1JA3X/(P[6G2V'#\9#0DEM*;SP0.)@X.0A*5$$EH!1 MT\TX))0TED*D M(16:O'N#)C54@5%R6ATTU8A#9+E"C5ZAFM'ZYAPP"'R>L[\V5^9&"R,+)!*? M68SK+YZ_'%[HEBS+J-%EU&IG:EAT":6'&L2HM;%$A0H.05#4)KF!IV-ESL')2R\L5M+-1 MR\0#D1B,1BK3M/^' $J8+]7Z%CZ;32@2^Z!FQTY(CQ#!A3G/WA%JBR2K"?1Z'I>*+&NUE8RI3ILH^]I$*/$+C0RG\9R[(!8)TF8NOEY MX0>2^B?1R'^BTNWXM49;\R%.+]4223R4:-1#=5+P@.2GVB2AF<0V#$E!E&@D M1,\5C@=$09-PW,JLF=0Z+(E2:%1&+Q29!Y1%U89#C0_644IL0Z-4JM6CMU$2 MA>\W+YJDA,E_ML+DE F+%6 ;::RFIA>Z(4F*$H:7/$P[DPBN37HV3W1E;A2X MQ$DT4=2@30-*6)FJY>"(HDD4HT&JDF M74H:&V?M,U[XBZ2U2G!Q4YMVIH/)DZ15<]8+8Y%458E&5M6HITECY*ROT@NW MD918B4:*U:[W26/UG!7P(MU*).U6HA%OO:Q'B@#RKNJ?,_*B[DHD>5>BT7<] MKTD*$'0E8::<8GJ1="62IBO1B+JZ:9(")%^IHH*C<<4Z6/G/?6F:;JQ[I !) M6!HI*.I%$I9(FK!$(PIKUB,%:,.21#UA]Z(.2R1Y6*+1AQV? UDV2;E2A#TL MBQ>J)"G,DLCK29$K]=C#I/B@!!6I*GZO;D^J1(TJ,E&D%: M*-4O[Z1R)5![6" O3$L2O"4:Q=L+,]^M$*XSP*%[8FZ2N2_:ZM[YN"+=M/EY$>HFDTDLT,KT& M-X0%0YNX(2ZW-(I3_O.P&A4\]88XH[G+E5CO82&\T$1)_)?$/B7NB"N%W\-R M>*&'DF(PT4@&&]P$.P.1?&2I_/7@RTMMNPCF/5GAW9NB*VZN^HWZ@=_RU:H- MMC7:Z]D L=/>Z?OAP!??4]G<^7SU^35+1D^GPLS-U=/Q0-_5S0/9=7V3[#W MO*Z; MO[9NW_P/4$L#!!0 ( >PB5@6K[SE]@0 ' ? 9 >&PO=V]R:W-H M965TI#D]Z#)GHM[N2%$@<>4 M97+J;93:7OB^7&Y(BN49WY),WUEQD6*E3\7:EUM!<%($IZ(^KJ]%?K, MKU42FI),4IX!0593[Q)>Q&B8!Q1/_$W)7AX<@[PK"\[O\Y/K9.H%>8L((TN5 M2V#]]4#FA+%<2;?C6R7JU3GSP,/C9_4/1>=U9Q98DCEG_]!$;:;>V ,)6>$= M4Y_Y_@]2=:AHX)(S67R"??EL-/# #81? ]$_K16RP\*F$6T[C[-\M_]3@E] ME^HX-;O3 RG9,0+X"ESMI+XK);A_ *^WL7@W8_O M)[[2J7,!?UFEF9=IT)$T$($;GJF-!+]E"4G: KYN<]UP]-SP*V15C,GR# 3P M9X "%)H:=$)X>#P\/CT<67H3UC]#6.A%1_1,Z,&_'_4U<*U(*O\S-/&JE S- MDOF"<2&W>$FFGEX1)!$/Q)O]] .,@E]-N%R*Q8[$6B@'-J;H M50RL.4_VE#$3/:M*7WJEV* 0RY?:AQF$:!P$P<1_. 33?2Z$\/"Q5I>'=9>' MUB[_2;)[GA"1MH?/#4D71!B'CE6O;^==BL6.Q%H0+NM@IDH#%$U ; N8\W>+LR01RU)D;PT$T?#F%YM:\ M?1$Y$FLA&M>(QE9$GWA6 .),WUD#FBFBDRBPY:(8>/J-//\=?,0+V099#5(3 MPC+A\ #A(#SOK$)S:[OZ(G0DUD)X7B,\MX\R;5"H7OAP 6R+:6*B5;%'O(8&G#84_3EX4JM#>3 Y<+_ M,04\V2V5_X4L-QEG?/VDBQ:&\_FDYQW.UG3!B'%*5<*'M$8C RUK_MZT'*FU M::&&%K+2NL'BGJA\43H5$NI "DU#RIJV-R1':FU(C6.'5A<[^TN_S@1@%"\H MTT[A")A7.&%@+*^<^G-7:FUTC4.'=HO^A2O,0$84P%(2)77UK_V6>%D75@@' MG;$%(\-+S9ZS-R%':FU"C:&'=D=_:A%3R1R:IC$T+4]./;HKM3:H=>\;>'+N%@IGC6YA[U)A[9#?WIQ4] M=I&^:%"W9H"!B8VKM&TVC<]';^7S[<*]>76K!F1X+\>NLK9Q-48?.3;Z=KW> ME+IEP\@TIM["Z*/&Z".[T>_E5NU:O0&%ITZ[MS#TJ#'TR,U_[G:9WG1>H68J MKF)7S6K3:\P^LIO]#_11S[QR/EWO1>M%:TTP"1E8Z-#@;Z8:*&ULK59M;],P$/XK M5D!HD]CRWG:CC;1N(! ,II7!!\0'-[DVUAR[V$X+_YZSDX6NI-60^-+:E[O' MSW.V[SS>2'6O2P!#?E9-G>U&96-9&\X$W"BBZZJBZM<4N-Q,O-![,-RR96FLP<_& M*[J$&9B[U8W"F=^A%*P"H9D41,%BXEV$YY=GUM\Y?&&PT5MC8I7,I;RWDW?% MQ LL(>"0&XM \6\-E\"Y!4(:/UI,KUO2!FZ/']#?..VH94XU7$K^E16FG'@C MCQ2PH#4WMW+S%EH]J<7+)=?NEVQ:W\ C>:V-K-I@9% QT?S3GVT>M@+"P9Z MJ V(=@.2/0%Q&Q [H0TS)^N*&IJ-E=P09;T1S0Y<;EPTJF'"[N+,*/S*,,YD M,SP61[Y=0S4']1T=[F97Y.CY,7E.?*)+JD 3)G Q9O1+-.+X MB@.(Q@(_)Z#(2/61D&AU$ MO(+\E,3A2Q(%4=Q#Z/+IX=$!.G&W0;'#&^S!F]8:+5H_SNX'M)%W!BK]O2]G M#63<#VD+P[E>T1PF'MY\#6H-7O;B63@(7O7I_4]@C]0GG?KD$'IV"VL0->!! M$6#ZE#;AB0NW%6N=I:G-^WI;P=].21 FG=,C9FG'+#W(["-66"YQ7RCG,J=S MO$)&DEQ6%>Z/.^:EY'@M>L]T^A>ADS@8ACNT>[R20;R']Z#C/7@:;[S-#4^\ MHE@(6=Y'M,$:;5,(3M-DAVBOURCN)SKLB [_G6C!>&UVKWE#=?@DJKU>^ZB. M.JJC@U2_NF:!=9.NL40N@8C:%C];--N"A_U3&ZQP3"P/I;M9)MT^S8-A.$IV M#W2/7SI,1N&H7\=9I^/LO^HXL!MG3U32X]>KQ-]J<16HI>O\&N];+4Q3VSMK M][BX<#UUQS[%1T?S1O@#T[Q8KJE:,FQN'!8(&9P.D95J7@'-Q,B5:Z1S:; M MNV&)#R=0U@&_+Z0T#Q.[0/<4RWX#4$L#!!0 ( >PB5A+-XB]/@0 : M 9 >&PO=V]R:W-H965T%@YW3A4_I=B?4 M!3><[\D6[D%\WM\Q>>8VE"3-H> I+1"#S<*YQE>1[ZF \HXO*1QYYQBIIJPI M?5 GM\G"\52-((-8* 21'X^PA"Q3)%F/;S74:H&S15O)AFO/R/CM6]D\!!\8$+FM?!L@9Y6E2? MY'LMHA. )R\$^'6 ?V[ N X8/P]XJ4J3.F!2FJF:4GJ(B"#AG-$C8NIN25,' MIH[?H\WV$ M7OW\>NX*69P*^$9B!/$( M>?@-\CU_W%.AI3E\19@Q/#JC]'%ON-::<:-^7/*"%W@W!RZO<(ZZO\'7#_(: MNA60\[][JGA3(5XI2P%CFX+V4N_KB!? ^OM04;@T,;;A$668)K( MH!$9V!^,@4V5-F&1)9BF\J)1>6'LDZNTD%U1/*$]L%B.2KE]Z)-GA R55\%F MG='EC:;/1J"E C4GEXV32Z.3/Z%XH FP7.]?AF%JY W58Q,668)I'F>-QYG] M83JSJ=(F++($TU1BK]WZ>>;%@_ =VM=+ITPAFK63< ZB=^6LB=HR-@FFSU>[ MI;GDH9ILT71/G2TR/F=WP?NV%\#?H%AY!,**MS*QZK56\:<=:W@R'C=327.Q@299H MNJ0V!<#&;7'X!TWEV/LB>]=!=BK3>F W%K-(B6S1=8KOYQQ/[BP*VF@18 MI46V:+K/-J? YJ2BJ]&\AS.#!DNN.Z?*COMK=7[T96A&W3@J,,-C+4&UW( M[LNJUPW5B:#[\@'\F@I!\_)P!R0!IFZ0WV\H%:<354#STB?\!U!+ P04 M" 'L(E8*B&?GPT# -"0 &0 'AL+W=OQFO37!L+Q\YLIZ7??F>G MA(ZZ86]:._'=[W]G^RZ3M50ON@ PY+7D0D^#PICJ+ SUO("2ZE-9@< W"ZE* M:G"JEJ&N%-#<&94\3*(H#4O*1)!-W+.9RB:R-IP)F"FBZ[*D:G,.7*ZG01R\ M/;ACR\+8!V$VJ>@2[L$\5C.%L[#UDK,2A&92$ 6+:? S/CN/>]; K?C-8*UW MQL2&\BSEBYU[ 3F5E]30;*+DFBB[&KW9@0O56:,X)NRNW!N% M;QG:F>P>MSFO.1"Y(%>UJ1606R9869?D!C!:,J,;W 2CR?$E&,JX/B%'A GR M4,A:4Y'K26A0A_46SK?,\X:9'&!>POR4].)O)(F2'GF\OR3'1R?_N@DQC#:6 MI(TE<7[3 WZ=8*^>QJ[GM[,'_TQ7= [3 $^V!K6"(/OZ)4ZC'QVJ>JVJ7I?W M#(/L^S0U5GUG9>_.*DOZ@TFX\J#Z+:K_&6K@0S56@_]!#5K4X#-4ZD,-]E"] M*/:CTA:5?H8:^E#I/BH^$-6P10T_0XU\J.$^RFZJ#S5J4:-.U$,!6$47!I0/ M.-H##L>1'SAN@>-NH#24DUKD3,]E+0SD!&N[HH:))>'NKE?;N^Y3--X_0TER M0%(?J%/4#6A]1J[+JK9Z&*K""VB\)27:$_ ]20\)V"E_<:> F;WPPI 5 MY;4K@A]SPAE]9IR9C5=4O'>)X_%!4>]U+.XL2-F3ZR68$+I",4O ]F<;[+LH M3%/IU=/M=T@V0)4F?5)*80I-DC[)Z49W5+GXOPB5BM30O70P( -($ 9 M >&PO=V]R:W-H965TOFEII(B&A MK&(A4H%5J[1J"-;MLTDNB57'SFP'VG\_VPD9DRA?$I]][_D]G\_)0:H772$: M>*VYT'-2&=/,@D!G%=94CV2#PJX44M74V%"5@6X4TMR#:AY$83@-:LH$21,_ MMU9I(EO#F<"U MW6-55O"^3R,"=C],D8G).=E"\N>,SG)'2"D&-F' .UOSTND7-' M9&7\Z3G)L*4#GHZ/[ _>N_6RHQJ7DO]FN:GFY(Y C@5MN=G(PS?L_=PZODQR M[;]PZ'-# EFKC:Q[L%50,]']Z6M_#B> *'H'$/6 R.ON-O(J5]30-%'R ,IE M6S8W\%8]VHICPA5E:Y1=919GTJVM6PI+J"!ULS#8^B M*[X[Q0UR:C '(^$[VM/0<+U"0QG7-W %3,#/2K::BEPG@;'ZW"Y!UFM9=%JB M=[2,(WB2PE0:OHH<\_\) FMLV1I!\_C*?AEPNJ)H.JR27V M]$>#RE9)E)"YXA6^>(62-L1E7Z M;M*0R5:8[LH-LT/#WG?W]%]ZU^U/5)5,:*NGL-!P]/F6@.HZJ N,;/RMW4EC M>\ /*_OHH'()=KV0TAP#M\'PC*5_ 5!+ P04 " 'L(E8'M>W?D4" "* M!0 &0 'AL+W=ON*R0272C4SSY-9"361(]X TS=;+FJBM"D*3S8"2&Y!=>4%OC_U M:D(93F-[MA)IS%M5408K@61;UT3\FD/%NP2/\>'@GA:E,@=>&C>D@#6HAV8E MM.4-+#FM@4G*&1*P3?#M>+:(C+]U^$ZADT=[9)1L.'\TQJ<\P;Y)""K(E&$@ M>MG! JK*$.DT?O:<> AI@,?[ _L'JUUKV1 )"U[]H+DJ$_P6HQRVI*W4/>\^ M0J]G8O@R7DG[19WSG0089:U4O.[!.H.:,K>2?5^'(\!X>@80](#@.2 Z PA[ M0&B%NLRLK"51)(T%[Y PWIK-;&QM+%JKHYE3!E2@>6::7 M$V?HD P6=%7H.['Y"JV?R/"EHE#UDVR:V!@SIBNE1=F"L5\RWKSI[,)=]-P9#SKC0)P5R#4[R^9,?>U]L;O\3 MV8[WL/,>[F-/[N@&]Y &R6AA7@ MTS78J^L13_P)XR>5%#FZMDIK&**MM'[P1ED_)/+MPJ).6+17V#7C#,]81G(A M['L_ZN4<>,,WNOHQ?A3;A<6=L'BOL&X7'Y-<"ON,Q?VTH?]V-?M!D1?8M9UU MVL[V:ON&*SC:NE3:?4RP]!!X3G&4X$U"%!824HHUXSG>,&VPS;/830VPG M[]]Y=J9CV$W'<.]TW M-"YNO8>\@6=:G']1?'W>K#)@2_)W*G'%%"E@@RCL] MP^6535EK.EI4=668"XUUIFXN\4\ I G \840^K5CBDWW;Y'\ 5!+ P04 M" 'L(E8U)Q=VJ\$ L'@ &0 'AL+W=O[H/?W9"$P*I@9[S!O+@^7MF/#8_[,&*BQ]R :#0^+Z<+""F M\IPO(=%O9ES$5.E;,??E4@"=9D9QY),@Z/@Q98DW&F3/QF(TX*F*6 )C@60: MQU2\?(*(KX8>]EX??&;SA3(/_-%@2>=P#^IA.1;ZSB]4IBR&1#*>( &SH?<[ MOK@, V.0M?C*8"4WKI$)Y9'S'^;F9CKT N,11#!11H+JKR>XA"@R2MJ/GVM1 MK^C3&&Y>OZI?9\'K8!ZIA$L>?6-3M1AZ/0]-84;32'WFJS]A'5#;Z$UX)+-/ MM,K;=@,/35*I>+PVUA[$+,F_Z?,Z$1L&N/6& 5D;D$,-PK5!F 6:>Y:%=445 M'0T$7R%A6FLU$$VF MZ(^?*5OJ\5+HY H499$\11_1P_T5.OEPBCX@EJ O"YY*W58.?*5=,8+^9-WM MI[Q;\D:W5S Y1R$^0R0@88WYY>'FI&KNZP0462!%%DBFUWE#[S7R,S2.J ZY MFH#OM[HYNE$0R[_K0LVUPWIM,P\OY)).8.CIB29!/($W^O47W E^JPOZ"5@DL9I1!5,]_MPO>VU?=Q;7K/4 *U.6[ON(!;_?Z6G[N-N@37N]DIW.Q8 MW;RCDX5^)+97@^]W$#^"J)T(5L5C)X(CL4KPW2+X;H/K0==E&AR)5=+0*]+0 M<[H>]':G.ND%6[7:VZG5?C>LK]5^X6?_?]4J^A?=L83%:6PM7VLGQXZ;([%* M/G!0_JH'#1;P6MQ1)ERI55.Q 3C86AP/$F9IA&[9#-#)7T"%/*V-V:X2HA=C M6AN?U?*]\97H@JU(<%#QT^>]Q6_OY>@Q;P)C<,DQ.&RR_*V4='0J'*E54U&2 M$K:CTJ'E;U?!@:7^K:;O#;#$*6SGJ>M4)$RE K)1OF;/YEK::]VJ>/0 .U*K MQE]R&NXT6>M.FI_DVVV7C?:!)9VOYY7< E6V$Y6 M>XKV0&"Q=W+TX#E2JZ:D9#C<;[*.G<*;*[7J9D1);\2*1(>NV7M4+,ABMWQO M?"62$3M,'5#]!Q"+O9.C]UV:H#BRL0'5Z Z4VRVH)N"-E/!&[+M0AU:_7<5& M+';3]P98(AG9MWM%)2QX-$4WL?ZQ>@(SQG9BL2L>/B'V7[=!:MZMT+*7>!)&1DLB(6R(CNT36PMM$1G:)C)!>/9*1$LF( M'2*52//3)9:8TY"Y3LF>>>F4P%RI53-0$AAIDL"(4P)SI58]!RD)++2S MT]$G(<%.W8:][O9)R&ZC]O9!B+]QE&?.4>^HF+-$H@AFVB@X[^JJ%_G19'ZC M^#([W7OD2O$XNUP G8(P#?3[&>?J]<8<&!8'Q*/_ %!+ P04 " 'L(E8 MTE\]GW?W7?VW7"M]+TI$"T\ED*:45!86YV%HH.P9%P&Z=#OS70Z5+457.),@ZG+DNFG,0JU'@51L-FXXHC1<2="X& 7GT=FD[_R]PS>.:[.U!J=DKM2] M,[[DHZ#G$D*!F74,C'XKG* 0CHC2>&@Y@RZD VZO-^R77CMIF3.#$R6^\]P6 MH^!C #DN6"WLC5I_QE;/L>/+E##^"^O&]R0)(*N-564+I@Q*+IL_>VSKL 6( M!J\ XA80OP3T7P$D+2#Q0IO,O*PILRP=:K4&[;R)S2U\;3R:U'#I;O'6:CKE MA+/I3-.#T/8)F,SAXJ'F%5V1/81K>D#[4[2,"P/73&OFRGT '^#N=@K[>P>P M!US"UT+5AJ!F&%K*QG&&61MYW$2.7XD/X M3<8I9D>01(<0]^)D1T*3?X?';Z23=*5-/-_@+Z4]A)E@TCZO,/PXGQNKZ17_ MW%6ZACG9S>PZ^\Q4+,-10*UK4*\P2-^_BP:]3[MD_R>R9T7H=T7HO\5.1272 MC#/?L_A(P\?@+L$-2]^SN,FS2J.$+F&UK>-/G]/3SJ7)+MSJA!+UT@\( YFJ MI6T>4K?;S:!SWWHO]LPB5AV^\KYH@, M -D1 9 >&PO=V]R:W-H965T_:2A M6DZLH85"F)-UI&[YYBMD!?4,7L CF?RB31;K6"A82\7C+%DSB"E+_\ES)D0I M 7?W)+A9@ON_"5Z6X"6%ILR2LBZ)(OY8\ T2)EJCF8-$FR1;5T.9F<8[)?15 MJO.4?Z?[(EQ'@/@<7>@^> SYAIG!50A,T3DE,WWQBBG"%M01'U$$/=Y?HP\E'=((H0_=+OI:$A7)L*\W/W,4.,BX7*1=W#Y=+"$Z1AS\A MUW&]FO3I_Z>[U71;JY)+X^;2N E>?P_>%\JH@LZU;K.P1H%?USH>72F(Y>^Z M6E-PKQ[*1'45 MIFG=),T\+IY\S^V/[:O31U: JOHT,]UZ#?V0^5!10L=2*+#)[00 M7-8^C%+87J5]>UOM6Q.#Z]MWD-,=--(]#X)UO(Z(TK-&8BX4_4O,AE;'<+!S M]\YHN,6P)J:T""L4ASG%X=L6_'#G7JX[V.*S&].K9S/*V8P:V4R331!$YQ92 MU0Y;[XW@A_9Y2V 5';!3;-7.,5=\AMZ2%&VA5;4HV19\G%6?X98;%&_W<'-, ME7'A)G#C)NW?"Q("^DYB:&[89IB#I^D8S@$7U@%[1VW91F=RL!8MH56U*'P+ M;C8N;V_9[FX[8F^[9W>#]K5LX3!PX\;M?R/B$11EBS<^>YOA#YZ^8[@,7-@, MW#]J*S>ZF(.U: FMJD7A87![)@;7.)22B]JWL#'XC3XFRRN_E8Q& MVXQV8_"VD[%+[]WFHX=>+PO*)(I@KI.$2 M]+8@3("^/N="X$&74=AW' MMS-,F!4&Q;D[$08\5Y0PN!-(YEF&Q9]KH'P[L7K6\XE[LDJ5.6&'P1JO8 'J M<7TG],RN76*2 9.$,R0@F5C3WM5L;.J+@N\$MG)OC$PG2\Z?S.0VGEB. 0(* MD3(.6!\V, -*C9'&^%UY6O4MC7!__.S^N>A=][+$$F:<_B"Q2B?6R$(Q)#BG MZIYOOT+5S\#X19S*XA=MJUK'0E$N%<\JL2;(""N/>%?EL"?H]5\1N)7 ?:O MJP1>T6A)5K0UQPJ'@>!;)$RU=C.#(IM"K;LAS/R+"R7T5:)U*ESHQR+.*2"> MH!NIB X&8C1E+,<433,N%/F+B\!O=OK)D8#.YZ PH?("?42/BSDZ/[M 9X@P M])#R7&(6R\!6FLSXVU%%<5U2N*]0S"&Z1%[O W(=UVN1S]XN=U_*;9U''8I; MA^(6?OXK?E\XC[>$4J2[0;=,8;8B2YW15$I0$LV)C"B7N0#T<[J42NAG\5=; MT^5=O/:[F/5Y)=@C;M4#?:Y7?^ N]/Y1.Y!S3TX MQNVW<0\:W+YW@-UI?"*V7V/[Q["';=A^,^Y#[$[C$[&'-?;P&/:H#7O8P'8/ MJ#M]3Z0>U=2C3NJ'%/2VG2@0;>RC!OMAXIWN)[*/:_9Q-SM7F+9ACQLO%*^Q M,)LUKE.7E#CVWH9H/D:^8;$B3"(*B18YET,=C"@W^'*B^+K8(Y=PB5BVV]BN*@0 -L; 9 M >&PO=V]R:W-H965T6E M#^/#P8:+![D$4.0I39@<6DNE5A>V+6=+2*D\XRM@^LV]03*AC>#.>R.POV11M'8O,UE+QM!#K$:0QRS_I4[$0 M>P*O>T#@%0+O6$&K$+1>"/12U@O:A:!]K*!3"#HO!:T#@FXAZ&9KGR]6MM(^ M570T$'Q#A&FM:>8ALRM3ZP6.F=E9]TKHM['6J=$U4Y0MXFD"Y%)*4)*\]T'1 M.)'D3RH$-;Y_(!_)EWN?O'_W@;PC,2.?EWPM*8ODP%9Z#(9DSXK^KO+^O /] MN1ZYX4PM)0E8!%$58.O!ES/PGF=PY342?9B=D9;["_$;TSODUT M>W*M()7?ZYS/X:UZN F1%W)%9S"T= R4(![!&OW\D]MU?JUS#1/F8\("3%B( M!*O8W2[M;C?11\'32L=W;742SZ'.T&:Y1[9 A22N0]+\*^VU242W=5%AC(?R M&U&GFHD)"Y%@%3,[I9F=QB6\3+E0\0^:G=>@G66RUM.V _ M[GOUNHG;JC;Q&\=RJ@>8L! )5O&@6WK0;?3@?J4](#[,S>*3R61,OMU .@7Q MG?Q#/L-LR7C"%UMR!PDUWSM]A))Q=L:#*"MW<5>6\CHC&X=R:K3%A/F8L 3 M%B+!*INC5VZ.WEL>KCU,NS%A/B8LP(2%2+"*W?W2[GYC+-ASF&8.UYG:B#C5 M5$R8CPD+,&%A_]7IU.F4IU/%JO/2JO-&J\:_D0F=2O+IZUO&Z\8QG.HU)LS' MA 68L! )5MD5KK/[:>R\9<0NZ$B.H])\5%J 2@NQ:%77]Q(B[O\/W,V,D[W% MI/FHM*"@[<=;K]^K_AP(L;JL6N;M+/,:+?L#V ./0*1O&;^;QW"RY9@T'Y46 MH-)"+%IU;^Q26NZ;YK1 @ $@@ !D !X M;"]W;W)K&ULK59=;]HP%/TK5E9-K=0U(2&A[2!2 M"ZLV:=-0:;>':0\FN1"K3LQL!^B_W[43,CX"ZL->B#_N.3[GVKZFOQ+R164 MFJQS7JB!DVF]N'5=E6204W4E%E#@S$S(G&KLRKFK%A)H:D$Y=WW/B]R4_EZ#URL!D['V0P\LGFFS8 ;]Q=T#A/0SXNQQ)[; ML*0LAT(Q41 )LX%SU[D=]DR\#?C!8*6VVL0XF0KQ8CI?TH'C&4' (=&&@>)G M"4/@W!"AC#\UI],L:8#;[0W[@_6.7J94P5#PGRS5V<"Y=D@*,UIR_2A6GZ'V M$QJ^1'!E?\FJCO4;P8HQ:&1_;[/XGLAWS06,^.,4>3RBG$C?ZDDRA@!G3V#)Y8$6"1P$O'TE$ M;DX*-1>R+145?]?RFW*RC*-.WUUN&SP,":,F9$=VMY'=/2G[0=(BR9@"HND: MRX3=M#9U)VG:-+"-RKG>(_,L+F7B824Z38+X<'2 M?C?_+=K8IM7LMJQQ7A,$.4 M=]5#\[)Z@:J.%@M;Q*="XY-@FQD^VB!- ,[/A-";CGD7FK\!\5]02P,$% M @ ![")6 H-"^:( @ T04 !D !X;"]W;W)K&UL?51-;]LP#/TK@@<,&[#5CA.[6Y<8:-H.[:% T6#K8=A!L9E8J#YNL<"K$*1DG"9)'BLN=%1,P]Z=+::F12DTW%GF6J6X?9F#--M9-(KV M&_=B7:/?B(MIP]>P /S1W%FRXAZE$@JT$T8S"ZM9=#XZF^?>/SC\%+!U!VOF ME2R->?3&336+$D\())3H$3C]-G !4GH@HO&TPXSZE#[P<+U'_QZTDY8E=W!A MY(.HL)Y%7R)6P8JW$N_-]AIV>C*/5QKIPI=M.]]3DN( V\NT2!Y25'7DRMV3+KO0G-+X+4$$WDA/:7LD!+IX+BL%C0 M+5>M!&96[!XZ@NI?@)BT](+2O:!Y>A3Q$LH3 M-AY]8FF2CIFKN05W!';6H$O[-?YTJ&EI_1[2&L',1Z&\.UU MYAI>PBRB_@FECHKW[T9Y\NT(P4E/<'(,O5AXI9_] ZU8:10UK>MNIY%<#Y'M MX+( YUMW4V1YDF?)--X,T,AZ&ME1&@_<6J[1,32L:6U9$R'/Q[\GY]_3$)7L M%97Q9))^32;#7/*>2WZ4"[UGM*)$JDA(S5HMT T1R%\1R"=9GOZ7/CYH,P5V M'8:)(W6MQJ[C^MU^7IUW;?K7O1MVM]RNA79,PHI"DY-3RFV[ =(9:)K0M$N# M- +"LJ:9"]8[T/G*&-P;/D$_Q8L_4$L#!!0 ( >PB5C\]!7_DP0 %@6 M 9 >&PO=V]R:W-H965T!@@\7B'=*M6[1Y>5'MAD@-$36)F.]!^^]E.&@B$ %VD]45);)^_ MCW]VCNW3VU'VRM< KU%8&B/ [NH%8UBPIBXB0KVQE\@T# MXFNC*#1MRW+-B 2Q,>CILDQ]!2'=] QL?!4_!:BU4 M@3GH;<@*GD'\L7ED\LW,5?P@@I@'-$8,EGUCB+LS["H#W>+/ ';\X!FIH2PH M?54O<[]O6,HC",$32H+(GRV,(0R5DO3CGTS4R/M4AH?/'^HS/7@YF 7A,*;A M7X$OUGVC;2 ?EB0)Q1/=_0;9@)I*SZ,AU__1+FMK&:V!FQGHR3136)KTA @R MZ#&Z0TRUEFKJ04^7MI: @UBMK&?!9&T@[<3@62Y5/PD!T26:Q^E*U3.^D,M0 MEG@0JZE'CR&)T<\3$"0(^2_H*^)KPH#W3"&=4%*FEW4X3CNTSW2(;71/8['F M:!K[X!<%3.E]/@3[8PACNU)Q MX=4)D\"BCF*HUM9K:^+:#=@LW[$[/W!XTFU1W^H++9FA::70K MU%-'F])1)_>S0,O-:;G7T%* CJ.?-A]5FY>/>^R>N.HV.FW'*3*=5FK?BJ5VI^$ MU0"![X@!Z6Z/;MU"ZA2;U216((NM_3'4^I\W M[\R!FM#7JC:K2ZT(_^ .@.OCK$FMB')_=\+5EZ=K#@47),[1=*ZC6>M= MJBZU(LW];0I77AIN.QJ,+HB=X_J)>TMY2*CU-E676I&\ND\52_9W!GSQU#^/ MO3#Q@?^ Y%^0YV6XH-XKHANU5W)$8A])CP0+/'5"22N3.! <^0'W$JZVS85* M)][)&2E(IOD<>FIU[9%-1./<(*NL8&J\#6*JOT$NT MBP_+9> !^X*&/HG0=]B^WY5A,@^26!&PE4XW"R\KM[J2L_1 WN],T]7A2X\J:--&V=RG-N=X3M@HD\A"6TCWKKB6# TO3 MF.F+H!N==EM0(6BD']= ?&"J@:Q?4BH^7E0'>3)Y\"]02P,$% @ ![") M6$39)B!*!0 @QL !D !X;"]W;W)K&ULM5E= M;]LV%/TKA#8,&]!$(O6=.082J\,"K%O08.M#T0=:HFVA^G I.H[__4A)EBR9 MHFW5?4DD^M[#>P\OR4-QLLWIUV)%" -O:9(5]]J*L?6=KA?ABJ2XN,W7).._ M+'*:8L9?Z5(OUI3@J'1*$QT9AJ.G.,ZTZ:1L>Z;32;YA29R19PJ*39IBNGLD M2;Z]UZ"V;_@8+U=,-.C3R1HOR0MA_ZZ?*7_3&Y0H3DE6Q'D&*%G<:P_P+D!( M.)06_\5D6QP\ Y'*/,^_BI>GZ%XS1$0D(2$3$)C_>R4SDB0"BS!P79)8GG^*(K>XU3P,16>!-PC[FVS])G9 M\,(\*#JA^1908XOC/)?8^['IB^\D*)-0D"^ $]92#(Q M#."%Y>%7\,^Z')H',30QVX%? \)PG!2_@1OP_MM&--4FGS^0=$[H%_X#,J / MGA/<:?P9Z*!884J*B!]%I&H"Z#S=)N< MT3[G1Z1$#$AX"TSXCL>*3$E L_/=D<0].-\=*K(QFQ$T2SQG: 0%KS>/O/8C M,,M3OB 4N!HW2G&V)'R2,C#?@4.[9[PKFQ^VF$;@\U\<$CPQDA9?9.-3]6_* M^Q<+TUVQQB&YU_C*4Q#Z2K3I+S]!Q_A=QNTUP8(K@75XMQK>+17Z].^-J&XQ M;_)R$A3O %]7"X:S*,Z6[\"<+.,LXX]\7>+3(20R:JLN[+(+L42_3FUD^:8[ MT5\/23LVLTQNYG?- F7 (^FP&SIL)1V?RA66UQ9^)93O&("\$1K&!0%K&H>D M0\YYW%3]0>,@:W1KVM""3H\>B26\=5S/M^T>0\H<1C+D- PYES%$B=B8!0LA M7^ HWP(W. &,T%1&AQK"4$)4H=,MR'3O73V+?ERQ_H;1,6=>S1_('1M$_7J2&+FVX9A](I(&=G( M(O*:O+WOFV8*%BID"#L3RG ,"_9XJ W1@:%Y:UH.M$VOQX4RVI%<^ T7_K4F ME)(7=2_0J*I8-I%&>P9*SY&\0:,5?<:ELV=?1U*&:KC#F7%C(K^WNL[4OY0BU7Z-)2XJ?1!8D' M)IL:[OR\9]<""L8 G2:PE>]0J5)/%YN:SA$26$[GE8"",4"GZ6Q5.;Q8EH=" M82;) (''VOK&\3W;ZL]7B1WDVL#H;9Z!.KZQ^;S(972OF-[XJ3< M)<0^EA/PUNJS\2,4-VPE-U0K4.E&MX[I0/;.\1A[CFOT,Y>8V9)"4(8V-O56 M($.U0CYC$QLFPI65@6N8"/4U\][T1!G\",T,6]$,U:KYU%F=U,?2X<-HW4'G MI.X8CGU4&Q([R8D^D-CUCO3=5%M-#"\4Q:IS^!EY^_)3N.%:1Y4P8'I\8 ]D MID/QE;=\:7?KJZ%UJ6IU;CH.AIWD#0H M&T(/^9[7WSK5D5S,VX_0NZC5NTBM=R\Z=)[B4-W5_IN.O?]\X@U^T5$C74SQ M516Q?G [D1*Z+&]Y"L[6)F/51_NFM;E)>BCO3WKMC_ NJ.Z#6ICJ>NH#ILLX M*T!"%AS2X*[]#>,WXLE@$0/-$G%P%E*F9V[ MKI@M@6+18!FDZLF<<8JE&O*%*S(..#8@FKB!YX4NQ21UHKZ9N^)1GZUD0E*X MXDBL*,5\.X*$;0:.[SQ.7)/%4NH)-^IG> $W(']E5UR-W)(E)A1205B*.,P' MSM _'_L=#3 K;@ELQ-X]TE*FC-WKP64\<#SM$20PDYH"J\L:QI DFDGY\;<@ M=4J;&KA__\C^W8A78J98P)@EOTDLEP.GZZ 8YGB5R&NV^0&%H+;FF[%$F%^T MR==V>@Z:K81DM K#RA)\RM^* *Q!U!"JP%! 0B. :UG ,T"T#1"<\^,K LL M<=3G;(.X7JW8](V)C4$K-235?^.-Y.HI43@9W:A]$:\20&R.AD+]F9F.KD K M 3$B*;I98@YG.E Q&C.J=H_ )OZ?+D!BDHC/?5&!QIUD&M6GX MPN>":H(V>AJT(>FNGA!O,8W?U4E.A2 A5_J@*6"TG+.6$5CD79$UB2&.T)9#$52IR?&_?;FDR=\VVXL"I M3NE4Q^K4MX=,I7UU2E2 :95/5OBID;7[TD9;P%Q8]GZW5-6U,DU(2NB*HKL) MT"GPRH-N93A56$UD!V)[I=C>.^?$7IVAJHGL(%2^MWLI>V_(B@7X*).U.V'K MZ!S:K;Q6Q5YIX=>5&0NF)]DL\(\E64V^5E*PDQ2\+1&]@*],'H4R*_*URG8E MBV]]S4<3_/!B,K)3G'K$ZF([%+PK//S6.RD_-;4PUTJ&)7W/CVZN:4E!16IZ16<"S):O*UDG:ED?_&VN@%?)&2 M4(BH:GB!9JQ52KSGJ^<+;\4#$U_?#0_TE\03!N\ MH\D_/TPP7Q#5QB8P5Y1>HZ.V'<\[^GP@66::XBF3JL4VMTO ,7"]0#V?,R8? M!]I ^5TE^@=02P,$% @ ![")6,"N^[DK! *A( !D !X;"]W;W)K M&ULQ5AM;^(X$/XK5NYTVI.V)$Y(@!X@%7HO*VU7 M55%O/ZSN@TD&B)K$G&V@_?=G.VE(2.(M/73WA=AFWIX9CV?L\8&R)[X!$.@Y M33(^L39";*]MFX<;2 GOT2UD\I\592D1*05/\&<.!5\9(05E2^J0FGZ*)Y2B+((%0*!%$ M?O8PAR11DJ0=?Q="K5*G8JR.7Z7_IL%+,$O"84Z3KW$D-A-K:*$(5F27B =Z M^ ,*0+Z2%]*$ZU]T*&@="X4[+FA:,$L+TCC+O^2Y<$2% 0<=#&[!X)XR]#L8 MO(+!TT!SRS2L6R+(=,SH 3%%+:6I@?:-YI9HXDR%<2&8_#>6?&*ZD/LBVB6 MZ H] !LUAP]#LCF5K[< N"Q G_&5VA'Y&-^(8PX&-;2#.4 M,#LL5,YRE6Z'2NRB.YJ)#4>_9A%$=0&VM+\$X;Z"F+E&B;<0]I"'/R+7<;T6 M@^9O9W<-YGBE3STM+^CRJ7+,U4QNK@C-:2HSCA.]9V^8=.4:9!8(M'Q!5;I[ M\J*7;PZ$1>C;9RD2?1*0\K_:')SK]]KUJ\R_YEL2PL22J9'+5Y8-!(A)'3]]R3'# J/S\'AB6JH1'55UU958++U):= EJK M^H(B(@"M2,S0GB0[>#O87-NP A;W^MX)5J-)YV,=E5A'YQUOZ[R6MN$8-8+F M#1QO< *D234*,.Z75#4SL7/L IP+!,5H?Z&A'@C//[&_E2K '?97NAC\W]61 M0E>MD/@.]D]CT4H7#-T.,.X1C'N18/PKC+D)&-<",0A\]_28*"BK$>OWNC;< ML47"QK:B&3!Y(UE!W+6WO);2[@[\T[)N5GI^GN-C'X/-C\'F]L54D$!_6E'YC> %?3]HP&J2U:M6W>ACOX&--?H]]<: )7A3 MA-JH*C6ICN38#N#S^H$B_\DR@59;FVT ]EIRYAU]P'=;''SL!O!%VH'O86WK M IIQ>4<;T W5KMRZ4V!K_1C!Y=&[RT1^=RU7RP>/&WW-/UF?J8<0?9L_BLE? M4>X(DYT/1PFLI$BG-Y#!9/G#1#X1=*OO]DLJ!$WU< ,D J8(Y/\K2L7K1"DH MGX>F_P!02P,$% @ ![")6'-EZI2J! /1L !D !X;"]W;W)K&ULM9E1;ZLV%,>_BL6F:9-N P9"DBZ)U)1=;0]WJFZU M]6':@P,G"2K@S'::]MO/!@))"DZ@]"4!XO,_]L_VX9QXNJ?LF6\ !'I-XI3/ MC(T0VUO3Y,$&$L('= NI_&5%64*$O&5KDV\9D# S2F+3MBS/3$B4&O-I]NR! MS:=T)^(HA0>&^"Y)"'M;0$SW,P,;AP??H_5&J ?F?+HE:W@$\=?V@#F8)>%P3^.G*!2;F3$V4 @KLHO%=[K_ M'8H!#95>0&.>?:)]WM9S#!3LN*!)82Q[D$1I_DU>"Q!'!K;78& 7!O:YP;#! MP"D,G&L-W,+ S%ID7NR&SQA&WVCJ=AP]%L:0G@J8,INEWVW#WU?V%I%'X(!Q$Z9N MR=35J<__W"5+8&IM[XOE_ 7)X,<%2<,H7:,EK*,TS:Y(3-( ZM#F+H:9"Q5& M7^:.YXSPQ)J:+\?4KFSG:[O<$0%F(SK"%Z!!1$'M&51 M !WHY/XP/AKV<( ]>XS/\%S;T->.H",?K^3CM>/#0+T\%8- !B^U_78D1@)8 M4@=#+VZC-R",(VRA)(^$V$$A>:L+IO=Z*:>0&AV4;+=)R==*>%2C= )S M5,(%JQ^GE'=>1ZTO$[Z%QLE>$!9"V_R+HC?8&LRDFFT=1[OM9Y;\.F@ZY=D('*U.*X@:#S/KZ-W:'GO0]O M>M=M&'U&!8"K$@#K:X"+2TX/S*T)<./).:L..7T]J\\H#G!5'6!]>5#_NMQ& MK %.AU2]?C_V).1W$;K,KZH><,ORX?W+M!FF5KH-S)Z$_"Y"EV%6U0-N7SX< MEZ=05*G-M6GAX*0D=UU[8KGG^[>F86WM?D7#T]%6"3_^8,;?=$G2SC^B&^S]4;9K>G#+N \!GYNEWEZW8_ M^7H3M4+^FH6A[TE;;GVIG7*KPB5B?2L3Q%A0 &15 0 9 >&PO=V]R:W-H965T/!*.DZUY\0LR-FH)MX3G.^5/+3:/Y["SH M= 9G\_%T<7+Q;O/8Y]7%N^5=/ILNLL\K;WTWGX]7/W_)9LO[]R?^R>,#OTVO M;_+R@;.+=[?CZ^Q+EO]^^WE5_';VI%Q.Y]EB/5TNO%5V]?[D@__6C(9E@\TK M_C;-[M=;/WOE6_FZ7'XK?U&7[T\ZY1)ELVR2E\2X^-_W[&,VFY52L1S_J-"3 MIS[+AML_/^IR\^:+-_-UO,X^+F?_.[W,;]Z?C$Z\R^QJ?#?+?UO>QUGUAOJE M-UG.UIO_>O?5:SLGWN1NG2_G5>-B">;3Q:7!>-3C? M;=!][H/K/'YRG6,7RG_ZL/<^[6=[>?RX_;W/^]DFCQ^XO_>)/]OD\2/W-Y_Y MV<.?[^9O/QSGXXMWJ^6]MRI?7WCE#YL"VK0O_N2GB[+6O^2KXMEIT2Z_^'(S M7F5_+:OETONXG!=#R'J\*<(_AUD^GL[6GAFO5N.R(/_B_=7[_4OH_?E/?WEW MEA=]E\+9I.I'/?03/-./'WAZN/2_Y+X!0_W%V? M>O[PC1=T@F[# GUT-]?CU:D7=)]M'A[1O#-ZMKEP-_]UO"B:/]^[=#?_-,F+ MYOZF>=#0/#IBU3F:Q\U'MZZ(/[^=C:;VBM M#[>N/K:FUN9PZV"P:=UQ5$#WJ7:[&V[@K-U?]FOW0U&QB^NLV"3GWM>?WO;K M/H]_;A[^<#]>77I_I 7IJ3R;K__>\'9^>>B_V]Q_N1OR=GT[GF3O3XK]C'6V M^IZ=7/S7?_J#SG\WU2.)A20F2$R26$1B,8DI$DM(+"4Q36(&PJS!HOGTW7DRRI@' :;8= $@L)#%!8I+$(A*+ M24P]8/T-5AY1?K\(^IW-OW=GW[>+^]@7IN3B:1(S$&85;O^IK MZ20OJO6A>+\7#TP7UV^\=;E=7S>5K5-L6[8D%I*8(#%)8A&)Q22F^GO5..CU M!\%.S9)=IB2F2Z'CCK^O?%*ILLKQ?3_RLKNRQE[^$P?+*]*Y_] M*']NW#8[^;9%3F(AB0D2DR06D5A,8NH!ZVT7^6A_PTQVF9*8)C$#85:1#Y^* M?.@L\B^;+79#78\7E^5>>..6O:G8G=VT+782"TE,D)@DL8C$8A)3P_W]:W^X M7^W#O3$A.-\?%%)RT32)&0BSZGCT5,ZYLW;#:;&CG2]7WA\ZFW_-5HTSW4ZB;7F26$AB M@L0DB44D%I.8(K&$Q%(2TR1F(,RJ=[]3G]/NO/*)L6H!H/$"U4)4$Z@F42U" MM1C5%*HEJ):BFD8U0VGVT+$5A_&=.POFKMQ%*/?OE[?ED+%^XUV7^_2[D95J M&/#WCKW.]T]L?'3WV;J^24V@FD2U"-5B5%.HEJ!:BFH:U0REV?4=U/4=..M; M_,A6D^DZ\VY7TTFV5>>-Y?U@C;;G3$X[_=WJ=O;8NKI)3:":1+4(U6)44ZB6 MH%J*:AK5#*79U5T'XGQGA.;B8>>]FD;W5F7.N]B WQ8E7^S:CZ\;3Z-5Y/GV M],MIL%?D9! H1#6!:A+5(E2+44VA6H)J*:II5#.49A=Y'63S#R39;J;9E5=L MR"=W92S=^W1U56S*Z^D][Y_>5F;FX0R<:^K/W5WK8WDTY89J M4DJD6H%J.: M0K4$U5)4TZAF*,T>*.K@G-]_[6E -&B':B&J"523J!:A6HQJ"M425$M13:.: MH31[Z*BS>;X[G%=/ ]XMIOF!24 TB(=J(:J)2MN>[NP..]VA?:PDT4XC5(L; MWH+O=P<]^RTHM-,$U5)4TZAF*,TNVSIMY[OC=K^]("OO)EN7+YJM0S7A[R?% M&LL7S\6*IJ/0[6XX1WT3O?*E.PR0;44U32J&4JSR[3.T_GN0%TU MX;;>A-C%_':V_)EEZY?/OZ'9.U0+44V@FD2U"-5B5%.HEJ!:BFH:U0REV==G MJ6-XP6O'\ (TAH=J(:H)5).H%J%:C&H*U1)42U%-HYJA-'OHJ&-XP;$QO,/S M;VZJ]2" 9O503:":1+4HV(]"CGK#_DX4,D8[5:B6H%J*:AK5#*79U5V'\ )W M".\ETW1NLG65HYD]5!.H)E$MJK2#58Z&\5 M0;44U32J&4JSJ[P.XP7.'-"A MV3QWZ]8%36HAJ@E4DZ@659H]TS@*=NN9[%.A6H)J*:II5#.49M=SG;L+W+F[ MH..?>Y]GXX5S-L^-M"YK-$V':@+5)*I%J!:CFD*U!-525-.H9BC-+O\Z31>\ M=IHN0--TJ!:BFD UB6H1JL6HIE M0;44U32J&4JSAXXZ31>XTW0ON_:L&VT] M'*"Y.E03J"91+4*U&-54L!_F&PW]7G!N'[[\>N#/\P^_:7.4H,N:HII&-=.P M'OO%>NP^K4:[[NLX7N".X[VP[M% 'JJ%J"903:):A&HQJBE42U M#?83BOV& M,4FCO9IG>GVN@NM$7N!.Y+6['(8;:UVY:$ /U02J252+4"U&-55IUL4J []_ M/MC=8KO_+)_;8J,)0%33#>^\-RIJ="?4::A>[8*OLWV!.]OWPDTV&N%#M1#5 M!*I)5(M0+48UA6H)JJ6HIBOM<*'_.\)YW3J"X^7%Y.RRWZ>%9>F/H% M->_VV]9\I5G?36FX1TB(]BI03:):A&HQJBE42U M136-:H;2[)JO4W5==ZIN M,S6_;B[Q-]ZXG*1OWK%WNZUK_4';OIQQT[1-B/8J4$VB6H1J,:HI5$M0+44U MC6J&TNQ:KS-V77?&SEWK6749O.9J1Z-VE6;=C*1S/A@-=ZL=#=&AFD2U"-5B M5%.HEJ!:BFH:U0REV=6^=2=89_:G(9OC_=,3_[B;YC^]3YN9.V=HQZVWKGA2 M"U%-H)I$M0C58E13J):@6HIJ&M4,I=GC0IW9Z_9>.;331?-^J!:BFD UB6H1 MJL6HIE M0;44U32J&4JSAXXZ[]=UWW>V/O7W\*4Z@F4$VB M6H1J,:JI[OY]9WU_V._NWGBVZ77G_?U;7:%+IU'-4)I=N'7:KNN.,[6ZQ+W; M:EVY:,@.U02J252+4"U&-55IY7T;\JV[( PZ/7^W=JM7!MLG<4Z[O8'?[XYV MZQ>-PZ&:H32[?NO47->=FMNYUV1CU:(1.50+44V@FD2U"-5B5%/=IMN][F]' MDX;7^4'#K271I=.H9BC-KMCD-S=*@6HII M-8EJ$:K%J*90+4&U%-4TJAE*LX>*.EW7/7_MZ3@TB8=J(:H)5).H%J%:C&H* MU1)42U%-HYJA-&OHZ-5YO9X[K_9G9N$]O[NADK M)MMC2O:C_+GQ^,'=5]M1 M5"5!.H)E$M0K48U=2!O\;NP)LO%_E-TYQ2@BY) MBFH:U0REV6-"G>?KN?-\+8\\IHN#1Q[N#EL/#.BU]%!-H)I$M0C58E13J):@ M6HIJ&M4,I=E#11T'[ 6O?.310U.#J!:BFD UB6H1JL6HIE M0;44U32J&4JS MAXXZ6]AS9I3@(P\R7?41U4)4$Z@F42U"M1C5U(&_1G_D.O(@ER1%-8UJAM+L M,:'.%?;:7@NP//)X]I:\C2,!&AQ$M1#5!*I)5(M0+48UA6H)JJ6HIE'-4)H] M-M3!P=YK7RBPA\8-42U$-8%J$M4B5(M13:%:@FHIJFE4,Y1F#QUU=+%W[&UW M#V>.W53K0:#AOK"]8+1S79H0[52@FD2U"-5B5%.HEJ!:BFH:U0REV=5=!QM[ M[F!CXT'#Q^)@;C6>Y,L#1PMHXA'50E03J"91+4*U&-44JB6HEJ*:1C5#:?:@ M4*Z/7/EI TY2H%J*:0#6):A&JQ:BF4"U!M135-*H92K.'CCI-V7-?J[#= MQ4G=6.MA $U&]O:O&=?PY3B!=BI1+4*U&-44JB6HEJ*:1C5#:59]]^O(8]\= M,FOU14:WU;:\42VL-.O+.#NEC78H42U"M1C5%*HEJ):BFD8U0VEV:=?)Q?X1 M5R+\5_;ZWU0[_W][N'.H]Q!2:!P8T$@CJH4'UI(?/'^N6Z!+(E$M0K48U12J M):B6HII&-4-I]HA1!QC[[NL9-DX>AJM3DTUGWL>;HD?KF2K^_&F1.:<5W9VV M'AS0T"*J"523J!:A6HQJ"M425$M13:.:H31[N*A#B_WN*T\K]LD\UT=4"U%- MH)I$M0C58E13J):@6HIJ&M4,I=E#1YUM[+NSC>VF%=U8ZV$ C3&BFD U66G; M4YZ#_>N31&BG,:HI5$M0+44UC6J&TNSZKO.)??>%#=M-*Z)10U0+44V@FJPT MQY1GA'88HYI"M0354E33J&8HS2[M.C_8/S8_^+3I_IZMG]MRHP%"5 M13:": M[#=$)9NVW&B $-44JB6HEJ*:1C5#:79YUP'"OCM V%#>Y5<-)T6!>_ER4^J- MA8YF!U$M1#6!:K+?<%/9_5NR16BG,:HI5$M0+44UC6J&TNQ"KT.!??-WR9V,ZTK&XWVH9I -7E@]8?9Y-3K^F\\+^@$W<9I-S3-AVH* MU1)42U%-HYJA-+OFZS1?WYWF>]D)OO^Y7[I/\*&I/U0+44V@FD2U"-5B5%.H MEJ!:BFH:U0RE6WK4:%@0U02JR4H;;6>(3ON[Q8U&!5%-H5J":BFJ:50SE&87 M=QT5'+BC@J(,#CWLZ=\^>VD M]&ZJ-%@(*H)5),'UKWKYF 1NB0QJBE42U M M136-:H;2[%JOTX*#%]R .5R=IMER41[!FVRV7K[DZ@#N?EN/#VB\$-4$JDE4 MBU M1C6%:@FJI:BF4U^:7BWNM%H(*HI5$M0 M+44UC6J&TNSJKJ.!0V>2Z*47!W"KK>NAW!&[HC>,B9O>)1/?XQG=_-G2?[W(O2>L1 WRH)E!- MHEJ$:C&J*51+4"U%-8UJAM+L0:3.^0T'KWRR;XB& U$M1#6!:A+5(E2+44VA M6H)J*:II5#.49@\==8IP"*0(W4;KZD=3A*@F4$T>6/?^R)$B1);^;C':98QJ"M425$M13:.:H32[N.LC0]06/F!5T M&ZV+</HII -7E@W;L"".B"Q*BF4"U!M135-*H92K-+O0X5CIQ9)F92\,@ M@GM16H\8I!:BFD UB6H1JL6HIE M0;44U32J&4JS!Y$ZL#AZ[6L0CM"T(ZJ% MJ"903:):A&HQJBE42U M136-:H;2[*&C#D".#MVK^)A##32YB&HAJ@E4DP?6 MO?,R1NB2Q*BF4"U!M135-*H92K-KON/%I5+O)P]WWJTZ.:J6&[_ M[8?@Y&SO<>6_3?RFQX.WOS:]_L-H\-84*ZCIF6'QS+!\YJQ>I(MWM^/K3(]7 MU]/B7<^RJV+Q.J=EO'0UO;YY^B5?WKX_\4^\K\L\7\XW/]YDX\ML5;Z@>/YJ MN_SVB:'9"ODFRH! M-'FO>*WF7JEU,_-]E950474K&JAQIA"RHAJ[>9)J(5G-6PY,DJJTJ*O_< Q?;N3?P]@//;%UJ,^"G24/7L 3]VCQ)[/F] M2\XJJ!43-9%0S+V[P>Q^:M;;!=\9;-5!FYB=K(1X,YW'?.X%)A!PR+1QH/C8 MP -P;HPPQN^=I].>UE1!0^"_V"Y+N?>Q",Y%+3E^EELO\)N M/Y'QRP17]I=LN[71R"-9J[2H=F),4+&Z>]+WW3D<",+PA"#<"4*;NP/9E NJ M:9I(L272K$8WT[!;M6H,QVIS*4LM<9:A3J=+O.6\Y4!$01:PTN2Q5EJV>.Q: MD>L%:,JXNB%7A-7DI12MHG6N$E\CVACXV0YSWV'"$Y@%9+=D./A$PB 0[>7>?UG MJJ$9S#U\OQ7(#7CIQP^#./A\)NFP3SH\YY[BQD>N3)UJ9%7F'[1))T'B;QRD M44\:72)%+E*GB@Y)4S*%IX#3'C@]#Q2:O0.1M/A M?RS_H,:8%0H"JX'6-4V97 KJ-%8\O.2F@L8K99XE<#I%F \X40 M>M\QE:S_#J5_ 5!+ P04 " 'L(E8=UG(T8 % !B*@ &0 'AL+W=O M? MY8HQA;ZF228GSDJI]97KRFC%4BHO^)IE^IL%%RE5>E,L7;D6C,Z+H#1QL><- MW)3&F3,=%_L>Q73,-RJ),_8HD-RD*17[&Y;PW<3QG><=[^/E2N4[W.EX39?L MB:F/ZT>AM]R:,H]3ELF89TBPQ<2Y]J\('N8!Q1%_Q&PG#SZC_%1FG'_.-^[F M$\?+1\02%JD<0?6_+;ME29*3]#B^5%"GSID''GY^IO]2G+P^F1F5[)8G?\9S MM9HX(P?-V8)N$O6>[WYCU0GUOWJ#7J%X@Q]6/&-I-ECQ\^AOL)7X0,4%\H.?$/9PKV5 M^?"]PB/BFBO[73LT2&+ M+E#@%^%!2SAY>3BV:!'4E0P*WN $[VG%A7K[@8D4A6RFT*=[?0"Z4RR5?[6, M[J:D!>VTO#]=R36-V,31#4@RL67.],G5)>C;Z M]%'$612O:8+T#:-[8B0V;*YO(L5T+M56%"NO:U$@86$)ZQ6P?/;93O%P.':W MAUJW'#,*ZF,,"?NUA'VKA+>_HGLZTPW)Z%.?'E@Z8Z+UNK;RNDH("0LA800( M9A1E4!=E -IJ!I E@82%D# "!#-*,JQ+,K3>)^7]L2[OC[8:6,.[U@ 2%I:P M_F'7"/RCS@*4T)!V5$L[^@\M"/V#GC8SR;YL6*80V>9_;>W)FJMK'2!A(22, M ,&,@EW6!;L$;4^7D"6!A(60, ($,TKB>XW/\*QWT?52,*8=II)(/_ZD;?;A MY@RBC_:,BK;(6WMD5]E!:02*9@I_8/!\JVIWU>,FTH:N=6:HXB\/&K!WX8W, M#GQKS])984@:@:*9"N-&86Q5N&@R<2:5V.07.%HS$?-Y'.73<;ZC573\S;-R M[UAQ:];.BD/2"!3-5+RQNK[5MIV8DG_/[,[ #NW:Z$%I(2B-0-',\C2VU^^! M3L ^J.T%I86@- )%,PO3F&G?[J;/N@1[?.=*@-KGBF88A1X^,@I0*4V!&V/L M6TW>]'J^I5G$GCL_X@NT%CR-I>1BCS)^8@8&-_YV:"K2;,G[%P04+L,2B-0-+-TC;7V1[ S!:A]!J6%H#0"13,+TUAH MWVH'7V;7[ B;70-UR: T D4S7V@U/AG;3>Y9NU;%G[%K]BQ=%0:E$2B:J7!C MB+'=$'^/7:N0A[-@_UAQ4(,,2B-0-%/QQB!CNT$F$<_T0U"$[K*_-_HY*(PE ME?HR1_><9M:)V [NVN]!:2$HC4#1S!(UCAK#OCW&H%X:E!:"T@@4S2Q,XZ6Q M_1WR^?D U#Q7-#\PIY=@>-3N0M"T!(IFBMSX8FSWQ=\U)8!:Y8IV.,'X>.@= MBP[Z"AF*9HK>>&5L]\HW7.B8.%NBB.HTL=JWR@SJC2N:\1O"P.M[WP@-^F(8 MBF8*W?AC;/?'Q2Q+RU\F6B4&=;L5S?C!X%A=4 L+12O5=0_6TJ5,+(M%C!)% M?).I*'E=+ \\VA_Z5Z1<[MA@RM67#U0L=;-!"5MHI'C*!S.N%$^+CRM&YTSD!^CO%YRKYXT\0;VL=/HO4$L#!!0 ( >P MB5AHX)+,OP4 &,Q 9 >&PO=V]R:W-H965T0TAN*.H>>/W+Q36XI5>@ICA*YZ&V5VIWW^S+8TIC(4[ZC MB3ZRX2(F2F^*^[[<"4K"7!1'?6LPF/1CPI+>!S MWQID@OR,/QA]E'O?4=:5->??LHWK<-$;9"VB$0U4AB#ZXX%>T2C*2+H=?Y?0 M7A4S$^Y_?Z&[>>=U9]9$TBL>_-2K%L0LZ3X)$_EA=@3X$,"JQ18QPJ&I6#X6C Y(!B5@M&Q M$<:E8'RL8%(*)L<*IJ5@>JQ@5@IF^=TM;D=^+VVBR'(N^",2V=F:EGW)#9&K M]2UD2>;=6R7T4:9U:GG%DP6\KW1;,F(_*./:15SK0%QLH1N>J*U$3A+2 ML GHZTY4/;%>>G)I&8FW='>*!M9'9 TLW-*@*[/\AHA3A/%!N6V6VS0X1<-" M/FR1.\?+K1:Y>TS?)P?EWC%]'Q^4^V;YKR0Y15:KO'$GAY4GASEO/*36.C MFZX31355(?JDIYJ2MKG(2.CJ(DB8/7Y[>?JV0*.)2(CV#IT^*)?^9Z@2/7_U;NY M]R!A/A"L8:II9:JIT52W-$@%#='^I'XE>,RDY.(YG]^C MKS7$&>@4?@;I/$B8#0ES M(&$N),R#A/E L(;SSBKGG?WO2=?9VWG+V:CYA+DR1NEJ(DB8 PES(6$>),P' M@C5,A =U6FQ@M-'OJ9**)*&>EJ%=_5:8A(@$@4CU0S9-=H2%B)5^:_.9.4;7 M80V49H/2'%":"TKS0&E^2=L?/(:#>GK:M-M>%A9_)_% T8X\Y[-_/6R12#VW M&LI(Z6PH2)H-2G- :2XHS0.E^25M_X4'3P_XR:K]9!G]=)>06,_ V#]ZH,I> M)5'(9)!EM%I=961U=A4DS0:E.: T%Y3F@=+\DO8J-W/ 5G5B'ANSKS^V(6C2'I3F@-)<4)H'2O.A:$V_UBE^/ 9-=�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 224 405 1 true 79 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://nexgel.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://nexgel.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://nexgel.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://nexgel.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://nexgel.com/role/StatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://nexgel.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Description of Business, Stock Split and Basis of Presentation Sheet http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentation Description of Business, Stock Split and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://nexgel.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies and Estimates Sheet http://nexgel.com/role/SignificantAccountingPoliciesAndEstimates Significant Accounting Policies and Estimates Notes 9 false false R10.htm 00000010 - Disclosure - Business Segments Sheet http://nexgel.com/role/BusinessSegments Business Segments Notes 10 false false R11.htm 00000011 - Disclosure - Acquisition Sheet http://nexgel.com/role/Acquisition Acquisition Notes 11 false false R12.htm 00000012 - Disclosure - Leases Sheet http://nexgel.com/role/Leases Leases Notes 12 false false R13.htm 00000013 - Disclosure - Inventory Sheet http://nexgel.com/role/Inventory Inventory Notes 13 false false R14.htm 00000014 - Disclosure - Property and Equipment, Net Sheet http://nexgel.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 14 false false R15.htm 00000015 - Disclosure - Intangible Assets Sheet http://nexgel.com/role/IntangibleAssets Intangible Assets Notes 15 false false R16.htm 00000016 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 16 false false R17.htm 00000017 - Disclosure - Common Stock Sheet http://nexgel.com/role/CommonStock Common Stock Notes 17 false false R18.htm 00000018 - Disclosure - Share-based Compensation Sheet http://nexgel.com/role/Share-basedCompensation Share-based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - Notes Payable Notes http://nexgel.com/role/NotesPayable Notes Payable Notes 19 false false R20.htm 00000020 - Disclosure - Convertible Notes Payable Notes http://nexgel.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 20 false false R21.htm 00000021 - Disclosure - Warrant Liability Sheet http://nexgel.com/role/WarrantLiability Warrant Liability Notes 21 false false R22.htm 00000022 - Disclosure - Commitments and Contingencies Sheet http://nexgel.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 00000023 - Disclosure - Concentrations of Risk Sheet http://nexgel.com/role/ConcentrationsOfRisk Concentrations of Risk Notes 23 false false R24.htm 00000024 - Disclosure - Related Party Transactions Sheet http://nexgel.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 00000025 - Disclosure - Income Taxes Sheet http://nexgel.com/role/IncomeTaxes Income Taxes Notes 25 false false R26.htm 00000026 - Disclosure - Subsequent Events Sheet http://nexgel.com/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 00000027 - Disclosure - Significant Accounting Policies and Estimates (Policies) Sheet http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies Significant Accounting Policies and Estimates (Policies) Policies http://nexgel.com/role/SignificantAccountingPoliciesAndEstimates 27 false false R28.htm 00000028 - Disclosure - Significant Accounting Policies and Estimates (Tables) Sheet http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesTables Significant Accounting Policies and Estimates (Tables) Tables http://nexgel.com/role/SignificantAccountingPoliciesAndEstimates 28 false false R29.htm 00000029 - Disclosure - Business Segments (Tables) Sheet http://nexgel.com/role/BusinessSegmentsTables Business Segments (Tables) Tables http://nexgel.com/role/BusinessSegments 29 false false R30.htm 00000030 - Disclosure - Acquisition (Tables) Sheet http://nexgel.com/role/AcquisitionTables Acquisition (Tables) Tables http://nexgel.com/role/Acquisition 30 false false R31.htm 00000031 - Disclosure - Leases (Tables) Sheet http://nexgel.com/role/LeasesTables Leases (Tables) Tables http://nexgel.com/role/Leases 31 false false R32.htm 00000032 - Disclosure - Inventory (Tables) Sheet http://nexgel.com/role/InventoryTables Inventory (Tables) Tables http://nexgel.com/role/Inventory 32 false false R33.htm 00000033 - Disclosure - Property and Equipment, Net (Tables) Sheet http://nexgel.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://nexgel.com/role/PropertyAndEquipmentNet 33 false false R34.htm 00000034 - Disclosure - Intangible Assets (Tables) Sheet http://nexgel.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://nexgel.com/role/IntangibleAssets 34 false false R35.htm 00000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilities 35 false false R36.htm 00000036 - Disclosure - Common Stock (Tables) Sheet http://nexgel.com/role/CommonStockTables Common Stock (Tables) Tables http://nexgel.com/role/CommonStock 36 false false R37.htm 00000037 - Disclosure - Share-based Compensation (Tables) Sheet http://nexgel.com/role/Share-basedCompensationTables Share-based Compensation (Tables) Tables http://nexgel.com/role/Share-basedCompensation 37 false false R38.htm 00000038 - Disclosure - Notes Payable (Tables) Notes http://nexgel.com/role/NotesPayableTables Notes Payable (Tables) Tables http://nexgel.com/role/NotesPayable 38 false false R39.htm 00000039 - Disclosure - Warrant Liability (Tables) Sheet http://nexgel.com/role/WarrantLiabilityTables Warrant Liability (Tables) Tables http://nexgel.com/role/WarrantLiability 39 false false R40.htm 00000040 - Disclosure - Income Taxes (Tables) Sheet http://nexgel.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://nexgel.com/role/IncomeTaxes 40 false false R41.htm 00000041 - Disclosure - Description of Business, Stock Split and Basis of Presentation (Details Narrative) Sheet http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative Description of Business, Stock Split and Basis of Presentation (Details Narrative) Details http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentation 41 false false R42.htm 00000042 - Disclosure - Going Concern (Details Narrative) Sheet http://nexgel.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://nexgel.com/role/GoingConcern 42 false false R43.htm 00000043 - Disclosure - Schedule of Marketable Securities (Details) Sheet http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails Schedule of Marketable Securities (Details) Details 43 false false R44.htm 00000044 - Disclosure - Schedule of Fair Value of Financial Assets (Details) Sheet http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails Schedule of Fair Value of Financial Assets (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Disaggregated Revenue by Sales Type (Details) Sheet http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails Schedule of Disaggregated Revenue by Sales Type (Details) Details 45 false false R46.htm 00000046 - Disclosure - Significant Accounting Policies and Estimates (Details Narrative) Sheet http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative Significant Accounting Policies and Estimates (Details Narrative) Details http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesTables 46 false false R47.htm 00000047 - Disclosure - Schedule of Reportable Segments (Details) Sheet http://nexgel.com/role/ScheduleOfReportableSegmentsDetails Schedule of Reportable Segments (Details) Details 47 false false R48.htm 00000048 - Disclosure - Schedule of Business Acquisitions (Details) Sheet http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails Schedule of Business Acquisitions (Details) Details 48 false false R49.htm 00000049 - Disclosure - Schedule of Unaudited Pro-Forma Results of Operations (Details) Sheet http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails Schedule of Unaudited Pro-Forma Results of Operations (Details) Details 49 false false R50.htm 00000050 - Disclosure - Acquisition (Details Narrative) Sheet http://nexgel.com/role/AcquisitionDetailsNarrative Acquisition (Details Narrative) Details http://nexgel.com/role/AcquisitionTables 50 false false R51.htm 00000051 - Disclosure - Schedule of Future Minimum Lease Payments (Details) Sheet http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails Schedule of Future Minimum Lease Payments (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Supplemental Cash Flows Information Related to Leases (Details) Sheet http://nexgel.com/role/ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesDetails Schedule of Supplemental Cash Flows Information Related to Leases (Details) Details 52 false false R53.htm 00000053 - Disclosure - Leases (Details Narrative) Sheet http://nexgel.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://nexgel.com/role/LeasesTables 53 false false R54.htm 00000054 - Disclosure - Schedule of Inventory (Details) Sheet http://nexgel.com/role/ScheduleOfInventoryDetails Schedule of Inventory (Details) Details 54 false false R55.htm 00000055 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 55 false false R56.htm 00000056 - Disclosure - Property and Equipment, Net (Details Narrative) Sheet http://nexgel.com/role/PropertyAndEquipmentNetDetailsNarrative Property and Equipment, Net (Details Narrative) Details http://nexgel.com/role/PropertyAndEquipmentNetTables 56 false false R57.htm 00000057 - Disclosure - Schedule of Breakdown of Identifiable Intangible Assets (Details) Sheet http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails Schedule of Breakdown of Identifiable Intangible Assets (Details) Details 57 false false R58.htm 00000058 - Disclosure - Schedule of Estimated Annual Amortization Expense (Details) Sheet http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails Schedule of Estimated Annual Amortization Expense (Details) Details 58 false false R59.htm 00000059 - Disclosure - Intangible Assets (Details Narrative) Sheet http://nexgel.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://nexgel.com/role/IntangibleAssetsTables 59 false false R60.htm 00000060 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 60 false false R61.htm 00000061 - Disclosure - Schedule of Reserved Common Stock For Issued Securities in Relation (Details) Sheet http://nexgel.com/role/ScheduleOfReservedCommonStockForIssuedSecuritiesInRelationDetails Schedule of Reserved Common Stock For Issued Securities in Relation (Details) Details 61 false false R62.htm 00000062 - Disclosure - Schedule of Information about Incentive Plan (Details) Sheet http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails Schedule of Information about Incentive Plan (Details) Details 62 false false R63.htm 00000063 - Disclosure - Schedule of Incentive Stock Option Activity (Details) Sheet http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails Schedule of Incentive Stock Option Activity (Details) Details 63 false false R64.htm 00000064 - Disclosure - Schedule of Assumptions used in Share-based Compensation (Details) Sheet http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails Schedule of Assumptions used in Share-based Compensation (Details) Details 64 false false R65.htm 00000065 - Disclosure - Schedule of Restricted Stock Units Granted (Details) Sheet http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails Schedule of Restricted Stock Units Granted (Details) Details 65 false false R66.htm 00000066 - Disclosure - Schedule of Common Stock Warrants (Details) Sheet http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails Schedule of Common Stock Warrants (Details) Details 66 false false R67.htm 00000067 - Disclosure - Share-based Compensation (Details Narrative) Sheet http://nexgel.com/role/Share-basedCompensationDetailsNarrative Share-based Compensation (Details Narrative) Details http://nexgel.com/role/Share-basedCompensationTables 67 false false R68.htm 00000068 - Disclosure - Schedule of Debt Instruments (Details) Sheet http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails Schedule of Debt Instruments (Details) Details 68 false false R69.htm 00000069 - Disclosure - Notes Payable (Details Narrative) Notes http://nexgel.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://nexgel.com/role/NotesPayableTables 69 false false R70.htm 00000070 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://nexgel.com/role/ConvertibleNotesPayable 70 false false R71.htm 00000071 - Disclosure - Schedule of Warrant Liability (Details) Sheet http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails Schedule of Warrant Liability (Details) Details 71 false false R72.htm 00000072 - Disclosure - Warrant Liability (Details Narrative) Sheet http://nexgel.com/role/WarrantLiabilityDetailsNarrative Warrant Liability (Details Narrative) Details http://nexgel.com/role/WarrantLiabilityTables 72 false false R73.htm 00000073 - Disclosure - Concentrations of Risk (Details Narrative) Sheet http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative Concentrations of Risk (Details Narrative) Details http://nexgel.com/role/ConcentrationsOfRisk 73 false false R74.htm 00000074 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://nexgel.com/role/RelatedPartyTransactions 74 false false R75.htm 00000075 - Disclosure - Schedule of Income Tax (Benefit) Provision (Details) Sheet http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails Schedule of Income Tax (Benefit) Provision (Details) Details 75 false false R76.htm 00000076 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 76 false false R77.htm 00000077 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 77 false false R78.htm 00000078 - Disclosure - Income Taxes (Details Narrative) Sheet http://nexgel.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://nexgel.com/role/IncomeTaxesTables 78 false false R79.htm 00000079 - Disclosure - Subsequent Events (Details Narrative) Sheet http://nexgel.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://nexgel.com/role/SubsequentEvents 79 false false All Reports Book All Reports form10-k.htm nxgl-20231231.xsd nxgl-20231231_cal.xml nxgl-20231231_def.xml nxgl-20231231_lab.xml nxgl-20231231_pre.xml http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "NXGL", "nsuri": "http://nexgel.com/20231231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "nxgl-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "nxgl-20231231_cal.xml" ] }, "definitionLink": { "local": [ "nxgl-20231231_def.xml" ] }, "labelLink": { "local": [ "nxgl-20231231_lab.xml" ] }, "presentationLink": { "local": [ "nxgl-20231231_pre.xml" ] } }, "keyStandard": 352, "keyCustom": 53, "axisStandard": 25, "axisCustom": 0, "memberStandard": 33, "memberCustom": 44, "hidden": { "total": 137, "http://nexgel.com/20231231": 22, "http://fasb.org/us-gaap/2023": 112, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 224, "entityCount": 1, "segmentCount": 79, "elementCount": 624, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 850, "http://xbrl.sec.gov/dei/2023": 43, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://nexgel.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://nexgel.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R3": { "role": "http://nexgel.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R4": { "role": "http://nexgel.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://nexgel.com/role/StatementsOfStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://nexgel.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:LossAttributableToNoncontrollingInterestInJointVenture", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentation", "longName": "00000007 - Disclosure - Description of Business, Stock Split and Basis of Presentation", "shortName": "Description of Business, Stock Split and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R8": { "role": "http://nexgel.com/role/GoingConcern", "longName": "00000008 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimates", "longName": "00000009 - Disclosure - Significant Accounting Policies and Estimates", "shortName": "Significant Accounting Policies and Estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://nexgel.com/role/BusinessSegments", "longName": "00000010 - Disclosure - Business Segments", "shortName": "Business Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://nexgel.com/role/Acquisition", "longName": "00000011 - Disclosure - Acquisition", "shortName": "Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://nexgel.com/role/Leases", "longName": "00000012 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://nexgel.com/role/Inventory", "longName": "00000013 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://nexgel.com/role/PropertyAndEquipmentNet", "longName": "00000014 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://nexgel.com/role/IntangibleAssets", "longName": "00000015 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilities", "longName": "00000016 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://nexgel.com/role/CommonStock", "longName": "00000017 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://nexgel.com/role/Share-basedCompensation", "longName": "00000018 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://nexgel.com/role/NotesPayable", "longName": "00000019 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://nexgel.com/role/ConvertibleNotesPayable", "longName": "00000020 - Disclosure - Convertible Notes Payable", "shortName": "Convertible Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://nexgel.com/role/WarrantLiability", "longName": "00000021 - Disclosure - Warrant Liability", "shortName": "Warrant Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:WarrantsLiabilityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:WarrantsLiabilityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://nexgel.com/role/CommitmentsAndContingencies", "longName": "00000022 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://nexgel.com/role/ConcentrationsOfRisk", "longName": "00000023 - Disclosure - Concentrations of Risk", "shortName": "Concentrations of Risk", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://nexgel.com/role/RelatedPartyTransactions", "longName": "00000024 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://nexgel.com/role/IncomeTaxes", "longName": "00000025 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://nexgel.com/role/SubsequentEvents", "longName": "00000026 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies", "longName": "00000027 - Disclosure - Significant Accounting Policies and Estimates (Policies)", "shortName": "Significant Accounting Policies and Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesTables", "longName": "00000028 - Disclosure - Significant Accounting Policies and Estimates (Tables)", "shortName": "Significant Accounting Policies and Estimates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://nexgel.com/role/BusinessSegmentsTables", "longName": "00000029 - Disclosure - Business Segments (Tables)", "shortName": "Business Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://nexgel.com/role/AcquisitionTables", "longName": "00000030 - Disclosure - Acquisition (Tables)", "shortName": "Acquisition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://nexgel.com/role/LeasesTables", "longName": "00000031 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://nexgel.com/role/InventoryTables", "longName": "00000032 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://nexgel.com/role/PropertyAndEquipmentNetTables", "longName": "00000033 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://nexgel.com/role/IntangibleAssetsTables", "longName": "00000034 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "00000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://nexgel.com/role/CommonStockTables", "longName": "00000036 - Disclosure - Common Stock (Tables)", "shortName": "Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://nexgel.com/role/Share-basedCompensationTables", "longName": "00000037 - Disclosure - Share-based Compensation (Tables)", "shortName": "Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R38": { "role": "http://nexgel.com/role/NotesPayableTables", "longName": "00000038 - Disclosure - Notes Payable (Tables)", "shortName": "Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R39": { "role": "http://nexgel.com/role/WarrantLiabilityTables", "longName": "00000039 - Disclosure - Warrant Liability (Tables)", "shortName": "Warrant Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:ScheduleOfFairValueWarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "NXGL:WarrantsLiabilityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:ScheduleOfFairValueWarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "NXGL:WarrantsLiabilityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://nexgel.com/role/IncomeTaxesTables", "longName": "00000040 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative", "longName": "00000041 - Disclosure - Description of Business, Stock Split and Basis of Presentation (Details Narrative)", "shortName": "Description of Business, Stock Split and Basis of Presentation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-03-01_custom_JointVentureMember", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://nexgel.com/role/GoingConcernDetailsNarrative", "longName": "00000042 - Disclosure - Going Concern (Details Narrative)", "shortName": "Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "NXGL:WorkingCapitalDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R43": { "role": "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails", "longName": "00000043 - Disclosure - Schedule of Marketable Securities (Details)", "shortName": "Schedule of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_USTreasurySecuritiesOneMember", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R44": { "role": "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails", "longName": "00000044 - Disclosure - Schedule of Fair Value of Financial Assets (Details)", "shortName": "Schedule of Fair Value of Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:MarketableSecuritiesPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_USTreasurySecuritiesMember", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R45": { "role": "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails", "longName": "00000045 - Disclosure - Schedule of Disaggregated Revenue by Sales Type (Details)", "shortName": "Schedule of Disaggregated Revenue by Sales Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:RevenueFromContractManufacturing", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:RevenueFromContractManufacturing", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R46": { "role": "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative", "longName": "00000046 - Disclosure - Significant Accounting Policies and Estimates (Details Narrative)", "shortName": "Significant Accounting Policies and Estimates (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DebtDefaultShorttermDebtAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:DebtPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DebtDefaultShorttermDebtAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:DebtPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R47": { "role": "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails", "longName": "00000047 - Disclosure - Schedule of Reportable Segments (Details)", "shortName": "Schedule of Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_ReportableSubsegmentsMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R48": { "role": "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "longName": "00000048 - Disclosure - Schedule of Business Acquisitions (Details)", "shortName": "Schedule of Business Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-12-012023-12-01_custom_KenkodermAcquisitionMember", "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R49": { "role": "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails", "longName": "00000049 - Disclosure - Schedule of Unaudited Pro-Forma Results of Operations (Details)", "shortName": "Schedule of Unaudited Pro-Forma Results of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_KenkodermAcquisitionMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_KenkodermAcquisitionMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R50": { "role": "http://nexgel.com/role/AcquisitionDetailsNarrative", "longName": "00000050 - Disclosure - Acquisition (Details Narrative)", "shortName": "Acquisition (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-03-012023-03-01", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-03-012023-03-01", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R51": { "role": "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "longName": "00000051 - Disclosure - Schedule of Future Minimum Lease Payments (Details)", "shortName": "Schedule of Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R52": { "role": "http://nexgel.com/role/ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesDetails", "longName": "00000052 - Disclosure - Schedule of Supplemental Cash Flows Information Related to Leases (Details)", "shortName": "Schedule of Supplemental Cash Flows Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NXGL:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NXGL:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R53": { "role": "http://nexgel.com/role/LeasesDetailsNarrative", "longName": "00000053 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://nexgel.com/role/ScheduleOfInventoryDetails", "longName": "00000054 - Disclosure - Schedule of Inventory (Details)", "shortName": "Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R55": { "role": "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "00000055 - Disclosure - Schedule of Property and Equipment (Details)", "shortName": "Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R56": { "role": "http://nexgel.com/role/PropertyAndEquipmentNetDetailsNarrative", "longName": "00000056 - Disclosure - Property and Equipment, Net (Details Narrative)", "shortName": "Property and Equipment, Net (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R57": { "role": "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails", "longName": "00000057 - Disclosure - Schedule of Breakdown of Identifiable Intangible Assets (Details)", "shortName": "Schedule of Breakdown of Identifiable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_TechnologyBasedIntangibleAssetsMember", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R58": { "role": "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails", "longName": "00000058 - Disclosure - Schedule of Estimated Annual Amortization Expense (Details)", "shortName": "Schedule of Estimated Annual Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R59": { "role": "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "longName": "00000059 - Disclosure - Intangible Assets (Details Narrative)", "shortName": "Intangible Assets (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R60": { "role": "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "00000060 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R61": { "role": "http://nexgel.com/role/ScheduleOfReservedCommonStockForIssuedSecuritiesInRelationDetails", "longName": "00000061 - Disclosure - Schedule of Reserved Common Stock For Issued Securities in Relation (Details)", "shortName": "Schedule of Reserved Common Stock For Issued Securities in Relation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R62": { "role": "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "longName": "00000062 - Disclosure - Schedule of Information about Incentive Plan (Details)", "shortName": "Schedule of Information about Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_TwoThousandAndNineteenLongTermIncentivePlanMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_TwoThousandAndNineteenLongTermIncentivePlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R63": { "role": "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "longName": "00000063 - Disclosure - Schedule of Incentive Stock Option Activity (Details)", "shortName": "Schedule of Incentive Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandAndNineteenLongTermIncentivePlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_TwoThousandAndNineteenLongTermIncentivePlanMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R64": { "role": "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "longName": "00000064 - Disclosure - Schedule of Assumptions used in Share-based Compensation (Details)", "shortName": "Schedule of Assumptions used in Share-based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R65": { "role": "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails", "longName": "00000065 - Disclosure - Schedule of Restricted Stock Units Granted (Details)", "shortName": "Schedule of Restricted Stock Units Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R66": { "role": "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails", "longName": "00000066 - Disclosure - Schedule of Common Stock Warrants (Details)", "shortName": "Schedule of Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R67": { "role": "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "longName": "00000067 - Disclosure - Share-based Compensation (Details Narrative)", "shortName": "Share-based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NXGL:UnrecognizedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R68": { "role": "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails", "longName": "00000068 - Disclosure - Schedule of Debt Instruments (Details)", "shortName": "Schedule of Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R69": { "role": "http://nexgel.com/role/NotesPayableDetailsNarrative", "longName": "00000069 - Disclosure - Notes Payable (Details Narrative)", "shortName": "Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtInstrumentIncreaseAccruedInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtInstrumentIncreaseAccruedInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R70": { "role": "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "longName": "00000070 - Disclosure - Convertible Notes Payable (Details Narrative)", "shortName": "Convertible Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "AsOf2022-03-15", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-09-022021-09-02_custom_SecuredConvertiblePromissoryNoteMember", "name": "us-gaap:InterestExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R71": { "role": "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "longName": "00000071 - Disclosure - Schedule of Warrant Liability (Details)", "shortName": "Schedule of Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "From2022-09-052022-09-06", "name": "NXGL:WarrantModificationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "NXGL:WarrantsLiabilityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "NXGL:ScheduleOfFairValueWarrantLiabilityTextBlock", "NXGL:WarrantsLiabilityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R72": { "role": "http://nexgel.com/role/WarrantLiabilityDetailsNarrative", "longName": "00000072 - Disclosure - Warrant Liability (Details Narrative)", "shortName": "Warrant Liability (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "From2022-09-052022-09-06", "name": "NXGL:WarrantModificationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "NXGL:WarrantsLiabilityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-09-02_us-gaap_PrivatePlacementMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "NXGL:WarrantsLiabilityDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R73": { "role": "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative", "longName": "00000073 - Disclosure - Concentrations of Risk (Details Narrative)", "shortName": "Concentrations of Risk (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R74": { "role": "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000074 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "AsOf2022-03-15", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-09-02_custom_Mr.SteinMember", "name": "NXGL:NumberOfDebtInstruments", "unitRef": "Integer", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R75": { "role": "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails", "longName": "00000075 - Disclosure - Schedule of Income Tax (Benefit) Provision (Details)", "shortName": "Schedule of Income Tax (Benefit) Provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R76": { "role": "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "00000076 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R77": { "role": "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "00000077 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R78": { "role": "http://nexgel.com/role/IncomeTaxesDetailsNarrative", "longName": "00000078 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R79": { "role": "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "longName": "00000079 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "From2024-02-152024-02-15_us-gaap_SubsequentEventMember_custom_RegisteredDirectOfferingMember_custom_SubscriptionAgreementsMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-02-152024-02-15_us-gaap_SubsequentEventMember_custom_RegisteredDirectOfferingMember_custom_SubscriptionAgreementsMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31", "r847" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r798" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r310", "r311" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Franchise tax accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36", "r90", "r817" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r73", "r215", "r658" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r148" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r126", "r847", "r1003" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r502", "r503", "r504", "r698", "r916", "r917", "r918", "r977", "r1005" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "NXGL_AdvancePaymentOfPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "AdvancePaymentOfPromissoryNote", "crdr": "credit", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advance payment of promissory note", "documentation": "Advance payment of promissory note." } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity." } } }, "auth_ref": [ "r196", "r744", "r809", "r852", "r944", "r982", "r983", "r985" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r223", "r314", "r349", "r352", "r353", "r998" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of deferred financing costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r423", "r571", "r831", "r832", "r910" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r67", "r71" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r874" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r541" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r169", "r219", "r242", "r274", "r295", "r301", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r543", "r547", "r562", "r649", "r737", "r847", "r859", "r936", "r937", "r986" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "ASSETS:", "verboseLabel": "Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r211", "r226", "r242", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r543", "r547", "r562", "r847", "r936", "r937", "r986" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Current Assets:", "verboseLabel": "Current assets:" } } }, "auth_ref": [] }, "NXGL_AuctusNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "AuctusNoteMember", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Auctus Note [Member]", "documentation": "Auctus Note [Member]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r874" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r871", "r873", "r874" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r871", "r873", "r874" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r871", "r873", "r874" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ] }, "NXGL_AwardsGrantedOutsideOfThe2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "AwardsGrantedOutsideOfThe2019PlanMember", "presentation": [ "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails" ], "lang": { "en-us": { "role": { "label": "Awards Granted Outside Of The 2019 Plan [Member]", "documentation": "Awards Granted Outside Of The 2019 Plan [Member]" } } }, "auth_ref": [] }, "NXGL_BrandedConsumerProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "BrandedConsumerProductsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Branded Consumer Products [Member]", "documentation": "Branded Consumer Products [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/AcquisitionTables", "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative", "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r536", "r839", "r840" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/AcquisitionTables", "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative", "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r92", "r94", "r536", "r839", "r840" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/AcquisitionTables", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r536" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acquisition percentage", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r93" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "presentation": [ "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss per share - basic", "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r884", "r885" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": [ "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss per share - diluted", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r884", "r885" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://nexgel.com/role/AcquisitionTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unaudited Pro-Forma Results of Operations", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r884", "r885" ] }, "NXGL_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - basic", "documentation": "Business acquisition pro forma weighted average number of shares outstanding basic." } } }, "auth_ref": [] }, "NXGL_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingDiluted", "presentation": [ "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - diluted", "documentation": "Business acquisition pro forma weighted average number of shares outstanding diluted." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss allocable to common shareholders", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r534", "r535" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues, net", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r534", "r535" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Consideration paid", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r3", "r4", "r14" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest portion of CG Labs contributed business", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r3", "r4", "r99", "r539" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Contingent consideration liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r5", "r100", "r540" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/Acquisition" ], "lang": { "en-us": { "role": { "label": "Acquisition", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r165", "r537" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Marketing related intangibles", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": [ "r96" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Product/Technology related intangibles", "verboseLabel": "Intangible assets", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r95", "r96" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r95", "r96" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r96" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Total net assets acquired", "verboseLabel": "Net tangible assets acquired", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r95", "r96" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Fixed assets", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r95", "r96" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Description of Business, Stock Split and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r119", "r145", "r146" ] }, "NXGL_CGLaboratoriesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CGLaboratoriesIncMember", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "C.G. Laboratories Inc. [Member]", "documentation": "C.G. Laboratories Inc. [Member]" } } }, "auth_ref": [] }, "NXGL_CGLabsJVMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CGLabsJVMember", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CG Labs JV [Member]", "documentation": "CG Labs JV [Member]" } } }, "auth_ref": [] }, "NXGL_CGLabsMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CGLabsMember", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/AcquisitionTables", "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "CG Labs [Member]", "documentation": "CG Labs [Member]" } } }, "auth_ref": [] }, "NXGL_CGLabsNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CGLabsNotesPayableMember", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CG Labs Notes Payable [Member]", "documentation": "CG Labs Notes Payable [Member]" } } }, "auth_ref": [] }, "NXGL_CGLabsNotesPayableOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CGLabsNotesPayableOneMember", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CG Labs Notes Payable One [Member]", "documentation": "CG Labs Notes Payable One [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r182", "r651", "r709", "r732", "r847", "r859", "r898" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash \u2009\u2013\u2009Beginning of year", "periodEndLabel": "Cash \u2013\u2009End of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r48", "r142", "r238" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r142" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash, FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "NXGL_CashFeeOfAggregateGrossProceedsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CashFeeOfAggregateGrossProceedsPercentage", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash fee of aggregate gross proceeds percentage", "documentation": "Cash fee of aggregate gross proceeds percentage" } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Non-cash Investing and Financing Activities" } } }, "auth_ref": [] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash, exceeding", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "NXGL_ChangeInFairValueOfWarrantLiabilityAndWarrantModificationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ChangeInFairValueOfWarrantLiabilityAndWarrantModificationExpense", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrant liability, net of warrant modification expense", "documentation": "Change In Fair Value Of Warrant Liability And Warrant Modification Expense.", "label": "ChangeInFairValueOfWarrantLiabilityAndWarrantModificationExpense" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r920" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r194", "r220", "r221", "r222", "r242", "r260", "r261", "r263", "r265", "r268", "r269", "r346", "r392", "r394", "r395", "r396", "r399", "r400", "r430", "r431", "r433", "r436", "r443", "r562", "r687", "r688", "r689", "r690", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r710", "r724", "r746", "r769", "r790", "r791", "r792", "r793", "r794", "r881", "r911", "r919" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "NXGL_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value, exercise of wararnts", "documentation": "Class of warrant or right exercise price of warrants or rights.", "label": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of warrant or right, exercise price of warrants or rights", "verboseLabel": "Exercise price", "terseLabel": "Exercise price, per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedPeriodEndLabel": "Warrants outstanding, exercise of warrants", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning balance", "periodEndLabel": "Warrants outstanding, ending balance", "label": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "NXGL_ClassOfWarrantOrRightOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ClassOfWarrantOrRightOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic value of vested outstanding warrants", "documentation": "Intrinsic value of vested outstanding warrants." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r541" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Note 16)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r40", "r114", "r650", "r723" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r154", "r386", "r387", "r799", "r934" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Awards Reserved For Issuance", "verboseLabel": "Common stock reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r42" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r849", "r850", "r851", "r853", "r854", "r855", "r856", "r916", "r917", "r977", "r1001", "r1005" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r125" ] }, "NXGL_CommonStockParValue0.001Member": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CommonStockParValue0.001Member", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value 0.001 [Member]", "documentation": "Common Stock, par value 0.001 [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "verboseLabel": "Common stock reserved for issuance", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r125", "r724" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r125", "r724", "r743", "r1005", "r1006" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,741,838 and 5,577,916 shares issued and outstanding as of December 31, 2023 and 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r125", "r653", "r847" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r52", "r54", "r106", "r107", "r309", "r798" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r52", "r54", "r106", "r107", "r309", "r684", "r798" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r52", "r54", "r106", "r107", "r309", "r798", "r883" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRisk" ], "lang": { "en-us": { "role": { "label": "Concentrations of Risk", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r146" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r798" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r52", "r54", "r106", "r107", "r309" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r51", "r52", "r54", "r55", "r106", "r168", "r798" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r52", "r54", "r106", "r107", "r309", "r798" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r196", "r244", "r543", "r544", "r547", "r548", "r592", "r809", "r895", "r896", "r897", "r935", "r938", "r939" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r196", "r244", "r543", "r544", "r547", "r548", "r592", "r809", "r895", "r896", "r897", "r935", "r938", "r939" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "NXGL_ContractManufacturingMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ContractManufacturingMember", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Contract Manufacturing [Member]", "documentation": "Contract Manufacturing [Member]" } } }, "auth_ref": [] }, "NXGL_ContractorMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ContractorMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contractor [Member]", "documentation": "Contractor [Member]" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://nexgel.com/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt Instruments", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r915" ] }, "us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock reserved for issuance", "documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance." } } }, "auth_ref": [ "r41" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "verboseLabel": "Cost of sales", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r137", "r242", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r562", "r936" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Current", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r887", "r914", "r975" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r887", "r914", "r975" ] }, "NXGL_CustomAndWhiteLabelFinishedGoodsMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CustomAndWhiteLabelFinishedGoodsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Custom and White Label Finished Goods [Member]", "documentation": "Custom and White Label Finished Goods [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r53", "r309" ] }, "NXGL_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Customer One [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelatedIntangibleAssetsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Customer-Related Intangible Assets [Member]", "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships." } } }, "auth_ref": [ "r27" ] }, "NXGL_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CustomerThreeMember", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "Customer Three [Member]" } } }, "auth_ref": [] }, "NXGL_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "CustomerTwoMember", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Customer Two [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDefaultShorttermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDefaultShorttermDebtAmount", "crdr": "credit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shor term line of credit", "documentation": "Amount of outstanding short-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r240" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r155", "r240", "r401", "r407", "r408", "r409", "r410", "r411", "r412", "r417", "r424", "r425", "r427" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r28", "r122", "r123", "r170", "r171", "r244", "r402", "r403", "r404", "r405", "r406", "r408", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r572", "r828", "r829", "r830", "r831", "r832", "r912" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount of debt", "verboseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r109", "r111", "r402", "r572", "r829", "r830" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal and accrued interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r912" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r38", "r403" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r39", "r244", "r402", "r403", "r404", "r405", "r406", "r408", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r572", "r828", "r829", "r830", "r831", "r832", "r912" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument periodic payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r39", "r117" ] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r39" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreements terms", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r108", "r111", "r941" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Margin Line of Credit", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r11" ] }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails", "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]", "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r929" ] }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails", "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r929" ] }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional common stock reserved for issuance", "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Deferred", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r914", "r974", "r975" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails", "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r914", "r974", "r975" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r521" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r972" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r91", "r973" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://nexgel.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets, operating loss carryforwards, state and local", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r91", "r973" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r91", "r973" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r522" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://nexgel.com/role/PropertyAndEquipmentNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r72" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r279" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r920", "r1002" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregated Revenue by Sales Type", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r943" ] }, "NXGL_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nexgel.com/20231231", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Future Minimum Lease Payments", "terseLabel": "Schedule Of Supplemental Cash Flows Information Related To Leases" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://nexgel.com/role/Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r465", "r468", "r498", "r499", "r501", "r842" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://nexgel.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Information about Incentive Plan", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r12", "r86" ] }, "NXGL_DisclosureWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nexgel.com/20231231", "localname": "DisclosureWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liability" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r873" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r871", "r873", "r874" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r871", "r873", "r874", "r876" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r872" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r860" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r873" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r873" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r875" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r863" ] }, "NXGL_Dr.JeromeZeldisMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "Dr.JeromeZeldisMember", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dr.Jerome Zeldis [Member]", "documentation": "Dr.Jerome Zeldis [Member]" } } }, "auth_ref": [] }, "NXGL_Dr.LeonardNelsonMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "Dr.LeonardNelsonMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dr.Leonard Nelson [Member]", "documentation": "Dr.Leonard Nelson [Member]" } } }, "auth_ref": [] }, "NXGL_Dr.NeilChesenMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "Dr.NeilChesenMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dr.Neil Chesen [Member]", "documentation": "Dr.Neil Chesen [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r234", "r250", "r251", "r252", "r253", "r254", "r258", "r260", "r263", "r264", "r265", "r266", "r558", "r559", "r645", "r665", "r820" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r234", "r250", "r251", "r252", "r253", "r254", "r260", "r263", "r264", "r265", "r266", "r558", "r559", "r645", "r665", "r820" ] }, "NXGL_EconomicInjuryDisasterLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "EconomicInjuryDisasterLoanMember", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Economic Injury Disaster Loan [Member]", "documentation": "Economic Injury Disaster Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income tax provision", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r516" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "U.S. federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r243", "r516", "r530" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r971", "r976" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "calculation": { "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Timing differences", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions." } } }, "auth_ref": [ "r971", "r976" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Non-deductible expenses", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r971", "r976" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "State tax rate, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r971", "r976" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Salaries, benefits, and incentive compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Period of recognition of stock based compensation expense", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r500" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r866" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r862" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r862" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r880" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r862" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r877" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r874" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r862" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r862" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r862" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r862" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r878" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/StatementsOfStockholdersEquity", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r207", "r230", "r231", "r232", "r245", "r246", "r247", "r249", "r255", "r257", "r267", "r347", "r348", "r445", "r502", "r503", "r504", "r526", "r527", "r549", "r550", "r551", "r552", "r553", "r554", "r557", "r563", "r564", "r565", "r566", "r567", "r568", "r585", "r679", "r680", "r681", "r698", "r769" ] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ExecutiveOfficerMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "documentation": "Person with designation of executive officer." } } }, "auth_ref": [ "r920" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability", "verboseLabel": "Fair value, change in fair value of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r2", "r9" ] }, "NXGL_FairValueAdjustmentOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "FairValueAdjustmentOfWarrantsShares", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants outstanding, change in fair value of warrant liability", "documentation": "Fair Value Adjustment Of Warrants Shares" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r415", "r457", "r458", "r459", "r460", "r461", "r462", "r561", "r599", "r600", "r601", "r829", "r830", "r836", "r837", "r838" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r415", "r457", "r462", "r561", "r599", "r836", "r837", "r838" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r415", "r457", "r462", "r561", "r600", "r829", "r830", "r836", "r837", "r838" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r415", "r457", "r458", "r459", "r460", "r461", "r462", "r561", "r601", "r829", "r830", "r836", "r837", "r838" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r415", "r457", "r458", "r459", "r460", "r461", "r462", "r599", "r600", "r601", "r829", "r830", "r836", "r837", "r838" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Federal:" } } }, "auth_ref": [] }, "us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Income tax provision", "documentation": "Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r975" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on operating lease liability", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r577", "r581" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of right of use asset", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r576", "r580", "r846" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails", "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails", "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r350", "r351", "r354", "r355", "r356", "r357", "r358", "r359", "r426", "r441", "r555", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r664", "r825", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r924", "r925", "r926", "r927" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r217", "r376" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r150" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r374", "r375", "r376", "r377", "r629", "r630" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Identifiable intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r149", "r630" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r629" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r68", "r70" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails", "http://nexgel.com/role/ScheduleOfEstimatedAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r149", "r629" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/StatementsOfCashFlows", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss on debt extinguishment", "negatedLabel": "Loss of extinguishment of debt", "verboseLabel": "Gains loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r9", "r74", "r75" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "verboseLabel": "Preliminary goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r216", "r363", "r643", "r827", "r847", "r931", "r932" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill and intangible asset impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r13", "r65" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r136", "r242", "r274", "r294", "r300", "r303", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r562", "r822", "r936" ] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "U.S. treasury bills held for sale", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r180", "r338", "r644", "r648" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r871", "r873", "r874" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r153" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r134", "r174", "r274", "r294", "r300", "r303", "r646", "r660", "r822" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r243", "r511", "r517", "r519", "r524", "r528", "r531", "r532", "r533", "r692" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/IncomeTaxesDetailsNarrative", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax expense", "verboseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r181", "r192", "r256", "r257", "r282", "r515", "r529", "r666" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r229", "r513", "r514", "r519", "r520", "r523", "r525", "r686" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r909" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r812" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r373" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Intangibles, net", "verboseLabel": "Intangibles", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r66", "r69" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r110", "r176", "r233", "r278", "r570", "r754", "r857", "r1004" ] }, "us-gaap_InventoryAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryAdjustments", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Less: Inventory reserve for excess and slow moving inventory", "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods." } } }, "auth_ref": [ "r64", "r904" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/Inventory" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r360" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r901" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory, gross", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r904" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://nexgel.com/role/ScheduleOfInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfInventoryDetails", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Inventory", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r225", "r815", "r847" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory and Cost of Revenues", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r183", "r213", "r224", "r360", "r361", "r362", "r627", "r818" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r903" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Work-in-progress", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r902" ] }, "us-gaap_InvestmentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentMaturityDate", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable securities, due date", "documentation": "Maturity date of investment, in YYYY-MM-DD format." } } }, "auth_ref": [ "r777", "r778", "r780", "r781", "r783", "r784", "r787", "r788", "r851", "r922", "r923" ] }, "NXGL_JointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "JointVentureMember", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Joint Venture [Member]", "documentation": "Joint Venture [Member]" } } }, "auth_ref": [] }, "NXGL_KenkodermAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "KenkodermAcquisitionMember", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/AcquisitionTables", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Kenkoderm Acquisition [Member]", "documentation": "Kenkoderm Acquisition [Member]" } } }, "auth_ref": [] }, "NXGL_KenkodermMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "KenkodermMember", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Kenkoderm [Member]", "documentation": "Kenkoderm [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r152" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r579" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://nexgel.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r981" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted operating lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r584" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r584" ] }, "NXGL_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "presentation": [ "http://nexgel.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Cash Flows Information Related to Leases", "documentation": "The tabular disclosure of supplemental cash flows information related to leases." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://nexgel.com/role/Leases" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r573" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r35", "r242", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r544", "r547", "r548", "r562", "r722", "r821", "r859", "r936", "r986", "r987" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r130", "r173", "r656", "r847", "r913", "r928", "r979" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "verboseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r212", "r242", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r544", "r547", "r548", "r562", "r847", "r936", "r986", "r987" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:", "verboseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r32" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r28", "r171", "r414", "r428", "r829", "r830", "r997" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r244", "r942" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r244", "r419" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r244", "r419" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r244", "r419" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r244", "r419" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r244", "r419" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r155" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Notes payable, net of current portion", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r39" ] }, "NXGL_LossAttributableToNoncontrollingInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "LossAttributableToNoncontrollingInterestInJointVenture", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loss attributable to non-controlling interest in joint venture", "documentation": "Loss attributable to non-controlling interest in joint venture." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r309", "r835", "r943", "r999", "r1000" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails", "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r115", "r899" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r899" ] }, "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized gain on investment in marketable securities", "label": "Marketable Security, Gain (Loss)", "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r116" ] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Realized gain on investments in marketable securities", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Marketable Securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingRelatedIntangibleAssetsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Marketing-Related Intangible Assets [Member]", "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark." } } }, "auth_ref": [ "r27" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r464", "r626", "r678", "r714", "r715", "r777", "r780", "r784", "r785", "r787", "r810", "r811", "r824", "r833", "r841", "r848", "r940", "r988", "r989", "r990", "r991", "r992", "r993" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r464", "r626", "r678", "r714", "r715", "r777", "r780", "r784", "r785", "r787", "r810", "r811", "r824", "r833", "r841", "r848", "r940", "r988", "r989", "r990", "r991", "r992", "r993" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-controlling interest in joint venture", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r44", "r172", "r242", "r346", "r392", "r394", "r395", "r396", "r399", "r400", "r562", "r655", "r726" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minority percentage", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "NXGL_Mr.StefanskyMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "Mr.StefanskyMember", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr.Stefansky [Member]", "documentation": "Mr.Stefansky [Member]" } } }, "auth_ref": [] }, "NXGL_Mr.SteinMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "Mr.SteinMember", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr. Stein [Member]", "documentation": "Mr. Stein [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r309", "r835", "r943", "r999", "r1000" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r237" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r237" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Operating Activities", "negatedLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r142", "r143", "r144" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://nexgel.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/StatementsOfCashFlows", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to NexGel stockholders", "verboseLabel": "Net loss", "negatedLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r135", "r144", "r175", "r210", "r227", "r228", "r232", "r242", "r248", "r250", "r251", "r252", "r253", "r256", "r257", "r262", "r274", "r294", "r300", "r303", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r559", "r562", "r663", "r745", "r767", "r768", "r822", "r857", "r936" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Loss attributable to non-controlling interest in joint venture", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r105", "r167", "r227", "r228", "r256", "r257", "r662", "r907" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "NXGL_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting Pronouncements Issued But Not Yet Adopted", "documentation": "New Accounting Pronouncements [Policy Text Block]" } } }, "auth_ref": [] }, "NXGL_NexgelMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "NexgelMember", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Nexgel [Member]", "documentation": "Nexgel [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "NXGL_NonAffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "NonAffiliatedEntityMember", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non Affiliated Entity [Member]", "documentation": "Non Affiliated Entity [Member]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Non-controlling interest contribution", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": [ "r15", "r83", "r97" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r101", "r445", "r916", "r917", "r918", "r1005" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://nexgel.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units Granted", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r26" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r28", "r171", "r997" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r34" ] }, "NXGL_NumberOfDebtInstruments": { "xbrltype": "integerItemType", "nsuri": "http://nexgel.com/20231231", "localname": "NumberOfDebtInstruments", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of debt instruments", "documentation": "Number of debt instruments." } } }, "auth_ref": [] }, "NXGL_OfficersAndEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OfficersAndEmployeesMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officers and Employees [Member]", "documentation": "Officers and Employees [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "verboseLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r274", "r294", "r300", "r303", "r822" ] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLossAbstract", "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://nexgel.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r980" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Present value of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating lease", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r578", "r581" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease - right of use asset", "verboseLabel": "Operating lease \u2013 right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r574" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r583", "r846" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://nexgel.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r582", "r846" ] }, "NXGL_OptionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OptionOneMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Option One [Member]", "documentation": "Option One [Member]" } } }, "auth_ref": [] }, "NXGL_OptionThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OptionThreeMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Option Three [Member]", "documentation": "Option Three [Member]" } } }, "auth_ref": [] }, "NXGL_OptionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OptionTwoMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Option Two [Member]", "documentation": "Option Two [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r218" ] }, "NXGL_OtherAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OtherAssetsPolicyPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Other Assets", "documentation": "Other Assets Policy [Policy Text Block]" } } }, "auth_ref": [] }, "NXGL_OtherIncomesMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OtherIncomesMember", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Other Incomes [Member]", "documentation": "Other Incomes [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r36", "r847" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r140" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r235" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "General prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r905", "r930" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due from related parties, current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r873" ] }, "NXGL_OutstandingPrincipalAndAccruedUnpaidInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "OutstandingPrincipalAndAccruedUnpaidInterest", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding principal and accrued unpaid interest", "documentation": "Outstanding Principal And Accrued Unpaid Interest." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "country_PA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "PA", "presentation": [ "http://nexgel.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "PANAMA" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "NXGL_PaymentsToAcquireBusinessesCashEarnout": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "PaymentsToAcquireBusinessesCashEarnout", "crdr": "credit", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments to acquire businesses, cash earn-out", "documentation": "Payments to acquire businesses, cash earn-out" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Cash contributed by the Company", "verboseLabel": "Cash payment for acquire assets", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r45", "r538" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment to acquire business", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r45" ] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in subsidiary", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": [ "r45" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investments in or purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r921" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r141" ] }, "NXGL_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "PlacementAgentMember", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "Placement Agent [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970" ] }, "srt_PlatformOperatorCryptoAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetLineItems", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206" ] }, "srt_PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PlatformOperatorCryptoAssetTable", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Table]", "documentation": "Disclosure of information about crypto-asset held for platform user." } } }, "auth_ref": [ "r206" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r867" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r868" ] }, "NXGL_PrePaymentPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "PrePaymentPenalty", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre payment penalty", "documentation": "Pre Payment Penalty" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r124", "r430" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r124", "r724" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r124", "r430" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://nexgel.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r124", "r724", "r743", "r1005", "r1006" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r124", "r652", "r847" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r906" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r816", "r826", "r930" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from issuance of initial public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan advance", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r908" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from margin line of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r46", "r912" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from notes payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations", "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r210", "r227", "r228", "r236", "r242", "r248", "r256", "r257", "r274", "r294", "r300", "r303", "r346", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r542", "r545", "r546", "r559", "r562", "r646", "r661", "r697", "r745", "r767", "r768", "r822", "r844", "r845", "r858", "r907", "r936" ] }, "NXGL_PropertyAndEquipmentAndIntangiblesContributedAsCapitalInvestmentToJv": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "PropertyAndEquipmentAndIntangiblesContributedAsCapitalInvestmentToJv", "crdr": "credit", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Property and equipment and intangibles contributed as capital investment to JV", "documentation": "Property and equipment and intangibles contributed as capital investment to jv." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/PropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r151", "r186", "r190", "r191" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r152", "r214", "r659" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r647", "r659", "r847" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r10", "r186", "r190", "r657" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://nexgel.com/role/PropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r152" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Useful Life (Years)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r456", "r464", "r494", "r495", "r496", "r602", "r626", "r678", "r714", "r715", "r777", "r780", "r784", "r785", "r787", "r810", "r811", "r824", "r833", "r841", "r848", "r851", "r933", "r940", "r989", "r990", "r991", "r992", "r993" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r456", "r464", "r494", "r495", "r496", "r602", "r626", "r678", "r714", "r715", "r777", "r780", "r784", "r785", "r787", "r810", "r811", "r824", "r833", "r841", "r848", "r851", "r933", "r940", "r989", "r990", "r991", "r992", "r993" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://nexgel.com/role/BusinessSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Reportable Segments", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r62", "r63" ] }, "NXGL_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r463", "r589", "r590", "r717", "r718", "r719", "r720", "r721", "r742", "r744", "r776" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r749", "r750", "r753" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r463", "r589", "r590", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r717", "r718", "r719", "r720", "r721", "r742", "r744", "r776", "r985" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r586", "r587", "r588", "r590", "r591", "r693", "r694", "r695", "r751", "r752", "r753", "r773", "r775" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on convertible notes", "label": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r47" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments of notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ReportableSubsegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportableSubsegmentsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Reportable Subsegments [Member]", "documentation": "Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r118", "r510", "r994" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r509" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r50" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r383", "r384", "r385" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r127", "r159", "r654", "r682", "r683", "r691", "r725", "r847" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r207", "r245", "r246", "r247", "r249", "r255", "r257", "r347", "r348", "r502", "r503", "r504", "r526", "r527", "r549", "r551", "r552", "r554", "r557", "r679", "r681", "r698", "r1005" ] }, "NXGL_RevenueClassifiedAsOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "RevenueClassifiedAsOthers", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Revenue classified as others." } } }, "auth_ref": [] }, "NXGL_RevenueFromConsumerProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "RevenueFromConsumerProducts", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails" ], "lang": { "en-us": { "role": { "label": "Consumer branded products", "documentation": "Revenue from consumer products." } } }, "auth_ref": [] }, "NXGL_RevenueFromContractManufacturing": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "RevenueFromContractManufacturing", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails" ], "lang": { "en-us": { "role": { "label": "Contract manufacturing", "documentation": "Revenue from contract manufacturing." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails", "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues, net", "verboseLabel": "Total revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r275", "r276", "r293", "r298", "r299", "r305", "r307", "r309", "r454", "r455", "r628" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r275", "r276", "r293", "r298", "r299", "r305", "r307", "r309", "r454", "r455", "r628" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r193", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r813" ] }, "NXGL_RevenueFromFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "RevenueFromFinishedGoods", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfDisaggregatedRevenueBySalesTypeDetails" ], "lang": { "en-us": { "role": { "label": "Custom and white label finished goods manufacturing", "documentation": "Revenue from finished goods." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remaining performance obligations", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r189" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "NXGL_RouAssetAndOperatingLeaseLiabilitiesRecognizedUponConsolidationOfJv": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "RouAssetAndOperatingLeaseLiabilitiesRecognizedUponConsolidationOfJv", "crdr": "credit", "presentation": [ "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "ROU asset and operating lease liabilities recognized upon consolidation of JV", "documentation": "Rou asset and operating lease liabilities recognized upon consolidation of jv." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, consideration received on transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, description of transaction", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": [ "r16", "r103", "r166" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, number of shares issued in transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://nexgel.com/role/ConcentrationsOfRiskDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r309", "r882" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://nexgel.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://nexgel.com/role/AcquisitionDetailsNarrative", "http://nexgel.com/role/AcquisitionTables", "http://nexgel.com/role/ScheduleOfBusinessAcquisitionsDetails", "http://nexgel.com/role/ScheduleOfUnauditedPro-formaResultsOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r92", "r94", "r536" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://nexgel.com/role/AcquisitionTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r92", "r94" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r541" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://nexgel.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income Tax (Benefit) Provision", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r164" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://nexgel.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://nexgel.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Financial Assets", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r560", "r561" ] }, "NXGL_ScheduleOfFairValueWarrantLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ScheduleOfFairValueWarrantLiabilityTextBlock", "presentation": [ "http://nexgel.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Liability", "documentation": "Schedule Of Fair Value Warrant Liability [Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative", "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r68", "r70", "r629" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://nexgel.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Breakdown of Identifiable Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r68", "r70" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://nexgel.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r30", "r131", "r132", "r133" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://nexgel.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://nexgel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r112", "r113", "r749", "r750", "r753" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://nexgel.com/role/DescriptionOfBusinessStockSplitAndBasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r383", "r384", "r385" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r59", "r60", "r61", "r65" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r466", "r467", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://nexgel.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Incentive Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r25", "r87" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://nexgel.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions used in Share-based Compensation", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r161" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTextBlock", "presentation": [ "http://nexgel.com/role/CommonStockTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Reserved Common Stock For Issued Securities in Relation", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": [ "r29", "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r124", "r125", "r157", "r158", "r159" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://nexgel.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://nexgel.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Estimated Annual Amortization Expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r70" ] }, "NXGL_SecuredConvertiblePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "SecuredConvertiblePromissoryNoteMember", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured Convertible Promissory Note [Member]", "documentation": "Secured Convertible Promissory Note [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r861" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r865" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r864" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r869" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r309", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r382", "r385", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r827", "r886", "r999" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://nexgel.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Geographical area." } } }, "auth_ref": [ "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r307", "r308", "r711", "r712", "r713", "r779", "r782", "r786", "r789", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r814", "r834", "r851", "r943", "r999" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/BusinessSegments" ], "lang": { "en-us": { "role": { "label": "Business Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r286", "r297", "r301", "r302", "r303", "r304", "r305", "r306", "r309" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r307", "r823" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r138" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "http://nexgel.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "verboseLabel": "Stock based compensation and restricted stock vesting", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r842" ] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of units exercisable", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable non vested number.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, exercised and converted to common shares", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercises in period weighted average grant date fair value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of units, forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of units, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r484" ] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average grant date fair value exercisable", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options non vested exercisable weighted average grant date fair value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of units outstanding beginning", "periodEndLabel": "Number of units outstanding ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r481", "r482" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value outstanding beginning", "periodEndLabel": "Weighted average grant date fair value outstanding ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r481", "r482" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options, expiry date", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth_ref": [ "r946" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r495" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r496" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails", "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r466", "r467", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of warrants, cancelled", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails", "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of units, exercised and converted to common shares", "negatedTerseLabel": "Number of warrants, exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of warrants, expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of warrants, forfeited", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of warrants, granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of warrants, outstanding beginning balance", "periodEndLabel": "Number of warrants, outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r18", "r19" ] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of warrants, exercisable", "documentation": "The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of warrants outstanding and currently exercisable under the warrants plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, outstanding beginning balance", "periodEndLabel": "Weighted average exercise price, outstanding ending balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercised": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercised", "presentation": [ "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails" ], "lang": { "en-us": { "role": { "label": "Awards Exercised", "documentation": "Share based compensation arrangement by share based payment award number of shares available for exercised." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Awards Available for Grant", "verboseLabel": "Number of options, granted", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r86" ] }, "NXGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options, cancelled", "documentation": "Share based compensation arrangement by share based payment award options cancelled in period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of options, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r480" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of options, forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r479" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options, granted", "verboseLabel": "Number of shares granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options, outstanding, beginning balance", "periodEndLabel": "Number of options, outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r473", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, outstanding beginning balance", "periodEndLabel": "Weighted average exercise price, outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r473", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options, expected to vest", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r489" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails" ], "lang": { "en-us": { "role": { "label": "Awards Issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfRestrictedStockUnitsGrantedDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ] }, "NXGL_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their warrants into shares.", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to warrants of the plan that expired.", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to warrants that were terminated.", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to warrants that were terminated.", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice" } } }, "auth_ref": [] }, "NXGL_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r478" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r480" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r479" ] }, "NXGL_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledPrice": { "xbrltype": "perShareItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledPrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, cancelled", "documentation": "Share based compensation arrangement by share based payment award options grants in period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "verboseLabel": "Exercise price of options", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r465", "r472", "r491", "r492", "r493", "r494", "r497", "r505", "r506", "r507", "r508" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award vesting rights, percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r945" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r843" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://nexgel.com/role/ScheduleOfAssumptionsUsedInShare-basedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r493" ] }, "NXGL_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://nexgel.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average remaining contractual term, exercisable", "documentation": "Weighted average remaining contractual term, exercisable.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" } } }, "auth_ref": [] }, "NXGL_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://nexgel.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nexgel.com/role/ScheduleOfCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for non option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual term, exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r86" ] }, "NXGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://nexgel.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual term, granted", "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 2." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r160" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options, vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock outstanding percentage", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "NXGL_ShippingAndHandlingRevenueAndExpensePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "ShippingAndHandlingRevenueAndExpensePolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Shipping and Handling Revenue and Expense", "documentation": "Shipping and handling revenue and expense policy text block." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Margin line of credit", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r121", "r170", "r847", "r996" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimates" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies and Estimates", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r145", "r239" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r870" ] }, "NXGL_SportDefenseLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "SportDefenseLlcMember", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sport Defense LLC [Member]", "documentation": "Sport Defense LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://nexgel.com/role/ScheduleOfIncomeTaxBenefitProvisionDetails" ], "lang": { "en-us": { "role": { "label": "State and local:" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r209", "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r309", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r378", "r382", "r385", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r827", "r886", "r999" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r194", "r220", "r221", "r222", "r242", "r260", "r261", "r263", "r265", "r268", "r269", "r346", "r392", "r394", "r395", "r396", "r399", "r400", "r430", "r431", "r433", "r436", "r443", "r562", "r687", "r688", "r689", "r690", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r710", "r724", "r746", "r769", "r790", "r791", "r792", "r793", "r794", "r881", "r911", "r919" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/StatementsOfStockholdersEquity", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r43", "r207", "r230", "r231", "r232", "r245", "r246", "r247", "r249", "r255", "r257", "r267", "r347", "r348", "r445", "r502", "r503", "r504", "r526", "r527", "r549", "r550", "r551", "r552", "r553", "r554", "r557", "r563", "r564", "r565", "r566", "r567", "r568", "r585", "r679", "r680", "r681", "r698", "r769" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://nexgel.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r195", "r205", "r307", "r308", "r711", "r712", "r713", "r779", "r782", "r786", "r789", "r797", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r814", "r834", "r851", "r943", "r999" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://nexgel.com/role/Cover", "http://nexgel.com/role/IncomeTaxesDetailsNarrative", "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r247", "r267", "r628", "r685", "r710", "r716", "r717", "r718", "r719", "r720", "r721", "r724", "r727", "r728", "r729", "r730", "r731", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r742", "r744", "r747", "r748", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r769", "r852" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://nexgel.com/role/Cover", "http://nexgel.com/role/IncomeTaxesDetailsNarrative", "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r245", "r246", "r247", "r267", "r628", "r685", "r710", "r716", "r717", "r718", "r719", "r720", "r721", "r724", "r727", "r728", "r729", "r730", "r731", "r733", "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r742", "r744", "r747", "r748", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r769", "r852" ] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares reserved for issuance, awarded", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r84", "r89" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://nexgel.com/role/ScheduleOfReservedCommonStockForIssuedSecuritiesInRelationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r17", "r79", "r124", "r125", "r159" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://nexgel.com/role/ScheduleOfReservedCommonStockForIssuedSecuritiesInRelationDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative", "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted stock issuances, shares", "verboseLabel": "Restricted stock units", "terseLabel": "Restricted stock vesting, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r17", "r159" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://nexgel.com/role/ScheduleOfReservedCommonStockForIssuedSecuritiesInRelationDetails", "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "verboseLabel": "Share-based compensation plan", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r17", "r124", "r125", "r159" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r17", "r124", "r125", "r159", "r478" ] }, "NXGL_StockIssuedDuringPeriodSharesStockWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock warrants, shares", "documentation": "Stock issued during period shares stock warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted stock issuances", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r17", "r124", "r125", "r159" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r88", "r124", "r125", "r159" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares reserved for issuance, exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r17", "r43", "r159" ] }, "NXGL_StockIssuedDuringPeriodValueStockWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised", "crdr": "credit", "presentation": [ "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "Stock issued during period value stock warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r851" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total NexGel stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r125", "r128", "r129", "r147", "r726", "r743", "r770", "r771", "r847", "r859", "r913", "r928", "r979", "r1005" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://nexgel.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r101", "r102", "r104", "r207", "r208", "r231", "r245", "r246", "r247", "r249", "r255", "r347", "r348", "r445", "r502", "r503", "r504", "r526", "r527", "r549", "r550", "r551", "r552", "r553", "r554", "r557", "r563", "r564", "r568", "r585", "r680", "r681", "r696", "r726", "r743", "r770", "r771", "r795", "r858", "r913", "r928", "r979", "r1005" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/CommonStock" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r156", "r241", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r445", "r556", "r772", "r774", "r796" ] }, "NXGL_SubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "SubscriptionAgreementsMember", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subscription Agreements [Member]", "documentation": "Subscription Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsConsolidationItemsAxis", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Subsegments Consolidation Items [Axis]", "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsConsolidationItemsDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r569", "r594" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r569", "r594" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r569", "r594" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r569", "r594" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/NotesPayableDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r569", "r594" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://nexgel.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r593", "r595" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://nexgel.com/role/ConvertibleNotesPayableDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://nexgel.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r120" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r27" ] }, "NXGL_TechnologyRelatedAndCustomerRelatedIntangiblesMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "TechnologyRelatedAndCustomerRelatedIntangiblesMember", "presentation": [ "http://nexgel.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Technology Related and Customer Related Intangibles [Member]", "documentation": "Technology Related and Customer Related Intangibles [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r920", "r984" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r177", "r178", "r179", "r312", "r313", "r315" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://nexgel.com/role/ScheduleOfBreakdownOfIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r98" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails", "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails", "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r426", "r441", "r555", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r664", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r924", "r925", "r926", "r927" ] }, "NXGL_TwoThousandAndNineteenLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "TwoThousandAndNineteenLongTermIncentivePlanMember", "presentation": [ "http://nexgel.com/role/ScheduleOfIncentiveStockOptionActivityDetails", "http://nexgel.com/role/ScheduleOfInformationAboutIncentivePlanDetails", "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2019 Plan [Member]", "documentation": "2019 Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r541" ] }, "NXGL_USTreasurySecuritiesFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "USTreasurySecuritiesFiveMember", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities Five [Member]", "documentation": "US Treasury Securities Five [Member]" } } }, "auth_ref": [] }, "NXGL_USTreasurySecuritiesFourMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "USTreasurySecuritiesFourMember", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities Four [Member]", "documentation": "US Treasury Securities Four [Member]" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://nexgel.com/role/ScheduleOfFairValueOfFinancialAssetsDetails", "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r819", "r836", "r838", "r995" ] }, "NXGL_USTreasurySecuritiesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "USTreasurySecuritiesOneMember", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities One [Member]", "documentation": "US Treasury Securities One [Member]" } } }, "auth_ref": [] }, "NXGL_USTreasurySecuritiesThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "USTreasurySecuritiesThreeMember", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities Three [Member]", "documentation": "US Treasury Securities Three [Member]" } } }, "auth_ref": [] }, "NXGL_USTreasurySecuritiesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "USTreasurySecuritiesTwoMember", "presentation": [ "http://nexgel.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities Two [Member]", "documentation": "US Treasury Securities Two [Member]" } } }, "auth_ref": [] }, "NXGL_UnrecognizedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "UnrecognizedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://nexgel.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized share based compensation expense", "documentation": "Unrecognized share based compensation expense." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://nexgel.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r512", "r518" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r56", "r57", "r58", "r184", "r185", "r187", "r188" ] }, "NXGL_VIEPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "VIEPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity" } } }, "auth_ref": [] }, "NXGL_WarrantLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantLiabilityCurrent", "crdr": "credit", "calculation": { "http://nexgel.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nexgel.com/role/BalanceSheets", "http://nexgel.com/role/ScheduleOfReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Warrant liability", "documentation": "Warrant liability current." } } }, "auth_ref": [] }, "NXGL_WarrantLiabilityPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantLiabilityPolicyPolicyTextBlock", "presentation": [ "http://nexgel.com/role/SignificantAccountingPoliciesAndEstimatesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant Liability", "documentation": "Warrant Liability Policy [Policy Text Block]", "label": "WarrantLiabilityPolicyPolicyTextBlock" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r849", "r850", "r853", "r854", "r855", "r856" ] }, "NXGL_WarrantModification": { "xbrltype": "sharesItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantModification", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants outstanding, warrant modification", "documentation": "Warrant Modification." } } }, "auth_ref": [] }, "NXGL_WarrantModificationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantModificationExpense", "crdr": "debit", "calculation": { "http://nexgel.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails", "http://nexgel.com/role/StatementsOfCashFlows", "http://nexgel.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant modification expense", "verboseLabel": "Fair value, modification of warrants", "documentation": "Warrant modification expense." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://nexgel.com/role/ScheduleOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value, beginning balance", "periodEndLabel": "Fair value, ending balance", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants expire term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r978" ] }, "NXGL_WarrantsExercisablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantsExercisablePeriod", "presentation": [ "http://nexgel.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable period", "documentation": "Warrants exercisable period" } } }, "auth_ref": [] }, "NXGL_WarrantsLiabilityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantsLiabilityDisclosureTextBlock", "presentation": [ "http://nexgel.com/role/WarrantLiability" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant Liability", "documentation": "Warrants Liability Disclosure [Text Block]", "label": "WarrantsLiabilityDisclosureTextBlock" } } }, "auth_ref": [] }, "NXGL_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants to Purchase Common Stock [Member]", "documentation": "Warrants to Purchase Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares used in computing net loss per common share - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r259", "r265" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://nexgel.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares used in computing net loss per common share - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r258", "r265" ] }, "NXGL_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://nexgel.com/20231231", "localname": "WorkingCapitalDeficit", "crdr": "credit", "presentation": [ "http://nexgel.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital deficit." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nexgel.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r879" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.28)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "4", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "FF", "Subsection": "Q2", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r881": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 101 0001493152-24-014127-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014127-xbrl.zip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end XML 103 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001468929 2023-01-01 2023-12-31 0001468929 NXGL:CommonStockParValue0.001Member 2023-01-01 2023-12-31 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2023-01-01 2023-12-31 0001468929 2023-06-30 0001468929 2024-04-10 0001468929 2023-12-31 0001468929 2022-12-31 0001468929 2022-01-01 2022-12-31 0001468929 us-gaap:CommonStockMember 2021-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2021-12-31 0001468929 us-gaap:RetainedEarningsMember 2021-12-31 0001468929 2021-12-31 0001468929 us-gaap:CommonStockMember 2022-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2022-12-31 0001468929 us-gaap:RetainedEarningsMember 2022-12-31 0001468929 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001468929 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001468929 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001468929 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001468929 us-gaap:CommonStockMember 2023-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-12-31 0001468929 us-gaap:RetainedEarningsMember 2023-12-31 0001468929 NXGL:JointVentureMember 2023-03-01 0001468929 NXGL:CGLabsMember 2023-03-01 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember 2024-02-15 0001468929 NXGL:USTreasurySecuritiesOneMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesOneMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesTwoMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesTwoMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesThreeMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesThreeMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesFourMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesFourMember 2022-12-31 0001468929 NXGL:USTreasurySecuritiesFiveMember 2023-12-31 0001468929 NXGL:USTreasurySecuritiesFiveMember 2022-12-31 0001468929 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001468929 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001468929 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001468929 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001468929 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001468929 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001468929 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001468929 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:ContractManufacturingMember 2023-01-01 2023-12-31 0001468929 NXGL:ContractManufacturingMember us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomAndWhiteLabelFinishedGoodsMember us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-12-31 0001468929 NXGL:BrandedConsumerProductsMember us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember NXGL:OtherIncomesMember 2023-01-01 2023-12-31 0001468929 NXGL:OtherIncomesMember us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember 2023-01-01 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:ContractManufacturingMember 2022-01-01 2022-12-31 0001468929 NXGL:ContractManufacturingMember us-gaap:ReportableSubsegmentsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomAndWhiteLabelFinishedGoodsMember us-gaap:ReportableSubsegmentsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:BrandedConsumerProductsMember 2022-01-01 2022-12-31 0001468929 NXGL:BrandedConsumerProductsMember us-gaap:ReportableSubsegmentsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember NXGL:OtherIncomesMember 2022-01-01 2022-12-31 0001468929 NXGL:OtherIncomesMember us-gaap:ReportableSubsegmentsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember 2022-01-01 2022-12-31 0001468929 NXGL:CGLabsMember 2022-01-01 2022-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2022-01-01 2022-12-31 0001468929 NXGL:NexgelMember 2023-12-31 0001468929 NXGL:CGLabsMember 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2023-12-31 0001468929 NXGL:KenkodermAcquisitionMember 2023-12-01 2023-12-01 0001468929 NXGL:KenkodermAcquisitionMember 2023-12-01 0001468929 NXGL:CGLaboratoriesIncMember 2023-03-01 0001468929 2023-03-01 2023-03-01 0001468929 NXGL:KenkodermAcquisitionMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember 2023-01-01 2023-12-31 0001468929 NXGL:CGLabsMember 2023-12-31 0001468929 NXGL:KenkodermAcquisitionMember 2022-01-01 2022-12-31 0001468929 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0001468929 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0001468929 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001468929 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001468929 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001468929 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001468929 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001468929 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001468929 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001468929 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001468929 us-gaap:ConstructionInProgressMember 2023-12-31 0001468929 us-gaap:ConstructionInProgressMember 2022-12-31 0001468929 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0001468929 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:CustomerRelatedIntangibleAssetsMember 2022-12-31 0001468929 us-gaap:TradeNamesMember 2023-12-31 0001468929 us-gaap:TradeNamesMember 2022-12-31 0001468929 us-gaap:MarketingRelatedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:MarketingRelatedIntangibleAssetsMember 2022-12-31 0001468929 NXGL:SportDefenseLlcMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2020-05-29 0001468929 NXGL:CGLabsJVMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2023-03-01 0001468929 NXGL:KenkodermMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2023-12-01 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2020-05-26 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-05-03 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-05-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 2023-03-23 0001468929 srt:ExecutiveOfficerMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 2023-03-23 0001468929 NXGL:ContractorMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-08 0001468929 NXGL:ContractorMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-08 2023-03-08 0001468929 srt:DirectorMember 2023-08-17 0001468929 srt:DirectorMember 2023-08-17 2023-08-17 0001468929 NXGL:Dr.NeilChesenMember NXGL:OptionOneMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:OptionOneMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:OptionTwoMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:OptionTwoMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:OptionThreeMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 0001468929 NXGL:Dr.NeilChesenMember NXGL:OptionThreeMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:OptionOneMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:OptionOneMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 srt:MaximumMember NXGL:Dr.LeonardNelsonMember NXGL:OptionOneMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:OptionTwoMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 0001468929 NXGL:Dr.LeonardNelsonMember NXGL:OptionTwoMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 srt:MaximumMember NXGL:Dr.LeonardNelsonMember NXGL:OptionTwoMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-10-01 2022-10-01 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-12-31 0001468929 srt:MinimumMember us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-01-01 2023-12-31 0001468929 srt:MaximumMember us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-01-01 2023-12-31 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2023-01-03 2023-01-03 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2023-01-03 0001468929 NXGL:OfficersAndEmployeesMember us-gaap:RestrictedStockMember 2022-08-01 2022-08-01 0001468929 NXGL:OfficersAndEmployeesMember us-gaap:RestrictedStockMember 2022-08-01 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2022-01-01 2022-01-01 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2022-01-01 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-12-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-01-01 2023-12-31 0001468929 NXGL:AwardsGrantedOutsideOfThe2019PlanMember 2023-12-31 0001468929 NXGL:AwardsGrantedOutsideOfThe2019PlanMember 2023-01-01 2023-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-01-01 2021-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2022-01-01 2022-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-01-01 2023-12-31 0001468929 srt:MinimumMember 2023-01-01 2023-12-31 0001468929 srt:MaximumMember 2023-01-01 2023-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001468929 2021-01-01 2021-12-31 0001468929 NXGL:CGLabsNotesPayableMember 2023-12-31 0001468929 NXGL:CGLabsNotesPayableMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001468929 NXGL:CGLabsNotesPayableMember us-gaap:SubsequentEventMember 2024-03-13 0001468929 NXGL:CGLabsNotesPayableOneMember 2023-12-31 0001468929 NXGL:CGLabsNotesPayableOneMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001468929 NXGL:CGLabsNotesPayableOneMember us-gaap:SubsequentEventMember 2024-03-13 0001468929 NXGL:EconomicInjuryDisasterLoanMember 2020-05-28 0001468929 NXGL:EconomicInjuryDisasterLoanMember 2020-05-27 2020-05-28 0001468929 NXGL:AuctusNoteMember 2021-03-11 0001468929 NXGL:AuctusNoteMember 2021-03-10 2021-03-11 0001468929 2022-03-15 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember us-gaap:PrivatePlacementMember 2021-09-02 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember 2021-09-02 2021-09-02 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember 2022-01-25 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0001468929 NXGL:SecuredConvertiblePromissoryNoteMember us-gaap:PrivatePlacementMember 2022-09-06 0001468929 us-gaap:PrivatePlacementMember 2021-09-02 0001468929 us-gaap:PrivatePlacementMember 2021-03-11 0001468929 us-gaap:PrivatePlacementMember 2021-02-03 0001468929 us-gaap:PrivatePlacementMember 2020-12-24 0001468929 us-gaap:PrivatePlacementMember 2020-03-18 0001468929 us-gaap:PrivatePlacementMember 2019-09-10 0001468929 us-gaap:PrivatePlacementMember 2019-11-06 0001468929 srt:MinimumMember us-gaap:PrivatePlacementMember 2023-12-31 0001468929 srt:MaximumMember us-gaap:PrivatePlacementMember 2023-12-31 0001468929 2022-09-05 2022-09-06 0001468929 us-gaap:WarrantMember 2021-12-31 0001468929 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001468929 us-gaap:WarrantMember 2022-12-31 0001468929 us-gaap:WarrantMember 2023-12-31 0001468929 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001468929 NXGL:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001468929 NXGL:Mr.SteinMember 2021-09-02 0001468929 NXGL:Mr.StefanskyMember 2021-09-02 0001468929 NXGL:Dr.JeromeZeldisMember 2021-09-02 0001468929 NXGL:Dr.JeromeZeldisMember 2023-12-31 0001468929 NXGL:Dr.JeromeZeldisMember 2022-12-31 0001468929 country:PA 2023-12-31 0001468929 country:PA 2022-12-31 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 us-gaap:CommonStockMember us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 us-gaap:CommonStockMember us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 us-gaap:WarrantMember us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 srt:MinimumMember us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 srt:MaximumMember us-gaap:SubsequentEventMember NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 NXGL:NonAffiliatedEntityMember us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 srt:AffiliatedEntityMember us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 us-gaap:SubsequentEventMember NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 iso4217:USD shares iso4217:USD shares pure NXGL:Segment NXGL:Integer false FY 0001468929 10-K true 2023-12-31 --12-31 2023 false 001-41173 NexGel, Inc. DE 26-4042544 2150 Cabot Blvd West Suite B Langhorne PA 19047 (215) 702-8550 Common Stock, par value $0.001 NXGL NASDAQ Warrants to Purchase Common Stock NXGLW NASDAQ No No No Yes Non-accelerated Filer true true false false false false 10695605 6227624 Portions of the registrant’s definitive proxy statement relating to its 2024 annual meeting of stockholders (the “2024 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the year to which this report relates. 76 Turner, Stone & Company, L.L.P Dallas, Texas 2700000 1101000 5508000 633000 222000 1319000 502000 400000 172000 5052000 7505000 1128000 311000 326000 20000 1499000 721000 1855000 1737000 95000 63000 9955000 10357000 1233000 265000 398000 130000 20000 80000 15000 146000 242000 439000 233000 207000 2549000 859000 1727000 1593000 513000 268000 4789000 2720000 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 25000000 25000000 5741838 5741838 5577916 5577916 6000 6000 19406000 19189000 -14715000 -11558000 4697000 7637000 469000 5166000 7637000 9955000 10357000 4089000 2048000 3470000 1792000 619000 256000 103000 367000 3993000 3237000 4096000 3604000 -3477000 -3348000 -96000 -76000 191000 9000 -150000 15000 1336000 2000 19000 3000 289000 -1398000 -3188000 -4746000 -3188000 -4746000 -31000 -3157000 -4746000 -0.56 -0.56 -0.85 -0.85 5671842 5671842 5574818 5574818 5572234 6000 18891000 -6812000 12085000 231000 231000 5682 67000 67000 -4746000 -4746000 5577916 6000 19189000 -11558000 7637000 5577916 6000 19189000 -11558000 7637000 5577916 6000 19189000 -11558000 7637000 3295 217000 217000 50907 109720 500000 500000 -31000 -3157000 -3188000 5741838 6000 19406000 469000 -14715000 5166000 5741838 6000 19406000 469000 -14715000 5166000 -3157000 -4746000 -31000 226000 112000 217000 298000 191000 9000 -125000 -133000 217000 189000 29000 57000 -150000 1324000 411000 13000 760000 211000 260000 95000 968000 11000 22000 74000 20000 -3236000 -2992000 696000 96000 547000 5699000 1500000 6999000 4456000 -5595000 175000 151000 315000 6000 3511000 245000 379000 -3662000 1599000 -12249000 1101000 13350000 2700000 1101000 500000 334000 <p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zgDskWdFdhMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_82E_zsoLQuP6jqSe">Description of Business, Stock Split and Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NexGel, Inc. (“NexGel” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the company. First, we launched our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2023, the Company acquired a <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230301__us-gaap--BusinessAcquisitionAxis__custom--JointVentureMember_z7hg927eFehe" title="Acquisition percentage">50</span>% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC, with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business. The JV is effective March 1, 2023. <span style="background-color: white">As a result of this transaction, the Company owns <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230301__us-gaap--BusinessAcquisitionAxis__custom--JointVentureMember_zyJgH3KTADke" title="Acquisition percentage">50%</span> of the JV, with the remaining <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230301__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zwkllj91FRVe" title="Acquisition percentage">50</span>% held by CG Labs.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated <span style="background-color: white">financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and are presented in US dollars.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles of Consolidation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its consolidated wholly-owned subsidiary, NexGelRx, Inc. and the fifty percent (<span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230301__us-gaap--BusinessAcquisitionAxis__custom--JointVentureMember_zegKUg9hCWgd" title="Acquisition percentage">50%</span>) owned JV (see Note 13).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.50 0.50 0.50 0.50 <p id="xdx_80F_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zncHraqB2LQ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_82B_zMd2juNJax0h">Going Concern</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had a cash balance of $<span id="xdx_902_eus-gaap--Cash_iI_pn5n6_c20231231_ziZJfBu8Lkxl" title="Cash">2.7</span> million. For the year ended December 31, 2023, the Company incurred a net loss of $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zcYvP0Ys6Ilg" title="Net loss">3.2</span> million and had a net usage of cash in operating activities of $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zVk97ykHruh1" title="Net cash used in operating activities">3.2</span> million. In addition, the Company had a working capital of $<span id="xdx_90B_ecustom--WorkingCapitalDeficit_iI_pn5n6_c20231231_zNS1v12whZdf" title="Working capital">2.5</span> million as of December 31, 2023. Additionally, we believe we have sufficient cash and marketable securities to operate our business plan into 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 15, 2024, the Company, entered into subscription agreements with investors, the Company’s Chief Financial Officer and certain members of its board of directors for a registered direct offering (“RDO”) of the Company’s common stock. The RDO sold an aggregate <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240215__20240215__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5BQRooH9fLb" title="Sale of stock, number of shares issued in transaction">242,891</span> units at a price to the public of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240215__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrIl0RoeZ7d6" title="Sale of stock, price per share">4.22</span> per unit, with <span id="xdx_903_eus-gaap--SaleOfStockDescriptionOfTransaction_c20240215__20240215__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGAo5O3nE6R4" title="Sale of stock, description of transaction">each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240215__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEiLHmClXLi5" title="Class of warrant or right, exercise price of warrants or rights">4.00</span> per share. The $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240215__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNkGu9qdm3pk" title="Sale of stock, price per share">4.22</span> purchase price equals two times the last reported sale price of $2.11 per share of the Company’s Common Stock on February 15, 2024 on The Nasdaq Capital Market.</span> The gross proceeds to the Company from the Offering are expected to be approximately $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n6_c20240215__20240215__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zURKmRIAEuL1" title="Sale of stock, consideration received on transaction">1.025</span> million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering for working capital and for general corporate purposes (See Note 20).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices. The Company has increased focus on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have sufficient capital to maintain as a going concern due to the recent capital raise. We intend to maintain and attempt to grow our existing contract manufacturing business. We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media, television and online marketplaces. Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology. Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2700000 -3200000 -3200000 2500000 242891 4.22 each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $4.00 per share. The $4.22 purchase price equals two times the last reported sale price of $2.11 per share of the Company’s Common Stock on February 15, 2024 on The Nasdaq Capital Market. 4.00 4.22 1025000.000 <p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zr6LbhID8oL3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_821_zLiMa94NQh3k">Significant Accounting Policies and Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_z0sQuJMbswJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zM0sx516nQGe">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zaK19L0rAdLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_869_zx7G2Yr3Xl88" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segment Reporting</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, <i>Segment Reporting</i>, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company has two reportable segments - the Nexgel segment and the CG labs segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nexgel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CG labs segment is comprised of the JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoiHsBhldDba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zfmkeG6Tpz5g">Cash</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_zJCltc7KPLxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_862_zXxNUP9uXUK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable Securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_z91vNCuS6dl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z5l5aOK4IGac" style="display: none">Schedule of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_zgZuk6cDWJCa" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20221231_zJdIKExOvqWl" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Marketable Securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesOneMember_zlEZ4gma2XI8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">United States treasury bills (due <span id="xdx_90D_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesOneMember_zIsRKPYybF42" title="Marketable securities, due date">February 23, 2023</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">492</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesTwoMember_zN3nhu5pTR96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_902_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesTwoMember_zHUo1mTRSj1g" title="Marketable securities, due date">April 27, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesThreeMember_zkZoWqUPKH81" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_905_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesThreeMember_zBrTip4iDpSd" title="Marketable securities, due date">June 15, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,384</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFourMember_zHmFycE1HnXk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_905_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFourMember_zqypA5H9Atr6" title="Marketable securities, due date">July 13, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFiveMember_zdMfmoAdQhh1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills (due <span id="xdx_907_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFiveMember_zBIerYCvBXJ5" title="Marketable securities, due date">August 10, 2023</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">485</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MarketableSecurities_iI_pn3n3_zMoVHK1LWkyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zjMTPGNtmahe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zFwbDgpPKxC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zRL9kbCwofQi">Margin Line of Credit</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a brokerage account through which we buy and sell U.S. treasury bills. The provisions of the account allow us to borrow on certain securities held in the account and to purchase additional securities based on the account equity (including cash). Amounts borrowed are collateralized by the securities held in the account and bear interest at a negotiated rate payable monthly. Securities pledged to secure margin balances cannot be specifically identified as a portion of all securities held in a brokerage account are used as collateral. As of December 31, 2023, there was $<span id="xdx_906_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231_zn87SUWiQSX8" title="Shor term line of credit">245</span> thousand outstanding under this short-term credit line which is included in accrued expenses and other current liabilities within the accompanying consolidated balance sheet (see Note 10). The short-term credit line will be repaid upon the maturity of U.S. treasury bills of $<span id="xdx_902_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn6n6_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zZKzmhHpAiH9" title="U.S. treasury bills held for sale">3</span> million with an original maturity of three months or less which are included in cash within the accompanying consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zRNUVCj8FyDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z5OzavR8i048">Accounts Receivable, net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $<span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zzCUDaQqkKr8" title="Allowance for doubtful accounts">11</span> thousand as of December 31, 2023 and $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_z8FwFdpDWD5i" title="Allowance for doubtful accounts">9</span> thousand as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zotHFe9nGZUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3R0BoiHjhId">Inventory and Cost of Revenues</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zY87I7kIp2qa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zojvSBtJa3ia">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--ShippingAndHandlingRevenueAndExpensePolicyTextBlock_zkiOSyT8Rrdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zpbA8Jz9UcOg">Shipping and Handling Revenue and Expense</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. Shipping revenue and expense are primarily generated through the Amazon marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6sJlnlrTtej" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zmaw9RMRPKne">Property and Equipment, net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zCmYHaFMjmMb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zcUsd9oRQJea">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOX6KfloxTKi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zStbFCT7sSxj">Goodwill and Intangible Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and <span id="xdx_907_eus-gaap--GoodwillAndIntangibleAssetImpairment_do_c20230101__20231231_zW6c9G9ZVK66" title="Goodwill and intangible asset impairment"><span id="xdx_90E_eus-gaap--GoodwillAndIntangibleAssetImpairment_do_c20220101__20221231_z73UJxGH4zca" title="Goodwill and intangible asset impairment">no</span></span> impairments were recognized in the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zBNvAr0lIWLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zdB8JrbbPpG8">Prepaid Expenses and Other Current Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $<span id="xdx_90D_eus-gaap--PrepaidInsurance_iI_pn3n3_c20231231_zI61gjr6Uab" title="Prepaid insurance">64</span> thousand and $<span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20221231_zWxeaAhRFKQ1" title="Prepaid insurance">63</span> thousand of prepaid insurance, and $<span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20231231_zPEjseZmBEK3" title="General prepaid expenses">336</span> thousand and $<span id="xdx_908_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20221231_zLmCjyWnRqd" title="General prepaid expenses">109</span> thousand general prepaid expenses and other current assets in the years ended December 31, 2023 and 2022 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--OtherAssetsPolicyPolicyTextBlock_z818VjI7yemi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Assets</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Assets is recorded at historical costs, and as of December 31, 2023 and 2022, the balance is primarily comprised of spare parts for manufacturing equipment. Spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zZ4wQlWbPjT3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zTwjwwfc1b35">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 1</i> —Quoted prices for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 2</i> —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 3</i> —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zBXre5rFIIlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zGBhadxIBD65" style="display: none">Schedule of Fair Value of Financial Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zyxFkAC32pjg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpkOqJLerH1d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_za4bOU8fDCnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zCeppr3ngY11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">     </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">     </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">      </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MarketableSecurities_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zw50sqCuf7Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_z7pjeFtI17El" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqTbV9o5dIGf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQxOdtve4uDg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhK8oCAXIfxj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zsmun45lmQ3a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z1owo6GpGQRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_pn3n3_zr5dQbvIcKP6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zB9jxybk4wba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84C_ecustom--WarrantLiabilityPolicyPolicyTextBlock_zZk9t9K6Rhc3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zolA0rKTEQ1c">Warrant Liability</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zZfA1cPvBUUk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z2JGWud8WUY4">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2018, the Company adopted ASC Topic 606, <i>Revenue from Contracts with Customers</i> (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_zfnMYXu9uFM4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated revenue by sales type ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zzKAh7fzJD41" style="display: none">Schedule of Disaggregated Revenue by Sales Type</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zCCHPzeQOc5b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20220101__20221231_z2i6hNVIId61" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_405_ecustom--RevenueFromContractManufacturing_pn3n3_maRFCWCzE8T_z8ES7lzhK9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturing</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,748</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,033</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--RevenueFromFinishedGoods_pn3n3_maRFCWCzE8T_zMSFFImSWA29" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Custom and white label finished goods manufacturing</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--RevenueFromConsumerProducts_pn3n3_maRFCWCzE8T_zTanvmgFo4qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer branded products</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,242</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">815</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_ecustom--RevenueClassifiedAsOthers_pn3n3_maRFCWCzE8T_zaSMZ5xQLNKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">166</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_iT_pn3n3_mtRFCWCzE8T_zY0tZ9ZYK5ei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,089</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,048</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zagZFXrJHVze" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company did not have any contract assets or contract liabilities from contracts with customers and there were <span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn3n3_do_c20231231_zHIGJ4sLoiP7" title="Remaining performance obligations"><span id="xdx_90D_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn3n3_do_c20221231_zLwQucWjZ7k7" title="Remaining performance obligations">no</span></span> remaining performance obligations that the Company had not satisfied except for deferred revenue of $<span id="xdx_90D_eus-gaap--DeferredRevenue_iI_pn3n3_c20231231_zVE1VDX06XJ1" title="Deferred revenue">20</span> thousand at December 31, 2023 that the Company had not satisfied as of the end of the year. The Company had no remaining performance obligations as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has four distinct lines of business; Contract Manufacturing, Custom &amp; White Label, Consumer Branded Products, and Medical Devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Manufacturing</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they convert and package into finished goods. Historically, this has been the Company’s primary source of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Custom and White Label</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consumer Branded Products</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical Devices/Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Devices are a hybrid business, combining elements of Custom &amp; White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBBOVb37aXpk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zRlRCQeFjPtd">Share-based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 12 below for further details regarding the 2019 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_ztY2lW0Za9g6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z5Zx0ww1k7cf">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zqBJpgxLQ1ha" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zDYAp0VoAc9l">Leases</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_84E_ecustom--VIEPolicyTextBlock_zraqCm9tM2w6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Variable Interest Entity</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, <i>Consolidation</i>. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. As of December 31, 2023, and on a quarterly basis thereafter, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zsCsNJpYQL14" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zLtULUrBy3Z4">Comprehensive loss</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8pJFybHa1sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_z6wbk4rimti4">Recently Issued Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023 and subsequent interim periods. The Company adopted this new standard in the current year and it did not have a material impact to its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--NewAccountingPronouncementsPolicyTextBlock_zsRBqWZK2Ki1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zlWkX8140wuh">Accounting Pronouncements Issued But Not Yet Adopted </span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced income tax related disclosures. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07<i>, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures relating to its reportable segments. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p id="xdx_85A_zWXtLrNrjnTc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_z0sQuJMbswJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zM0sx516nQGe">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zaK19L0rAdLc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_869_zx7G2Yr3Xl88" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segment Reporting</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, <i>Segment Reporting</i>, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company has two reportable segments - the Nexgel segment and the CG labs segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nexgel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CG labs segment is comprised of the JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoiHsBhldDba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zfmkeG6Tpz5g">Cash</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_zJCltc7KPLxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_862_zXxNUP9uXUK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable Securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_z91vNCuS6dl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z5l5aOK4IGac" style="display: none">Schedule of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_zgZuk6cDWJCa" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20221231_zJdIKExOvqWl" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Marketable Securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesOneMember_zlEZ4gma2XI8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">United States treasury bills (due <span id="xdx_90D_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesOneMember_zIsRKPYybF42" title="Marketable securities, due date">February 23, 2023</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">492</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesTwoMember_zN3nhu5pTR96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_902_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesTwoMember_zHUo1mTRSj1g" title="Marketable securities, due date">April 27, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesThreeMember_zkZoWqUPKH81" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_905_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesThreeMember_zBrTip4iDpSd" title="Marketable securities, due date">June 15, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,384</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFourMember_zHmFycE1HnXk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_905_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFourMember_zqypA5H9Atr6" title="Marketable securities, due date">July 13, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFiveMember_zdMfmoAdQhh1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills (due <span id="xdx_907_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFiveMember_zBIerYCvBXJ5" title="Marketable securities, due date">August 10, 2023</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">485</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MarketableSecurities_iI_pn3n3_zMoVHK1LWkyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zjMTPGNtmahe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_z91vNCuS6dl6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had the following marketable securities as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z5l5aOK4IGac" style="display: none">Schedule of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_zgZuk6cDWJCa" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20221231_zJdIKExOvqWl" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Marketable Securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesOneMember_zlEZ4gma2XI8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">United States treasury bills (due <span id="xdx_90D_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesOneMember_zIsRKPYybF42" title="Marketable securities, due date">February 23, 2023</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">492</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesTwoMember_zN3nhu5pTR96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_902_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesTwoMember_zHUo1mTRSj1g" title="Marketable securities, due date">April 27, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesThreeMember_zkZoWqUPKH81" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_905_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesThreeMember_zBrTip4iDpSd" title="Marketable securities, due date">June 15, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,384</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFourMember_zHmFycE1HnXk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">United States treasury bills (due <span id="xdx_905_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFourMember_zqypA5H9Atr6" title="Marketable securities, due date">July 13, 2023</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFiveMember_zdMfmoAdQhh1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills (due <span id="xdx_907_eus-gaap--InvestmentMaturityDate_iI_dd_c20221231__us-gaap--FinancialInstrumentAxis__custom--USTreasurySecuritiesFiveMember_zBIerYCvBXJ5" title="Marketable securities, due date">August 10, 2023</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">485</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MarketableSecurities_iI_pn3n3_zMoVHK1LWkyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2023-02-23 492000 2023-04-27 20000 2023-06-15 4384000 2023-07-13 127000 2023-08-10 485000 5508000 <p id="xdx_84D_eus-gaap--DebtPolicyTextBlock_zFwbDgpPKxC5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zRL9kbCwofQi">Margin Line of Credit</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a brokerage account through which we buy and sell U.S. treasury bills. The provisions of the account allow us to borrow on certain securities held in the account and to purchase additional securities based on the account equity (including cash). Amounts borrowed are collateralized by the securities held in the account and bear interest at a negotiated rate payable monthly. Securities pledged to secure margin balances cannot be specifically identified as a portion of all securities held in a brokerage account are used as collateral. As of December 31, 2023, there was $<span id="xdx_906_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231_zn87SUWiQSX8" title="Shor term line of credit">245</span> thousand outstanding under this short-term credit line which is included in accrued expenses and other current liabilities within the accompanying consolidated balance sheet (see Note 10). The short-term credit line will be repaid upon the maturity of U.S. treasury bills of $<span id="xdx_902_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn6n6_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zZKzmhHpAiH9" title="U.S. treasury bills held for sale">3</span> million with an original maturity of three months or less which are included in cash within the accompanying consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 245000 3000000 <p id="xdx_843_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zRNUVCj8FyDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z5OzavR8i048">Accounts Receivable, net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $<span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zzCUDaQqkKr8" title="Allowance for doubtful accounts">11</span> thousand as of December 31, 2023 and $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_z8FwFdpDWD5i" title="Allowance for doubtful accounts">9</span> thousand as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 11000 9000 <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zotHFe9nGZUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3R0BoiHjhId">Inventory and Cost of Revenues</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zY87I7kIp2qa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zojvSBtJa3ia">Research and Development</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--ShippingAndHandlingRevenueAndExpensePolicyTextBlock_zkiOSyT8Rrdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zpbA8Jz9UcOg">Shipping and Handling Revenue and Expense</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. Shipping revenue and expense are primarily generated through the Amazon marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z6sJlnlrTtej" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zmaw9RMRPKne">Property and Equipment, net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zCmYHaFMjmMb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zcUsd9oRQJea">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOX6KfloxTKi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zStbFCT7sSxj">Goodwill and Intangible Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and <span id="xdx_907_eus-gaap--GoodwillAndIntangibleAssetImpairment_do_c20230101__20231231_zW6c9G9ZVK66" title="Goodwill and intangible asset impairment"><span id="xdx_90E_eus-gaap--GoodwillAndIntangibleAssetImpairment_do_c20220101__20221231_z73UJxGH4zca" title="Goodwill and intangible asset impairment">no</span></span> impairments were recognized in the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zBNvAr0lIWLj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zdB8JrbbPpG8">Prepaid Expenses and Other Current Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $<span id="xdx_90D_eus-gaap--PrepaidInsurance_iI_pn3n3_c20231231_zI61gjr6Uab" title="Prepaid insurance">64</span> thousand and $<span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20221231_zWxeaAhRFKQ1" title="Prepaid insurance">63</span> thousand of prepaid insurance, and $<span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20231231_zPEjseZmBEK3" title="General prepaid expenses">336</span> thousand and $<span id="xdx_908_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20221231_zLmCjyWnRqd" title="General prepaid expenses">109</span> thousand general prepaid expenses and other current assets in the years ended December 31, 2023 and 2022 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 64000 63000 336000 109000 <p id="xdx_845_ecustom--OtherAssetsPolicyPolicyTextBlock_z818VjI7yemi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Assets</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Assets is recorded at historical costs, and as of December 31, 2023 and 2022, the balance is primarily comprised of spare parts for manufacturing equipment. Spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zZ4wQlWbPjT3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zTwjwwfc1b35">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 1</i> —Quoted prices for identical assets or liabilities in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 2</i> —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 3</i> —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zBXre5rFIIlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zGBhadxIBD65" style="display: none">Schedule of Fair Value of Financial Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zyxFkAC32pjg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpkOqJLerH1d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_za4bOU8fDCnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zCeppr3ngY11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">     </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">     </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">      </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MarketableSecurities_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zw50sqCuf7Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_z7pjeFtI17El" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqTbV9o5dIGf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQxOdtve4uDg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhK8oCAXIfxj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zsmun45lmQ3a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z1owo6GpGQRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_pn3n3_zr5dQbvIcKP6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zB9jxybk4wba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zBXre5rFIIlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zGBhadxIBD65" style="display: none">Schedule of Fair Value of Financial Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zyxFkAC32pjg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpkOqJLerH1d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_za4bOU8fDCnd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zCeppr3ngY11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">     </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">     </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">      </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MarketableSecurities_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zw50sqCuf7Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_z7pjeFtI17El" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqTbV9o5dIGf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQxOdtve4uDg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhK8oCAXIfxj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zsmun45lmQ3a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">    </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketable securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z1owo6GpGQRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">United States treasury bills</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--MarketableSecurities_iI_pn3n3_zr5dQbvIcKP6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5508000 5508000 5508000 5508000 <p id="xdx_84C_ecustom--WarrantLiabilityPolicyPolicyTextBlock_zZk9t9K6Rhc3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zolA0rKTEQ1c">Warrant Liability</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zZfA1cPvBUUk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z2JGWud8WUY4">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2018, the Company adopted ASC Topic 606, <i>Revenue from Contracts with Customers</i> (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_zfnMYXu9uFM4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated revenue by sales type ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zzKAh7fzJD41" style="display: none">Schedule of Disaggregated Revenue by Sales Type</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zCCHPzeQOc5b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20220101__20221231_z2i6hNVIId61" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_405_ecustom--RevenueFromContractManufacturing_pn3n3_maRFCWCzE8T_z8ES7lzhK9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturing</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,748</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,033</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--RevenueFromFinishedGoods_pn3n3_maRFCWCzE8T_zMSFFImSWA29" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Custom and white label finished goods manufacturing</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--RevenueFromConsumerProducts_pn3n3_maRFCWCzE8T_zTanvmgFo4qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer branded products</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,242</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">815</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_ecustom--RevenueClassifiedAsOthers_pn3n3_maRFCWCzE8T_zaSMZ5xQLNKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">166</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_iT_pn3n3_mtRFCWCzE8T_zY0tZ9ZYK5ei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,089</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,048</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zagZFXrJHVze" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company did not have any contract assets or contract liabilities from contracts with customers and there were <span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn3n3_do_c20231231_zHIGJ4sLoiP7" title="Remaining performance obligations"><span id="xdx_90D_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn3n3_do_c20221231_zLwQucWjZ7k7" title="Remaining performance obligations">no</span></span> remaining performance obligations that the Company had not satisfied except for deferred revenue of $<span id="xdx_90D_eus-gaap--DeferredRevenue_iI_pn3n3_c20231231_zVE1VDX06XJ1" title="Deferred revenue">20</span> thousand at December 31, 2023 that the Company had not satisfied as of the end of the year. The Company had no remaining performance obligations as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has four distinct lines of business; Contract Manufacturing, Custom &amp; White Label, Consumer Branded Products, and Medical Devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Manufacturing</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they convert and package into finished goods. Historically, this has been the Company’s primary source of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Custom and White Label</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consumer Branded Products</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical Devices/Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Devices are a hybrid business, combining elements of Custom &amp; White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_zfnMYXu9uFM4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated revenue by sales type ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zzKAh7fzJD41" style="display: none">Schedule of Disaggregated Revenue by Sales Type</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zCCHPzeQOc5b" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20220101__20221231_z2i6hNVIId61" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_405_ecustom--RevenueFromContractManufacturing_pn3n3_maRFCWCzE8T_z8ES7lzhK9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturing</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,748</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,033</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--RevenueFromFinishedGoods_pn3n3_maRFCWCzE8T_zMSFFImSWA29" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Custom and white label finished goods manufacturing</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--RevenueFromConsumerProducts_pn3n3_maRFCWCzE8T_zTanvmgFo4qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer branded products</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,242</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">815</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_ecustom--RevenueClassifiedAsOthers_pn3n3_maRFCWCzE8T_zaSMZ5xQLNKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">166</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_iT_pn3n3_mtRFCWCzE8T_zY0tZ9ZYK5ei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,089</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,048</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2748000 1033000 15000 34000 1242000 815000 84000 166000 4089000 2048000 0 0 20000 <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBBOVb37aXpk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zRlRCQeFjPtd">Share-based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 12 below for further details regarding the 2019 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_ztY2lW0Za9g6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z5Zx0ww1k7cf">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zqBJpgxLQ1ha" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zDYAp0VoAc9l">Leases</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_84E_ecustom--VIEPolicyTextBlock_zraqCm9tM2w6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Variable Interest Entity</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, <i>Consolidation</i>. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. As of December 31, 2023, and on a quarterly basis thereafter, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zsCsNJpYQL14" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zLtULUrBy3Z4">Comprehensive loss</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8pJFybHa1sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_z6wbk4rimti4">Recently Issued Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023 and subsequent interim periods. The Company adopted this new standard in the current year and it did not have a material impact to its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--NewAccountingPronouncementsPolicyTextBlock_zsRBqWZK2Ki1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zlWkX8140wuh">Accounting Pronouncements Issued But Not Yet Adopted </span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced income tax related disclosures. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07<i>, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures relating to its reportable segments. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zOtf93ng0OBh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_826_zcCZPIYqghY3">Business Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="background-color: white">The Company’s Chief Executive Officer, who serves as the chief operating decision maker (“CODM”), evaluates the financial performance of the Company’s segments based upon segment adjusted operating income or (loss) as the profitability measure. Items outside of adjusted operating income or (loss) are not reported by segment, since they are excluded from the single measure of segment profitability reviewed by the CODM. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_891_eus-gaap--ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_zjVI9nKTr0Ii" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized financial information concerning the Company’s reportable segments for the years ended December 31, 2023 and 2022 is presented below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zgXG3m8LhFY8" style="display: none">Schedule of Reportable Segments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">For Year Ended December 31, 2023 ($ in thousands)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NexgelMember_zdoMtvqr7Oz4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nexgel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--CGLabsMember_zfE831duqjWa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CG Labs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230101__20231231__us-gaap--SubsegmentsConsolidationItemsAxis__us-gaap--ReportableSubsegmentsMember_zcLX0uoHUUMe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ContractManufacturingMember_znTWICtE4ndi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 52%; text-align: left">Contract Manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">769</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,748</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--CustomAndWhiteLabelFinishedGoodsMember_zEgAV4c1cHe5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Custom and White Label Finished Goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--BrandedConsumerProductsMember_zVXDTNbPeEv" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Branded Consumer Products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,242</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,242</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherIncomesMember_zMG8Pe5jfQKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">84</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zaskBfMPJft4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,987</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,089</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfRevenue_pn3n3_zJMuI81EPMMh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,470</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_zDPcxfyLfg3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">492</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_pn3n3_z6GdvJ5cQFwl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,413</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(64</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,477</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">For Year Ended December 31, 2022 ($ in thousands)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NexgelMember_ze1obqN38S65" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nexgel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--CGLabsMember_zR1YJW6qc1Jh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CG Labs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--SubsegmentsConsolidationItemsAxis__us-gaap--ReportableSubsegmentsMember_zztYvF1BygEj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ContractManufacturingMember_zSNc16ptOeCd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 52%; text-align: left">Contract Manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--CustomAndWhiteLabelFinishedGoodsMember_zXv9EnypB5Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Custom and White Label Finished Goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--BrandedConsumerProductsMember_zsREn5Y8jwBb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Branded Consumer Products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherIncomesMember_zS3o9yhmiGIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zHCcICACwqA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfRevenue_pn3n3_zP2rDgyM3NL6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_zBEFCDpYQMdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_pn3n3_z2EHvIatSeyc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">As of December 31, 2023 ($ in thousands)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__srt--ConsolidatedEntitiesAxis__custom--NexgelMember_z5xNNNunt8X4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nexgel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__srt--ConsolidatedEntitiesAxis__custom--CGLabsMember_zREUVtQBJt68" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CG Labs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__us-gaap--SubsegmentsConsolidationItemsAxis__us-gaap--ReportableSubsegmentsMember_zg4jvxrR0f3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zG8kAvqydHW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zUVzuvrDVyu" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Cash_i02I_maCzS2q_zgbqfIrKG7kh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 52%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,458</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">242</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzS2q_zzxroxY37RGe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">607</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">633</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_i02I_maCzS2q_zyo6tMlYe6b2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,319</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzS2q_zOUyisgzEAEi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">312</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">88</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzS2q_maCzcSy_zHF8Woi2HXRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,418</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,634</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,052</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Goodwill_i01I_maCzcSy_zYGYeA41A60i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,128</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maCz6ac_z1IUU6IxcH73" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">326</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzcSy_zmrgz56rkJ8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">898</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,499</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzcSy_zfStEB5t73A9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease – right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,543</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,855</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_i01I_maCzcSy_zAco1bZpfZsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_i01TI_mtCzcSy_zQjYUMHCsuT7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,204</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zLS6V2rQAu91" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities and Stockholders’ Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zJTOwzEG84e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzcTV_zAzlTFV5UR75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">509</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">724</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,233</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzcTV_zLXyMXXN2a0k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">261</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredRevenue_i02I_maCzcTV_zplmlMDKbWU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--NotesPayableCurrent_i02I_maCzcTV_z8FQTDvGYMkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current portion of note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilityCurrent_i02I_maCzcTV_zUbFXXGfK6ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationLiability_i02I_maCzcTV_z4yFk1IMFlBb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent consideration liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzcTV_z998N4KuSgF6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability, current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">207</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">233</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_mtCzcTV_maCz8Lq_zOyzxYd5o3Aj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,464</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,085</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCz8Lq_zlhrvt6PPG69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease liability, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,438</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">289</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LongTermNotesPayable_i02I_maCz8Lq_z5ZGPQQcQxv1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Notes payable, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">241</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">513</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--Liabilities_i02TI_mtCz8Lq_maCzIda_z56RLKcvL2yg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,174</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,615</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,789</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zBHcSjKL1Adg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eus-gaap--ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_zjVI9nKTr0Ii" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized financial information concerning the Company’s reportable segments for the years ended December 31, 2023 and 2022 is presented below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zgXG3m8LhFY8" style="display: none">Schedule of Reportable Segments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">For Year Ended December 31, 2023 ($ in thousands)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NexgelMember_zdoMtvqr7Oz4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nexgel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--CGLabsMember_zfE831duqjWa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CG Labs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230101__20231231__us-gaap--SubsegmentsConsolidationItemsAxis__us-gaap--ReportableSubsegmentsMember_zcLX0uoHUUMe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ContractManufacturingMember_znTWICtE4ndi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 52%; text-align: left">Contract Manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">769</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,748</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--CustomAndWhiteLabelFinishedGoodsMember_zEgAV4c1cHe5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Custom and White Label Finished Goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--BrandedConsumerProductsMember_zVXDTNbPeEv" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Branded Consumer Products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,242</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,242</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherIncomesMember_zMG8Pe5jfQKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">84</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zaskBfMPJft4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,987</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,089</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfRevenue_pn3n3_zJMuI81EPMMh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,470</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_zDPcxfyLfg3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">492</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_pn3n3_z6GdvJ5cQFwl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,413</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(64</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,477</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">For Year Ended December 31, 2022 ($ in thousands)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NexgelMember_ze1obqN38S65" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nexgel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--CGLabsMember_zR1YJW6qc1Jh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CG Labs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231__us-gaap--SubsegmentsConsolidationItemsAxis__us-gaap--ReportableSubsegmentsMember_zztYvF1BygEj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ContractManufacturingMember_zSNc16ptOeCd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 52%; text-align: left">Contract Manufacturing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--CustomAndWhiteLabelFinishedGoodsMember_zXv9EnypB5Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Custom and White Label Finished Goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--BrandedConsumerProductsMember_zsREn5Y8jwBb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Branded Consumer Products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherIncomesMember_zS3o9yhmiGIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zHCcICACwqA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfRevenue_pn3n3_zP2rDgyM3NL6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_zBEFCDpYQMdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_pn3n3_z2EHvIatSeyc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">As of December 31, 2023 ($ in thousands)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20231231__srt--ConsolidatedEntitiesAxis__custom--NexgelMember_z5xNNNunt8X4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nexgel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__srt--ConsolidatedEntitiesAxis__custom--CGLabsMember_zREUVtQBJt68" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CG Labs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__us-gaap--SubsegmentsConsolidationItemsAxis__us-gaap--ReportableSubsegmentsMember_zg4jvxrR0f3g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zG8kAvqydHW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zUVzuvrDVyu" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Cash_i02I_maCzS2q_zgbqfIrKG7kh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 52%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,458</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">242</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzS2q_zzxroxY37RGe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">607</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">633</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_i02I_maCzS2q_zyo6tMlYe6b2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,319</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzS2q_zOUyisgzEAEi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">312</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">88</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzS2q_maCzcSy_zHF8Woi2HXRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,418</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,634</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,052</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Goodwill_i01I_maCzcSy_zYGYeA41A60i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,128</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maCz6ac_z1IUU6IxcH73" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">326</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzcSy_zmrgz56rkJ8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">898</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,499</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzcSy_zfStEB5t73A9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease – right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,543</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,855</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_i01I_maCzcSy_zAco1bZpfZsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_i01TI_mtCzcSy_zQjYUMHCsuT7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,204</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zLS6V2rQAu91" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities and Stockholders’ Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zJTOwzEG84e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzcTV_zAzlTFV5UR75" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">509</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">724</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,233</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzcTV_zLXyMXXN2a0k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">261</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredRevenue_i02I_maCzcTV_zplmlMDKbWU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--NotesPayableCurrent_i02I_maCzcTV_z8FQTDvGYMkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current portion of note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilityCurrent_i02I_maCzcTV_zUbFXXGfK6ic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationLiability_i02I_maCzcTV_z4yFk1IMFlBb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent consideration liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzcTV_z998N4KuSgF6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability, current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">207</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">233</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_mtCzcTV_maCz8Lq_zOyzxYd5o3Aj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,464</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,085</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCz8Lq_zlhrvt6PPG69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease liability, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,438</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">289</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,727</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LongTermNotesPayable_i02I_maCz8Lq_z5ZGPQQcQxv1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Notes payable, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">241</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">513</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--Liabilities_i02TI_mtCz8Lq_maCzIda_z56RLKcvL2yg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,174</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,615</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,789</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 769000 1979000 2748000 15000 15000 1242000 1242000 76000 8000 84000 2102000 1987000 4089000 1911000 1559000 3470000 3604000 492000 4096000 -3413000 -64000 -3477000 1033000 1033000 34000 34000 815000 815000 166000 166000 2048000 2048000 1792000 1792000 3604000 3604000 -3348000 -3348000 2458000 242000 2700000 26000 607000 633000 622000 697000 1319000 312000 88000 400000 3418000 1634000 5052000 1128000 1128000 122000 204000 326000 898000 601000 1499000 1543000 312000 1855000 95000 95000 7204000 2751000 9955000 509000 724000 1233000 137000 261000 398000 20000 20000 6000 74000 80000 146000 146000 439000 439000 207000 26000 233000 1464000 1085000 2549000 1438000 289000 1727000 272000 241000 513000 3174000 1615000 4789000 <p id="xdx_806_eus-gaap--BusinessCombinationDisclosureTextBlock_zThTymfh7NY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_827_ztxPNberjqf2">Acquisition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Kenkoderm Acquisition</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 1, 2023, the Company closed a transaction related to an Asset Purchase Agreement dated November 30, 2023 (the “Purchase Agreement”) with Olympus Trading Company, LLC, a Virginia limited liability company (the “Seller”), whereby the Company purchased all assets related to the Seller’s skincare line focused on reducing symptoms associated with psoriasis operating under the tradename “Kenkoderm” (“Kenkoderm acquisition”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Kenkoderm acquisition, the Company paid the Seller a cash payment of $<span id="xdx_908_eus-gaap--PaymentsToAcquireBusinessesGross_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zgR29cd4XEv" title="Cash payment for acquire assets">546,500</span>. Additionally, the Company shall pay the Seller a cash earn-out of the same amount each quarter, payable in the subsequent month flowing quarter end, of $<span id="xdx_904_ecustom--PaymentsToAcquireBusinessesCashEarnout_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zVL98xB4B1u6" title="Payments to acquire businesses, cash earn-out">136,625</span>. The cash earn-out can fluctuate higher or lower based on the quarterly results of the Kenkoderm business during 2024 according to the formula contained in the Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Purchase Agreement and the transaction contemplated thereby were not subject to approval by the shareholders of the Company. The Purchase Agreement contains standard representations and warranties regarding the Seller and the Kenkoderm business and certain limited representations and warranties regarding the Company. The Purchase Agreement also contains indemnification provisions for the benefit of the Company and the Seller. Neither the Company nor the Seller shall be liable for more than the Purchase Price under the indemnification provisions except in the case of fraud or willful misconduct. The Seller and the Seller’s President and owner agreed to 3-year non-compete provisions as part of the Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisional fair value of the purchase consideration issued to the Seller was allocated to the net tangible assets acquired. The Company accounted for the Kenkoderm acquisition as the purchase of a business under GAAP under the acquisition method of accounting, and the assets and liabilities acquired were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company. The fair value of the net assets acquired was approximately $<span id="xdx_90A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zYLfqEQ9oPtk" title="Net tangible assets acquired">169</span> thousand. The excess of the aggregate fair value of the net tangible assets has been allocated to goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zvJ9fE9CRYF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below shows a preliminary analysis for the Kenkoderm acquisition ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zO1tlbWj0MPk" style="display: none">Schedule of Business Acquisitions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-weight: bold; text-align: justify">Provisional purchase consideration at preliminary fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Purchase price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zpy47lQIUDNj" style="width: 16%; text-align: right" title="Purchase price">547</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Contingent consideration liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zoS8GU1Pg9E1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration liability">439</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Amount of consideration</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zNfmmDe2yZJk" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of consideration">986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired and liabilities assumed at preliminary fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Inventory</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zFnqXg4kG8da" style="text-align: right" title="Inventory">56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Product/technology related intangibles</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zN30lll0mQT5" style="text-align: right" title="Product/Technology related intangibles">77</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketing related intangibles</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zqgAT1lyvKM4" style="text-align: right" title="Marketing related intangibles">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zu9or9qOMfT5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net tangible assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z97gqL07bMbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net tangible assets acquired">169</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zesWdN14styg" style="padding-bottom: 1.5pt; text-align: right" title="Total net assets acquired">169</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Consideration paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zRdg6kKIacd6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consideration paid">986</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Preliminary goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Goodwill_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zrx0ha5iVjN" style="border-bottom: Black 2.5pt double; text-align: right" title="Preliminary goodwill">817</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zBO7L1KfWfPe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-controlling Interest in Joint Venture – CG Labs</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On March 1, 2023, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company acquired a <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230301__us-gaap--BusinessAcquisitionAxis__custom--JointVentureMember_zo3q12tn3234" title="Acquisition percentage">50%</span> interest in the JV (see Note 1). The JV is owned <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20230301__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zMw9r11Epbci" title="Acquisition percentage">50%</span> by the Company and <span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230301__srt--OwnershipAxis__custom--CGLaboratoriesIncMember_zJG3qbYrb9t5" title="Minority percentage">50</span>% by CG Labs. CG Labs contributed its existing converting and packaging division to the JV, including, but not limited to, its facilities, equipment, employees, and customers. The Company will contribute $<span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_c20230301__20230301_zyBl1eEALbxi" title="Payment to acquire business">500,000</span> to the JV, on a schedule to be determined, to be used for equipment and facility upgrades as well as general corporate purposes for the JV. As of December 31, 2023, the Company has contributed its full $<span id="xdx_90C_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_c20230101__20231231_zyM4bm2ByMV7" title="Payment to acquire business">500,000</span> commitment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The JV is considered to be a VIE and we have consolidated the JV. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_895_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zzPvW2IDwG4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The recorded assets acquired and liabilities assumed in connection with the formation of CG Labs based on their estimated fair values as of the March 1, 2023. The preliminary purchase price allocation is as follow ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zEANWoObPNx1" style="display: none">Schedule of Business Acquisitions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Provisional purchase consideration at preliminary fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash contributed by the Company</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zRdcTAcwXHAk" style="width: 16%; text-align: right" title="Cash contributed by the Company">500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Noncontrolling interest portion of CG Labs contributed business</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zxUzS8s4nbLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Noncontrolling interest portion of CG Labs contributed business">500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Amount of consideration</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zFnL7ngcr6ni" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of consideration">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired and liabilities assumed at preliminary fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Cash contributed by the Company</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_z5uQd0DMjoWf" style="text-align: right" title="Cash contributed by the Company">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zvd4dzNKJS74" style="text-align: right" title="Fixed assets">213</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Product/technology related intangibles</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zaMv57FO0ERl" style="text-align: right" title="Product/Technology related intangibles">217</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Marketing related intangibles</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zRae1jX5uGvd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketing related intangibles">70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net tangible assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zkev2kg56tZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Net tangible assets acquired">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zDTzqOn1Q2xl" style="padding-bottom: 1.5pt; text-align: right" title="Total net assets acquired">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Consideration paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zP0Ws1I3yXQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consideration paid">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Preliminary goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zQmRvonLtBP3" style="border-bottom: Black 2.5pt double; text-align: right" title="Preliminary goodwill"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z6KpJeU62Jvc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The allocation of the purchase price to identifiable assets is based on the preliminary valuations performed to determine the fair value of the net assets as of the acquisition date. The measurement period for the valuation of net assets acquired ends as soon as information on the facts and circumstances that existed as of the acquisition dates becomes available, but not to exceed 12 months following the acquisition date. Adjustments in purchase price allocations may require a change in the amounts allocated to net assets acquired during the periods in which the adjustments are determined.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the Kenkoderm acquisition and CG Labs JV been completed as of January 1, 2022 or to project potential operating results as of any future date or for any future periods ($ in thousands except share and per share amounts):</span></p> <p id="xdx_895_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z1LSYuS4sG84" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zYKjr9MCLbsb">Schedule of Unaudited Pro-Forma Results of Operations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zCDc4DaMao43" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20221231_z1LcNE5MizRc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaRevenue_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zHSRxgikG4hd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Revenues, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,522</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z7AonAjH77be" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Net loss allocable to common shareholders</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,071</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,634</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_pid_uUSDPShares_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zfjoIPhkd59" title="Net loss per share - basic"><span id="xdx_903_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareDiluted_pid_uUSDPShares_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zQmuOix3aqGc" title="Net loss per share - diluted">(0.54</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_pid_uUSDPShares_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z4h1AtoAhV1k" title="Net loss per share - basic"><span id="xdx_909_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareDiluted_pid_uUSDPShares_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z7DFbjuZ5h38" title="Net loss per share - diluted">(0.83</span></span></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average number of shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_ztEw5tm2wbm2" title="Weighted average number of shares outstanding - basic"><span id="xdx_906_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingDiluted_pid_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zpswP7sQNp3a" title="Weighted average number of shares outstanding - diluted">5,671,842</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zr2roYgPdk8h" title="Weighted average number of shares outstanding - basic"><span id="xdx_903_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingDiluted_pid_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zs8hky8DYah" title="Weighted average number of shares outstanding - diluted">5,574,818</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zyCTlnPijeE2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 546500 136625 169000 <p id="xdx_89D_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zvJ9fE9CRYF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below shows a preliminary analysis for the Kenkoderm acquisition ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zO1tlbWj0MPk" style="display: none">Schedule of Business Acquisitions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-weight: bold; text-align: justify">Provisional purchase consideration at preliminary fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Purchase price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zpy47lQIUDNj" style="width: 16%; text-align: right" title="Purchase price">547</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Contingent consideration liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zoS8GU1Pg9E1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration liability">439</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Amount of consideration</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zNfmmDe2yZJk" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of consideration">986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired and liabilities assumed at preliminary fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Inventory</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zFnqXg4kG8da" style="text-align: right" title="Inventory">56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Product/technology related intangibles</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zN30lll0mQT5" style="text-align: right" title="Product/Technology related intangibles">77</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Marketing related intangibles</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zqgAT1lyvKM4" style="text-align: right" title="Marketing related intangibles">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zu9or9qOMfT5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net tangible assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z97gqL07bMbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net tangible assets acquired">169</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zesWdN14styg" style="padding-bottom: 1.5pt; text-align: right" title="Total net assets acquired">169</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Consideration paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20231201__20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zRdg6kKIacd6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consideration paid">986</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Preliminary goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Goodwill_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zrx0ha5iVjN" style="border-bottom: Black 2.5pt double; text-align: right" title="Preliminary goodwill">817</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 547000 439000 986000 56000 77000 36000 169000 169000 986000 817000 0.50 0.50 0.50 500000 500000 <p id="xdx_895_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zzPvW2IDwG4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The recorded assets acquired and liabilities assumed in connection with the formation of CG Labs based on their estimated fair values as of the March 1, 2023. The preliminary purchase price allocation is as follow ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zEANWoObPNx1" style="display: none">Schedule of Business Acquisitions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Provisional purchase consideration at preliminary fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash contributed by the Company</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zRdcTAcwXHAk" style="width: 16%; text-align: right" title="Cash contributed by the Company">500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Noncontrolling interest portion of CG Labs contributed business</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zxUzS8s4nbLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Noncontrolling interest portion of CG Labs contributed business">500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Amount of consideration</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zFnL7ngcr6ni" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of consideration">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired and liabilities assumed at preliminary fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Cash contributed by the Company</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_z5uQd0DMjoWf" style="text-align: right" title="Cash contributed by the Company">500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zvd4dzNKJS74" style="text-align: right" title="Fixed assets">213</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Product/technology related intangibles</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zaMv57FO0ERl" style="text-align: right" title="Product/Technology related intangibles">217</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Marketing related intangibles</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zRae1jX5uGvd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketing related intangibles">70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net tangible assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zkev2kg56tZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Net tangible assets acquired">1,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zDTzqOn1Q2xl" style="padding-bottom: 1.5pt; text-align: right" title="Total net assets acquired">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Consideration paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zP0Ws1I3yXQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consideration paid">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Preliminary goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--CGLabsMember_zQmRvonLtBP3" style="border-bottom: Black 2.5pt double; text-align: right" title="Preliminary goodwill"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 500000 500000 1000000 500000 213000 217000 70000 1000000 1000000 1000000 <p id="xdx_895_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z1LSYuS4sG84" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zYKjr9MCLbsb">Schedule of Unaudited Pro-Forma Results of Operations</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zCDc4DaMao43" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20221231_z1LcNE5MizRc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessAcquisitionsProFormaRevenue_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zHSRxgikG4hd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Revenues, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,522</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,014</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z7AonAjH77be" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Net loss allocable to common shareholders</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,071</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,634</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_pid_uUSDPShares_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zfjoIPhkd59" title="Net loss per share - basic"><span id="xdx_903_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareDiluted_pid_uUSDPShares_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zQmuOix3aqGc" title="Net loss per share - diluted">(0.54</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareBasic_pid_uUSDPShares_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z4h1AtoAhV1k" title="Net loss per share - basic"><span id="xdx_909_eus-gaap--BusinessAcquisitionProFormaEarningsPerShareDiluted_pid_uUSDPShares_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_z7DFbjuZ5h38" title="Net loss per share - diluted">(0.83</span></span></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average number of shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_ztEw5tm2wbm2" title="Weighted average number of shares outstanding - basic"><span id="xdx_906_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingDiluted_pid_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zpswP7sQNp3a" title="Weighted average number of shares outstanding - diluted">5,671,842</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zr2roYgPdk8h" title="Weighted average number of shares outstanding - basic"><span id="xdx_903_ecustom--BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingDiluted_pid_c20220101__20221231__us-gaap--BusinessAcquisitionAxis__custom--KenkodermAcquisitionMember_zs8hky8DYah" title="Weighted average number of shares outstanding - diluted">5,574,818</span></span></td><td style="text-align: left"> </td></tr> </table> 5522000 4014000 -3071000 -4634000 -0.54 -0.54 -0.83 -0.83 5671842 5671842 5574818 5574818 <p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_z3GR334Jl8ba" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_820_zUNCaPfJTJY6">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania that runs through January 2031. There are two options that can extend the lease term for five years each. The exercise of the lease options to renew is solely at the Company’s discretion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also has a sublease for office and manufacturing space in Granbury, Texas that runs through February 2028.There is an option that can extend the lease term for an additional five years through February 2033. The exercise of the lease options to renew is solely at the Company’s discretion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pJYprXPNkl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2023 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zp9mjZIunpX2" style="display: none">Schedule of Future Minimum Lease Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Maturity of Lease Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zfr1cNlBcvH4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_i01I_pn3n3_maLOLLPzhGc_zeEeiFGE7RQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">245</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_i01I_pn3n3_maLOLLPzhGc_z4Jwo6yD1Nng" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_i01I_pn3n3_maLOLLPzhGc_zjylI3D7UUq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_i01I_pn3n3_maLOLLPzhGc_zjIFQnSxMsz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">315</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_i01I_pn3n3_maLOLLPzhGc_zPQDbOz7kQL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">324</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_i01I_pn3n3_maLOLLPzhGc_zcjMmB6qB8B8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">790</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPzhGc_zjEZ9KksI7B7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted operating lease payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,220</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_zyv4t8BgfsHb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zVr6a89ziGL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zQN7DMF8Np8j" title="Weighted average remaining lease term">7.4</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zpbSlMljAXM7" style="text-align: right" title="Weighted average discount rate">3.0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zG88kzoOgYN2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease expense for the years ended December 31, 2023, and 2022, was $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pn3n3_c20230101__20231231_zfIa7O5hvEi1" title="Operating lease expense">303</span> thousand and $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20221231_zR9S63Ki0vZg" title="Operating lease expense">246</span> thousand, respectively, and is recorded in cost of goods sold and selling, general, and administrative expenses in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_zzuWAdftcL3g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flows information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zv58eOyQVCzi" style="display: none">Schedule of Supplemental Cash Flows Information Related to Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zzoL5W9NF3A1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liability ($ in thousands): </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasePayments_pn3n3_zAEYx4DUo1Ud" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Operating cash flows from operating lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">238</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z6kWKgpeu5h7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pJYprXPNkl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2023 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zp9mjZIunpX2" style="display: none">Schedule of Future Minimum Lease Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Maturity of Lease Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zfr1cNlBcvH4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_i01I_pn3n3_maLOLLPzhGc_zeEeiFGE7RQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">245</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_i01I_pn3n3_maLOLLPzhGc_z4Jwo6yD1Nng" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_i01I_pn3n3_maLOLLPzhGc_zjylI3D7UUq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_i01I_pn3n3_maLOLLPzhGc_zjIFQnSxMsz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">315</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_i01I_pn3n3_maLOLLPzhGc_zPQDbOz7kQL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">324</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_i01I_pn3n3_maLOLLPzhGc_zcjMmB6qB8B8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">790</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPzhGc_zjEZ9KksI7B7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted operating lease payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,220</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_zyv4t8BgfsHb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zVr6a89ziGL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zQN7DMF8Np8j" title="Weighted average remaining lease term">7.4</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zpbSlMljAXM7" style="text-align: right" title="Weighted average discount rate">3.0</td><td style="text-align: left">%</td></tr> </table> 245000 245000 301000 315000 324000 790000 2220000 260000 1960000 P7Y4M24D 0.030 303000 246000 <p id="xdx_896_ecustom--LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_zzuWAdftcL3g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flows information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zv58eOyQVCzi" style="display: none">Schedule of Supplemental Cash Flows Information Related to Leases</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zzoL5W9NF3A1" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liability ($ in thousands): </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasePayments_pn3n3_zAEYx4DUo1Ud" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Operating cash flows from operating lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">238</td><td style="width: 1%; text-align: left"> </td></tr> </table> 238000 <p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_zaGkqnWwcPc3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_821_zn65hY7AowW5">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zJDgOH1gt6lf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zbg4AWYy80Bb" style="display: none">Schedule of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20231231_zdCHS9RCCxvb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20221231_z02Fp44vgv14" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzJZx_zjEjFzyFgMf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">899</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">295</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzJZx_zusbY6JDfDo4" style="vertical-align: bottom; background-color: White"> <td>Work-in-progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzJZx_zznEMOtBkzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">156</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzJZx_maINzQec_z7SEkTOhcAF2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, gross</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">1,319</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">502</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryAdjustments_iI_pn3n3_msINzQec_zYDCnNu3iyC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Inventory reserve for excess and slow moving inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINzQec_zLE6uB9Go031" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,319</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">502</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zL82H6bqMQ6c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon, Walmart and CVS. The Company builds its contract manufacturing products based on customer orders and immediately ships the products upon completion of the production process.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zJDgOH1gt6lf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zbg4AWYy80Bb" style="display: none">Schedule of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20231231_zdCHS9RCCxvb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20221231_z02Fp44vgv14" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzJZx_zjEjFzyFgMf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">899</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">295</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzJZx_zusbY6JDfDo4" style="vertical-align: bottom; background-color: White"> <td>Work-in-progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzJZx_zznEMOtBkzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">156</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzJZx_maINzQec_z7SEkTOhcAF2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, gross</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">1,319</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">502</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryAdjustments_iI_pn3n3_msINzQec_zYDCnNu3iyC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Inventory reserve for excess and slow moving inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINzQec_zLE6uB9Go031" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,319</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">502</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 899000 295000 12000 51000 408000 156000 1319000 502000 1319000 502000 <p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ziFIUWiGFE28" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_820_zlycrPcBMzfl">Property and Equipment, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zsXBtFwJ1JQ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consist of the following ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zuEYALx8Vwc7" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20231231_zIOHGldiBTN" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20221231_zZryrrfef7il" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Machinery and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpyV06pyrdUk" title="Useful Life">3</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zJyM2gdRgmN7" title="Useful Life">10</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zX6yhYiqylz2" style="width: 11%; text-align: right" title="Property and equipment, gross">1,280</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zw7MCO1ttpE5" style="width: 11%; text-align: right" title="Property and equipment, gross">973</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmNsxhcyA6Ee" title="Useful Life">3</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZfHXeXmryZ4" title="Useful Life">10</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQDLRGPR93cc" style="text-align: right" title="Property and equipment, gross">139</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZdtjiAQN45" style="text-align: right" title="Property and equipment, gross">59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIJlKwcpjoy1" title="Useful Life (Years)">6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb2bVBjeumh8" style="text-align: right" title="Property and equipment, gross">419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPsuSsNyvzqj" style="text-align: right" title="Property and equipment, gross">228</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z0UeV35ZkaLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z99195swmZ46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">55</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzMfz_zIYYgkwjBsx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment</span></td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,315</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzMfz_zDwR00sfOcAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(726</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(594</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzMfz_zatlR9xwBOxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,499</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">721</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zfKKf2XQ37M8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the year ended December 31, 2023 and 2022 was $<span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z4ZNOECRJZAi" title="Depreciation expense">132</span> thousand and $<span id="xdx_90D_eus-gaap--Depreciation_pn3n3_c20220101__20221231_zpx3B5Wxvbk3" title="Depreciation expense">99</span> thousand, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zsXBtFwJ1JQ5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consist of the following ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zuEYALx8Vwc7" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20231231_zIOHGldiBTN" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20221231_zZryrrfef7il" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Machinery and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpyV06pyrdUk" title="Useful Life">3</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zJyM2gdRgmN7" title="Useful Life">10</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zX6yhYiqylz2" style="width: 11%; text-align: right" title="Property and equipment, gross">1,280</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zw7MCO1ttpE5" style="width: 11%; text-align: right" title="Property and equipment, gross">973</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmNsxhcyA6Ee" title="Useful Life">3</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZfHXeXmryZ4" title="Useful Life">10</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQDLRGPR93cc" style="text-align: right" title="Property and equipment, gross">139</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZdtjiAQN45" style="text-align: right" title="Property and equipment, gross">59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIJlKwcpjoy1" title="Useful Life (Years)">6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb2bVBjeumh8" style="text-align: right" title="Property and equipment, gross">419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPsuSsNyvzqj" style="text-align: right" title="Property and equipment, gross">228</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z0UeV35ZkaLj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z99195swmZ46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">55</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzMfz_zIYYgkwjBsx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment</span></td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,315</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzMfz_zDwR00sfOcAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(726</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(594</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzMfz_zatlR9xwBOxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,499</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">721</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P3Y P10Y 1280000 973000 P3Y P10Y 139000 59000 P6Y 419000 228000 387000 55000 2225000 1315000 726000 594000 1499000 721000 132000 99000 <p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2QLEVLp7pZ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_820_zhBga9Au3boj">Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zqsqOnHhGJi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides a breakdown of identifiable intangible assets as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zPYaXbQoHwLl" style="display: none">Schedule of Breakdown of Identifiable Intangible Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Product/Technology Related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Identifiable intangible assets, gross</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_z7aD4Cyca3Ph" style="width: 16%; text-align: right" title="Identifiable intangible assets, gross">325</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zSnLz9iyUeBh" style="width: 16%; text-align: right" title="Identifiable intangible assets, gross">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zhzgII6adQ24" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(98</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zLMLDCHz8NBe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Product/technology related identifiable intangible assets, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zsm0I1GBhfij" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">227</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zcuaVilGooZ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Marketing Related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Customer related intangible asset, gross</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelatedIntangibleAssetsMember_zC9ye0ZI5FOa" style="text-align: right" title="Identifiable intangible assets, gross">17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelatedIntangibleAssetsMember_zSIQDJhs0Btf" style="text-align: right" title="Identifiable intangible assets, gross">17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Tradename related intangible asset, gross</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zXXnSFT4YN7e" style="text-align: right" title="Identifiable intangible assets, gross">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zxcJUccwx4N2" style="text-align: right" title="Identifiable intangible assets, gross">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zUdNtmaHMxQi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zbLDn3IUScF5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Marketing related identifiable intangible assets, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zLd7vmuH5Ul9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zC1IL78gLfZ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total identifiable intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_z37GfMnBLpNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zsjFqCwwDIZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zL0IgyROMTe1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the May 29, 2020 acquisition of Sports Defense, the Company identified intangible assets of $<span id="xdx_90D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20200529__us-gaap--BusinessAcquisitionAxis__custom--SportDefenseLlcMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyRelatedAndCustomerRelatedIntangiblesMember_ztlnw7sOWVqj" title="Intangible assets">55</span> thousand representing technology related and customer related intangibles.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the March 1, 2023 CG Labs JV, the Company identified intangible assets of $<span id="xdx_90A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20230301__us-gaap--BusinessAcquisitionAxis__custom--CGLabsJVMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyRelatedAndCustomerRelatedIntangiblesMember_zBj33pGtvJhh" title="Intangible assets">287</span> thousand representing technology related and customer related intangibles.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the December 1, 2023 acquisition of Kenkoderm, the Company identified intangible assets of $<span id="xdx_902_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20231201__us-gaap--BusinessAcquisitionAxis__custom--KenkodermMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyRelatedAndCustomerRelatedIntangiblesMember_z1TDB81l9Ox6" title="Intangible assets">113</span> thousand representing technology related and customer related intangibles.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These assets are being amortized on a straight-line basis over their weighted average estimated useful life of <span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20230101__20231231_zDAUavL3MdRa" title="Expected life"><span id="xdx_909_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20220101__20221231_zkRQpnbuPvka" title="Expected life">2.9</span></span> years and amortization expense amounted to $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_z3yLN0DUtvEb" title="Amortization expense">94</span> and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220101__20221231_ztLJV8KZlVT2" title="Amortization expense">13</span> thousand for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2PORI1dPUej" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zh1m1STrAGO9" style="display: none">Schedule of Estimated Annual Amortization Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20231231_zmcWUe8CT6Ya" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzRW0_zVtjGczihzll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">119</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzRW0_znDu51Vz3Um3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzRW0_zwQWj0H5b10l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzRW0_zsDnzCdqJJp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzRW0_zXxWOPdxfBSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzRW0_z9ONaUIXOOBl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzRW0_zDjAuupiu9bf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zSCbqE4BwFTk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zqsqOnHhGJi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides a breakdown of identifiable intangible assets as of December 31, 2023 and 2022 ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zPYaXbQoHwLl" style="display: none">Schedule of Breakdown of Identifiable Intangible Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Product/Technology Related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Identifiable intangible assets, gross</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_z7aD4Cyca3Ph" style="width: 16%; text-align: right" title="Identifiable intangible assets, gross">325</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zSnLz9iyUeBh" style="width: 16%; text-align: right" title="Identifiable intangible assets, gross">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zhzgII6adQ24" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(98</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zLMLDCHz8NBe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Product/technology related identifiable intangible assets, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zsm0I1GBhfij" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">227</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zcuaVilGooZ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Marketing Related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Customer related intangible asset, gross</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelatedIntangibleAssetsMember_zC9ye0ZI5FOa" style="text-align: right" title="Identifiable intangible assets, gross">17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelatedIntangibleAssetsMember_zSIQDJhs0Btf" style="text-align: right" title="Identifiable intangible assets, gross">17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Tradename related intangible asset, gross</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zXXnSFT4YN7e" style="text-align: right" title="Identifiable intangible assets, gross">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zxcJUccwx4N2" style="text-align: right" title="Identifiable intangible assets, gross">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zUdNtmaHMxQi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zbLDn3IUScF5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Marketing related identifiable intangible assets, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zLd7vmuH5Ul9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--MarketingRelatedIntangibleAssetsMember_zC1IL78gLfZ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total identifiable intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_z37GfMnBLpNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zsjFqCwwDIZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 325000 31000 -98000 -26000 227000 5000 17000 17000 113000 7000 -31000 -9000 99000 15000 326000 20000 55000 287000 113000 P2Y10M24D P2Y10M24D 94000 13000 <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2PORI1dPUej" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zh1m1STrAGO9" style="display: none">Schedule of Estimated Annual Amortization Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20231231_zmcWUe8CT6Ya" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzRW0_zVtjGczihzll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">119</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzRW0_znDu51Vz3Um3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzRW0_zwQWj0H5b10l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzRW0_zsDnzCdqJJp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzRW0_zXxWOPdxfBSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzRW0_z9ONaUIXOOBl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzRW0_zDjAuupiu9bf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 119000 126000 63000 13000 2000 3000 326000 <p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zWAJcNPAhNNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_82E_zAW6y5AGprUi">Accrued Expenses and Other Current Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z3ENb8R1m4ui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities consist of the following ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zO97jzVB0X6h" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20231231_zOwSC2HCO4ji" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20221231_zrxcwG9L02of" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALAOLzpc8_zSJ94yo9a1Fh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Salaries, benefits, and incentive compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">56</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_pn3n3_maALAOLzpc8_zMGRdncUVNGg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Franchise tax accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_maALAOLzpc8_zZgH1HidEPu6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Margin line of credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_iI_pn3n3_maALAOLzpc8_zOgm4Z10H8gi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtALAOLzpc8_zkgrpxdFqlNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">398</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zt8VzNldKOUf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z3ENb8R1m4ui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities consist of the following ($ in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zO97jzVB0X6h" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20231231_zOwSC2HCO4ji" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20221231_zrxcwG9L02of" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALAOLzpc8_zSJ94yo9a1Fh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Salaries, benefits, and incentive compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">61</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">56</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_pn3n3_maALAOLzpc8_zMGRdncUVNGg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Franchise tax accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_maALAOLzpc8_zZgH1HidEPu6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Margin line of credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_iI_pn3n3_maALAOLzpc8_zOgm4Z10H8gi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtALAOLzpc8_zkgrpxdFqlNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">398</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 61000 56000 52000 245000 92000 22000 398000 130000 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWfhkvDFQYs8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_82E_z1M5uFAvNzpi">Common Stock</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfStockByClassTextBlock_zx71tvpSOkci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, the Company has reserved common stock for issuance in relation to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zweTkJwd50zk" style="display: none">Schedule of Reserved Common Stock For Issued Securities in Relation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Share-based compensation plan</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20231231_zi8SDUIimB8" style="width: 16%; text-align: right" title="Share-based compensation plan">560,650</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230101__20231231_zqelrLq59FYk" style="text-align: right" title="Warrants to purchase common stock">3,442,904</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230101__20231231_zJpmxpaGoE58" style="text-align: right" title="Restricted stock units">64,562</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_zf13sEf7nfFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfStockByClassTextBlock_zx71tvpSOkci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, the Company has reserved common stock for issuance in relation to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zweTkJwd50zk" style="display: none">Schedule of Reserved Common Stock For Issued Securities in Relation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Share-based compensation plan</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20231231_zi8SDUIimB8" style="width: 16%; text-align: right" title="Share-based compensation plan">560,650</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230101__20231231_zqelrLq59FYk" style="text-align: right" title="Warrants to purchase common stock">3,442,904</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230101__20231231_zJpmxpaGoE58" style="text-align: right" title="Restricted stock units">64,562</td><td style="text-align: left"> </td></tr> </table> 560650 3442904 64562 <p id="xdx_80E_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zKOrS9EOXd9h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_822_zR8P3LDShMs">Share-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initially reserved a total of <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200526__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zZDnGWQPFJY8" title="Common stock reserved for issuance">57,143</span> shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020 and May 3, 2021, respectively, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20200526__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zKy1dCvCnRMf" title="Common stock reserved for issuance">57,143</span> shares of common stock to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210503__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zBY1GpUWKEHd" title="Number of shares available for grant">485,715</span> and from <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesReservedForFutureIssuance_iI_pid_c20210503__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zLYqmGzo10Og" title="Common stock reserved for issuance">485,715</span> shares of common stock to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210531__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zoEQwGsjTni9" title="Common stock reserved for issuance">571,429</span> shares of common stock, all of which may be delivered pursuant to incentive stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 23, 2023, the Board approved an additional <span id="xdx_90B_eus-gaap--DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_iI_pid_c20230323__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zjgFVWAPRHJb" title="Additional common stock reserved for issuance">300,000</span> shares of common stock to be reserved under the 2019 Plan, such that total of number of shares underlying the Plan is <span id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pid_c20230323__20230323__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zObtvTy2oae" title="Shares reserved for issuance, awarded">871,429</span> of which <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pid_c20230323__20230323__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_ztF3tbcbxAVb" title="Shares reserved for issuance, exercised">609,687</span> shares have already been awarded or exercised. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230323__20230323__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zdM5b3Bkiepe" title="Number of shares granted">14,286</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ztXFRl0CZD3d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table contains information about the 2019 Plan as of December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zRaeiticqf9l" style="display: none">Schedule of Information about Incentive Plan</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Reserved for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Available for</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercised</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019 Plan<sup>(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_z833ZFzzc0n6" style="width: 11%; text-align: right" title="Awards Reserved For Issuance">871,429</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_zswgft5Zbk32" style="width: 11%; text-align: right" title="Awards Issued">649,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercised_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_zfaboFSNifni" style="width: 11%; text-align: right" title="Awards Exercised">17,916</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_zNWo9Baa0ILh" style="width: 11%; text-align: right" title="Awards Available for Grant">221,596</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards issued in excess of 2019 Plan<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_zvGTEqMueCfc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Reserved For Issuance"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_zxRQgHTbph6a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Issued">48,401</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercised_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_zxhVRzZbNH56" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Exercised">48,401</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_z3DpxQeTkGfb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Available for Grant"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F02_zVCfj0iw6RN6">(1)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zpl5GHAnJ9Wi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes incentive stock options and restricted stock units discussed below.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F05_zbsVxUoSh3Z5">(2)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zdAs39eF00Fj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.</span></td></tr> </table> <p id="xdx_8A9_zCguaWfRAvWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive stock options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 8, 2023, the Company granted a contractor an option to purchase up to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230308__srt--TitleOfIndividualAxis__custom--ContractorMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXVOC5HpyhT9">17,532 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock at a per share exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230308__20230308__srt--TitleOfIndividualAxis__custom--ContractorMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zernWi05KWub">2.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Company’s 2019 Plan. This option award vests over a period of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20230308__20230308__srt--TitleOfIndividualAxis__custom--ContractorMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zIBkAKvMaQg6">12 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">months. </span>The options expired unexercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2023, the Company granted options to purchase up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230817__srt--TitleOfIndividualAxis__srt--DirectorMember_z9llxZlUG6o3" title="Number of options, granted">90,000</span> shares of the Company’s common stock at a per share exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230817__20230817__srt--TitleOfIndividualAxis__srt--DirectorMember_zJrVdGVtPtZ2" title="Exercise price of options">2.05</span> to members of the Board of Directors, all of which vests over a period of one year with <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230817__20230817__srt--TitleOfIndividualAxis__srt--DirectorMember_zDREne2Sp4Mi" title="Award vesting rights, percentage">25</span>% vested upon issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2022, the Company appointed Dr. Neil Chesen to the Company’s Scientific Advisory Board and in consideration for his appointment to the board, the Company granted Dr. Chesen an option to purchase up to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zU7Bmg309znj" title="Number of options, granted">65,000</span> shares of common stock at a per share exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zJ0gSNmzqrI3" title="Exercise price of options">2.00</span> under the Company’s 2019 Long-Term Incentive Plan. A portion of the award, <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_z0ihrR5fuVl7" title="Number of options, vested">15,000</span> options, fully vested as of the date of grant and the remaining <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_z1djdV4a0FS5" title="Number of options, expected to vest">50,000</span> options are contingent upon certain sales based milestones being achieved. The options expire on <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_pid_dd_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zsXQndGlv3z3" title="Options, expiry date">December 31, 2023</span> if the milestones are not achieved prior to that date. Also on October 1, 2022, the Company issued a second option grant to Dr. Chesen, to purchase up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zLj46JcJezbg" title="Number of options, granted">25,000</span> shares of common stock at a per share exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zVmTSCGf2c21" title="Exercise price of options">2.00</span> under the Company’s 2019 Long-Term Incentive Plan and are fully contingent upon certain sales based milestones being achieved with 18 months of commercial release. Also on October 1, 2022, the Company issued a third option grant to Dr. Chesen to purchase up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionThreeMember_z11ETmsBGvpk" title="Number of options, granted">37,500</span> shares of common stock at a per share exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zW2FFo9O5ba4" title="Exercise price of options">5.50</span> under the Company’s 2019 Long-Term Incentive Plan and are fully contingent upon certain sales based milestones being achieved within <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pid_dtM_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.NeilChesenMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zcS35aOmTbgk" title="Expiration period">36</span> months of commercial release. As of December 31, 2022 the new product has not launched. The product launched in August 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zfgrq2Qe35i5">30,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock at a per share price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_z6b8xsK13YJe">2.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Company’s 2019 Long-Term Incentive Plan. A portion of the award, <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zwBbFJqtMRz7">5,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options, fully vested as of the date of the grant and the remaining <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zErX8NN1FHe8">25,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options are contingent upon certain sales based milestones being achieved. The options expire within <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtM_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember__srt--RangeAxis__srt--MaximumMember_zpk6VWO5Bse9">18 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">months of commercial launch of a new product if the milestones are not achieved prior to that date or <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionOneMember_zbT40MpIqfhj">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years from the grant date, whichever comes first. </span>The product launched in August 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zq9ZZkNxUUb9" title="Number of options, granted">37,500</span> shares of the Company’s common stock at a per share price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionTwoMember_z7spvtC9JLq5" title="Exercise price of options">5.50</span> under the Company’s 2019 Long-Term Incentive Plan. The options are contingent upon certain sales based milestones being achieved. The options expire within <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtM_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionTwoMember__srt--RangeAxis__srt--MaximumMember_z6Ge2JMYxyY5" title="Expiration period">36</span> months of commercial launch of a new product if the milestones are not achieved prior to that date or <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20221001__20221001__srt--TitleOfIndividualAxis__custom--Dr.LeonardNelsonMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zvYmxTHKXox1" title="Expiration period">10</span> years from the grant date, whichever comes first. The product launched in August 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zetb6au4m1kb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zhPY72Fg5248" style="display: none">Schedule of Incentive Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term in</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zhoLY8aW1yra" style="width: 14%; text-align: right" title="Number of options, outstanding, beginning balance">434,939</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zbk3mU3aXR46" style="width: 14%; text-align: right" title="Weighted average exercise price, outstanding beginning balance">1.678955</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi01L12oD9W8" title="Weighted average remaining contractual term">8.56</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_za8mvQiwu1Ya" style="text-align: right" title="Number of options, granted">195,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zrJ9etAzBRZb" style="text-align: right" title="Weighted average exercise price, granted">3.3461538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zslOjUuuE1ea" title="Weighted average remaining contractual term, granted">10.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z126a44Hj1kb" style="text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1230">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXJ6biEQnshj" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1232">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z8DkL6tpYuSl" style="text-align: right" title="Number of options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1234">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zgdifBnTxxnc" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1236">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z23DYc4ZClac" style="text-align: right" title="Number of options, cancelled">(100,001</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zYb9bTm74lBg" style="text-align: right" title="Weighted average exercise price, cancelled">1.40000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXVCx8ssx75a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, expired">(5,001</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zanS1CsMBeUk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">1.40000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z1QYEt1IJBcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding, beginning balance">524,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z7zaWgToLL1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding beginning balance">2.351416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3sASfn71WZd" title="Weighted average remaining contractual term">8.38</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_znqYlg2hdaR8" style="text-align: right" title="Number of options, granted">117,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zgoNhyIeteSf" style="text-align: right" title="Weighted average exercise price, granted">2.06041</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTbiWTglVYZ2" title="Weighted average remaining contractual term, granted">10.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXXpsVFvLJf5" style="text-align: right" title="Number of options, exercised">(3,295</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zJb9IzSntnY3" style="text-align: right" title="Weighted average exercise price, exercised">1.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zRIzgelEUli8" style="text-align: right" title="Number of options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1262">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zAOFKmDf4roh" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1264">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zsCXNzH6Z8ak" style="text-align: right" title="Number of options, cancelled">(69,854</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zQ9pVgjqGIng" style="text-align: right" title="Weighted average exercise price, cancelled">1.965823</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zRCu7zHSXIZh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, expired">(8,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zpm7WAlvENu2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">1.703222</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z4VsCe2GaOMi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding, ending balance">560,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zpg80tlpkEKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance">2.350742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpmCRGZgM4V1" title="Weighted average remaining contractual term">7.95</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zEUJ76zdQF1g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">398,150</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zjPYlWIaCBP1" title="Weighted average exercise price, exercisable">1.829884</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z27ukqY8jnCh" title="Weighted average remaining contractual term, exercisable">7.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zItJb44EVw1e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, vested outstanding stock options had $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zz8tbj2jGwLi" title="Intrinsic value">295</span> thousand and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zQqwW2UhKfnh" title="Intrinsic value">124</span> thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock, respectively. As of December 31, 2023, there was no unrecognized share-based compensation related to unvested stock options, excluding options fully contingent upon certain sales-based milestones being achieved within <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtM_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zJLDcVj3IXnd" title="Period of recognition of stock based compensation expense">18</span> to <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtM_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zorpqfQMWwFj" title="Period of recognition of stock based compensation expense">36</span> months of commercial release.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate share-based compensation expense for year ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z1gVzdH1YCpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zcMjbsSAivH9" style="display: none">Schedule of Assumptions used in Share-based Compensation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zSc8exvHe04f" title="Volatility">257.64</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zWe2yeElPx5i" title="Volatility">258.01</span></span></td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zauc9f1bpbKj" title="Volatility">277.84</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zovWgceLt1ge" title="Risk-free interest rate">4.21</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zKmEo85hQgs8" title="Risk-free interest rate">4.42</span></span></td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zl45lilUJbKa" title="Risk-free interest rate">4.06</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231_zj8QOnyCE2Fa" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_zdRadGDX4D07" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z8kEKSh6UNO2" title="Expected term">5</span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zxGiD3mBLttf" title="Expected term">5.50</span> years</span></td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_z0J5P6tQY5ck" title="Expected term">5.0</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_zTJy30YF5rUk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted-average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictive stock awards</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of January 3, 2023, the Company granted a restricted stock award of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230103__20230103__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjDW8Q50KWt4" title="Number of units, granted">37,037</span> shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated December 30, 2022, all of which shares vested monthly from January 3, 2023 through December 31, 2023. Under ASC 718, the Company has measured the value of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230103__20230103__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8TX6jVZdCvj" title="Restricted stock vesting, shares">37,037</span> shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230103__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8EfsKAzR4Vd" title="Share price">1.35</span> per share).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of August 1, 2022, the Company granted a restricted stock award of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220801__20220801__srt--TitleOfIndividualAxis__custom--OfficersAndEmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zM3f6i0DyZhb">84,750 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock to certain officers and employees, all of which shares vest in four equal installments on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Under ASC 718, the Company has measured the value of the <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220801__20220801__srt--TitleOfIndividualAxis__custom--OfficersAndEmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcLEmrlUsYXj">84,750 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares granted based on a closing price of the closing price of the Company’s stock at the grant date of the RSU Grant ($<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20220801__srt--TitleOfIndividualAxis__custom--OfficersAndEmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYhIJE4Mlxvc">1.82 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of January 1, 2022, the Company granted a restricted stock award of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20220101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWdKmgqN7RNk" title="Number of units, granted">11,364</span> shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated November 4, 2021, all of which shares vested monthly from January 1, 2022 through December 31, 2022. Under ASC 718, the Company has measured the value of the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20220101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zauZDqYcHyld" title="Restricted stock vesting, shares">11,364</span> shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20220101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziRzjG23RkQ9" title="Share price">4.40</span> per share).</span></p> <p id="xdx_89A_eus-gaap--NonvestedRestrictedStockSharesActivityTableTextBlock_zh0mXRxvAiz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_z9Xh88f0Z1n2" style="display: none">Schedule of Restricted Stock Units Granted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Units</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z633LrQ3H6B1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1335">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8rZBqKItlO8" title="Weighted average grant date fair value outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1337">—</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLU2X6thkidd" style="width: 16%; text-align: right" title="Number of units, granted">96,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0LCRURkTBch" style="width: 16%; text-align: right" title="Weighted average grant date fair value, granted">1.61</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised and converted to common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGektSfRCZBi" style="text-align: right" title="Number of units, exercised and converted to common shares">(5,682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjCYw3fOmm5c" style="text-align: right" title="Weighted average grant date fair value, exercised and converted to common shares">4.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkMeDgUZhUT4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of units, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1347">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2DHMVyRrSJ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1349">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdvdNdIgpaJf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units outstanding beginning">90,432</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7vI9pmBFHF1" title="Weighted average grant date fair value outstanding beginning">1.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYVY9c74rhSl" style="text-align: right" title="Number of units, granted">37,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9sb0O3DbA91" style="text-align: right" title="Weighted average grant date fair value, granted">1.35</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised and converted to common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPPJD9RSLdNg" style="text-align: right" title="Number of units, exercised and converted to common shares">(50,157</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhxEtnxmdcj5" style="text-align: right" title="Weighted average grant date fair value, exercised and converted to common shares">1.76522</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3wSzrXBV1Q4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of units, forfeited">(12,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zilsy0qx1DP7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">1.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2eSxcA1qD12" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units outstanding ending">64,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA3k6EHgYFXb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value outstanding ending">1.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeBHEWeREAMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units exercisable">13,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zisjcxut97f8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value exercisable">1.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_ziXSHQo1GwI4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation expense for forfeited awards. As of December 31, 2023, there was $<span id="xdx_906_ecustom--UnrecognizedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zgquJJn4NGN9" title="Unrecognized share based compensation expense">68</span> thousand unrecognized share-based compensation related to unvested RSUs, which the Company expects to recognize through December 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation and restricted stock vesting of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231_z8Z4HDcz5sn3" title="Stock based compensation and restricted stock vesting">217</span> thousand and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20221231_zjhEIPEwVeHi" title="Stock based compensation and restricted stock vesting">298</span> thousand has been recorded for the year ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1RLyGGMUnOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows a summary of common stock warrants for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zWcYEUcKXjTg" style="display: none">Schedule of Common Stock Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-bottom: 2.5pt">Outstanding at December 31, 2021</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zweWYaaUnyz9" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Number of warrants, outstanding beginning balance">3,637,190</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zEw95JyjXdT9" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Weighted average exercise price, outstanding beginning balance">5.16281</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zuawthamATW3" title="Weighted average remaining contractual term">4.63</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_zLqSIpq13oK8" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1389">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zDPNJZ30kmj7" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1391">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231_zbaVzhwLb9Pb" style="text-align: right" title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1393">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zrCvlKkSAzXj" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1395">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zGwmRcmDZ2b1" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1397">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z9G1VSgGJ6Xb" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1399">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20220101__20221231_zs1kr9sHb9v9" style="text-align: right" title="Number of warrants, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1401">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20220101__20221231_zVHUvu0VXFp" style="text-align: right" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1403">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231_zw3eAeLuRN71" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl1405">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zxShacynrfPh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl1407">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zkTGNGeGbSEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants, outstanding beginning balance">3,637,190</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zeYanE3cx0K8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding beginning balance">5.16281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zyYf9Yk7Q0fa" title="Weighted average remaining contractual term">3.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zyZt8jQHeFzg" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1415">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zatPS2VzOmmi" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1417">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_zU2abAUxVcr6" style="text-align: right" title="Number of warrants, exercised">(109,720</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z9UyLZMzsNY6" style="text-align: right" title="Weighted average exercise price, exercised">0.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231_zGWEFjvZ4fye" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1423">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zHxvpkDQoqnh" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1425">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20230101__20231231_z9seiyHFM9w7" style="text-align: right" title="Number of warrants, cancelled">(84,566</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20230101__20231231_zQWN3ft0NNT9" style="text-align: right" title="Weighted average exercise price, cancelled">0.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20231231_zbJDJjlwIC2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl1431">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z6jPkVuQIwYg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl1433">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_zV0OwQFNlRxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants, outstanding ending balance">3,442,904</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zjY6mobQULr7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance">5.414793</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zyu6wVtEkw5d" title="Weighted average remaining contractual term">2.87</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231_zvarBPNsgEFj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants, exercisable">3,442,904</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zpiw9Q4RWeG7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">5.414793</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zKVE1uCmiWN5" title="Weighted average remaining contractual term, exercisable">2.87</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zwZ3S4kBq725" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, vested outstanding warrants had $<span id="xdx_900_ecustom--ClassOfWarrantOrRightOutstandingIntrinsicValue_iI_pn3n3_c20231231_zBL0h5Zrdkih" title="Intrinsic value of vested outstanding warrants">0</span> and $<span id="xdx_900_ecustom--ClassOfWarrantOrRightOutstandingIntrinsicValue_iI_pn3n3_c20221231_zmyTJObYkY0h" title="Intrinsic value of vested outstanding warrants">114</span> thousand, respectively, intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 57143 57143 485715 485715 571429 300000 871429 609687 14286 <p id="xdx_895_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ztXFRl0CZD3d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table contains information about the 2019 Plan as of December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zRaeiticqf9l" style="display: none">Schedule of Information about Incentive Plan</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Reserved for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Available for</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercised</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019 Plan<sup>(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_z833ZFzzc0n6" style="width: 11%; text-align: right" title="Awards Reserved For Issuance">871,429</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_zswgft5Zbk32" style="width: 11%; text-align: right" title="Awards Issued">649,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercised_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_zfaboFSNifni" style="width: 11%; text-align: right" title="Awards Exercised">17,916</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_fKDEp_zNWo9Baa0ILh" style="width: 11%; text-align: right" title="Awards Available for Grant">221,596</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards issued in excess of 2019 Plan<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_zvGTEqMueCfc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Reserved For Issuance"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_zxRQgHTbph6a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Issued">48,401</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForExercised_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_zxhVRzZbNH56" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Exercised">48,401</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--AwardsGrantedOutsideOfThe2019PlanMember_fKDIp_z3DpxQeTkGfb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Awards Available for Grant"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F02_zVCfj0iw6RN6">(1)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zpl5GHAnJ9Wi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes incentive stock options and restricted stock units discussed below.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F05_zbsVxUoSh3Z5">(2)</sup></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zdAs39eF00Fj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.</span></td></tr> </table> 871429 649833 17916 221596 48401 48401 17532 2.00 P12M 90000 2.05 0.25 65000 2.00 15000 50000 2023-12-31 25000 2.00 37500 5.50 P36M 30000 2.00 5000 25000 P18M P10Y 37500 5.50 P36M P10Y <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zetb6au4m1kb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zhPY72Fg5248" style="display: none">Schedule of Incentive Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Term in</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zhoLY8aW1yra" style="width: 14%; text-align: right" title="Number of options, outstanding, beginning balance">434,939</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zbk3mU3aXR46" style="width: 14%; text-align: right" title="Weighted average exercise price, outstanding beginning balance">1.678955</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi01L12oD9W8" title="Weighted average remaining contractual term">8.56</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_za8mvQiwu1Ya" style="text-align: right" title="Number of options, granted">195,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zrJ9etAzBRZb" style="text-align: right" title="Weighted average exercise price, granted">3.3461538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zslOjUuuE1ea" title="Weighted average remaining contractual term, granted">10.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z126a44Hj1kb" style="text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1230">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXJ6biEQnshj" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1232">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z8DkL6tpYuSl" style="text-align: right" title="Number of options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1234">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zgdifBnTxxnc" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1236">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z23DYc4ZClac" style="text-align: right" title="Number of options, cancelled">(100,001</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zYb9bTm74lBg" style="text-align: right" title="Weighted average exercise price, cancelled">1.40000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXVCx8ssx75a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, expired">(5,001</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zanS1CsMBeUk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">1.40000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z1QYEt1IJBcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding, beginning balance">524,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z7zaWgToLL1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding beginning balance">2.351416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3sASfn71WZd" title="Weighted average remaining contractual term">8.38</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_znqYlg2hdaR8" style="text-align: right" title="Number of options, granted">117,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zgoNhyIeteSf" style="text-align: right" title="Weighted average exercise price, granted">2.06041</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTbiWTglVYZ2" title="Weighted average remaining contractual term, granted">10.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zXXpsVFvLJf5" style="text-align: right" title="Number of options, exercised">(3,295</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zJb9IzSntnY3" style="text-align: right" title="Weighted average exercise price, exercised">1.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zRIzgelEUli8" style="text-align: right" title="Number of options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1262">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zAOFKmDf4roh" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1264">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zsCXNzH6Z8ak" style="text-align: right" title="Number of options, cancelled">(69,854</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zQ9pVgjqGIng" style="text-align: right" title="Weighted average exercise price, cancelled">1.965823</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zRCu7zHSXIZh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, expired">(8,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zpm7WAlvENu2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">1.703222</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z4VsCe2GaOMi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding, ending balance">560,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zpg80tlpkEKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance">2.350742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpmCRGZgM4V1" title="Weighted average remaining contractual term">7.95</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zEUJ76zdQF1g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">398,150</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_zjPYlWIaCBP1" title="Weighted average exercise price, exercisable">1.829884</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenLongTermIncentivePlanMember_z27ukqY8jnCh" title="Weighted average remaining contractual term, exercisable">7.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 434939 1.678955 P8Y6M21D 195000 3.3461538 P10Y -100001 1.40000 5001 1.40000 524937 2.351416 P8Y4M17D 117532 2.06041 P10Y 3295 1.75 -69854 1.965823 8670 1.703222 560650 2.350742 P7Y11M12D 398150 1.829884 P7Y5M8D 295000 124000 P18M P36M <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z1gVzdH1YCpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zcMjbsSAivH9" style="display: none">Schedule of Assumptions used in Share-based Compensation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zSc8exvHe04f" title="Volatility">257.64</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zWe2yeElPx5i" title="Volatility">258.01</span></span></td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zauc9f1bpbKj" title="Volatility">277.84</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zovWgceLt1ge" title="Risk-free interest rate">4.21</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zKmEo85hQgs8" title="Risk-free interest rate">4.42</span></span></td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zl45lilUJbKa" title="Risk-free interest rate">4.06</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231_zj8QOnyCE2Fa" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_zdRadGDX4D07" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z8kEKSh6UNO2" title="Expected term">5</span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zxGiD3mBLttf" title="Expected term">5.50</span> years</span></td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_z0J5P6tQY5ck" title="Expected term">5.0</span> years</span></td><td style="text-align: left"> </td></tr> </table> 2.5764 2.5801 2.7784 0.0421 0.0442 0.0406 0.000 0.000 P5Y P5Y6M P5Y 37037 37037 1.35 84750 84750 1.82 11364 11364 4.40 <p id="xdx_89A_eus-gaap--NonvestedRestrictedStockSharesActivityTableTextBlock_zh0mXRxvAiz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_z9Xh88f0Z1n2" style="display: none">Schedule of Restricted Stock Units Granted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Units</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z633LrQ3H6B1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1335">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8rZBqKItlO8" title="Weighted average grant date fair value outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1337">—</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLU2X6thkidd" style="width: 16%; text-align: right" title="Number of units, granted">96,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0LCRURkTBch" style="width: 16%; text-align: right" title="Weighted average grant date fair value, granted">1.61</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised and converted to common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGektSfRCZBi" style="text-align: right" title="Number of units, exercised and converted to common shares">(5,682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjCYw3fOmm5c" style="text-align: right" title="Weighted average grant date fair value, exercised and converted to common shares">4.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkMeDgUZhUT4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of units, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1347">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2DHMVyRrSJ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1349">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdvdNdIgpaJf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units outstanding beginning">90,432</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7vI9pmBFHF1" title="Weighted average grant date fair value outstanding beginning">1.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYVY9c74rhSl" style="text-align: right" title="Number of units, granted">37,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9sb0O3DbA91" style="text-align: right" title="Weighted average grant date fair value, granted">1.35</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised and converted to common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPPJD9RSLdNg" style="text-align: right" title="Number of units, exercised and converted to common shares">(50,157</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhxEtnxmdcj5" style="text-align: right" title="Weighted average grant date fair value, exercised and converted to common shares">1.76522</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3wSzrXBV1Q4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of units, forfeited">(12,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zilsy0qx1DP7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">1.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2eSxcA1qD12" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units outstanding ending">64,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA3k6EHgYFXb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value outstanding ending">1.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeBHEWeREAMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of units exercisable">13,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zisjcxut97f8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value exercisable">1.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 96114 1.61 5682 4.40 90432 1.43 37037 1.35 50157 1.76522 12750 1.82 64562 1.82 13750 1.82 68000 217000 298000 <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1RLyGGMUnOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows a summary of common stock warrants for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zWcYEUcKXjTg" style="display: none">Schedule of Common Stock Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; padding-bottom: 2.5pt">Outstanding at December 31, 2021</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zweWYaaUnyz9" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Number of warrants, outstanding beginning balance">3,637,190</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zEw95JyjXdT9" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Weighted average exercise price, outstanding beginning balance">5.16281</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zuawthamATW3" title="Weighted average remaining contractual term">4.63</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_zLqSIpq13oK8" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1389">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zDPNJZ30kmj7" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1391">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231_zbaVzhwLb9Pb" style="text-align: right" title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1393">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zrCvlKkSAzXj" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1395">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zGwmRcmDZ2b1" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1397">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z9G1VSgGJ6Xb" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1399">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20220101__20221231_zs1kr9sHb9v9" style="text-align: right" title="Number of warrants, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1401">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20220101__20221231_zVHUvu0VXFp" style="text-align: right" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1403">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231_zw3eAeLuRN71" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl1405">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zxShacynrfPh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl1407">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zkTGNGeGbSEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants, outstanding beginning balance">3,637,190</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zeYanE3cx0K8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding beginning balance">5.16281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zyYf9Yk7Q0fa" title="Weighted average remaining contractual term">3.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zyZt8jQHeFzg" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1415">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zatPS2VzOmmi" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1417">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_zU2abAUxVcr6" style="text-align: right" title="Number of warrants, exercised">(109,720</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z9UyLZMzsNY6" style="text-align: right" title="Weighted average exercise price, exercised">0.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231_zGWEFjvZ4fye" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1423">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zHxvpkDQoqnh" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1425">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_c20230101__20231231_z9seiyHFM9w7" style="text-align: right" title="Number of warrants, cancelled">(84,566</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageCancelledPrice_pid_c20230101__20231231_zQWN3ft0NNT9" style="text-align: right" title="Weighted average exercise price, cancelled">0.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20231231_zbJDJjlwIC2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl1431">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z6jPkVuQIwYg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl1433">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_zV0OwQFNlRxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants, outstanding ending balance">3,442,904</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zjY6mobQULr7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance">5.414793</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zyu6wVtEkw5d" title="Weighted average remaining contractual term">2.87</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231_zvarBPNsgEFj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants, exercisable">3,442,904</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zpiw9Q4RWeG7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">5.414793</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zKVE1uCmiWN5" title="Weighted average remaining contractual term, exercisable">2.87</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3637190 5.16281 P4Y7M17D 3637190 5.16281 P3Y7M24D 109720000 0.55 -84566000 0.89 3442904 5.414793 P2Y10M13D 3442904 5.414793 P2Y10M13D 0 114000 <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_znLg966Jn3t5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_82A_zpLKA7Mf48K8">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CG Labs Notes Payable</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CG Labs has entered into a $<span id="xdx_90E_eus-gaap--NotesPayable_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableMember_zf4k49RnFCU1" title="Notes payable">231</span> thousand promissory note agreement for certain equipment. The equipment was installed in December 2023. <span style="background-color: white">The promissory note has a </span> term of <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dc_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWlQJkrIwaqa" title="Agreements terms">five years</span> beginning on March 13, 2024. The promissory note accrues interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableMember_zlpBDl8TJcvd" title="Interest rate">8</span>% and requires interest only payments through March 13, 2024 and monthly payments of $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240313__20240313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableMember_z7E0PKoz8WT9" title="Debt instrument periodic payment">4</span> thousand thereafter. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">CG Labs has entered into a $<span id="xdx_904_eus-gaap--NotesPayable_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableOneMember_zg2dxnStFQi9" title="Notes payable">242</span> thousand promissory note agreement for certain equipment. The funding advances of $<span id="xdx_90F_ecustom--AdvancePaymentOfPromissoryNote_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableOneMember_ziIB4oNPMeua" title="Advance payment of promissory note">84</span> thousand have been <span style="background-color: white">issued </span> as of December 2023. <span style="background-color: white">The promissory note has a </span> term of <span id="xdx_907_eus-gaap--DebtInstrumentTerm_dc_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableOneMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjPiw3Eg3GYa" title="Agreements terms">five years</span> beginning on March 13, 2024. The promissory note accrues interest at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableOneMember_zbbP7ZWdQuA3" title="Interest rate">8</span>% and requires interest only payments through March 13, 2024 and monthly payments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240313__20240313__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--CGLabsNotesPayableOneMember_zF5jn0scBsQ7" title="Debt instrument periodic payment">5</span> thousand thereafter. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Economic Injury Disaster Loan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan is up to $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20200528__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zfQjgNCwuTu5" title="Borrowing capacity">260,500</span>, with proceeds to be used for working capital purposes. Interest accrues at the rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200528__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zJix8xMo5bXf" title="Interest rate">3.75</span>% per annum. Installment payments, including principal and interest, are due monthly beginning May 28, 2021 (twelve months from the date of the SBA Note) in the amount of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20200527__20200528__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zFcQT3spV1Qh" title="Debt instrument periodic payment">1,270</span>. The balance of principal and interest is payable thirty years from the date of the SBA Note. In connection therewith, the Company received an $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20200527__20200528__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zF4ErlycEq1d" title="Loan advance">8</span> thousand advance, which does not have to be repaid. On March 26, 2021, the SBA announced that all EIDL loans issued in 2020 will start repayment 24 months from the date of the SBA Note. The SBA has since extended the repayment start to 30 months from the date of the SBA Note. The Company made its first payment in December 2022. The balances of the principal and accrued interest amounted to $<span id="xdx_900_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20230101__20231231_zdmIw6kd1fl4" title="Principal and accrued interest">277</span> thousand and $<span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20220101__20221231_zi61LvcbymX3" title="Principal and accrued interest">283</span> thousand as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zMGbC8XdiUv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future annual principal amounts and accrued interest to be paid as of December 31, 2023 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zLphPuZkVRvd" style="display: none">Schedule of Debt Instruments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_zcSZ5DR4UfU" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">For the year ending December 31 ($ in thousands):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDz0GY_zQN9iDHd28bh" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">80</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDz0GY_z06c2CLFL1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz0GY_zMqtIUPbANz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz0GY_zVSMF3IadM4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pn3n3_maLTDz0GY_zZpl0yhQ87gd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_pn3n3_maLTDz0GY_ziu4scyNLhkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">259</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz0GY_zY48EKR3kgwi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">593</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z03jddQ3ThUg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 231000 P5Y 0.08 4000 242000 84000 P5Y 0.08 5000 260500000 0.0375 1270000 8000 277000 283000 <p id="xdx_89D_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zMGbC8XdiUv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future annual principal amounts and accrued interest to be paid as of December 31, 2023 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zLphPuZkVRvd" style="display: none">Schedule of Debt Instruments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_zcSZ5DR4UfU" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">For the year ending December 31 ($ in thousands):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDz0GY_zQN9iDHd28bh" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">80</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDz0GY_z06c2CLFL1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz0GY_zMqtIUPbANz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz0GY_zVSMF3IadM4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pn3n3_maLTDz0GY_zZpl0yhQ87gd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_pn3n3_maLTDz0GY_ziu4scyNLhkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">259</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz0GY_zY48EKR3kgwi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">593</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 80000 89000 51000 55000 59000 259000 593000 <p id="xdx_807_eus-gaap--LongTermDebtTextBlock_z4sSOcFl6ai9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. <span id="xdx_82B_z0UskdL0ctx9">Convertible Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2021, the Company issued Auctus Fund, LLC, a Delaware limited liability company a one-year senior secured convertible promissory note in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20210311__us-gaap--ClassOfWarrantOrRightAxis__custom--AuctusNoteMember_zWV1SeowtXs4">1.68</span> million, which included $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pn3n3_c20210310__20210311__us-gaap--ClassOfWarrantOrRightAxis__custom--AuctusNoteMember_zp6ZpFa5dlG3">180</span> thousand of interest which was deemed fully earned as of the issuance date (the “Auctus Note”). The Auctus Note was fully repaid (including all principal and interest) on March 15, 2022 with a one-time cash payment of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20220315_zNG1oYz0MXkg">1.68</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2021, the Company issued to certain holders one-year subordinated secured convertible promissory notes in the aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210902__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBdAgjLNz6w9" title="Principal amount of debt">1,814</span> thousand, which included $<span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20210902__20210902__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zdDnlufM60d5" title="Interest expense">194 </span>thousand of interest which was deemed fully earned as of the issuance date (the “September 2 Notes”). On January 25, 2022, the Company repaid one of the September 2 Notes in full with a one-time cash payment of $<span id="xdx_906_ecustom--OutstandingPrincipalAndAccruedUnpaidInterest_iI_pn3n3_c20220125__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zCM2CBJCX7be" title="Outstanding principal and accrued unpaid interest">300</span> thousand of outstanding principal and accrued but unpaid interest. The Company incurred pre-payment penalty of $<span id="xdx_909_ecustom--PrePaymentPenalty_iI_pn3n3_c20220125__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zYH4kvnMsbNg" title="Pre payment penalty">17</span> thousand with respect to the repayment of the note and the remaining unamortized debt discount in the amount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20220125__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zHZ0r099J41h" title="Unamortized debt discount">133</span> thousand was written off and both amounts were recorded as a loss on extinguishment of debt of $<span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zdojZrGgunwk" title="Gains loss on extinguishment of debt">150</span> thousand in accompany statement of operations during 2022. The repayment extinguished the note in its entirety. On September 6, 2022, the outstanding balance on the remaining September 2 Notes’ was repaid in full which consisted of principal of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20220906__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBL1wnf505Q">1,478</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1680000 180000 1680000 1814000 194000 300000 17000 133000 150000 1478000 <p id="xdx_804_ecustom--WarrantsLiabilityDisclosureTextBlock_zem4tMGJ8x1e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15. <span id="xdx_820_zO7xoCK2kX24">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2021, March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019, and November 6, 2019, the Company issued <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210902__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zB2UcOdJ12se" title="Warrants outstanding">22,019</span>, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210311__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRYJ8gmxJWCe" title="Warrants outstanding">34,285</span>, <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210203__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6qszT5tT6ag" title="Warrants outstanding">7,429</span>, <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDylEzqiZo9e" title="Warrants outstanding">7,286</span>, <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20200318__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNtK4uB4c208" title="Warrants outstanding">44,286</span>, <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20190910__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2iLJCmPsnCd" title="Warrants outstanding">35,714</span> and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20191106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zG68tRgEJOh3" title="Warrants outstanding">114,286</span> warrants, respectively, as equity issuance consideration, in connection with a private placement of the Company’s common stock. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6GJva1BsUVa" title="Exercise price">0.49</span> to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIWGGVokOAb5" title="Exercise price">5.25</span> per share at any time on or after their issuance date and on or prior to the close of business 3 years after the issuance date (the “Termination Date”). The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants required classification as a liability pursuant to ASC 815, <i>Derivatives and Hedging</i>. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income (expense) in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 6, 2022, the Company agreed to extend the September 10, 2019 and November 6, 2019 warrants an additional six months until March 9, 2023 and May 5, 2023, respectively. The warrants were remeasured as of September 6, 2022 and consequently resulted in a warrant modification expense of $<span id="xdx_90C_ecustom--WarrantModificationExpense_pn3n3_c20220905__20220906_zANAKHn21uw7" title="Warrant modification expense">57</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfFairValueWarrantLiabilityTextBlock_z8EBNxwSB4e9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants outstanding and fair values at each of the respective valuation dates are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_z8iybyX9lVt" style="display: none">Schedule of Warrant Liability</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-weight: bold">Fair value as of year ended 12/31/2021</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9z22a3qIX7j" style="width: 11%; font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">265,305</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOojrSLiRCek" style="width: 11%; font-weight: bold; text-align: right" title="Fair value, beginning balance">318</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Modification of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantModification_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWSm6uFsAuod" style="text-align: right" title="Warrants outstanding, warrant modification"><span style="-sec-ix-hidden: xdx2ixbrl1545">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">     </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_98D_ecustom--WarrantModificationExpense_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRh1BVOPCO5h" style="text-align: right" title="Fair value, modification of warrants">57</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrantsShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJUN3tLAKXEk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIoYLeb5dNWk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, change in fair value of warrant liability">(133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Fair value as of year ended 12/31/2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRlvYkjPbvg2" style="font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">265,305</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdXgMRmOHSYe" style="font-weight: bold; text-align: right" title="Fair value, beginning balance">242</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iNE_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZH4xO016624" style="text-align: right" title="Warrants outstanding, exercise of warrants">(194,286</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_984_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYbfA8wDVdf6" style="text-align: right" title="Fair value, exercise of wararnts">(144</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Modification of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantModification_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjvleELFTEDk" style="text-align: right" title="Warrants outstanding, warrant modification"><span style="-sec-ix-hidden: xdx2ixbrl1561">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--WarrantModificationExpense_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsURWf07T537" style="text-align: right" title="Fair value, modification of warrants">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrantsShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr91SOth6Ag7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl1565">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY8FA6WU9xsl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, change in fair value of warrant liability">19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value as of year ended 12/31/2023</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcyspl42Kpxf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding, ending balance">71,019</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1tCmvkQkz6j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value, ending balance">146</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zCs1y6viXaYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility of Guideline Public Companies as inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 22019 34285 7429 7286 44286 35714 114286 0.49 5.25 57000 <p id="xdx_891_ecustom--ScheduleOfFairValueWarrantLiabilityTextBlock_z8EBNxwSB4e9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants outstanding and fair values at each of the respective valuation dates are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_z8iybyX9lVt" style="display: none">Schedule of Warrant Liability</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-weight: bold">Fair value as of year ended 12/31/2021</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9z22a3qIX7j" style="width: 11%; font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">265,305</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOojrSLiRCek" style="width: 11%; font-weight: bold; text-align: right" title="Fair value, beginning balance">318</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Modification of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantModification_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWSm6uFsAuod" style="text-align: right" title="Warrants outstanding, warrant modification"><span style="-sec-ix-hidden: xdx2ixbrl1545">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">     </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_98D_ecustom--WarrantModificationExpense_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRh1BVOPCO5h" style="text-align: right" title="Fair value, modification of warrants">57</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrantsShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJUN3tLAKXEk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIoYLeb5dNWk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, change in fair value of warrant liability">(133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Fair value as of year ended 12/31/2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRlvYkjPbvg2" style="font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">265,305</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdXgMRmOHSYe" style="font-weight: bold; text-align: right" title="Fair value, beginning balance">242</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iNE_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZH4xO016624" style="text-align: right" title="Warrants outstanding, exercise of warrants">(194,286</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_984_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYbfA8wDVdf6" style="text-align: right" title="Fair value, exercise of wararnts">(144</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Modification of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantModification_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjvleELFTEDk" style="text-align: right" title="Warrants outstanding, warrant modification"><span style="-sec-ix-hidden: xdx2ixbrl1561">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--WarrantModificationExpense_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsURWf07T537" style="text-align: right" title="Fair value, modification of warrants">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrantsShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr91SOth6Ag7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl1565">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY8FA6WU9xsl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, change in fair value of warrant liability">19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value as of year ended 12/31/2023</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcyspl42Kpxf" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Warrants outstanding, ending balance">71,019</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1tCmvkQkz6j" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value, ending balance">146</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 265305 318000 57000 -133000 265305 242000 194286000 144000 29000 19000 71019 146000 <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKvfxTmCiek1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. <span id="xdx_82A_zOkfNlJtsclh">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will have a material effect on the financial position, results of operations, or cash flows of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2023, the Company entered into a Services Agreement with GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (“Haleon”) to supply material for a consumer product to be developed and released in the future. There can be no guaranty that a consumer product will be released or, if released, that it will be successful. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_802_eus-gaap--ConcentrationRiskDisclosureTextBlock_znIrYb7WTfy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. <span id="xdx_82E_zGcjvE4mTJx1">Concentrations of Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenues are concentrated in a small group of customers with some individually comprising more than 10% of total revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, the Company had revenue from one customer that approximated <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqXunsOGjfBe">20</span>% of total revenue. For the year ended December 31, 2022, the Company had revenue from one customer that approximated <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziW2aeD4q4vi">29</span>% of total revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had one customer with accounts receivable balances that approximated <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIUQJTXuE811" title="Concentration risk, percentage">69</span>% of total accounts receivable as of December 31, 2023. The Company had three customers with accounts receivable balances that approximated <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zrQsFSm77vJ6" title="Concentration risk, percentage">40</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvR8KTECK1dk" title="Concentration risk, percentage">22</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zT6kjhTHTvK7" title="Concentration risk, percentage">18</span>% of total accounts receivable as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Cash balances are maintained principally at major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. Such cash balances are currently in excess of the FDIC insurance limit of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zmnDcjfRHpCf" title="Cash, FDIC insured amount">250</span> thousand. As of December 31, 2023, the total amount exceeding such limit was $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn3n3_c20231231_zbrS2G8MDCK7" title="Cash, exceeding">106</span> thousand. The Company has not experienced any credit losses associated with its cash balances in the past. The Company invests its cash equivalents in U.S. treasury bills with original maturities of three months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities are comprised of U.S. treasury bills with original maturities greater than three months. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.20 0.29 0.69 0.40 0.22 0.18 250000 106000 <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPV8cZMwuELl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. <span id="xdx_82D_zprBcendDvtf">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible Promissory Note</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2021, the Company issued <span id="xdx_901_ecustom--NumberOfDebtInstruments_iI_dc_uInteger_c20210902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Mr.SteinMember_zp10ODiqY1Ag" title="Number of debt instruments">three</span> Secured Convertible Promissory Notes to members of the board of directors in an aggregate amounts of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Mr.SteinMember_z2LrKZSb7DU2" title="Debt instrument face amount">150,000</span> to Mr. Stein, $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Mr.StefanskyMember_zCzWlYXHBsPg" title="Debt instrument face amount">150,000</span> to Mr. Stefansky (Bezalel Partners, LLC), and $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20210902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.JeromeZeldisMember_zDrHDtiYreq" title="Debt instrument face amount">50,000</span> to Dr. Zeldis as part of the September 2 Notes. The notes were repaid in full in 2022 (See Note 14).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Advances</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $<span id="xdx_908_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.JeromeZeldisMember_z6CzFhUyFBwi" title="Due from related parties, current">25,000</span> and $<span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.JeromeZeldisMember_z5XxjvhOz8tg" title="Due from related parties, current">40,000</span> for services as of December 31, 2023 and 2022, respectively, included in accounts payable in the accompanying consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 150000000 150000000 50000000 25000000 40000000 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zdTUogxYmUf7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19. <span id="xdx_826_zwqrFxtFfJ98">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has established a full valuation allowance for its deferred tax assets based on management’s belief that it is not more likely than not that the related deferred tax assets will be realized. For the years ended December 31, 2023 and 2022, there was <span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_z7gm8Uh5XmZh" title="Income tax expense (benefit)::XDX::-"><span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zFr8D3kpUSb5" title="Income tax expense (benefit)::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1607"><span style="-sec-ix-hidden: xdx2ixbrl1609">no</span></span></span></span> income tax expense or benefit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, the Company had <span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20231231_zZHZFPXsvmF8" title="Unrecognized tax benefits"><span id="xdx_902_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_z1MSBTeajVgg" title="Unrecognized tax benefits">no</span></span> recorded tax liabilities for uncertain tax positions. The Company does not expect any significant changes to the estimate amount of liabilities associated with uncertain tax positions in the next 12 months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z5SvVkHlo48a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax (benefit) provision consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zg4GQPHHQoTe" style="display: none">Schedule of Income Tax (Benefit) Provision</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_za9UKhH3KIv2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zgv11aD5AD9c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For The Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zI1WVOB2uOX" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Federal:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zGHJE8OrE8Z6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(617</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(619</p></td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_zbC5P04F5pBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">617</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">619</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zENoxweJZU4j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State and local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zBmm5baQnQni" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(156</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_z8qsRQEaW4O7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">156</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_pn3n3_zDqiw7kHybYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1635">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1636">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zDl5uE8LY2U3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8aLFgY0eoxk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zrYKMEVb2Mc7" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zz2ECMcZJLGi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zmGt5hesjFD5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For The Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maITP001_zTdZQB2l5bM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">U.S. federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maITP001_zYGC0XVIdbnj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State tax rate, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maITP001_z0j38viv8Dma" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1.9</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9.7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_iN_pid_dpi0_uPure_msITP001_zVsjaQRpEdla" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Timing differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"></td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maITP001_zubiD4UsPvna" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp0_uPure_mtITP001_zlz25tjYXf51" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income tax provision</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A4_zoc7f2xRAlh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, differences between the expected tax expense based on the federal statutory rate and the actual tax expense is primarily attributable to the net losses incurred and the corresponding increase to the valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPJRx5SJHEv7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zwUN8HOgmHZa" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_498_20231231_z8tFGRmFQP43" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20221231_zwdyH1wfCX78" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNetAbstract_iB_ztR4dv0vvrT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzB9U_zmV9XauJW5He" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,882</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,112</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzB9U_zYdL23yDUQ8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzB9U_maDTANzneS_maDTALNzaDy_z4jDLj0ZZJMa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred tax assets</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,891</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,118</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTANzneS_z6HALvq8yTX4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,891</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,118</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTANzneS_zSsEmG4jI1Ub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, net of valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1675">—</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1676">—</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_zzY17jFcEll7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company has approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20231231_zlncM8WlFGpb" title="Deferred tax assets, operating loss carryforwards, state and local">18.6</span> million and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20221231_zvJqqXGq2TK6" title="Deferred tax assets, operating loss carryforwards, state and local">15.6</span> million of federal NOL carryovers, respectively, which begin to expire in 2029 through 2036. Similarly, the subsidiary’s Pennsylvania state returns reported state NOL carryovers of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20231231__srt--StatementGeographicalAxis__country--PA_zpDxDlHoP6b2" title="Deferred tax assets, operating loss carryforwards, state and local">18.6</span> million and $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20221231__srt--StatementGeographicalAxis__country--PA_zc41Qs9prOXb" title="Deferred tax assets, operating loss carryforwards, state and local">15.6 </span>million, as of December 31, 2023 and 2022, respectively. However, these loss carryforwards on a separate company basis may be subject to limitations on the amounts that may be utilized pursuant to Internal Revenue Code section 382 and applicable state law. Section 382 imposes significant limitations on the utilization of net operating losses after certain changes of corporate ownership. The Company will need to determine the amount of loss carryforwards that may be utilized in the future as necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the years in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2023 and 2022 because management has determined that it is more likely than not that these deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2023 and 2022, the Company does not have any significant uncertain tax positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z5SvVkHlo48a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax (benefit) provision consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zg4GQPHHQoTe" style="display: none">Schedule of Income Tax (Benefit) Provision</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_za9UKhH3KIv2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zgv11aD5AD9c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For The Years Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zI1WVOB2uOX" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Federal:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zGHJE8OrE8Z6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(617</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(619</p></td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_zbC5P04F5pBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">617</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">619</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zENoxweJZU4j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State and local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zBmm5baQnQni" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(156</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_z8qsRQEaW4O7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">156</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_pn3n3_zDqiw7kHybYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1635">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1636">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -617000 -619000 617000 619000 -156000 -159000 156000 159000 <p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8aLFgY0eoxk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2023 and 2022, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zrYKMEVb2Mc7" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zz2ECMcZJLGi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zmGt5hesjFD5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For The Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maITP001_zTdZQB2l5bM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">U.S. federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 2%; text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maITP001_zYGC0XVIdbnj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State tax rate, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maITP001_z0j38viv8Dma" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1.9</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9.7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_iN_pid_dpi0_uPure_msITP001_zVsjaQRpEdla" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Timing differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"></td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maITP001_zubiD4UsPvna" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp0_uPure_mtITP001_zlz25tjYXf51" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income tax provision</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.053 0.053 -0.019 -0.097 -0 -0 -0.244 -0.166 0 0 <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPJRx5SJHEv7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zwUN8HOgmHZa" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_498_20231231_z8tFGRmFQP43" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49D_20221231_zwdyH1wfCX78" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNetAbstract_iB_ztR4dv0vvrT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzB9U_zmV9XauJW5He" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,882</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,112</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzB9U_zYdL23yDUQ8c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzB9U_maDTANzneS_maDTALNzaDy_z4jDLj0ZZJMa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred tax assets</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,891</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,118</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTANzneS_z6HALvq8yTX4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,891</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,118</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTANzneS_zSsEmG4jI1Ub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, net of valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1675">—</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1676">—</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 4882000 4112000 9000 6000 4891000 4118000 4891000 4118000 18600000 15600000 18600000 15600000 <p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z5FmsKdxoEll" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20. <span id="xdx_82B_zQLJI6ma8zHj">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management of the Company has performed a review of events and transactions occurring after the consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying consolidated financial statements, noting no such events or transactions other than the following.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 15, 2024 (the “Closing Date”), the Company, entered into subscription agreements with investors, the Company’s Chief Financial Officer and certain members of its board of directors for a registered direct offering (“RDO”) of the Company’s common stock. The RDO sold an aggregate <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zmSb3RejtQJ7" title="Sale of stock, number of shares issued in transaction">242,891</span> units at a price to the public of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zLyg7lFRSmv1" title="Sale of stock, price per share">4.22</span> per unit, with each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of Common Stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zKNdfHiBeum5" title="Exercise price, per share">4.00</span> per share. The $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zlZbss6kjJ4d" title="Sale of stock, price per share">4.22</span> purchase price equals two times the last reported sale price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzB1CVvexSAd" title="Sale of stock, price per share">2.11</span> per share of the Company’s common stock on February 15, 2024 on The Nasdaq Capital Market. The Company issued <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmQBGlCCwAX7" title="Sale of stock, number of shares issued in transaction">485,782</span> shares of common stock and warrants to purchase up to <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRtlqvTn7pIb" title="Sale of stock, number of shares issued in transaction">242,891</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to certain ownership limitations, each of the warrants will become exercisable on the Closing Date, will have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zLdDuuF3CNo1" title="Exercise price, per share">4.00</span> per share and will expire <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z2sJPSQvPNB5" title="Warrants expire term">five years</span> after the Closing Date. The warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained in the registration statement is not available for, the issuance or resale of shares of common stock underlying the warrants to or by the holder. The holder of a warrant is prohibited from exercising of any such warrants to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--RangeAxis__srt--MinimumMember_z1lAVIU5Ksr4" title="Common stock outstanding percentage">4.99</span>% of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--RangeAxis__srt--MaximumMember_zoxNvaIDAvb5" title="Common stock outstanding percentage">9.99</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross proceeds to the Company from the RDO are expected to be approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n6_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zzdTMBuEK5M8" title="Gross proceeds from issuance of initial public offering">1.025</span> million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the warrants. The Company intends to use the net proceeds from the RDO for working capital and for general corporate purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company retained Alere Financial Partners, LLC (A division of Cova Capital Partners, LLC) to act as the placement agent for the RDO. The Company agreed to pay the placement agent a cash fee of <span id="xdx_902_ecustom--CashFeeOfAggregateGrossProceedsPercentage_pid_dp_uPure_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonAffiliatedEntityMember_zU08J2OE4sSb" title="Cash fee of aggregate gross proceeds percentage">6</span>% of the aggregate gross proceeds in the RDO received from non-affiliates of the Company and <span id="xdx_904_ecustom--CashFeeOfAggregateGrossProceedsPercentage_pid_dp_uPure_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zU4nUh6Hm0De" title="Cash fee of aggregate gross proceeds percentage">3</span>% of the aggregate gross proceeds in the RDO received from affiliates of the Company. Additionally, and upon the closing of the RDO, the Company agreed to issue to the placement agent warrants exercisable for a period of <span id="xdx_906_ecustom--WarrantsExercisablePeriod_iI_dc_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zjmB6p7zew6f" title="Warrants exercisable period">five years</span> to purchase up to <span id="xdx_90D_ecustom--CashFeeOfAggregateGrossProceedsPercentage_pid_dp_uPure_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zfkkrimXm9Vd" title="Cash fee of aggregate gross proceeds percentage">6</span>% of the number of shares sold in this offering, or up to <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240215__20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zBRT8d1YW0L" title="Sale of stock, number of shares issued in transaction">27,725</span> shares, at a per share exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zFRZp1eVABi1" title="Exercise price, per share">4.00</span>.</span></p> 242891 4.22 4.00 4.22 2.11 485782 242891 4.00 P5Y 0.0499 0.0999 1025000.000 0.06 0.03 P5Y 0.06 27725 4.00 Includes incentive stock options and restricted stock units discussed below. Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.